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 The present functional magnetic resonance imaging (fMRI) study compared 
the effects of two commonly prescribed medications for Attention Deficit 
Hyperactivity Disorder (ADHD), the stimulant methylphenidate (MPH), and the non-
stimulant Atomoxetine (ATX) in ADHD.  
 Brain activation and task performance during motor inhibition (Stop), time 
discrimination (TD) and working memory (WM) tasks were compared in 20 
medication-naïve ADHD boys (10-17 years-old) after a single dose of MPH 
(0.3mg/kg), ATX (1mg/kg) or placebo (Vit C, 50mg) using a randomized, double-
blind, placebo-controlled design. To test for potential normalization effects, brain 
activation in patients under each drug was compared to that of 20 age-matched 
unmedicated healthy boys.  
 Both drugs showed task-dependent drug-specific and shared effects. 
Performance-wise, only MPH improved inhibitory speed and reduced TD errors in 
patients, while both drugs improved WM. MPH relative to ATX upregulated and 
normalised underactivation in patients relative to controls in right VLPFC and 
cerebellar/occipital areas during motor inhibition, in left IFC during TD and WM and 
in left putamen and SMA/ACC during TD. During WM, ATX showed drug-specific 
upregulation and normalisation effects relative to MPH in right DLPFC, which was 
reduced in patients relative to controls.  
 Shared effects were normalisation of underactivation in patients relative to 
controls in left VLPFC during motor inhibition and in right VLPFC during TD. 
During WM, both drugs enhanced performance-associated fronto-temporo-striatal 
activation and deactivated default-mode network regions in patients relative to 
controls. 
 In conclusion, ATX and MPH have task-dependent drug-specific effects on 
task-relevant prefrontal regions, suggesting different mechanisms of action despite 
their shared prefrontal catecholaminergic effects. Their differential prefrontal 
lateralisation suggests potentially stronger effects of MPH on left- lateralised 
dopaminergic networks, and of ATX on right- lateralised noradrenergic networks. 
Their shared effects were not restricted to prefrontal regions or task-positive 
networks, but extended to default-mode networks, suggesting they act on wider 
dopaminergic and noradrenergic neural networks.  
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CHAPTER 1. NEUROPSYCHOLOGICAL EVIDENCE OF COGNITIVE 
DEFICITS IN ADHD 
  
1.1 Introduction: Attention Deficit Hyperactivity Disorder 
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental 
disorder, characterised by age- inappropriate symptoms of inattention and 
hyperactivity/impulsivity (American Psychiatric Association, 2000), and its 
prevalence is estimated to be between 3-8% in school-aged children (American 
Psychiatric Association, 2000; Froehlich et al., 2007; Merikangas et al., 2010). 
Although traditionally conceptualised as a childhood disorder, it is now accepted that 
it persists into adulthood in up to 65% of the cases (Barkley, Fischer, Smallish, & 
Fletcher, 2002; Biederman et al., 2006; Gittelman, Mannuzza, Shenker, & Bonagura, 
1985; Taylor, Chadwick, Heptinstall, & Danckaerts, 1996; Weiss, Hechtman, Milroy, 
& Perlman, 1985), affecting 4% of the adult population (Faraone & Biederman, 2005; 
Kessler et al., 2006).  
The Diagnostic Statistic Manual of Mental Disorders (4th Edition, text 
revision) (American Psychiatric Association, 2000) is a descriptive symptom-based 
classification, as an attempt to avoid theory-based classifications which were 
predominant in previous versions of the DSM. According to this international 
classification, symptoms of ADHD are clustered into three different domains, 
including inattention (e.g. difficulties in sustaining attention during school/work, 
easily distracted by external/internal stimuli, careless mistakes in school/work, 
difficulties in following instructions, forgetful), hyperactivity (e.g. fidgety, always on 
the go) or impulsivity (e.g. intruding in conversations, difficulty to wait his/her turn, 
excessive talk) (Table 1.1.). ADHD is therefore characterised by the heterogeneity of 
the symptoms presented by the patients, addressed by the international classifications 
by grouping them in different subtypes depending on the number of symptoms present 
in each domain (inattentive, hyperactive, combined subtypes) (American Psychiatric 








Table 1.1. DS M-IV-TR Diagnostic criteria for ADHD  
  
 ADHD is a very pervasive disorder, with high impact on academic and social 
development (Harpin, 2005), and high rates of psychiatric comorbidites both in 
 21 
childhood (Biederman, Newcorn, & Sprich, 1991; Blackman, Ostrander, & Herman, 
2005; Jensen, Martin, & Cantwell, 1997; Spencer, 2006) and adulthood (Kessler et al., 
2006; McGough et al., 2005; Sobanski et al., 2007; Sobanski et al., 2008). 
Furthermore, the presence of psychiatric comorbidities in children with ADHD has 
been identified as a risk factor for the persistence of ADHD in adulthood (Biederman, 
Petty, Clarke, Lomedico, & Faraone, 2010; Lara et al., 2009). 
 Genome-wide, twin and adoption studies have shown high heritability of the  
disorder with some evidence for genetic associations, although no single gene has 
consistently been associated with ADHD and it is currently thought that ADHD may 
be associated with multiple genes of small effects (Faraone & Mick, 2010). The most 
consistent evidence so far suggests a role in the aetiology of ADHD for those genes 
coding for dopaminergic receptors DRD4 and DRD5, dopamine transporter 
(SCL6A3), serotonin receptor HTR1B and the aminoacid protein SNAP-25, part of a 
presynaptic plasma membrane protein involved in the regulation of neurotransmitters 
release (Faraone & Mick, 2010). However, not only genetic but also environmental 
factors need to be considered, as these may trigger, modify or exacerbate the 
presentation of the disorder (Thapar, Langley, Asherson, & Gill, 2007; Wermter et al., 
2010).  
 
 1. 2 Neuropsychological deficits in ADHD 
Executive functions (EF) are high- level cognitive processes necessary for goal-
directed behaviours (Stuss & Alexander, 2000). They include the abilities to form a 
goal, plan and carry out the goal-directed plan, as well as performance monitoring and 
modification of the plan according to the feedback in order to achieve the goal. Thus, 
EF involves planning, decision making, temporal foresight, working memory, higher 
level and selective attention, motor inhibition, interference control, set maintenance 
and set-shifting as well as integration across space and time (Stuss & Alexander, 
2000).  
EF can be differentiated between “cool” and “hot” (Zelazo & Muller, 2002). 
“Cool” EF are elicited by relatively abstract and de-contextualized problems and 
mediated by ventrolateral and dorsolateral fronto-striatal, fronto-cerebellar and fronto-
parietal neural networks (Zelazo & Muller, 2002). On the other hand,  “hot” EF 
involve affection and motivation, are elicited by paradigms loading on motivation and 
 22 
reward, such as tasks of reward-related decision making, reversal of rewarded 
stimulus-response associations or temporal discounting and are mediated by 
mesolimbic ventromedial (VMPFC) and orbitofrontal (OFC)-striatal and limbic 
circuits (Zelazo & Muller, 2002). 
Deficits in “cool” and “hot” EF have been observed in children with ADHD (for 
reviews, see Cubillo, Halari, Smith, Taylor, & Rubia, 2012; Rubia, 2011). For 
example children with ADHD have deficits in motor inhibition (Alderson, Rapport, & 
Kofler, 2007; Klein, Wendling, Huettner, Ruder, & Peper, 2006; Lijffijt, Kenemans, 
Verbaten, & van Engeland, 2005; Nigg, 2005; Oosterlaan, Logan, & Sergeant, 1998; 
Rommelse et al., 2008; Rubia, Oosterlaan, Sergeant, Brandeis, & von Leeuwen, 1998; 
Willcutt, Doyle, Nigg, Faraone, & Pennington, 2005; Wodka et al., 2007), 
interference inhibition (Lansbergen, Kenemans, & van Engeland, 2007; Mullane, 
Corkum, Klein, & McLaughlin, 2008),  switching (Gau & Shang, 2010a; Gualtieri & 
Johnson, 2006; Rhodes, Coghill, & Matthews, 2005; Willcutt et al., 2005), sustained 
attention (Huang-Pollock, Nigg, & Halperin, 2006; Willcutt et al., 2005) and working 
memory (Martinussen, Hayden, Hogg-Johnson, & Tannock, 2005; Willcutt et al., 
2005).  
Furthermore, there is evidence for deficits in reward-related decision-making 
tasks such as temporal discounting and gambling tasks (Garon, Moore, & 
Waschbusch, 2006; Luman, Oosterlaan, & Sergeant, 2005; Luman, Tripp, & Scheres, 
2010; Toplak, Jain, & Tannock, 2005). ADHD is associated an enhanced preference 
for small immediate versus larger delayed rewards and to a decreased sensibility for 
reinforcement at a psychophysiological level (Luman et al., 2005; Luman et al., 
2010), as well as with less advantageous choices during gambling tasks (Garon et al., 
2006; Toplak et al., 2005). 
Different theoretical models have tried to account for the cognitive deficits and 
symptoms observed in youth and adults with ADHD. Most of them hypothesise an 
etiological pathway linked to the cognitive dysfunctions observed, which would be 
related to the symptoms observed in the patients, and to the abnormal structure and/or 
function of the neural circuits underlying defective cognitive functions. Thus, 
behavioural inhibition processes were considered the “core” deficit, with underlying 
dysfunctions in fronto-striatal regions (Barkley, 1997). Sergeant (Sergeant, 2000) 
proposed an arousal/activation dysregulation, in which arousal deficits would be due 
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to a hypofunctioning right lateralized noradrenergic neural system (which would 
involve the mesencephalic reticular formation and amygdala), and activation deficits 
that would arise from a hypofunctional dopaminergic network (including basal 
ganglia/striatum). Deficits in working memory (WM) arising from a dysfunctional 
dorsolateral prefrontal cortex (DLPFC) have also been identified as core deficits for 
ADHD (Castellanos & Tannock, 2002). Sagvolden et al (Sagvolden, Johansen, Aase, 
& Russell, 2005) proposed an underfunctioning nigrostriatal dopaminergic branch that 
would lead to disrupted reinforcement processes. Finally, Sonuga-Barke (Sonuga-
Barke, 2002) hypothesized a dual pathway model, with inhibitory deficits (mediated 
by the mesocortical branch of the dopaminergic system) and delay aversion (mediated 
by the mesolimbic dopaminergic branch associated with reward circuits) as the neural 
endophenotypes of ADHD. 
However, these approaches have only been able to partially account for the 
deficits observed in patients with ADHD (Nigg, 2005). The available evidence shows 
that in any given cognitive deficit studied, there is always a proportion of children 
with ADHD that is not affected, whose performance overlaps with that of healthy 
control children (Nigg, Willcutt, Doyle, & Sonuga-Barke, 2005; Sonuga-Barke, 
Bitsakou, & Thompson, 2010), which suggests that the cognitive aetiology of ADHD 
is more likely to be multifactorial. Recent attempts to explain this heterogeneity ha ve 
suggested multiple developmental pathways for ADHD (Hart, Radua, Mataix-Cols, & 
Rubia, 2012; Hart, Radua, Nakao, Mataix-Cols, & Rubia, 2012; Makris, Biederman, 
Monuteaux, & Seidman, 2009; Nigg & Casey, 2005; Sonuga-Barke et al., 2010), with 
structural and functional abnormalities in shared but dissociable functional networks 
underlying the observed deficits (Makris et al., 2009; Nigg & Casey, 2005).  
 Furthermore, there is consistent evidence for deficits in other non-EF 
functions. For example, ADHD patients show consistent deficits in temporal 
processing (Rubia, Halari, Christakou, & Taylor, 2009; Toplak, Dockstader, & 
Tannock, 2006). In addition there is evidence for slower reaction time across tasks 
(Alderson et al., 2007; Gualtieri & Johnson, 2006; Klein et al., 2006; Lijffijt et al., 
2005) and increased intra-subject variability (ISV) across a large range of cognitive 
tasks (Alderson et al., 2007; de Zeeuw et al., 2008; Epstein et al., 2003; Epstein, 
Langberg, et al., 2011; Klein et al., 2006; Lijffijt et al., 2005; Lipszyc & Schachar, 
2010; Oades & Christiansen, 2008; Rubia, Smith, Brammer, & Taylor, 2007a; Vaurio, 
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Simmonds, & Mostofsky, 2009). These differences in ISV have shown large effect 
sizes (Lijffijt et al., 2005), and high ability to discriminate between patients and 
controls (Rubia, Smith, et al., 2007a). Thus, ISV has been proposed as being 
potentially the most robust neuropsychological marker of ADHD (Castellanos, 
Sonuga-Barke, Milham, & Tannock, 2006). It has been suggested that increased ISV 
may be associated with difficulties in sustained attention, arousal or state regulation, 
thus involving noradrenergic transmission (Sergeant, Geurts, Huijbregts, Scheres, & 
Oosterlaan, 2003), to timing deficits with underlying cerebellar dysfunctions (Toplak, 
Rucklidge, Hetherington, John, & Tannock, 2003), and more recently to spontaneous 
low frequency activity in the Default Mode Network (DMN), which co mpetes with 
task-related activation, leading to attention lapses and increased ISV (Sonuga-Barke 
& Castellanos, 2007). 
Also, elongated mean reaction time (MRT) to stimuli has been reported 
consistently across different cognitive tasks (Alderson et al., 2007; Epstein, Langberg, 
et al., 2011; Gualtieri & Johnson, 2006; Kerns, McInerney, & Wilde, 2001; Klein et 
al., 2006; Lijffijt et al., 2005; Lipszyc & Schachar, 2010; Pasini, Paloscia, 
Alessandrelli, Porfirio, & Curatolo, 2007).  
In addition, children with ADHD have shown deficits in the context of reward 
(for reviews, see Luman et al., 2005; Luman et al., 2010). In line with the 
hypothesized disruption in reinforcement processes (Sagvolden et al., 2005), ADHD 
is associated with improved performance under reinforcement manipulations, with 
poorer performance under partial compared to continued rewards and with impaired 
reinforcement- learning and acquisition of behaviour (Luman et al., 2005; Luman et 
al., 2010). Reinforcement manipulations during time reproduction tasks have shown 
some effect on performance however, the deficits were improved but not remediated 
by motivational manipulations (Luman, Oosterlaan, & Sergeant, 2008; McInerney & 
Kerns, 2003; Van Meel, Oosterlaan, Heslenfeld, & Sergeant, 2005).  
Thus, the most consistent neuropsychological deficits observed in children 
with ADHD are in tasks of motor response inhibition, sustained attention, temporal 
processing and working memory (for reviews, see Cubillo et al., 2012; Rubia, 2011), 
which are therefore the domains which were chosen for the fMRI tasks of this PhD. 
The evidence for neuropsychological impairment in these tasks will be reviewed 




1.2.1. Deficits in inhibitory functions  
 
1.2.1.1 Motor response inhibition deficits 
Behavioural inhibition has traditionally been divided into three types of 
inhibitory processes: stopping of an ongoing response, inhibition of a prepotent 
response and interference control (Barkley, 1997). Inhibitory deficits, in particular 
during those tasks requiring inhibition of motor responses, are the most consistent and 
replicated findings in children with ADHD. 
Motor inhibition processes are typically measured using the Go/NoGo (GNG) 
task or the Stop Signal Task (SST). Both involve the inhibition of a motor response; 
however, they have significant differences. In the GNG task, Go and NoGo stimuli 
requiring different responses (Go- press button/ NoGo- do not press) are presented 
pseudorandomly to the subject. The typically high proportion of Go trials (at least 
70%) compared to the much lower proportion of NoGo trials elicits a highly prepotent 
response tendency (and inhibitory load), which increases with proportion of Go trials 
included in the task. Thus, this paradigm involves selective attention, response 
selection and response inhibition. On the other hand in the SST, the Stop signal is 
presented with a variable delay after the presentation of the Go signal, therefore the 
response has already been triggered and the subject has to inhibit a motor response 
that is on its way of execution. Thus, this paradigm has a higher load on motor 
response inhibition processes than the GNG task (Eagle, Bari, & Robbins, 2008; 
Rubia, Russell, et al., 2001).  
The “race” model of behavioural inhibition as described by Logan et al 
(Logan, Schachar, & Tannock, 1997) proposes the “go” and “stop” processes as 
independent of one another, and describes the “race” that occurs between the two of 
them for completion after the presentation of a Stop signal. If the Stop process can 
overtake the Go process, the subject will be able to inhibit the response (Logan et al., 
1997). The dependent variable is the probability of inhibition, which is sometimes 
also presented as commission errors. The Stop Signal Reaction Time (SSRT; time 
needed for inhibition to be successful after the presentation of a stop signal), is 
considered to be the main indicator of the efficiency of the inhibitory processes. In the 
traditional version of the Stop task, the Stop Signal Delay (SSD) is constant and the 
SSRT is calculated as the RT in the nth rank-ordered distribution of RTs minus the 
 26 
SSD (where the SSD is fixed and nth RT is defined by the product between the 
number of RTs in the distribution and the probability of responding to the Stop signal) 
(Oosterlaan & Sergeant, 1998). However, in more recent studies the SSD is 
individually adjusted depending on the performance of the subject so as to ensure 
50% of successful inhibitory trials (Logan et al., 1997; Rubia, Smith, et al., 2007a). In 
this version, the SSRT is usually calculated as the average of the RT to Go signals 
(MRT Go) minus the average of the Stop Signal Delay (SSD) (Logan et al., 1997). 
Neuropsychological studies have consistently shown that children with ADHD 
compared to healthy controls perform worse in both motor response inhibition tasks. 
Meta-analytic studies have shown that children with ADHD have longer SSRTs than 
healthy controls (Alderson et al., 2007; Lijffijt et al., 2005; Lipszyc & Schachar, 
2010; Nigg et al., 2005; Willcutt et al., 2005), also observed in later studies (de Zeeuw 
et al., 2008; Epstein, Langberg, et al., 2011; Lee et al., 2008; Martel, Nikolas, & Nigg, 
2007; Rommelse et al., 2008; Rubia, Smith, et al., 2007a).  
Commission errors during motor inhibition tasks (responses to NoGo/ Stop 
stimuli) are traditionally interpreted as reflecting impaired inhibitory control, whereas 
omission errors (no responses to go stimuli) may be interpreted as a sign of attention 
deficits (Rubia, Smith, et al., 2007a). Children with ADHD compared to healthy 
controls have shown consistently an increased number of commission errors during 
GNG tasks (Rubia, Smith, et al., 2007a; Rubia, Taylor, et al., 2001; Slaats-Willemse, 
Swaab-Barneveld, de Sonneville, van der Meulen, & Buitelaar, 2003 ; Wodka et al., 
2007) and SST (Bedard et al., 2003; Huang-Pollock, Mikami, Pfiffner, & McBurnett, 
2007; Oosterlaan et al., 1998; Overtoom et al., 2002; Rommelse et al., 2008; Rubia et 
al., 1998; Solanto et al., 2001; Stevens, Quittner, Zuckerman, & Moore, 2002). 
However, also increased omission errors, suggestive of attention deficits, have been 
reported during GNG tasks (Kerns et al., 2001; Klein et al., 2006; Rubia, Taylor, et 
al., 2001; Wodka et al., 2007) and SST (Klein et al., 2006). 
Furthermore, the deficits observed in ADHD during motor response inhibition 
have shown their independence of any working memory or reward manipulations of 
the task (Wodka et al., 2007), which according to the authors suggests a primary role 
for impaired inhibition in ADHD (Wodka et al., 2007).  
Nevertheless, there are also studies where no differences  on inhibitory indexes 
have been observed between children with ADHD and healthy control subjects (Kerns 
et al., 2001; Rhodes et al., 2005; Scheres, Oosterlaan, & Sergeant, 2001). However, 
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this may have been influenced by differences in the design of the paradigms. As an 
example, in the study from Rhodes et al (Rhodes et al., 2005), their GNG task had the 
same percentages of Go and NoGo signals (50%), thus having less inhibitory load 
than other versions which as mentioned above typically include at least 70% Go trials 
to elicit a strong prepotent response.  
 
1.2.1.2 Interference inhibition deficits 
 Children with ADHD have also shown impaired performance in other tasks 
that involve inhibitory processes with however, less consistent results. Interference 
inhibition is defined as the ability to ignore irrelevant information that interferes or 
competes with the processing of relevant information. To assess this, the most widely 
used tasks are the Stroop (Golden, 1978), Simon (Simon, 1990) or the Flanker 
(Eriksen & Schultz, 1979) tasks. While in the Flanker task, the participants have to 
ignore other stimuli that interfere with the relevant characteristic of the target 
stimulus, in the Stroop and Simon tasks, participants have to a) ignore a feature of the 
target stimulus that is providing irrelevant information, and b) focus on the relevant 
characteristic, necessary to perform the task.  
 Recent studies have also mostly failed to find differences during interference 
inhibition between children with ADHD and healthy controls using variations of the 
Stroop (Brocki, Randall, Bohlin, & Kerns, 2008; van Mourik et al., 2009; van Mourik, 
Sergeant, Heslenfeld, Konig, & Oosterlaan, 2010), Simon (Rubia, Smith, et al., 
2007a; van Mourik et al., 2009) or the Flanker tasks (Adolfsdottir, Sorensen, & 
Lundervold, 2008; Booth, Carlson, & Tucker, 2007; Yordanova et al., 2011), although 
some positive findings have also been reported, with more errors and increased MRT 
observed in children with ADHD compared to healthy peers  (Gualtieri & Johnson, 
2006; Johnson, Robertson, et al., 2008; for meta-analyses of results during Stroop 
tasks, see Lansbergen et al., 2007; for a meta-analysis of results during Simon and 
Flanker tasks, see Mullane et al., 2008; Mullane, Corkum, Klein, McLaughlin, & 
Lawrence, 2010; and van Mourik, Oosterlaan, & Sergeant, 2005), and one meta-







1.2.1.3. Cognitive inhibition deficits 
Different paradigms have been used to assess cognitive inhibition, cognitive 
flexibility or cognitive switching, such as the Wisconsin Card Sorting Test (WCST) 
(Grant & Berg, 1948) or the intra-dimensional/extra-dimensional set-shifting tasks 
(Kempton et al., 1999). These paradigms typically require from the participants to 
identify a classification criteria that changes unexpectedly, and therefore they must 
inhibit their current responses, change the criteria they are following to respond and 
adjust their responses according to this new classification criteria.  
 Findings from studies using these tasks are less consistent than those for motor 
inhibition tasks. Willcutt et al in their meta-analytic review observed impaired 
performance in ADHD patients compared to controls during the WCST (Willcutt et 
al., 2005). However, no differences (Goldberg et al., 2005; Happe, Booth, Charlton, & 
Hughes, 2006) or differences with small effect sizes during ID/ED tasks (Gau & 
Shang, 2010a; Rhodes et al., 2005) have also been reported. Other studies using 
simpler switch task versions that had a lower load on working memory functions have 
also shown inconsistent effects. Children with ADHD compared to healthy controls 
have shown fewer correct responses and more errors during a shifting attention test 
(Gualtieri & Johnson, 2006) and, in another study using a simple visual-spatial 
cognitive switching paradigm, a trend for higher Switch cost in children with ADHD 
compared to healthy participants was reported (Rubia, Smith, et al., 2007a). When 
interpreting these findings it is necessary to consider that these paradigms however 
typically co-measure other cognitive processes, most prominently, attention functions 
but also working memory (in particular during the WCST) whose effect on the 
performance of the subject may be difficult to disentangle.  
 It can therefore be concluded from the evidence that children with ADHD 
show deficits during inhibitory processes. The evidence is very consistent with 
regards to the deficits in motor response inhibition tasks, particularly when measured 
using the SSRT and commission errors during the GNG. However, it cannot be 
overlooked that also omission errors, suggestive of attention difficulties, have been 
reported. 
 The evidence is not that conclusive with regards to interference inhibition or 
cognitive switching. Mixed results have been reported during interference inhibition 
tasks, as shown by different meta-analytic studies. Similarly, mixed results have been 
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reported during cognitive flexibility tasks: during complex tasks loading also on 
working memory processes, small effects have been reported however, deficits have 
been reported during simpler switching tasks.  
 It is important to note here that although paradigms are typically designed to 
isolate the cognitive process studied, other cognitive processes unavoidably co-occur. 
Thus, sustained attention is necessary to perform all the inhibitory tasks mentioned in 
this chapter. Depending on the task, other processes may be heavily involved, like 
selective attention or attention allocation, which are very prominently engaged in 
particular during interference inhibition tasks and to some extent also during cognitive 
inhibition tasks. Hence, the design of the paradigm is crucial to be able to detect 
potential deficits, as well as to correctly identify the cognitive process impaired in that 
population.  
 Differences in the paradigms used may underlie part of the discrepancies 
reported however, the evidence suggests that the use of motor response inhibition 
tasks may be particularly sensitive to the inhibitory deficits presented by children with 
the disorder.  
 
1.2.2. Sustained attention deficits 
 Sustained attention can be defined as the ability to voluntary maintain the 
focus of attention to critical but infrequent events (Parasuraman, Warm, & See, 1998; 
Warm, 1984), but it has also been defined as a decrement of vigilance/sustained 
attention over time, which has been influential in the ADHD literature (Sergeant, 
1996).  
 The Continuous Performance Test (CPT) is typically used to measure 
sustained attention (Conners, 1993). In its simplest version, subjects are presented a 
stream of letters, and they have to respond only to one of them (e.g. X). Variations of 
the task have also been used, and thus in the CPT A-X version subjects have to 
respond to every “X” only when it has been preceded by the letter “A”. During these 
tasks, commission errors are typically interpreted as an index of impulsive difficulties, 
and omission errors as a sign of attention problems (Epstein et al., 2003; Halperin et 
al., 1988).  
A classic meta-analytic review by Losier et al (Losier, McGrath, & Klein, 
1996) showed that children with ADHD made more commission and omission errors 
than comparison subjects (Losier et al., 1996). This was also observed in a more 
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recent meta-analytic review where the majority of the reviewed studies that included 
sustained attention paradigms observed between-group  performance differences, with 
children with ADHD making more omission and commission errors than healthy 
subjects (Willcutt et al., 2005). More recent studies have also confirmed these deficits. 
Using the CPT, children and adolescents with ADHD compared to healthy controls 
have shown an increased number of commission and omission errors (Epstein et al., 
2003; Gualtieri & Johnson, 2006; Huang-Pollock et al., 2006; Kerns et al., 2001; 
Klein et al., 2006; Rubia, Smith, et al., 2007a).  
A deterioration of performance over time has also been reported. Thus, 
Huang-Pollock et al reported a worsened performance in the task over time, with a 
significantly increased number of errors and slowed RT with increased time on task 
(Huang-Pollock et al., 2006). In the Sustained Attention to Response Task (SART) 
(Robertson, Manly, Andrade, Baddeley, & Yiend, 1997) subjects are shown numbers 
(1-9) presented to them in a predictable and repeated sequence, and they are required 
to respond to every number but one (e.g. “3”). During this task, children with ADHD 
have shown more omission (Johnson et al., 2007; Yang et al., 2007) and commission 
errors (Johnson et al., 2007) compared to healthy peers, as well as an increased fast 
trail- to-trial RT variability and a significant slowing of their RT over the task 
(Johnson et al., 2007). They showed no change in the number of omission or 
commission errors over time, but deficits where observed from the start, which 
according to the authors is suggestive of deficits in sustained attention over short 
periods of time, reflective of fronto-parietal dysfunction, whereas the progressive 
slowing in RT may be due to a decrease in arousal levels potentially involving 
noradrenergic system (Johnson et al., 2007). 
Thus, children with ADHD have consistently shown deficits during sustained 
attention tasks, both with regards to the number of omission errors and deterioration 
of performance with time, but also on the impulsivity measures of the task, with an 
increased number of commission errors being consistently reported.  
 
1.2.3. Working memory deficits 
Working memory (WM) refers to a limited capacity system that allows for the 
temporary storage and manipulation of information, necessary to guide behaviour 
(Baddeley, 1996). Thus, it allows for the behavioural independence from 
environmental cues, given the internal representation of information guides the 
 31 
behaviour of the subject for future actions (Baddeley, 1996). Baddeley’s model of 
WM describes two slave systems, the phonological loop and visuo-spatial sketchpad, 
controlled by a modality- free central executive. Deficits in WM have been 
hypothesised as a core deficit in ADHD (Castellanos & Tannock, 2002). However, the 
variety and complexity of the tasks used make difficult the interpretation of the 
findings.  
 Verbal-auditory WM is typically measured by tasks such as the 
Forward/Backward Digits Span task, the California Verbal Learning Test (CVLT), or 
the N-Back task. In the Digit Span task, series of digits are sequentially presented to 
the participant, digits that have to be recalled in the correct order 
(forward/backwards). In the CVLT, participants are presented paired words, which 
they have to learn and recall immediately and after a 20 minutes delay interval. In the 
N-Back task, series of letters are presented to the subject one by one.  In the 
conditions “1-back”, “2-back” and “3-back”, the subject has to press  the button 
whenever the letter presented on the screen is the same as the letter one, two or three 
before it, respectively. To measure visuo-spatial WM, the Corsi Blocks (Milner, 1971) 
or variations of this tasks are traditionally used. In this task, nine blocks are 
irregularly distributed over a black/wooden board and the subject has to tap out 
exactly the same sequence pattern as previously shown by the examiner.  
Children with ADHD compared with controls have shown deficits in 
performance during tasks measuring verbal-auditory and visuo-spatial WM in 
different meta-analytical studies (Martinussen et al., 2005; Willcutt et al., 2005). As 
described by Martinussen et al. (Martinussen et al., 2005), the larger effect sizes 
observed in visuo-spatial WM tasks when compared to verbal-auditory WM tasks 
may be due to visuo-spatial tasks being more challenging than verbal-auditory tasks 
or involving less automated or familiar material, or maybe due to the influence of 
potential comorbidities such as developmental coordination disorder. Furthermore, 
they show the moderator role of the presence of reading difficulties or learning 
impairment not only in the results of those tasks tapping on verbal-auditory WM but 
also on visuo-spatial WM tasks (Martinussen et al., 2005). More recent studies have 
also observed deficits in visuo-spatial WM in children with ADHD compared to 
healthy controls (Gau & Shang, 2010a; Rhodes et al., 2005; Rhodes, Park, Seth, & 
Coghill, 2011; Rommelse et al., 2008; Toplak, Jain, & Rosemary, 2008; Yang et al., 
2007) even in preschoolers (Re, De Franchis, & Cornoldi, 2010). 
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Impairments in verbal-auditory WM have also been described in later studies. 
During the CVLT, children with ADHD compared to control peers have shown 
impaired performance in the number of words recalled after temporal delay (Crocker, 
Vaurio, Riley, & Mattson, 2011), and reduced accuracy was reported during the Digit 
span test (Rommelse et al., 2008; Toplak et al., 2008). 
Using the N-Back task, children with ADHD have shown an enhanced number 
of omission errors (Klein et al., 2006). In a modified version of the N-Back task, 
children with ADHD showed worse performance than healthy controls in both a 
visual-object version and a phonological version (Pasini et al., 2007). 
 Thus, the available evidence supports the presence of deficits in verbal-
auditory and visuo-spatial WM in children with ADHD, despite the variety of tasks 
used. 
 
1.2.4. Temporal processing deficits  
Impulsivity is conceptualised as a behavioural style which is premature and 
inadequate, where responses are made too early, inaccurately and without 
consideration of the consequences (Rubia et al., 2000; Smith, Taylor, Rogers, 
Newman, & Rubia, 2002). Deficits in temporal processes have been hypothesized as 
one of the key neuropsychological underpinnings for the impulsiveness typically 
observed in children with ADHD (Rubia, Halari, Christakou, et al., 2009).  
Different tasks are used to assess the presence of temporal processing deficits: 
a) motor timing tasks (sensorimotor synchronization/ anticipation in the milliseconds 
or seconds range); b) time perception tasks (time discrimination of short intervals in 
the seconds/milliseconds range; verbal time estimation, temporal production, time 
reproduction) and c) temporal foresight or temporal discounting tasks (gambling or 
temporal discounting) (Rubia, Halari, Christakou, et al., 2009). Temporal anticipation 
tasks require from the subject the prediction of the onset of an upcoming stimulus. 
During sensorimotor synchronization tasks, participants have to adjust their motor 
response to externally timed sensory stimuli in finger tapping tasks. During time 
estimation tasks, participants may have to give a verbal estimate of the duration of a 
specific stimulus, whereas during time production/reproduction tasks they have to 
(re)produce specified time periods precisely. Time or duration discrimination tasks 
require from the participants the discrimination of temporal intervals which differ in 
their duration in the order of milliseconds to seconds.  
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As described in the review by Toplak et al (Toplak et al., 2006), the methods 
vary significantly between studies, and therefore no meta-analysis has as yet been 
conducted. Nevertheless, the evidence supports the presence of deficits during 
duration discrimination tasks, duration reproduction and finger tapping tasks, and less 
consistently have been reported differences on verbal temporal estimation and 
anticipation tasks (Rubia, Halari, Christakou, et al., 2009; Toplak et al., 2006).  
During sensorimotor synchronization tasks, children with ADHD showed 
impaired performance (Ben-Pazi, Gross-Tsur, Bergman, & Shalev, 2003; Gualtieri & 
Johnson, 2006; Landau, Auerbach, Gross-Tsur, & Shalev, 2003; Pitcher, Piek, & 
Barrett, 2002) and increased intra-individual variability relative to healthy subjects 
(Rubia, Noorloos, Smith, Gunning, & Sergeant, 2003; Rubia, Taylor, Taylor, & 
Sergeant, 1999; Toplak & Tannock, 2005a). These findings suggest the presence of 
difficulties to adjust the timing of their motor responses. However, some studies have 
also shown negative results (Aase & Sagvolden, 2006; Tiffin-Richards, Hasselhorn, 
Richards, Banaschewski, & Rothenberger, 2004; see Toplak et al., 2006 for a review). 
Children with ADHD did not differ from controls in a time production task 
where they had to give a verbal estimate of 10 secs duration (Smith et al., 2002), 
although it has recently been reported that children with ADHD compared to healthy 
controls underestimated time intervals of 6, 12 and 24 secs but not shorter intervals of 
1 and 3 secs (Huang et al., 2012). Under-reproduction of time intervals, which 
suggests that time is subjectively elongated to these children, has been observed 
during tasks of time reproduction, where youths with ADHD compared to healthy 
peers were reported to display significant deficits, which were more marked as 
difficulty increased (longer duration of stimuli) (Gonzalez-Garrido et al., 2008; Huang 
et al., 2012; Hwang, Gau, Hsu, & Wu, 2010; Luman et al., 2008; Plummer & 
Humphrey, 2009; Rommelse, Oosterlaan, Buitelaar, Faraone, & Sergeant, 2007; 
Smith et al., 2002; Valko et al., 2010). These deficits were observed both when 
stimuli are auditory and visually presented (Rommelse et al., 2007), although there is 
some evidence for more severe impairments when visually presented (Plummer & 
Humphrey, 2009). However, negative results have also been reported (Toplak et al., 
2003). 
Small and longer time durations are processed differently, possibly due to the 
greater load on working memory, sustained attention to time and inhibition of the 
interference as temporal intervals increase (Smith et al., 2002). These factors may 
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influence performance during time production and reproduction tasks, but would not 
affect performance in a duration discrimination task, where seconds- long intervals 
that differ by several hundreds of milliseconds need to be discriminated (Smith et al., 
2002). Thus, to avoid these potential confounds, several studies have investigated the 
presence of deficits in children with ADHD during temporal discrimination tasks. 
Children with ADHD compared to healthy controls have shown difficulties to 
discriminate between durations that differed between 250-450 ms, needing larger 
interval duration to discriminate durations accurately (Rubia, Smith, et al., 2007a; 
Smith et al., 2002; Valko et al., 2010). Similarly, children with ADHD compared to 
healthy controls required higher thresholds to discriminate durations at short (300ms), 
median (800 ms) and long (1200ms) durations, which was specially marked in the 
long intervals (Huang et al., 2012; Yang et al., 2007). Toplak and Tannock reported 
duration discrimination deficits which were especially prominent when stimuli were 
visual, observed at short (200ms) and long (1000 ms) intervals (Toplak & Tannock, 
2005b). Finally, Himpel et al (Himpel et al., 2009) have shown that children with 
ADHD performed significantly worse than healthy controls in a time discrimination 
(TD) task in very short (50ms) and longer (1000ms) stimuli durations.  
The interdependence between different cognitive functions, although 
mentioned in a previous section of this chapter, needs to be mentioned again here. 
Temporal discounting tasks require participants to choose between variable smaller 
immediate or larger delayed rewards and thus assess the subjective value of reward as 
a function of its delayed administration (Richards, Zhang, Mitchell, & deWit, 1999). 
Thus, the task requires reward-related decision making processes, but also temporal 
processes (i.e. temporal foresight to consider the future reward) and sustained 
attention, and the influence of each of these cognitive processes in the performance of 
the subject during the task is difficult to disentangle.  
Children with ADHD have shown an enhanced preference for small 
immediate versus larger delayed rewards and less advantageous performance than that 
of healthy comparison subjects during different versions of temporal discounting tasks 
(Antrop et al., 2006; Bitsakou, Psychogiou, Thompson, & Sonuga-Barke, 2009; 
Marco et al., 2009; Scheres, Lee, & Sumiya, 2008; Scheres, Tontsch, Thoeny, & 
Kaczkurkin, 2010; Solanto et al., 2001; Toplak et al., 2008; Wilson, Mitchell, Musser, 
Schmitt, & Nigg, 2011)(for reviews see (Luman et al., 2005; Luman et al., 2010)), 
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although some studies have found no between group differences (Scheres et al., 
2006).  
Delay–aversion has been considered as the observable consequence of time 
perception deficits (Rubia et al., 2009), result of a “fast internal clock” during waiting 
periods (Sonuga-Barke, Saxton, & Hall, 1998) or increased susceptibility to the 
passage of time due to an elongated subjective time sense (Rubia, Halari, Christakou, 
et al., 2009). In a study by Antrop et al (Antrop et al., 2006), performance differences 
disappeared when visual stimulation between stimuli and response was introduced, 
thus making the delays more tolerable for children with ADHD (Antrop et al., 2006). 
However, whether the main deficit observed during these tasks in children with 
ADHD is the abnormal sensitivity to reward itself, the hypersensitivity to the passage 
of time (temporal processing deficits), or both still needs to be elucidated (Rubia, 
Halari, Christakou, et al., 2009). Furthermore, timing deficits have been recently 
considered as a potential separate pathway to ADHD (Sonuga-Barke et al., 2010), 
with the strongest familial effects observed in the inhibition and timing factors rather 
than in delay-aversion factor (Sonuga-Barke et al., 2010).  
Thus, evidence is suggestive of deficits in temporal processes. The most 
consistent deficits have been observed a) during time discrimination tasks, when 
stimuli have a duration of approximately 1 second and differ between them by 
hundreds of milliseconds and b) during time reproduction and estimation tasks, in 
particular during longer time intervals. The observed impairment during time 
discrimination tasks supports the presence of pure time perception deficits, given their 
minimum motor component and relatively low working memory load.  
 
1.3. Summary and conclusions  
Findings from neuropsychological studies in ADHD show consistent 
evidence for the presence of impaired motor response inhibition, temporal processing, 
working memory and sustained attention. With respect to deficits in interference 
inhibition or cognitive flexibility the results are less consistent. Furthermore, ADHD 
patients have also shown deficits in temporal discounting and other reward-related 
tasks. Whether this is due to abnormal sensitivity to reinforcers or to abnormal 
sensitivity to the temporal delay period typically involved in these paradigms still 
needs further research.  
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However, children with ADHD show a significant heterogeneity in the 
observed deficits in EF (Nigg et al., 2005; Sonuga-Barke et al., 2010), with some 
children not being impaired, and further research is necessary investigating subtypes 
of ADHD. Many of the studies reviewed include subjects with different subtypes of 
ADHD, collapsing these in the analyses (Gau & Shang, 2010a; Huang et al., 2012; 
Johnson et al., 2007; Klein et al., 2006; Luman et al., 2008; Rubia, Smith, et al., 
2007a; Toplak et al., 2003; Toplak et al., 2008; Wodka et al., 2007; Yang et al., 2007). 
Most frequently, studies include only the combined and predominantly inattentive 
subtypes and exclude the hyperactive subtype whose validity has been questioned, as 
it is less frequent in adolescence (Froehlich et al., 2007; Merikangas et al., 2010) and 
has been considered as a potential precursor of the combined subtype (Barkley, 1997; 
Lahey, Pelham, Loney, Lee, & Willcutt, 2005). There is a high degree of overlap 
between the inattentive and combined subtypes (Lee et al., 2008), as both share 
above-threshold symptoms in one dimension (inattention domain) and differ in the 
level of symptoms in a second dimension (hyperactive/impulsive). In this second 
dimension, the combined subtype presents with more than 6 symptoms, and the 
inattentive subtype falls below the 6 symptoms’ cut-off (American Psychiatric 
Association, 2000). Therefore, children with the combined subtype would 
theoretically be more impaired as they display a higher total number of symptoms. 
However, the different studies typically do not provide a detailed description of the 
characteristics of the children included in the inattentive subgroup such as their 
number of symptoms/ hyperactivity levels. The predominantly inattentive group could 
include children who fell short of hyperactive/impulsive behaviours as to receive the 
diagnosis of combined subtype, as well as those who are more purely inattentive and 
show an inattentive sluggish tempo (Stefanatos & Baron, 2007). Thus, the inclusion 
of both subtypes in the studies may lead to heterogeneous results. Furthermore, some 
authors have suggested that motor inhibition deficits may be more associated with the 
combined subtype (Nigg, Blaskey, Huang-Pollock, & Rappley, 2002). However, 
several studies showed that are symptoms of inattention ra ther than those of 
hyperactivity are associated with impaired inhibitory measures (Chhabildas, 
Pennington, & Willcutt, 2001; Huang-Pollock et al., 2007; Willcutt et al., 2005), or 
with deficits in EF (Martel et al., 2007). Therefore, the debate about whether or not 
the combined and predominantly inattentive subtypes are etiologically similar or 
distinct entities (Barkley, 2001; Hinshaw, 2001; Milich, Balentine, & Lynam, 2001; 
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Swanson et al., 2007) is not as yet resolved. Given the significant symptomatic 
overlap between subtypes (Lee et al., 2008), which is unlikely to be solved by the new 
version of the classification system DSM-V, a better definition of the subgroups 
recruited that increase the homogeneity of the sample is required in future studies. In 
order to increase the homogeneity of the sample, in this study we only included 
children with a diagnosis of ADHD combined subtype.  
Another issue is the lack of specificity of the deficits (Lipszyc & Schachar, 
2010; Sergeant, Geurts, & Oosterlaan, 2002), as none of the deficits observed in 
ADHD populations is specific or unique to this disorder. Furthermore, the inclusion of 
subjects with comorbid disorders (Gau & Shang, 2010a; Goldberg et al., 2005; Huang 
et al., 2012; Johnson et al., 2007; Klein et al., 2006; Luman et al., 2008; Martel et al., 
2007; Pasini et al., 2007; Rhodes et al., 2005; Rubia, Smith, et al., 2007a; Smith et al., 
2002; Toplak et al., 2003; Toplak et al., 2008; Wodka et al., 2007; Yang et al., 2007) 
may confound the findings of cognitive deficits in children with ADHD, even when 
comorbidity is restricted to comorbid conduct disorder (CD) or oppositional defiant 
disorder (ODD), as it has been shown to have an additive effect on the cognitive 
deficits observed in ADHD (Rhodes et al., 2011). Studies where the contribution of 
comorbid conditions to the observed deficits can be ruled out are therefore required. 
In this PhD we tried to include mostly non-comorbid patients. However, two patients 
presented with a confirmed diagnosis of comorbid CD/ODD.  
Another aspect that increases the heterogeneity of the samples and therefore 
complicates the integration of the findings is the inclusion of girls and boys in the 
samples, collapsing their results (de Zeeuw et al., 2008; Epstein, Langberg, et al., 
2011; Gau & Shang, 2010a; Goldberg et al., 2005; Huang et al., 2012; Klein et al., 
2006; Luman et al., 2008; Martel et al., 2007; Smith et al., 2002; Solanto et al., 2001; 
Toplak et al., 2003; Toplak et al., 2008; van Mourik et al., 2009; Yang et al., 2007). 
Some authors have shown differential cognitive deficits suggesting different cognitive 
profiles depending on gender (Balint et al., 2009; Nigg et al., 2002), which is in line 
with observed gender-related differences in brain function, presentation of the 
disorder and brain maturation (De Bellis et al., 2001; Gershon, 2002; Mahone & 
Wodka, 2008; Rubia, Hyde, Halari, Giampietro, & Smith, 2010; Valera et al., 2010). 
Therefore, the inclusion of males and females may mask or attenuate differences that, 
should the samples have been gender-homogeneous, would have been present. To 
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avoid heterogeneity due to gender, in this PhD we therefore included only male 
patients and controls. 
It is also necessary to take into account the effect of the inclusion of children 
with ADHD who had a previous history of stimulant medication. Few studies have 
included medication naïve samples (Epstein, Langberg, et al., 2011; Pasini et al., 
2007; Rhodes et al., 2005; Rhodes et al., 2011; van Mourik et al., 2009; Yang et al., 
2007). Given its observed long-term effects on brain structure and function (Konrad, 
Neufang, Hanisch, Fink, & Herpertz-Dahlmann, 2007; Nakao, Radua, Rubia, & 
Mataix-Cols, 2011; Shaw, Sharp, et al., 2009), this may have had an impact on the 
findings, which need to be interpreted with caution. Therefore, in this PhD only 
medication naïve patients were included in order to avoid any confounds related to 
long-term effects of stimulant medication 
Finally, it is necessary to highlight the key role of the correct design of the 
paradigm on the study of the cognitive deficits associated with any disorder. Ideally, 
paradigms should facilitate the measure of isolated cognitive functions without the 
potential confound of other functions interfering in the performance of the task. 
However, as it has been reviewed, different variations and modifications of the 
paradigms have been used, which complicate the interpretation and replication of the 
findings. 
Therefore, it can be concluded that despite the limitations, the reviewed 
evidence supports the presence of cognitive deficits in children with ADHD in motor 
inhibition, temporal processing and working memory processes. However, not all the 
children with the disorder show cognitive deficits, but different subgroups of children 
with ADHD show differential neuropsychological profiles (Nigg et al., 2005; Sonuga-
Barke et al., 2010). The role of these differential cognitive profiles in the symptomatic 
manifestation of the disorder still needs to be elucidated. Studies with more well-
defined, homogeneous, non-comorbid, medication-naïve samples are required.  
 39 
CHAPTER 2. STRUCTURAL AND FUNCTIONAL BRAIN IMAGING IN 
ADHD  
 
 The previous chapter has reviewed the evidence from neuropsychological 
studies in ADHD, which have shown that children with ADHD have deficits in a 
range of cognitive functions including motor response inhibition, working memory 
and temporal processing, as well as deficits in sustained attention and delay of 
gratification. Early descriptions of the disorder already included references to the lack 
of control and impulsivity problems presented by these children, symptoms of 
hyperactivity, impulsivity as well as those of inattention whose biological aetiology 
was also very early hypothesised to be associated with abnormal brain structure 
and/or function (for reviews, see Lange, Reichl, Lange, Tucha, & Tucha, 2010; 
Taylor, 2011). Thus, the biological aetiology of the disorder is either explicitly or 
indirectly implied in Still’s descriptions of “defect of moral control”, the concept of 
“Minimal Brain Damage or “Minimal Brain Dysfunction”, as well as in the 
description of Kramer and Pollnow of “hyperkinesis of childhood” (Lange et al., 
2010; Taylor, 2011), all of them very close to the symptomatic description of ADHD 
as we know it today. Furthermore, lesion studies as well as the encephalitic lethargica 
epidemic that affected the world in the 1920’s helped to confirm the connection 
between abnormalities in brain structure or dysfunction and behavioural symptoms of 
hyperactivity, impulsivity and deficits in attention, as these patients showed 
symptoms and cognitive deficits similar to those displayed by children with ADHD 
(Lange et al., 2010; Mattes, 1980; Taylor, 2011).  
 The development of modern brain imaging techniques has allowed 
neurosciences to provide accurate evidence on the association between brain 
abnormalities and cognition or symptoms, evidence that has grown exponentially 
since the development of the first Computerised Tomography (CT) scan by the British 
electric engineer Sir Godfrey Hounsfield in the mid-70s (Ambrose & Hounsfield, 
1973; Hounsfield, 1973). This meant a significant step forward on the study of the 
abnormalities of the human brain, which moved from lesion and post-mortem studies, 
or the use of X-rays and angiography methods, to the modern methods of brain 
imagining developed mostly in the last 40 years: CT scanning and structural Magnetic 
Resonance Imaging (see (Hoeffner, Mukherji, Srinivasan, & Quint, 2012) for a 
review). The development of modern structural and functional imaging techniques has 
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changed completely the way clinicians and researchers have been able to determine 
the association between basic and higher cognitive functions and neural tissue, with a 
particularly remarkable impact on those sciences whose main focus is the brain and its 
structural and functional abnormalities, such as, Neurology and Psychiatry.  
 The next section will provide a brief review of the basic concepts underlying 
the most commonly used structural and functional brain imaging methods. This will 
be followed by the review of the evidence provided by these techniques on structural 
and functional brain abnormalities in ADHD. 
 
2.1 Structural and functional brain imaging methods  
 
2.1.1. Methods used for the study of brain structure  
CT-scans and Magnetic Resonance Imaging (MRI) scanning allow obtaining 
three dimensional (3-D) structural brain images of a given subject. CT-scanning is 
based in the use of X-rays and the different densities of the tissues in the brain 
(Ambrose & Hounsfield, 1973; Hounsfield, 1973), information which is captured and 
used by the CT-scan to create a 3-D image of the brain studied.  
MRI (Damadian, 1971; Mansfield et al., 1980) is based on the magnetic 
properties of the different components of the brain. Protons in different tissues have 
different magnetic properties. The MRI scan has a determined strong static magnetic 
field (e.g. 3 Tesla), which aligns all the magnetically sensitive particles in that 
direction (for reviews, see Banich, 2004; Higgins, Platts, & Pickman, 1996). Thus, 
when the subject is placed inside the scan, the protons present in the differe nt tissues 
of the brain will align in that direction. The subject then receives short radio-
frequency pulses that affect the magnetic alignment of the protons in a determined 
tissue to align with the new magnetic force. The time it takes these protons to re-align 
again to the magnetic field of the scan are the “relaxation times” (T1 and T2), which 
provides the scan with the information to reconstruct a 3-D image of the studied brain 
(Higgins et al., 1996). The main advantages of MRI compared to CT scans are the 
better spatial resolution and the fact that it does not involve X-rays. However, because 
the scanner contains a very big and strong magnet, it cannot be used in some cases 
(i.e. metal in their bodies). Furthermore, because of the small space inside the scan, it 
can be claustrophobic. 
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Diffusion Tensor Imaging (DTI) techniques (Basser, Mattiello, & LeBihan, 
1994), based on water diffusion characteristics, allow for the measurement of 
anatomical connectivity between brain regions. DTI fiber tracking provides several 
indexes of water diffusion in white matter tracts (Assaf & Pasternak, 2008), thus 
providing information not only about macrostructural characteristics of white matter 
tracts (which tracts connect which brain areas) (Assaf & Pasternak, 2008; Wakana, 
Jiang, Nagae-Poetscher, van Zijl, & Mori, 2004), but also (indirectly) about the 
microstructural characteristics of these tracts (their integrity of the white matter tracts) 
(Beaulieu, 2002).  
However, these techniques (CT scans, MRI, DTI) cannot provide us with 
information about brain function, but only about potential brain structure 
abnormalities.  
 
2.1.2. Functional Magnetic Resonance Imaging 
The development of functional magnetic resonance imaging (fMRI) 
techniques in the early 90s (Kwong et al., 1992; Ogawa, Lee, Kay, & Tank, 1990) 
allowed for the study of brain function. It takes advantage of the MRI technique 
described above, and the different magnetic properties of oxygen-rich and 
deoxygenated blood. Oxygen-rich blood is diamagnetic, whereas deoxygenated blood 
is paramagnetic and influences the magnetic field of the neighbouring protons (Ogawa 
et al., 1990). When neurons are active, they consume oxygen, and as a result of their 
increased need for oxygen, there is a local increase on rich-oxygenated blood supply 
which exceeds the needs of that brain region (Fox & Raichle, 1986), therefore 
increasing the ratio oxygenated/deoxygenated blood (Bandettini, Wong, Hinks, 
Tikofsky, & Hyde, 1992; Fox & Raichle, 1986). Making use of the different magnetic 
properties, fMRI scans measure this increase in the ratio oxygenated/deoxygenated 
blood while a brain area is active compared to when it is not, which is taken as a 
baseline (Bandettini et al., 1992; Ogawa et al., 1990). This is the so called Blood 
Oxygen Level Dependent (BOLD) signal (Ogawa et al., 1990). The accurate 
interpretation of changes in BOLD signal depends on the understanding of the way 
neural activity produces changes in haemodynamic response, known as neurovascular 
coupling (Arthurs & Boniface, 2002). Changes in BOLD signal are thought to reflect 
neural activity associated with the input and local processing rather than output 
activity (Lauritzen & Gold, 2003; Logothetis, 2002; Logothetis & Wandell, 2004).  
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Figure 2.1. Changes in oxygenated/deoxygenated ratio, origin of the BOLD signal in 
fMRI. The proportions of oxygenated (tandem blue+red circles)/ deoxygenated (single red 
circles) blood in the blood flow is increased as a consequence of increased neuronal activity. 
Image from http://psychcentral.com 
 
This has an important implication, as we are measuring an increase, a 
difference between two situations. Thus, to identify brain areas associated with 
increased neuronal activity during a given cognitive process as measured by a 
cognitive task, typically a control task is being subtracted from the task of interest, 
that controls for all functions that are not the interest of the study. For example, in an 
inhibition task, the control task would contain the same visual stimulation and motor 
response as the active task, but not the inhibitory process itself, which would be 
subtracted out, by the contrast of the active versus the control task (Gusnard & 
Raichle, 2001; Logothetis, 2008). The key concept therefore is “subtraction”: fMRI 
data analyses subtract that activation related to the baseline condition from the signal 
observed during the condition of interest. By doing this, fMRI does not provide with 
an absolute measure of brain activity but only with the relative regional increase of 
oxygenated blood supply, an indirect measure of brain activation. Therefore, the 
design of the task is of utmost relevance when using subtraction methods. The better 
matched the tasks for all conditions of no interest, the better the function of interest 
can be isolated. However, the subtraction method is not perfect. It is important to note 
that the different cognitive processes do not follow strictly an additive model but 
interact with each other, and therefore even the best baseline task will not allow for 
the absolute isolation of the cognitive process of interest.  
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Using fMRI, we are not obtaining a direct measure of brain activation, but 
only a relative measure of changes in hemodynamic response compared to a previous 
baseline, which is one of the main drawbacks of the technique. This hemodynamic 
response is furthermore not immediate but takes between 4-6 seconds to peak (Huettel 
& McCarthy, 2000), which also needs to be taken into account when interpreting 
BOLD images, as neural events happen in the milliseconds range, while the 
hemodynamic response occurs with a delay of several seconds.  
 
2.1.3. Other methods used for the study of brain function 
Electroencephalography (EEG) and Event-Related Potentials (ERPs) allow for 
the study of the electrical fields resulting from neural firing in the participants, with a 
temporal resolution within the milliseconds range (Gruzelier, Burgess, & Baldeweg, 
1996; Luck, 2005). EEG allows for the measurement of the electrical activity 
resulting from neural firing by using electrodes placed on the scalp of the subject 
(Coles & Rugg, 1995). The voltage and the frequency of the recorded electric activity 
provide a continued measure of brain activity (Gruzelier et al., 1996). ERPs record 
brain activity elicited by an event, and by analysing the changes in the components of 
the waveform recorded on the scalp it can provide information about different 
cognitive processes, their temporal course and their potential disturbances in the 
milliseconds range (Banich, 2004; Coles & Rugg, 1995). Both EEG and ERPs are 
relatively inexpensive compared to other techniques and have an excellent temporal 
resolution. However their main drawback is the comparatively reduced spatial 
resolution, as it is difficult to locate the exact origin of the recorded activity, 
especially when it comes to deep brain structures (Gruzelier et al., 1996; Luck, 2005).  
Magnetoencephalography (MEG) (for a review, see Andrews, 1996) allows 
for the detection and recording of the magnetic fields associated with the electric 
activity of the neurons (Banich, 2004; Otsubo & Snead, 2001).  
Positron Emission Tomography (PET) is very versatile and can measure brain 
activity in the form of blood flow, glucose utilisation or the distribution of 
neurotransmitter receptors and transmitters (Sokoloff, 1977). Radioactive agents, 
denominated radioligands or radiotracers, are administered to the subject typically 
intravenously as a bolus and, once inside the blood flow, they reach the brain and are 
taken by the neurons as the non- ionized form of the molecules (Banich, 2004; 
Raichle, 1983; Zimmer, 2009). These molecules are unstable and to reach a more 
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stable form they typically release a positron, a positively charged molecule, which 
travels a very short distance in the brain until it colludes with an electron, which is 
charged negatively, in a process called annihilation (for more exhaustive reviews see 
Esser, 2010; or Raichle, 1983). This process releases energy in the form of two 
gamma rays, two photons of light, which travel in exactly opposite directions. These 
are detected by coincidence detectors, situated in a ring shape around the subjects’s 
head, which reconstruct the data to locate the origin of the photons (Esser, 2010). 
Thus, PET allows for the acquisition of images that show the proportional 
concentration of the radiotracer in the brain (Esser, 2010). Depending on the 
radiotracer used, it allows for measures of regional Cerebral Blood Flow (rCBF) or 
Volume (rCFV), oxygen or glucose utilization, as well as the distribution and 
availability of different receptors or transporters (Carter & Shieh, 2010; Ichise, 2010; 
Raichle, 1983). However, it has the associated disadvantage of the use of short- lived 
radiotracers, which require a room-sized machine called cyclotron in order to 
synthesise these compounds (Carter & Shieh, 2010). A similar technique is the Single 
Photon Emission Computed Tomography (SPECT) (Bonne, Krausz, & Lerer, 1992; 
Lewis, 1996). SPECT uses a different type of radiotracers, isotopes which decay with 
the emission of single photons, and a smaller set of detectors, programmed to detect 
those single photons, with the associated reduced spatial resolution (Lewis, 1996). 
Both techniques shared the use of ionizing radiation (Esser, 2010), which limits their 
frequency of use in a single subject to 4-5 per year. Furthermore, for ethical reasons, 
these cannot be used in children.   
Finally, optical imaging measures such as functional near- infrared 
spectroscopy (fNIRS) (Jobsis, 1977), use optical fiber detectors placed on the scalp to 
calculate separately changes in the concentration of oxygenated and deoxygenated 
blood (Hoshi, 2003).  
 
2.1.4. Advantages of the use of fMRI in ADHD compared to other functional 
brain imaging methods 
The previous sections have reviewed the basic technical concepts of the most 
commonly used brain functional imaging methods. When selecting the technique to 
be used in a study, it is necessary to consider its main advantages and disadvantages, 
and whether it is the most adequate technique to serve for the main aim of the study.  
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Thus, the use of fMRI to study brain function in ADHD has several strengths 
when compared to other functional brain imaging techniques. Although its temporal 
resolution is worse than those from EEG/ERPs or fNIRS, it has a better spatial 
resolution than these methods (Volkow, Rosen, & Farde, 1997). Furthermore, PET 
cannot be used in children for ethical reason because it requires the injection of a 
radioactive substance into the blood stream. In addition, EEG, ERP and fNIRS 
methods do not allow for the study of subcortical structures, which have shown to 
have a crucial role in the pathophysiology of the disorder, as it will be reviewed in the 
next sections of this chapter.  It furthermore is non- invasive, as it does not use ionizing 
radiation like PET. Thus, fMRI is a crucial technique, as it has the best spatial 
resolution and allows for the study of the function of subcortical structures with a 
relatively better temporal resolution than PET, the only other technique that allows for 
that which, as mentioned, cannot be used in children due to the need to inject 
radioactive substances. MRI is also the only method that allows to study the structure 
of the brain. The additional advantage is that during an fMRI scan a structural MRI 
scan can be acquired in relatively short time of 5 minutes, which allows for co-
measuring of brain structure. 
The limitations of fMRI need to be considered when selecting this technique. 
Thus, the use of subtraction methods that only permit to obtain measures of relative 
increases on brain activity is a drawback shared by fMRI, fNIRS and EEG methods. 
Furthermore, the nature of the relationship between the BOLD signal and brain 
activity is still not yet well understood. Changes in BOLD signal are thought to reflect 
neural activity associated with the input and local processing (Lauritzen & Gold, 
2003; Logothetis, 2002; Logothetis & Wandell, 2004). However, with increased 
neural activity, glucose supply has been shown to match neural consumption however, 
oxygen supply exceeds the needs of that brain region (Fox & Raichle, 1986) and the 
reason for this mismatch is still not understood (Logothetis & Wandell, 2004). 
Furthermore, whether neural inhibition results in enhanced or reduced BOLD signal is 
still under discussion (Arthurs & Boniface, 2002). In addition, the meaning of the 
negative BOLD signal is not easy to interpret, as it may be due either to active 
neuronal suppression or to “vascular steal”, which would reflect the reduction in 
blood flow in a region due to the increase blood flow demand in a neighbouring 
region (Wade, 2002). As recently reviewed by Logothetis (Logothetis, 2008), fMRI 
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cannot differentiate between neuromodulation and function-specific activity, and may 
potentially confuse excitatory and inhibitory responses (Logothetis, 2008).  
The main goal of the present study was to observe changes in the different 
brain networks underlying the performance of ADHD boys in different cognitive tasks 
after single dose MPH and ATX challenges compared to placebo. Thus, out of those 
techniques that can be used for research purposes in children, fMRI was selected for 
this study, given the adequate spatial resolution that would allow for the identification 
of networks including cortical and subcortical structures underlying the performance 
of the participants during the different tasks selected.  
 
2.2 Abnormalities in brain structure and structural connectivity in children with 
ADHD 
 As reviewed above, the association between behavioural symptoms o f ADHD 
and the presence of structural or functional abnormalities has long been hypothesised 
(Lange et al., 2010; Taylor, 2011). Similarities between impulsivity and inhibitory 
problems shown by patients with frontal lobe damage and children with ADHD led to 
the hypothesis that frontal lobe abnormalities would underlie the inhibitory deficits 
that, as reviewed in the previous chapter, have been consistently reported in children 
with ADHD. In the early 90’s, the first structural MRI studies conducted in children 
with ADHD provided the first available evidence of structural brain abnormalities in 
ADHD patients (Hynd et al., 1993; Hynd, Semrud-Clikeman, Lorys, Novey, & 
Eliopulos, 1990; Hynd et al., 1991).   
  Gray matter consists on the neuronal and glial cell bodies, arranged as an 
outer layer covering the surface of the cerebrum, as well as in deep grey matter nuclei 
(Patestas & Gartner, 2006). White matter consists of cell axons, which may be 
covered by the myelin sheath, responsible for their white aspect (Patestas & Gartner, 
2006). As every organ in our bodies, the integrity of the brain is crucial to preserve its 
function. The use of structural MRI methods provides information about the integrity 
of the brain. Thus, regional or general cortical, grey and white matter volumetric 
differences are presumed to be associated with abnormal neural proliferation and 
distribution, integrity or myelinisation processes in white matter fibers. Also measures 
of cortical thickness have been used, defined as the 3-D distance between the two 
surfaces of the grey matter sheet (from the grey/white matter boundary to the 
grey/CSF boundary), which represents the number, size, density and arrangements of 
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cells (neurons, neuroglia and nerves fibers) within the cortical mantle (von Economo, 
2009).  
 It is relevant at this stage to mention the differences between Region of 
Interest (ROI) and Whole Brain Voxel-Based Morphometric (VBM) methods. The 
use of ROI methods may be adequate under a number of circumstances such as when 
there is a strong a-priory hypothesis, as it restricts the analyses conducted to a region 
of interest hypothesised to be abnormal in a determined pathology (Poldrack, 2007). 
The limited number of comparisons conducted in ROI analyses increases the 
statistical power to detect differences between groups however, it does not allow for 
the identification of abnormalities in other structures that, although not hypothesised 
a-priori, may be playing a role in the disorder or function studied. On the other hand, 
VBM methods involve voxel-wise comparisons and therefore do not restrict the 
analysis to any particular brain region, which allows for a comprehensive study of 
structures which may be involved in the pathophysiology of the disorder (Ashburner 
& Friston, 2001). However, given the high number of voxels compared, these 
methods show decreased statistical power to detect differences, as they have to control 
for multiple comparisons (Poldrack, Mumford, & Nichols, 2011).  
 
2.2.1. Brain structure abnormalities in children with ADHD  
Cross-sectional case-control studies have shown brain structure abnormalities 
in several regions. Thus, possibly the most consistent abnormalities have been 
reported in the basal ganglia, where children with ADHD have shown volumetric 
reductions (Brieber et al., 2007; Carmona et al., 2009; Castellanos et al., 2002; 
Castellanos et al., 1996; Overmeyer et al., 2001; Qiu et al., 2009; Wang, Jiang, Cao, 
& Wang, 2007). Furthermore, the relevance of these abnormalities in ADHD is 
highlighted by the inverse association between the reduced volumes of the ventral 
striatum in children with ADHD compared to controls and parental ratings of 
hyperactivity/impulsivity (Carmona et al., 2009), and between the caudate volume and 
clinician-rated severity of symptoms and with parent-rated attention problems 
(Castellanos et al., 2002).   
These results are compelling and extremely relevant to ADHD, as the 
evidence has shown the key role of basal ganglia as part of fronto-striatal networks 
that mediate executive processes (Aron & Poldrack, 2006; Chambers, Garavan, & 
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Bellgrove, 2009; Rubia, Smith, Taylor, & Brammer, 2007) which, as reviewed in the 
previous chapter, are impaired in children with ADHD.  
In addition, structural abnormalities in the cerebellum have also consistently 
been reported. Thus, ADHD patients have reduced cerebellar volumes relative to 
controls (Berquin et al., 1998; Castellanos et al., 2002; Castellanos et al., 1996; 
Durston et al., 2004; Hill et al., 2003; Mackie et al., 2007), with particularly consistent 
evidence in the cerebellar vermis where volumetric reduction (Berquin et al., 1998; 
Bledsoe, Semrud-Clikeman, & Pliszka, 2009; Castellanos et al., 2001; Mackie et al., 
2007; McAlonan et al., 2007), reduced area (Bledsoe et al., 2009) and grey matter 
volumes (Carmona et al., 2005) have been reported. These abnormalities have been 
associated with the symptomatic presentation of the disorder, as the volume in the 
vermis of the cerebellum has been negatively associated with severity of ADHD 
symptoms as assessed by the clinician (Castellanos et al., 2001; Castellanos et al., 
2002), and by parent-rated rated scales (Castellanos et al., 2002). Furthermore, a 
longitudinal study provided some evidence for the association between the 
developmental trajectory in the structural abnormalities of the cerebellum and clinical 
outcome (Mackie et al., 2007). Thus, while all children with ADHD showed 
persistently reduced cerebellar volumes (Mackie et al., 2007), the developmental 
trajectory of those patients who exhibited a better clinical outcome (as measured by 
the Children’s Global Assessment Scale –CGAS) paralleled that observed in healthy 
controls. However, those patients with worse clinical outcomes showed a 
progressively more pronounced total volumetric difference relative to controls 
(Mackie et al., 2007).  
Abnormalities have been reported not only in specific structures, but also at a 
more global level. Thus, compared to healthy adolescents, children with ADHD have 
shown reduced total cerebral brain volume (between 3-8%) (Batty et al., 2010; 
Carmona et al., 2005; Castellanos et al., 2002; Hill et al., 2003; Mostofsky, Cooper, 
Kates, Denckla, & Kaufmann, 2002; Narr et al., 2009; Qiu et al., 2011; Wolosin, 
Richardson, Hennessey, Denckla, & Mostofsky, 2009) as well as reduced total 
cerebral grey matter (Batty et al., 2010; Brieber et al., 2007; Carmona et al., 2005; 
Mostofsky et al., 2002; Narr et al., 2009). Furthermore, reduced overall cortical 
surface and cortical folding has also been reported (Wolosin et al., 2009). 
Structural abnormalities have also been reported in frontal regions, including  
dorsolateral (DLPFC), orbitofrontal (OFC), medial and superior prefrontal regions 
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(MFC/SFC), where children with ADHD relative to controls have shown volumetric 
reductions (Hill et al., 2003; Mostofsky et al., 2002; Wang et al., 2007; Wolosin et al., 
2009), reduced surface (Sowell et al., 2003), cortical folding (Wolosin et al., 2009), as 
well as reduced grey matter volumes (Batty et al., 2010; Brieber et al., 2007; Carmona 
et al., 2005; Castellanos et al., 2002; Durston et al., 2004; McAlonan et al., 2007; 
Mostofsky et al., 2002; Overmeyer et al., 2001; Plessen et al., 2006; Sasayama et al., 
2010). Furthermore, reduced grey matter volumes have also been reported in the 
cingulate cortex, somatosensory, motor and premotor regions (Carmona et al., 2005; 
Mostofsky et al., 2002; Overmeyer et al., 2001). Reduced frontal grey matter volumes 
were negatively associated with severity of symptoms as assessed by the clinician and 
with parent-rated attention problems (Castellanos et al., 2002), and with inattention 
symptoms (Brieber et al., 2007), supporting thus the association between structural 
abnormalities and symptoms of ADHD. 
 At this point, it is necessary to mention again the relevance of the use of ROI 
or VBM methods, as only few studies used VBM methods in children with ADHD 
(Brieber et al., 2007; Carmona et al., 2005; Kobel et al., 2010; McAlonan et al., 2007; 
Overmeyer et al., 2001; Sasayama et al., 2010; Wang et al., 2007; Yang et al., 2008). 
ROI analyses restrict the search area, which may bias the results towards selected 
regions previously hypothesised that will be consistently reported while regions that 
may be relevant for the disorder but not initially hypothesised may remain 
unidentified.  
 Though less frequently studied, volumetric reductions in paediatric ADHD 
samples have also been reported in other areas involved in emotion processes such as 
reduced grey matter volume in the parahippocampal gyrus (Carmona et al., 2005), the 
hippocampus (Brieber et al., 2007) or amygdala (Sasayama et al., 2010), which has 
also shown reduced surface (Plessen et al., 2006). Furthermore, the morphological 
abnormalities in the amygdala have been associated with inattention scores (Plessen et 
al., 2006). Deficits have also been observed in areas that are relevant to attention such 
as the thalamus (Ivanov et al., 2010), and in temporo-parietal cortices, which have 
shown reduced volumes (Wang et al., 2007; Wolosin et al., 2009), grey matter volume 
(Batty et al., 2010; Brieber et al., 2007; Carmona et al., 2005; Kobel et al., 2010; 
McAlonan et al., 2007; Sasayama et al., 2010) or surface (Wolosin et al., 2009) in 
children with ADHD compared to healthy controls.  
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Nevertheless, the abnormalities observed in brain structure in children and 
adolescents with ADHD are not limited to volumetric reductions, but also increased 
volumes have been reported in the right inferior prefrontal cortex (IFC) and caudate 
(Garrett et al., 2008), as well as increased grey matter volumes in the left posterior 
cingulate cortex (Nakao et al., 2011), bilaterally in parietal regions (Brieber et al., 
2007), and right occipital cortex (Wang et al., 2007), as well as increased grey matter 
density in temporal, parietal and occipital cortices (Sowell et al., 2003). Larger 
hippocampus has also been reported (Plessen et al., 2006), and morphological 
abnormalities in the hippocampus have been inversely associated with symptom 
severity (Plessen et al., 2006).  
  
2.2.2. Meta-analyses on brain structure abnormalities in children with ADHD 
 Further support to the structural abnormalities observed in children with 
ADHD is provided by the results from recent meta-analytic studies. A meta-analysis 
of studies using ROI methods observed reduced volumes in children with ADHD 
compared to healthy controls in right and total cerebral volumes, posterior inferior 
cerebellar regions, splenium, right caudate and prefrontal grey matter volumes 
(Valera, Faraone, Murray, & Seidman, 2007). On the other hand, meta-analytic 
studies of findings from VBM studies in children with ADHD have shown that the 
most significant volumetric grey matter reductions are in the right basal ganglia 
(Ellison-Wright, Ellison-Wright, & Bullmore, 2008; Frodl & Skokauskas, 2012; 
Nakao et al., 2011). Furthermore, using meta-regression analysis both age and 
medication status have been associated with these abnormalities, with older patients 
showing more normal striatal grey matter volumes (Nakao et al., 2011), and those 
studies with a higher proportion of medicated patients no longer showing striatal grey 
matter volumetric abnormalities (Frodl & Skokauskas, 2012; Nakao et al., 2011). The 
normalisation of grey matter volumes in the basal ganglia with age is in line with the 
first longitudinal imaging study in ADHD that showed normalisation with age of the 
abnormally reduced caudate volumes in children with ADHD, but not of the other 
cortical regions that were reduced in gray matter/volume (Castellanos et al., 2002).  
 Thus, the evidence suggests that ADHD in children most consistently is 
associated with reduced grey matter volumes in the basal ganglia and cerebellum, 
which form part of fronto-striatal and fronto-cerebellar cognitive networks underlying 
diverse executive functions including inhibition, timing, sustained attention and 
 51 
working memory (Arnsten & Rubia, 2012; Chambers et al., 2009; Rubia, Smith, 
Taylor, et al., 2007), which, as reviewed in the previous chapter, are typically 
impaired in children with ADHD. Further mounting evidence supports the presence of 
reduced regional and grey matter volumes in prefrontal regions. However, given that 
the majority of the studies used ROI methods, more evidence from VBM studies 
would be necessary.  
  
2.2.3. Cortical thickness and developmental delay in ADHD  
Brain structure abnormalities in ADHD are not restricted to volumetric 
reductions, but also to reduced cortical thickness, which have been suggested as 
potential anatomical markers for ADHD (Narr et al., 2009). As defined above, cortical 
thickness is associated with the size, density and arrangement of the cells within the 
cortical mantle (von Economo, 2009). Reduced global and regional cortical thinning 
has been reported, particularly in (but not reduced to) different regions of the 
prefrontal cortex, anterior temporal regions and lateral and posterior parietal areas 
(Almeida et al., 2010; Almeida Montes et al., 2012; Batty et al., 2010; Narr et al., 
2009; Qiu et al., 2011; Shaw, Eckstrand, et al., 2007; Shaw et al., 2006; Shaw, Sharp, 
et al., 2009). However, also increased cortical thickness in ADHD patients compared 
to controls has been reported in posterior temporo-occipital regions, which were 
positively associated with ADHD criteria (DSM-IV-TR) and whose extent was 
reduced with age (Almeida Montes et al., 2012).  
 One the most significant contributions to our knowledge of structural brain 
abnormalities in ADHD are the recent longitudinal studies on cortical thickness in 
ADHD by the group from Shaw (Shaw, Eckstrand, et al., 2007; Shaw et al., 2011; 
Shaw, Gornick, et al., 2007; Shaw, Lalonde, et al., 2009; Shaw et al., 2006; Shaw et 
al., 2012; Shaw, Sharp, et al., 2009), which have provided the first direct evidence on 
the previously hypothesised presence of a developmental delay in ADHD (Rubia, 
2007).  
 Brain maturation processes have been associated with an increase in cortical 
thickness until the age of 7-8, when it peaks and gives way to cortical thinning, which 
is thought to be associated with synaptic pruning and increased myelinisation (Shaw, 
Eckstrand, et al., 2007). This process has shown regional variations, with primary 
sensory areas attaining their peak of cortical thickness earlier than higher association 
areas (Shaw, Eckstrand, et al., 2007). Children with ADHD compared to healthy 
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controls show a developmental delay (up to 4-5 years in prefrontal regions) in the 
peak of cortical thickness (Shaw, Eckstrand, et al., 2007). However, the 
developmental trajectory was parallel to that observed in healthy children (Shaw, 
Eckstrand, et al., 2007). Children with ADHD have shown a developmental delay not 
only on cortical thickness but also on another index of brain maturation processes, the 
development of cortical surface area (Shaw et al., 2012). Thus, parallel but delayed 
trajectories were described across all cortical surfaces, with the more pronounced 
differences in the right prefrontal and left parietal regions, where they showed a 2-
years delay in the mean age of attaining peak surface area (Shaw et al., 2012). Thus, 
this evidence shows for the first time that ADHD is associated with a delay in the 
developmental processes in the brain, rather than a deviation from normal 
developmental trajectories.  
 In typically developing children, hyperactivity/impulsivity symptoms have 
been associated with slower cortical thinning rate especially in prefrontal, premotor 
and temporal regions (Shaw et al., 2011). Furthermore, in healthy developing children 
under the age of 10, thinner prefrontal (especially right IFC and OFC), cingulate and 
premotor cortices as well as left temporo-parietal regions were associated with higher 
scores of attention problems. However, this association disappeared with age, as they 
showed a slower rate of cortical thinning (Ducharme et al., 2011). Thus, the evidence 
suggests that children with ADHD show the extreme end of these two dimensions, 
with reduced cortical thickness and slower rate of cortical thinning, supporting the 
presence of delay in cortical maturation in ADHD. 
 Therefore, these studies are highly relevant, as they have provided the first 
direct evidence of the previously hypothesised maturation delay in the brain of 
children with ADHD (Rubia, 2007). However, whether patients catch up is unclear, 
since similar structural abnormalities have been observed in cross-sectional studies in 
adults with ADHD (for reviews, see Cubillo et al., 2012; as well as Cubillo & Rubia, 
2010).  Also, if and once the “catch up” has occurred, the efficiency of the network 
may not be comparable to the one of those who have undergone a typical brain 
developmental process (Fair et al., 2009). This highlights the need for longitudinal 
studies that are prolonged well into adulthood to determine the changes in brain 
structure with age, as well as their association with symptomatic changes in time, 
whether there are differences in the developmental trajectories of persistent and 
remitted cases as well as between the different subtypes of the disorder, and how the 
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presence of comorbid disorders influences the observed developmental delay in 
ADHD.  
 In summary, the evidence from MRI studies investigating cortical thickness in 
ADHD suggests that ADHD is associated with reduced cortical thickness in prefrontal 
cortices, anterior temporal and posterior parietal regions. These regions showed not 
only a reduced cortical thickness but also a delay in the time to reach the peak cortical 
thickness and cortical surface area, which are indexes of brain maturation processes, 
and associated with cognitive maturation. These studies showing a maturational delay 
in brain structure development constitute therefore the first evidence for the 
hypothesis of delayed brain maturation processes in ADHD, a landmark in the field. 
Furthermore, the reported association in healthy children of both slower cortical 
thinning rates and thinner prefrontal and temporo-parietal cortices with increased 
severity of attention problems, hyperactivity and impulsivity symptoms suggests that 
children with ADHD are at the very end of a spectrum, where the more disturbed 
these brain maturation processes, the more the severity of the symptoms presented. 
This is in line with dimensional scales of ADHD symptoms, commonly used in 
clinical environments, such as the Conner’s Parent Rating Scale (CPRS) (Conners, 
Sitarenios, Parker, & Epstein, 1998) or the Strengths and Difficulties Questionnaire 
(SDQ) (Goodman, 1999). Furthermore, the use of a dimensional adjunct in addition to 
the categorical diagnosis of ADHD is at present being considered for its inclusion in 
DSM-V (Swanson, Wigal, & Lakes, 2009).  
 Thus, the fact that the most pronounced developmental delay was in prefrontal 
regions followed by temporo-parietal areas, together with the mounting evidence of 
reduced regional volumes and grey matter volumes in prefrontal and temporo-parietal 
regions, highlights the relevance of the presence of structural abnormalities in these 
areas in the disorder.  
 
2.2.4. Abnormalities in structural connectivity in children with ADHD  
The different regions in the brain do not work in isolation, but are part of 
wider neural networks that interact (Castellanos & Proal, 2012), and are connected by 
white matter fiber tracts (Wakana et al., 2004). Disturbances in white matter are 
suggestive of altered axonal myelinisation and/or maturation processes. Not only the 
disruption of a component of the network may be greatly impairing, but also 
disruptions in the connections between the different components may alter its 
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functioning. The development of Diffusion Tensor Imaging (DTI) techniques (defined 
in section 2.1.1.) allows for the investigation of the disrupted integrity in specific 
white matter fiber tracts. Thus, there is evidence supporting that the structural 
abnormalities observed in ADHD patients are not restricted to localized regions but 
affect inter-regional structural connectivity.  
The corpus callosum is the largest fiber tract and the main connector of the 
two hemispheres of the brain, and plays a key role in not only in facilitating the 
integration of information from the two hemispheres (Aboitiz, Ide, & Olivares, 2003) 
but also during attention processes (Banich, 2003). Abnormalities in the corpus 
callosum have consistently been reported in children with ADHD, who compared to 
controls have shown global and regional reduced volumes (Hill et al., 2003; 
McAlonan et al., 2007), areas (Cao et al., 2010; Schnoebelen, Semrud-Clikeman, & 
Pliszka, 2010), as well as reduced callosal thickness (Luders et al., 2009), with the 
most consistent findings supporting a volumetric reduction in the splenium of the 
corpus callosum, as shown by a meta-analytic study (Hutchinson, Mathias, & Banich, 
2008). The splenium of the corpus callosum projects to primary sensory regions, 
posterior parietal and occipital areas, allowing for the interhemispheric connection of 
homologous regions of the two cerebral hemispheres (Hofer & Frahm, 2006). 
Furthermore, abnormal developmental trajectories have also recently been reported, 
with an increased growth rate described in children with ADHD relative to that of 
healthy controls, which was significant in the anterior corpus callosum, connecting 
homologous prefrontal fibers, and has been hypothesised as being potentially 
associated with the abnormalities (structural and functional) observed in prefrontal 
regions (Gilliam et al., 2011).  
Although less consistently, white matter abnormalities have also been 
described in other brain regions. Thus, reduced white matter volumes have also been 
reported in bilateral prefrontal, temporal and parietal lobes (Castellanos et al., 2002; 
Durston et al., 2004; McAlonan et al., 2007; Mostofsky et al., 2002; Overmeyer et al., 
2001). However, there are also inconsistent results, with studies where either no 
differences (Batty et al., 2010; Carmona et al., 2005) or an increased global white 
matter volume (Narr et al., 2009) have been reported.  
DTI studies have furthermore shown disrupted structural connectivity in 
youths with ADHD in multiple white matter tracts, most consistently in those 
connecting key fronto-striatal and fronto-parietal projections such as the anterior 
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corona radiata (connecting the anterior cingulate cortex to the striatum and prefrontal 
regions), and the right superior longitudinal fasciculus (SLF, connecting posterior 
temporo-parietal regions to medial prefrontal cortical areas) (for reviews, see Konrad 
& Eickhoff, 2010; Liston, Malter Cohen, Teslovich, Levenson, & Casey, 2011; van 
Ewijk, Heslenfeld, Zwiers, Buitelaar, & Oosterlaan, 2012). This was confirmed by a 
recent meta-analytic study, where reduced white matter integrity was observed in 
patients with ADHD compared to controls in the right anterior corona radiata, left 
cerebellar white matter, the internal capsule and the forceps minor (projections from 
the genu of the corpus callosum to OFC)(van Ewijk et al., 2012). Finally, there is also 
some evidence for disrupted integrity in the cerebellar peduncles, white matter tracts 
connecting the cerebellum to cortical and subcortical structures (Bechtel et al., 2009; 
Kobel et al., 2010; Nagel et al., 2011).  
 In conclusion, findings from DTI studies show that not only isolated brain 
regions are impaired in ADHD, but also the inter-regional connections between brain 
structures that have consistently shown volumetric, white matter, grey matter or 
cortical thickness reductions in sMRI, most prominently white matter tracts of the 
corpus callosum, and those comprising fronto-striatal and fronto-parietal projections.  
 
2.2.5. Conclusions on brain structure abnormalities in children with ADHD 
Structural MRI studies have provided consistent evidence not only on 
structural abnormalities in ADHD relative to healthy controls in isolated brain 
regions, but also in white matter fibers that connect these regions. There is mounting 
evidence about the presence of volumetric reductions and grey matter abnormalities in 
the basal ganglia and cerebellum, as well as in the splenium of the corpus callosum 
and in white matter fiber tracts connecting fronto-parietal and fronto-subcortical 
regions (for reviews, see Konrad & Eickhoff, 2010; Liston et al., 2011; van Ewijk et 
al., 2012).  
 The findings from recent meta-analytic studies on structural MRI are 
conclusive, and consistently report volumetric grey matter reduction in the right basal 
ganglia (Ellison-Wright et al., 2008; Frodl & Skokauskas, 2012; Nakao et al., 2011; 
Valera et al., 2007). This is highly relevant, as the basal ganglia together with their 
connections to frontal and other regions have been shown to be crucial for different 
executive functions (including temporal processing, attention, inhibition or 
motivation) in which children with ADHD are impaired (Nigg et al., 2005; Rubia, 
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Smith, et al., 2007a; Rubia, Halari, Christakou, et al., 2009; Willcutt et al., 2005)(for  
review see (Rubia, 2011)). Furthermore, an association between the abnormalities in 
the basal ganglia and symptom severity has been documented (Castellanos et al., 
2002). Both meta-regression analyses with age and mixed cross-sectional/longitudinal 
studies have in addition provided evidence for the normalisation of these deficits with 
age (Castellanos et al., 2002; Frodl & Skokauskas, 2012; Nakao et al., 2011).  
 Another key region where the evidence for structural abnormalities in ADHD 
is compelling is the cerebellum, in particular (but not only) with regards to reduced 
volumes in the cerebellar vermis (Berquin et al., 1998; Bledsoe et al., 2009; Carmona 
et al., 2005; Castellanos et al., 2001; Mackie et al., 2007; McAlonan et al., 2007), 
which has been associated with symptoms of the disorder (Castellanos et al., 2001; 
Castellanos et al., 2002) and clinical outcome (Mackie et al., 2007). Furthermore, 
although less numerous, there is also evidence not only of reduced volume of the 
cerebellum has but also of structural reduced integrity of the cerebellar peduncles, 
which are white matter fibers connecting the cerebellum with cortical and subcortical 
structures (Bechtel et al., 2009; Nagel et al., 2011). This is especially relevant as the 
cerebellum is involved not only in motor control but also in other higher cognitive 
functions in which children with ADHD consistently show deficits, such as in higher-
level executive functions (including inhibitory processes or sustained attention) 
(Arnsten & Rubia, 2012; Steinlin, 2007; Stoodley & Schmahmann, 2009), as well as 
in temporal processing (Aso, Hanakawa, Aso, & Fukuyama, 2010; Rubia & Smith, 
2004; Wiener, Turkeltaub, & Coslett, 2010).  
 The evidence is also mounting for the presence of reduced regional volumes 
and grey matter volumes in prefrontal regions and, although less numerous, also in 
temporo-parietal regions. This evidence, together with the recent findings of reduced 
cortical thickness and a developmental delay in brain maturation processes in ADHD, 
which are particularly pronounced in prefrontal and temporo-parietal cortices, 
highlight the relevance of the structural abnormalities in these regions in the disorder. 
Interestingly, recent studies have linked the presence of inattention and hyperactivity 
symptoms to the developmental trajectories of cortical thickness in prefrontal and 
temporo-parietal regions in healthy children (Ducharme et al., 2011; Shaw et al., 
2011). Thus, these studies suggest that children with ADHD may show the extreme 
expression of the attention problems and hyperactive/impulsive dimensions, as they 
have consistently shown reduced cortical thickness and slowed (delayed) cortical 
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thinning rate (Almeida et al., 2010; Almeida Montes et al., 2012; Narr et al., 2009; 
Shaw, Eckstrand, et al., 2007; Shaw, Lalonde, et al., 2009; Shaw et al., 2006; Shaw, 
Sharp, et al., 2009). 
However, although this constitutes an extremely relevant evidence, longer-
term longitudinal studies prolonged well into adulthood are needed in order to identify 
age-related changes in brain structure, their association with symptomatic 
improvement, differences in developmental brain maturation processes between 
persistent and remitted cases or between ADHD subtypes, as well as the influence of 
comorbid diagnoses on such developmental delay in ADHD.  
The evidence from studies on structural abnormalities in children with ADHD 
suggests that ADHD is characterised not only by disrupted isolated components of 
brain networks, but also by altered connections between their different components. 
Thus, the evidence is highly consistent with regards to the presence of reduced inter-
regional structural connectivity, in particular in the splenium of the corpus callosum 
and in white matter fiber tracts connecting fronto-parietal and fronto-subcortical areas 
(for reviews, seeKonrad & Eickhoff, 2010; Liston et al., 2011; van Ewijk et al., 2012).  
 An important aspect to consider when reviewing the evidence on brain 
structural abnormalities in ADHD is the use of ROI or VBM methods. This is highly 
relevant, as ROI analyses increase the power to detect differences between groups but 
limit the search area, and may therefore bias the results as only certain regions 
previously hypothesised will be consistently reported while regions that may be 
relevant for the disorder but not initially hypothesised may remain unidentified. Two 
recent meta-analysis (Frodl & Skokauskas, 2012; Nakao et al., 2011) have shown that 
out of the wealth of studies conducted, very few had used VBM methods in children 
with ADHD (Brieber et al., 2007; Carmona et al., 2005; Kobel et al., 2010; McAlonan 
et al., 2007; Overmeyer et al., 2001; Sasayama et al., 2010; Wang et al., 2007; Yang 
et al., 2008).  
 A second area where question marks are still present is the relationship and 
interdependence between the reported abnormalities in white and grey matter. From 
the available evidence, it cannot be concluded whether grey matter abnormalities 
(cortical thickness, volume, area, surface, density) influence (or how they do it) the 
structure, volume or integrity of white matter tracts, or viceversa. As mentioned 
above, only longitudinal studies with large samples that follow up subjects into 
adulthood and study the developmental trajectories of grey and white matter, as well 
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as their association with symptoms and cognitive function would provide some light 
on this question.  
Despite the relative consistency of the structural abnormalities reported, their 
functional significance still needs to be elucidated. We can only hypothesise about 
their role in the disorder, as these structural abnormalities have not yet shown to be 
specific to ADHD, and do not necessarily lead to ADHD symptoms. Despite its 
relevance, only some authors have investigated the association between the reported 
structural abnormalities and ADHD symptoms. Some studies have shown an 
association between inattention or hyperactivity symptoms and reduced grey matter 
volumes in frontal and temporal cortices, caudate and cerebellum (Castellanos et al., 
2002), with grey matter volumetric reduction in the left MFC (which was not 
significantly reduced in ADHD patients) (Brieber et al., 2007), reduced volume of 
right  ventral striatum (VS) (Carmona et al., 2009), surface alterations in the amygdala 
(Plessen et al., 2006) and thalamus (Ivanov et al., 2010), reduced grey matter density 
in occipital regions (Sowell et al., 2003) and reduced cortical thickness in frontal 
(Almeida et al., 2010; Almeida Montes et al., 2012) and parietal regions (Almeida 
Montes et al., 2012). However, there are also studies where no association has been 
reported between symptoms and structural abnormalities, such as with the reduced 
cortical thickness reported by Narr et al (Narr et al., 2009) or with the abnormal 
volume in the cerebellum reported by Berquin et al (Berquin et al., 1998). 
Also, how these structural abnormalities relate to impaired cognitive function 
still need to be elucidated, as very few of the studies have tried to establish that 
connection, unfortunately without conclusive results. Thus, performance during a 
GNG task has shown no association between the reduced grey matter volumes or 
thinner IFC observed in ADHD patients relative to controls (Batty et al., 2010), but a 
positive association with the circumference of the corpus callosum was observed (that 
did not differ between children with ADHD and healthy controls) (McNally et al., 
2010). Furthermore, in children with ADHD, better inhibitory function was associated 
with greater grey matter volumes in the anterior cingulate (ACC), right lentiform 
nucleus and medial temporal lobe (McAlonan et al., 2009), whereas response shifting 
was associated with greater grey matter volumes in the right basal ganglia and 
cerebellum (McAlonan et al., 2009). However, it is necessary to note here that only 
volumetric reductions were observed in the basal ganglia, whereas the cerebellum, 
temporal regions and ACC did not show volumetric differences in grey matter 
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between healthy children and those with ADHD (McAlonan et al., 2007).  Finally, 
during a CPT task, within children with ADHD (but not within the control group), 
worse performance was associated with larger SFC volumes (reduced in ADHD 
children compared to healthy controls) (Hill et al., 2003). Thus, there is very limited 
evidence about the association between the reported structural abnormalities and 
impaired cognitive functioning in ADHD.  
Nevertheless, it is important to highlight the small sample sizes of most of the 
studies, which significantly limits the statistical power to detect significant differences 
or associations with behaviour or cognitive performance. Additionally, the inclusion 
of subjects with different ADHD diagnostic subtypes (Carmona et al., 2005; Durston 
et al., 2004; Garrett et al., 2008; Mackie et al., 2007; Mostofsky et al., 2002; Qiu et 
al., 2009; Wolosin et al., 2009), comorbid conditions (Almeida et al., 2010; Batty et 
al., 2010; Carmona et al., 2005; Durston et al., 2004; Garrett et al., 2008; Hill et al., 
2003; Mackie et al., 2007; McAlonan et al., 2007; McAlonan et al., 2009; Mostofsky 
et al., 2002; Overmeyer et al., 2001; Plessen et al., 2006; Qiu et al., 2009; Wolosin et 
al., 2009), previously medicated (Brieber et al., 2007; Carmona et al., 2009; 
Castellanos et al., 2001; Durston et al., 2004; Garrett et al., 2008; Hill et al., 2003; 
Mackie et al., 2007; McAlonan et al., 2007; McAlonan et al., 2009; Mostofsky et al., 
2002; Narr et al., 2009; Overmeyer et al., 2001; Plessen et al., 2006; Qiu et al., 2009; 
Sowell et al., 2003) and mixed genders (Almeida et al., 2010; Batty et al., 2010; 
Carmona et al., 2009; Carmona et al., 2005; Garrett et al., 2008; Hill et al., 2003; Narr 
et al., 2009; Overmeyer et al., 2001; Plessen et al., 2006; Qiu et al., 2009; Sowell et 
al., 2003; Wolosin et al., 2009) increases the heterogeneity of the samples and 
therefore decreases the ability of the studies to detect differences or to replicate 
previous results. 
A potential caveat of the reviewed studies is the inclusion of subjects with 
comorbid conditions, most commonly the frequent diagnosis of CD/ODD, as their 
contribution to the structural abnormalities cannot be easily disentangled. Those 
studies that have tried to identify the impact of those comorbid conditions on the 
findings showed inconsistent results. Some studies have reported a lack of effect of 
the presence of comorbid ODD/CD on the reduced volumes, surfaces, cortical folding 
index or cortical thickness of the corpus callosum observed in ADHD children 
compared to controls (Luders et al., 2009; Plessen et al., 2006; Wolosin et al., 2009). 
However, others have reported an increased effect of the abnormalities in children 
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with ADHD when they presented with comorbid CD/ODD, as the more pronounced 
volumetric reductions in globus pallidus and cerebellum shown by children with 
ADHD and comorbid ODD/CD compared to those children without comorbid 
conditions (McAlonan et al., 2007). The opposite has also been reported, with more 
pronounced structural abnormalities when comorbid cases are accounted for. Thus, 
children with pure ADHD showed smaller caudate volumes than those with comorbid 
CD (Hill et al., 2003), or more marked reductions of grey matter volumes in temporo-
occipital regions and amygdala (Sasayama et al., 2010). Therefore, preferably non-
comorbid samples should be studied in order to avoid this confound.  
Finally, as with neuropsychological studies, the inclusion of different subtypes 
of the disorder in some of the studies may have increased the heterogeneity of the 
already small samples. It seems necessary to study each of the different subtypes 
separately, or at least to include sample sizes that are large enough to allow for 
comparisons between the different subtypes.  
Therefore, studies including large samples with longitudinal measures of 
cognitive function, brain structure, fMRI measures, structural and functional 
connectivity measures and symptomatic changes that allow for the study of the 
association between abnormalities on brain structure/connectivity and symptoms 
and/or cognitive functions are still needed. These studies would shed light not only on 
the presence of abnormalities in grey and white matter and structural connectivity in 
the brain of children with ADHD but also on their progress in time, their association 
with symptoms and cognitive functions, and the differences and similarities between 
subtypes.  
 
2.3 ADHD and fMRI studies  
The description of the cognitive deficits in EF in children with ADHD 
suggested the presence of abnormalities in frontal brain regions, given the similarities 
between these deficits and those observed in patients with frontal lobe damage 
(Mattes, 1980). FMRI studies have in fact confirmed the view that fronto-striatal 
networks in the context of inhibitory control functions are underfunctioning in 
children with ADHD. However, abnormalities have been reported not only during 
inhibitory tasks in fronto-striatal regions but also in more wide-spread fronto-strato-
parietal and fronto-cerebellar networks during tasks involving other cognitive 
processes such as sustained attention, temporal processing, working memory, reward 
 61 
and motivation related processes (Castellanos & Proal, 2012; Cubillo et al., 2012; 
Cubillo & Rubia, 2010; Durston, van Belle, & de Zeeuw, 2010; Makris et al., 2009; 
Rubia, 2011)). This evidence is reviewed below.  
  
2.3.1 Deficits during inhibitory processes 
 
2.3.1.1. Motor inhibition 
During motor response inhibition tasks like the GNG and SST tasks (described 
in the previous chapter), healthy adults and adolescents show activation in a network 
comprising predominantly right IFC and right DLPFC, supplementary motor area 
(SMA), ACC, caudate, thalamus and inferior parietal regions (Chambers et al., 2009; 
Rubia, Russell, et al., 2001; Rubia, Smith, Brammer, & Taylor, 2003; Rubia, Smith, 
Taylor, et al., 2007; Rubia et al., 2006). Especially relevant is the right IFC, a key 
inhibitory region underlying motor inhibition processes (Aron et al., 2007; Aron, 
Fletcher, Bullmore, Sahakian, & Robbins, 2003; Aron & Poldrack, 2006; Aron, 
Robbins, & Poldrack, 2004; Chambers et al., 2006; Chambers et al., 2009; Chevrier, 
Noseworthy, & Schachar, 2007; Goghari & MacDonald, 2009; Ridderinkhof, van den 
Wildenberg, S.J., & Carter, 2004; Rubia, Smith, et al., 2003; Rubia, Smith, Taylor, et 
al., 2007; Rubia et al., 2006) as well as the caudate (Chambers et al., 2009; Chevrier 
et al., 2007; Li, Yan, Sinha, & Lee, 2008). The ACC is involved in performance and 
conflict monitoring processes (Botvinick, Cohen, & Carter, 2004; Ridderinkhof, 
Ullsperger, Crone, & Nieuwenhuiss, 2004), while the SMA and pre-SMA are 
involved in motor inhibition as well as motor execution processes such as response 
selection, attention to action and attention to intention (Lau, Rogers, Ramnani, & 
Passingham, 2004; Lau, Rogers, Haggard, & Passingham, 2004; Mostofsky & 
Simmonds, 2008; Sharp et al., 2010; Simmonds, Pekar, & Mostofsky, 2008; Tabu, 
Mima, Aso, Takahashi, & Fukuyama, 2011). 
Children with ADHD have consistently shown underactivation in these key 
fronto-striatal areas when compared to healthy participants during motor response 
inhibition paradigms. Thus, reduced activation has been reported during successful 
inhibitory trials in the SST and GNG tasks in right and left IFC (Booth et al., 2005; 
Durston, Mulder, Casey, Ziermans, & van Engeland, 2006; Epstein et al., 2007; 
Rubia, Halari, Mohammad, Taylor, & Brammer, 2011; Rubia, Cubillo, et al., 2010; 
Rubia et al., 2008; Rubia, Overmeyer, et al., 1999; Rubia, Smith, Brammer, Toone, & 
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Taylor, 2005), DLPFC and MFC (Booth et al., 2005; Durston et al., 2006; Epstein et 
al., 2007; Mulder et al., 2008; Rubia et al., 2008; Rubia, Overmeyer, et al., 1999; 
Tamm, Menon, Ringel, & Reiss, 2004); ACC/SMA (Durston et al., 2006; Epstein et 
al., 2007; Mulder et al., 2008; Rubia, Halari, Mohammad, et al., 2011; Rubia, Cubillo, 
et al., 2010; Rubia, Overmeyer, et al., 1999; Smith, Taylor, Brammer, Toone, & 
Rubia, 2006; Suskauer et al., 2008; Tamm et al., 2004) and striatum (most 
prominently, in the caudate nucleus)(Booth et al., 2005; Durston et al., 2003; Epstein 
et al., 2007; Rubia, Overmeyer, et al., 1999; Rubia et al., 2005; Suskauer et al., 
2008)((Cubillo et al., 2012; for a meta-analisis, see Dickstein, Bannon, Castellanos, & 
Milham, 2006; Durston et al., 2010; for reviews, see Rubia, 2011).  
During unsuccessful inhibition in the tracking SST reduced activation has 
been reported in children with ADHD compared to healthy controls in right and left 
MFC and IFC (Rubia, Halari, Mohammad, et al., 2011; Rubia, Cubillo, et al., 2010) 
and ACC (Pliszka, Glahn, et al., 2006; Rubia, Cubillo, et al., 2010). Furthermore, the 
underactivation observed in right IFC/MFC during unsuccessful inhibition, and in left 
DLPFC during successful inhibition in the SST, were disorder-specific when 
compared to children with obsessive compulsive disorder (OCD) and CD, 
respectively ((Rubia, Cubillo, et al., 2010; Rubia et al., 2008), for a review see (Rubia, 
2011)).  
 Dysfunctions in other regions have been less consistently reported. The Stop 
stimuli are highly salient during the task and therefore, in addition to inhibitory areas, 
regions involved in visuo-spatial attention allocation to salient stimuli including the 
posterior cingulate cortex (PCC), precuneus or temporo-parietal regions (Arnsten & 
Rubia, 2012; Cavanna & Trimble, 2006; Mesulam, Nobre, Kim, Parrish, & Gitelman, 
2001; Mohanty, Gitelman, Small, & Mesulam, 2008; Sack, 2009; Steinlin, 2007) are 
also activated. Children with ADHD compared to healthy controls have shown 
reduced activation during both successful and unsuccessful inhibition in bilateral 
thalamus (Booth et al., 2005; Rubia, Halari, Mohammad, et al., 2011). Furthermore, 
underactivation has been observed during successful inhibition trials in GNG and SST 
tasks in the temporo-parietal junction (Booth et al., 2005; for a meta-analysis, see 
Dickstein et al., 2006; Durston et al., 2006; Epstein et al., 2007; Rubia, Halari, 
Mohammad, et al., 2011; Rubia et al., 2005; Schulz et al., 2004; Suskauer et al., 
2008), cerebellum (Rubia, Halari, Mohammad, et al., 2011; Schulz et al., 2004; 
Suskauer et al., 2008), and in precuneus and PCC both during failed and successful 
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inhibitory trials (Rubia, Halari, Mohammad, et al., 2011; Rubia et al., 2008; Rubia et 
al., 2005).  
The abnormalities observed in ADHD are not restricted to reduced activation, 
but also increased activation has been reported. This has been traditionally interpreted 
either as a compensatory recruitment to perform the tasks, or as enhanced activation 
that interferes with the recruitment of key areas for the performance of the task. Thus, 
a meta-analytic study showed increased activation in children with ADHD compared 
to healthy control subjects during response inhibition tasks in the left MFC and in the 
right paracentral gyrus (Dickstein et al., 2006). During Stop tasks, enhanced activation 
in children with ADHD compared to healthy controls has been reported during 
successful inhibition in left superior temporal gyrus (STG) (Rubia et al., 2008). 
During GNG tasks, increased activation was observed in IFC and MFC regions, 
ACC/PCC, temporo-parietal and occipital cortices (Durston et al., 2003; Schulz et al., 
2004; Tamm et al., 2004). 
Whereas Tamm et al (Tamm et al., 2004) highlight the potential compensatory 
role of the enhanced activation observed in temporal regions, it is noteworthy the 
special characteristics of the samples in the other studies. Schulz et al (Schulz et al., 
2004) included subjects who were older than other samples (mean age was 18 years) 
and who had had a long history of stimulant medication. Furthermore, 50% of the 
sample did not fulfil criteria for a full diagnosis of ADHD at the time of the study 
(Schulz et al., 2004). In the case of Durston et al (Durston et al., 2003), the relatively 
young age of the subjects needs to be considered when compared to other studies 
(children are 6-10 years old).  
FMRI studies that have used these paradigms have observed not only brain 
activation differences between groups but also performance differences, which is 
remarkable given the small number of participants (with the accompanying loss of 
power to detect between-group differences) typically included in fMRI studies as 
compared to those included in neuropsychological studies. However, there is some 
debate about how to interpret performance differences between groups in functional 
imaging studies. If performance of the two groups in the task differs, brain activation 
differences must be interpreted with caution, as there may be other factors associated 
with those performance differences that can account for the reported brain activation 
differences rather than the diagnosis (Church, Petersen, & Schlaggar, 2010). The other 
side of the argument is also possible: when the clinical group does not differ from the 
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control group and differences on brain activation are observed, then the question 
arises on what does it mean? There are a number of options to address these 
performance differences. One of them is to use paradigms where patients have 
consistently shown deficits in neuropsychological studies, and to adjust them for their 
use in fMRI studies in order to ensure everyone performs as its best level, such as in 
the individually tracked version of the SST (Rubia, Smith, et al., 2003). Another 
option is to investigate the association between performance and brain activation 
differences. However, and potentially due to the small sample sizes of the majority of 
the studies reviewed, the evidence for such association in ADHD is reduced.   
Thus, activation differences in the left DLPFC were associated with the main 
inhibitory index (SSRT) in healthy controls, but not in the ADHD group (Rubia et al., 
2008). Epstein et al (Epstein et al., 2007) showed that activation in right IFC, which 
was reduced in patients compared to controls, was associated both in ADHD patients 
and controls (separately) with better discrimination (d-prime, index of perceptual 
sensitivity to targets) in the inhibitory task (Epstein et al., 2007). Activation in 
frontopolar and cingulate regions (where patients showed enhanced activation 
compared to healthy controls) was positively associated with commission errors 
(increased in patients compared to controls) only within the healthy control group but 
not within patients (Schulz et al., 2004). Finally, in ADHD boys, post-error go 
reaction times were positively associated with activation in left IFC, premotor, dorsal 
MFC and thalamic regions, which were underactivated in patients when compared to 
healthy control boys (Rubia, Halari, Mohammad, et al., 2011).  
Some of the studies have also tested for the potential association between 
ADHD symptoms and areas of observed dysfunction. Hyperactivity symptoms as 
measured by the Strengths and Difficulties Questionaire (SDQ) have been associated 
with the underactivation observed in patients compared to controls in the key 
inhibitory function, the right IFC (Rubia et al., 2005) and in the PCC/precuneus 
(Rubia et al., 2005). There are also some studies where this association has been 
tested and no significant results have been reported (Rubia, Cubillo, et al., 2010; 
Schulz et al., 2004).  
To sum up, the evidence from studies using motor response inhibition tasks 
suggests that children with ADHD show underactivation in key regions for this 
process, most consistently in the bilateral IFC and the caudate.  
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2.3.1.2. Interference inhibition 
During interference inhibition tasks, healthy subjects show activation in a 
predominantly (but not exclusively) left lateralised network (Nee, Wager, & Jonides, 
2007) including IFC and DLPFC, ACC, basal ganglia and left parietal regions  
(Cabeza & Nyberg, 2000; Christakou et al., 2009; Derrfuss, Brass, Neumann, & von 
Cramon, 2005; Laird et al., 2005; Liu, Banich, Jacobson, & Tanabe, 2004; Rubia et 
al., 2006).  
The left IFC has shown to be crucial for interference inhibition and response 
selection (Chikazoe et al., 2009; Dodds, Morein-Zamir, & Robbins, 2011; Goghari & 
MacDonald, 2009), the ACC is key for performance monitoring and conflict detection 
processes (Botvinick et al., 2004; Braver, Barch, Gray, Molfese, & Snyder, 2001; 
Rushworth, Walton, Kennerley, & Bannerman, 2004) whereas the striatum, in 
particular the putamen has been involved in stimulus-response learning patterns 
(Grahn, Parkinson, & Owen, 2008).  
Interference inhibition tasks typically load also on selective attention 
processes, as the subjects have to selectively focus their attention on the relevant 
aspects of the target stimuli in the task so as to perform correctly. Thus, activation is 
typically also observed in the temporo-parietal junction and PCC, areas engaged in 
selective attention (Corbetta & Shulman, 2002; Mesulam et al., 2001; Mohanty et al., 
2008; Sack, 2009; Small et al., 2003). 
During conflict/interference inhibition conditions in Simon tasks (Rubia, 
Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2011) and similar interference 
inhibition tasks (Konrad et al., 2006; Vaidya, Bunge, Dudukovic, & Zalecki, 2005; 
Vloet et al., 2010), children with ADHD compared to healthy peers have shown 
reduced activation in right and left IFC (Rubia, Halari, Cubillo, et al., 2011; Vaidya et 
al., 2005), basal ganglia (mostly putamen) (Konrad et al., 2006; Rubia, Cubillo, et al., 
2011; Rubia, Halari, Cubillo, et al., 2011; Vloet et al., 2010), in SMA/ACC (Rubia, 
Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2011), PCC (Rubia, Halari, 
Cubillo, et al., 2011), temporal cortices (Rubia, Halari, Cubillo, et al., 2011; Rubia, 
Halari, Smith, et al., 2009), precuneus (Rubia, Halari, Smith, et al., 2009), and right 
parietal lobe (Rubia, Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2011). 
Furthermore, a discriminant analysis showed that activation patterns in the right 
inferior parietal lobe (IPL), which showed disorder-specific underactivation in 
children with ADHD compared to children with OCD, correctly classified ADHD 
 66 
patients with 90% sensitivity (Rubia, Cubillo, et al., 2011). In addition, not only 
reduced activation in isolated brain regions has been reported, but also reduced 
functional connectivity between IFC and superior parietal lobe during interference 
inhibition (Vloet et al., 2010), which supports the presence of dysfunctional fronto-
parietal interference inhibition networks.  
However, there are also studies where either no between group differences in 
brain activation (Smith, Taylor, et al., 2006) or increased activation was detected in 
the group of patients compared to controls during these paradigms (Konrad et al., 
2006; Schulz et al., 2005). Increased and presumably compensatory activation was 
observed in patients compared to typically developing children in left superior parietal 
lobe (Konrad et al., 2006). During a stimulus-response interference inhibition task, 
increased activation was observed in left IFC (ventrally located) (Schulz et al., 2005). 
In a more cognitively demanding integrated task with both stimulus-response 
interference and response competition interference, enhanced activation in children 
with ADHD compared to controls was observed in the left ACC, anterior right MFC, 
right IFC and left basal ganglia (caudate and globus pallidus) (Schulz et al., 2005). 
However, it is necessary to consider once more the special characteristics of the 
sample to interpret the results correctly, since 50% of the participants did not fulfil 
criteria for a full diagnosis of ADHD at the time of the study, had a long-term 
medication history and were older than other samples studied (Schulz et al., 2005).  
Despite the presence of performance differences between children with ADHD 
and controls in some of the studies (Rubia, Halari, Smith, et al., 2009; Smith, Taylor, 
et al., 2006) (Konrad et al., 2006; Rubia, Halari, Cubillo, et al., 2011; Vaidya et al., 
2005; Vloet et al., 2010), only few have reported an association between differences 
in brain activation and performance in the task. Thus, a regression analysis showed 
that better interference suppression in ADHD was positively associated with BOLD 
response in left IFC, insula, caudate, thalamus and temporo-parietal regions (Vaidya 
et al., 2005), and conflict error was negatively associated with activation in PCC and 
precuneus (underactivated in ADHD patients relative to controls) in the control group 
but not in the ADHD group (Rubia, Halari, Smith, et al., 2009). Furthermore, the 
underactivation shown by children with ADHD relative to controls in basal ganglia 
was associated with ADHD symptom severity (Konrad et al., 2006; Rubia, Halari, 
Cubillo, et al., 2011). Other studies, however, have shown no association between 
differences in BOLD response and ADHD symptoms (Rubia, Cubillo, et al., 2011; 
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Rubia, Halari, Smith, et al., 2009; Vaidya et al., 2005), potentially due to small 
sample sizes.  
The reviewed evidence suggests therefore that children with ADHD during 
interference inhibition tasks show underactivation in key areas for conflict detection, 
stimulus-response learning and selective attention, necessary for the correct 
performance of the task, most prominently in the ACC, putamen and temporo-parietal 
regions.  
 
2.3.1.3. Cognitive flexibility  
During cognitive flexibility tasks healthy subjects typically show activation in 
bilateral DLPFC and IFC, ACC and IPL (Buchsbaum, Greer, Chang, & Berman, 
2005; Derrfuss et al., 2005; Rubia et al., 2006; Smith, Taylor, Brammer, & Rubia, 
2004) (for a meta-analysis, see Wager, Jonides, & Reading, 2004). The DLPFC has 
been associated with the monitoring of task-relevant information (Luks, Simpson, 
Dale, & Hough, 2007) and the selection of an alternative response (Badre & Wagner, 
2004). Furthermore, the medial basal ganglia have shown a relevant role in flexibility 
of responding processes (Grahn et al., 2008). Attention shifting has been associated 
with the IPL, in particular the region close to the intraparietal sulcus (Dodds et al., 
2011; Wager et al., 2004).  
At the brain activation level, reduced activation during cognitive flexibility 
tasks has been reported in children with ADHD relative to controls bilaterally in key 
regions including bilateral IFC (Rubia, Hyde, et al., 2010; Rubia, Halari, et al., 2010; 
Smith, Taylor, et al., 2006), left DLPFC (Rubia, Halari, et al., 2010), basal ganglia 
(Rubia, Cubillo, et al., 2010),}(Smith, Taylor, et al., 2006),  ACC and PCC (Rubia, 
Hyde, et al., 2010; Rubia, Cubillo, et al., 2010; Rubia, Halari, et al., 2010), and 
temporo-parietal regions (Rubia, Hyde, et al., 2010; Rubia, Halari, et al., 2010; Smith, 
Taylor, et al., 2006). It was furthermore observed that when patterns of brain 
activation in children with ADHD are compared to those observed in children with 
other paediatric psychiatric disorders, the underactivation observed in IFC, left basal 
ganglia, ACC and PCC and parietal cortex was specific to ADHD and not shared by 
paediatric OCD patients (Rubia, Cubillo, et al., 2010). Furthermore, the pattern of 
reduced activation in bilateral IFC and left DLPFC was also disorder-specific when 
compared to children with CD (Rubia, Halari, et al., 2010). 
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Only one fMRI study has reported differences at a performance level during a 
cognitive flexibility paradigm, with children with ADHD compared to healthy peers 
showing slower reaction times to repeat trials and greater within-subject variability 
during repeat trials (Smith, Taylor, et al., 2006). However, no association between 
these performance differences (or symptoms) and brain activation has been observed.  
It can hence be concluded from the available evidence that children with 
ADHD show underactivation relative to controls in typical areas that mediate 
cognitive flexibility, in bilateral IFC, caudate and putamen, ACC/PCC and parietal 
regions during cognitive flexibility tasks.  
 
2.3.1.4. Summary of findings from inhibitory tasks 
A number of factors need to be considered when interpreting the findings from 
the reviewed studies, such as the small samples sizes (Booth et al., 2005; Durston et 
al., 2006; Durston et al., 2003; Epstein et al., 2007; Mulder et al., 2008; Schulz et al., 
2005; Tamm et al., 2004; Vaidya et al., 2005; Vloet et al., 2010), which in most of the 
cases are below the suggested number of 20 participants in each group (Thirion et al., 
2007). Furthermore, the frequent inclusion of comorbid disorders (Durston et al., 
2006; Durston et al., 2003; Epstein et al., 2007; Konrad et al., 2006; Mulder et al., 
2008; Pliszka, Glahn, et al., 2006; Suskauer et al., 2008), different subtypes of ADHD 
(Booth et al., 2005; Durston et al., 2003; Epstein et al., 2007; Konrad et al., 2006; 
Mulder et al., 2008; Schulz, Bedard, Czarnecki, & Fan, 2011; Schulz et al., 2005; 
Suskauer et al., 2008; Vloet et al., 2010), or males and females within the same 
sample (Booth et al., 2005; Durston et al., 2003; Epstein et al., 2007; Pliszka, Glahn, 
et al., 2006; Suskauer et al., 2008; Vaidya et al., 2005) increase the heterogeneity of 
the samples and complicates the interpretation of the findings, especially in studies 
with such small sample sizes. However, possibly the most important confound is the 
inclusion of subjects with a previous history of stimulant medication (Booth et al., 
2005; Durston et al., 2006; Durston et al., 2003; Epstein et al., 2007; Mulder et al., 
2008; Pliszka, Glahn, et al., 2006; Schulz et al., 2005; Suskauer et al., 2008; Tamm et 
al., 2004; Vaidya et al., 2005), given the long-term effects of stimulant medication 
administration on brain structure and function (Frodl & Skokauskas, 2012; Konrad, 
Neufang, Fink, & Herpertz-Dahlmann, 2007; Nakao et al., 2011; Shaw, Sharp, et al., 
2009).  Finally, we also need to take into account the frequent use of ROI analysis 
(Durston et al., 2006; Epstein et al., 2007; Mulder et al., 2008; Pliszka, Glahn, et al., 
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2006; Schulz et al., 2004; Suskauer et al., 2008), that restricts the areas to study and 
increases the statistical power to detect differences in these regions, although at the 
expense of leaving aside other regions that may be playing a role in the disorder 
(Friston, Rotshtein, Geng, Sterzer, & Henson, 2006). Therefore, the use of ROI 
analyses over whole brain methods may bias the results as only some areas are 
studied, and therefore may increase the consistency of the findings with regards to the 
dysfunctions observed on brain areas, while other regions that may be relevant for the 
disorder are left aside and although may be dysfunctional, these will remain 
undetected.  
However, and despite these limitations, the evidence is relatively consistent 
with regards to abnormalities in children and adolescents with ADHD during 
inhibitory tasks, as brain imaging studies have most consistently shown reduced 
activation in bilateral IFC, and caudate during motor response inhibition (Mulder et 
al., 2008; Rubia, Halari, Mohammad, et al., 2011; Rubia, Cubillo, et al., 2010; Rubia 
et al., 2008; Rubia, Overmeyer, et al., 1999; Rubia et al., 2005), in ACC and temporo-
parietal regions during interference inhibition (Konrad et al., 2006; Rubia, Cubillo, et 
al., 2011; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Smith, et al., 2009) and in 
bilateral IFC, putamen and caudate, ACC/PCC and parietal regions during cognitive 
flexibility (Rubia, Halari, et al., 2010; Smith, Taylor, et al., 2006).  
 
2.3.2 Deficits during attention processes   
 
2.3.2.1 Sustained attention 
 Healthy subjects during sustained attention tasks such as the CPT activate a 
predominantly right lateralized network including IFC and DLPFC, pre-SMA, 
striatum, thalamus, temporal areas, inferior parietal regions and cerebellum (Adler et 
al., 2001; Cabeza & Nyberg, 2000; Lawrence, Ross, Hoffmann, Garavan, & Stein, 
2003; Smith, Halari, Giampetro, Brammer, & Rubia, 2011; Tana, Montin, Cerutti, & 
Bianchi, 2010; Voisin, Bidet-Caulet, Bertrand, & Fonlupt, 2006). The cerebellum as 
part of the fronto-cerebellar neural circuits is involved in sustained attention processes 
(Arnsten & Rubia, 2012; Lawrence et al., 2003; Steinlin, 2007; Stoodley & 
Schmahmann, 2009; Voisin et al., 2006), the pre-SMA is involved in attention to 
action and response selection (Lau, Rogers, Ramnani, et al., 2004; Mostofsky & 
Simmonds, 2008; Sharp et al., 2010; Simmonds et al., 2008), and temporo-parietal 
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regions have shown to be involved in visual-spatial attention control (Corbetta & 
Shulman, 2002).  
Children with ADHD have shown deficits in these areas underlying sustained 
attention processes. During fMRI adaptations of sustained attention tasks, reduced 
activation has been reported in ADHD boys compared to healthy controls in 
dorsolateral, ventrolateral and ventromedial/orbito/inferior prefrontal cortices 
(Christakou et al., 2012; Rubia, Halari, Cubillo, Mohammad, & Taylor, 2009; Rubia, 
Smith, et al., 2009), as well as in striatum, thalamus, temporo-parietal regions and 
cerebellum (Christakou et al., 2012; Rubia, Halari, Cubillo, et al., 2009). However, 
enhanced potentially compensatory activation has also been described in precuneus, 
temporo-occipital regions and cerebellum, which was furthermore correlated with the 
reduced activation in prefrontal areas (Christakou et al., 2012; Rubia, Smith, et al., 
2009). In addition, the reduced activation in ventrolateral prefrontal cortex (VLPFC) 
and increased activation observed in the cerebellum were disorder-specific to children 
with ADHD when compared to children with CD (Rubia, Smith, et al., 2009). The 
increased number of omission errors observed in patients compared to healthy 
controls was associated with activation in VLPFC (across all subjects) (Rubia, Smith, 
et al., 2009), and with parietal activation within ADHD (Rubia, Halari, Cubillo, et al., 
2009). Furthermore, within ADHD patients, the number of premature responses was 
negatively associated with the enhanced activation observed in the precuneus 
compared to that of healthy controls (Christakou et al., 2012). 
In addition, ADHD patients relative to healthy controls have shown reduced 
functional connectivity during sustained attention between IFC, basal ganglia, parietal 
cortices and cerebellum (Rubia, Halari, Cubillo, et al., 2009), which supports the 
presence of dysfunctions not only on isolated specific brain regions, but in fronto-
striato-parieto-cerebellar network underlying sustained attention processes.  
Therefore, the evidence suggests the presence of reduced functioning and 
reduced functional connectivity in children with ADHD compared to controls in 
regions involved in sustained attention most consistently in lateral prefrontal, striato-
thalamic and temporo-parietal regions and cerebellum.  
 
2.3.2.2. Attention allocation 
During oddball tasks measuring attention allocation, healthy subjects have 
shown brain activation in a network involving IFC and DLPFC, insula, ACC and 
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PCC, as also in IPL and temporo-occipital regions (Ardekani et al., 2002; Clark, 
Fannon, Lai, Benson, & Bauer, 2000; Downar, Crawley, Mikulis, & Davis, 2002; 
Rubia, Smith, Taylor, et al., 2007). Activation differences have been reported between 
children with ADHD and healthy comparison subjects during different oddball tasks. 
In patients, reduced activation has been observed in IFC/MFC (Rubia, Halari, Smith, 
et al., 2009), ACC (Konrad et al., 2006), basal ganglia (Konrad et al., 2006; Rubia, 
Cubillo, et al., 2011; Rubia, Smith, Brammer, & Taylor, 2007b) and thalamus (Rubia, 
Smith, et al., 2007b; Tamm, Menon, & Reiss, 2006). As mentioned above, 
underactivation in regions involved in visuo-spatial attention has also been reported 
during oddball tasks, in particular in PCC (Rubia, Cubillo, et al., 2011; Rubia, Smith, 
et al., 2007b) and temporo-parietal cortices (Rubia, Smith, et al., 2007b; Stevens, 
Pearlson, & Kiehl, 2007; Tamm et al., 2006). The underactivation observed in left 
IFC/MFC, caudate and PCC was disorder specific when compared to children with 
CD and OCD (Rubia, Cubillo, et al., 2011; Rubia, Halari, Smith, et al., 2009).  
Some performance differences have been reported in these studies, although 
not all the studies have investigated their association with brain activation. Children 
with ADHD compared to healthy controls have shown an increased intra-subject 
variability of response to oddball trials (Rubia, Smith, et al., 2007b) which was 
negatively associated with the BOLD signal in the basal ganglia, thalamus, temporal 
regions and cerebellum within ADHD patients as shown by a whole brain regression 
analysis (Rubia, Smith, et al., 2007b). The increased commission errors committed by 
ADHD children compared to controls was negatively associated with the percentage 
of voxels activated in parietal regions within controls but not within the ADHD 
groups (Tamm et al., 2006). Finally, longer reaction time (RT) to target stimuli for 
ADHD subjects compared to healthy controls has also been reported, but the authors 
did not investigate their association with BOLD signal changes (Stevens, Pearlson, et 
al., 2007). Only one study has shown association between symptoms and brain 
activation, where symptom severity was negatively associated within ADHD patients 
with intensity of the BOLD signal in PCC, which was underactivated in ADHD boys 
(Rubia, Cubillo, et al., 2011).  
The reviewed evidence therefore suggests underactivation in children with 
ADHD relative to healthy control children during attention allocation tasks most 
consistently in the PCC and temporo-parietal cortices, as well as in thalamus and 
basal ganglia.  
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2.3.2.3 Summary of findings from attention tasks 
 It can therefore be concluded that the available evidence supports the presence 
of dysfunctions in brain networks underlying sustained attention and attention 
allocation processes, most consistently in lateral prefrontal, striato-thalamic and 
temporo-parietal regions as well as in the cerebellum. Limitations in the studies 
include the use of ROI approach (Stevens, Pearlson, et al., 2007), the inclusion of 
different subtypes of ADHD (Konrad et al., 2006), of a significant proportion of 
comorbid cases (Konrad et al., 2006) or of patients with a previous history of 
stimulant medication (Stevens, Pearlson, et al., 2007; Tamm et al., 2006) within small 
samples.  
  
2.3.3 Deficits during working memory processes 
Verbal WM tasks in healthy subjects have shown to activate a cortical network 
including the DLPFC, key region involved in the storage and manipulation of the 
information and in the coding of the temporal sequence of stimuli (Amiez & Petrides, 
2007; Owen, McMillan, Laird, & Bullmore, 2005), as well as the lateral IFC, 
temporo-parietal regions and cerebellum (Cabeza & Nyberg, 2000; Mayer et al., 
2007; Owen et al., 2005; Volle et al., 2008).  
Some differences between children with ADHD and healthy controls have 
been observed during the fMRI adaptations of various WM tasks. In the only study 
that has used the N-Back in paediatric ADHD populations, patients showed reduced 
activation compared to controls in left precentral cortex and IPL, in bilateral superior 
parietal lobes (SPL) and cerebellum (Kobel et al., 2009), as well as reduced responses 
compared to healthy controls in the 2-Back and 3-Back conditions (Kobel et al., 
2009). However, the association between these performance differences and brain 
activation was not investigated. 
Using a delayed match-to-sample verbal WM task, girls with ADHD showed 
reduced activation during high WM load in the right IFC/insula, as well as in right 
SPL (Sheridan, Hinshaw, & D'Esposito, 2007). The authors furthermore observed that 
in ADHD girls, activation in the left VLPFC as associated negatively with faster 
retrieval (Sheridan et al., 2007). 
In the Visual Serial Addition Task (VSAT), a variation of the Paced Auditory 
Serial Addition (PASAT) (Gronwall, 1977), subjects are presented with the first 
number of a mathematical addition, and after a short delay they are presented with the 
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second number and the result, and need to press whether the result is correct or not. In 
this case, the authors used both whole brain and ROI methods (Fassbender et al., 
2011). They identified enhanced activation in patients compared to controls in right 
IFC, putamen, insula bilaterally and left MFC, and only when using a ROI approach 
they observed enhanced WM-related activity in controls compared to ADHD patients 
in a different region of the left premotor cortex. Across all subjects, activation in the 
left putamen and bilateral insula was positively associated with longer RT, and within 
ADHD patients with the total ADHD symptoms score (Fassbender et al., 2011). 
However, the increased number of omission errors observed in ADHD patients was 
not significantly associated with any of the clusters of observed BOLD signal 
differences. 
During visuo-spatial WM tasks, medication-naïve children with ADHD 
compared to controls have shown reduced activation in bilateral IFC and left SFC 
(Silk et al., 2005), caudate (Silk et al., 2005; Vance et al., 2007), in right STG (Silk et 
al., 2005) and in occipito-parietal regions (Silk et al., 2005; Vance et al., 2007). In 
addition, children with ADHD showed enhanced activation compared to healthy 
controls in left medial temporal gyrus (MTG) and STG, in PCC and in medial 
superior frontal cortex (Silk et al., 2005). Although these authors also observed 
reduced accuracy in the ADHD group compared to the group of healthy children (Silk 
et al., 2005), they did not investigate further the association between brain activation 
and performance differences.  
 The evidence therefore supports the presence of brain dysfunction especially 
in temporo-parietal regions, but also in MFC during WM tasks. However, the variety 
of tasks used, the small sample sizes (Fassbender et al., 2011; Kobel et al., 2009; 
Sheridan et al., 2007; Silk et al., 2005; Vance et al., 2007), the increased heterogeneity 
of the samples due to the inclusion of males and females (Fassbender et al., 2011), of 
different subtypes of the disorder or of comorbid conditions (Fassbender et al., 2011; 
Kobel et al., 2009; Sheridan et al., 2007; Silk et al., 2005; Vance et al., 2007) 
significantly complicates the interpretation of the findings.  
 
2.3.4 Deficits during temporal processing tasks 
In healthy subjects, fronto-striatal, parietal and cerebellar regions have been 
involved in temporal processing (Rubia, 2006; Rubia, Halari, Christakou, et al., 2009; 
Rubia & Smith, 2004; Wiener et al., 2010). The DLPFC and IFC have been directly 
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involved in time perception processes (Aso et al., 2010; Bueti, Walsh, Frith, & Rees, 
2008; Coull & Nobre, 2008; Lewis & Miall, 2006b; Rao, Mayer, & Harrington, 2001; 
Rubia, 2006; Rubia & Smith, 2004; Shih, Kuo, Yeh, Tzeng, & Hsieh, 2009; Smith, 
Taylor, Brammer, Halari, & Rubia, 2008; Smith, Taylor, Lidzba, & Rubia, 2003; 
Wiener et al., 2010). SMA/pre-SMA and ACC have been associated with both the 
estimation of stimuli duration and fine temporal adjustment of the motor output (Bueti 
et al., 2008; Coull & Nobre, 2008; Coull, 2004; Macar et al., 2002; Rao et al., 2001; 
Rubia, 2006; Rubia & Smith, 2004; Shih et al., 2009; Smith et al., 2003; Wiener et al., 
2010). In line with the hypothesis of dopaminergic regulation in temporal processes 
(Lewis & Miall, 2006a), striatum/basal ganglia have been considered as “time 
generators” (Aso et al., 2010; Bueti et al., 2008; Coull & Nobre, 2008; Koch, Oliveri, 
& Caltagirone, 2009; Lewis & Miall, 2006a; Rao et al., 2001; Shih et al., 2009; Shih, 
Yeh, Kuo, Tzeng, & Hsieh, 2010; Wiener et al., 2010). The cerebellum is furthermore 
a key region for timing processes (see Rubia & Smith, 2004 for a review,; and Wiener 
et al., 2010for a meta-analysis), especially for those processes in the sub-seconds 
range (Aso et al., 2010; Rubia & Smith, 2004; Smith et al., 2003; Wiener et al., 2010).  
Reduced activation in temporal processing brain networks has been reported in 
medication-naïve children with ADHD compared to controls during temporal 
discrimination tasks in bilateral OFC/ IFC (Rubia, Halari, Christakou, et al., 2009; 
Smith et al., 2008), right DLPFC (Rubia, Halari, Christakou, et al., 2009; Smith et al., 
2008), caudate (Rubia, Halari, Christakou, et al., 2009), ACC/SMA (Rubia, Halari, 
Christakou, et al., 2009; Smith et al., 2008) and cerebellum (Rubia, Halari, 
Christakou, et al., 2009). Enhanced activation was also reported during a TD 
paradigm in children with ADHD compared to controls in dorsomedial prefrontal 
cortex and posterior temporo-occipital regions (Rubia, Halari, Christakou, et al., 
2009). In previously medicated children with ADHD similar results have also been 
reported, with reduced activation relative to controls in the left ACC and posterior 
cerebellum, and reduced functional connectivity between right IFC and left 
cerebellum during a temporal discrimination task (Vloet et al., 2010).  
During temporal synchronization and tapping tasks children with ADHD have 
shown underactivation compared to controls in ACC and PCC (Rubia, Overmeyer, et 
al., 1999), right superior parietal region (Mostofsky et al., 2006) and in a ROI 
analyses conducted in the same study from Mostofsky et al, (Mostofsky et al., 2006), 
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in the contralateral primary motor cortex. Also, enhanced activation has been reported 
in the right SMA (Rubia, Overmeyer, et al., 1999).   
During a GNG task with a component of timing manipulation children with 
ADHD compared to healthy controls have shown reduced activation in the inferior 
cerebellum during unpredictable compared to predictable stimuli timing (Durston et 
al., 2007; Mulder et al., 2008). 
Finally, during temporal discounting tasks, measuring temporal foresight, 
reduced activation has been reported in children with ADHD in IFC/OFC, putamen, 
thalamus, PCC, parietal regions and cerebellum (Rubia, Halari, Christakou, et al., 
2009). Furthermore, all the clusters of underactivation were associated with enhanced 
hyperactivity symptoms (Rubia, Halari, Christakou, et al., 2009)  
Association between performance differences and brain activation differences 
has been reported so far by only one study, where children with ADHD showed a 
shorter RT for delayed reward choices (they deliberate shorter than controls when 
choosing delayed over immediate rewards), which was positively correlated with the 
reduced BOLD response observed in the cerebellum (Rubia, Halari, Christakou, et al., 
2009). Although other studies have reported impaired performance in these tasks in 
children with ADHD, with errors during TD (Vloet et al., 2010) and reduced accuracy 
during temporal manipulations of stimuli in a GNG task (Durston et al., 2007; Mulder 
et al., 2008), none of these studies tested for the association between these 
performance differences and between-group differences in BOLD response. So far, 
the only association between brain activation during time processing and ADHD 
symptoms has been reported by Rubia et al (Rubia, Halari, Christakou, et al., 2009), 
where there was an inverse association between the reduced activation in children 
with ADHD during temporal foresight showed in IFC/OFC, putamen, thalamus, PCC, 
parietal regions and cerebellum and hyperactivity symptoms (Rubia, Halari, 
Christakou, et al., 2009)  
 Thus, during motor timing, time estimation, time discrimination and temporal 
foresight processes, children with ADHD show consistently reduced activation 
compared to healthy controls in key areas that have consistently been associated with 
temporal processes, such as in IFC, DLPFC, SMA, ACC, striatum and cerebellum, 
However, as in all previous sections, findings need to be interpreted with caution 
given the restriction to the results imposed by the use of ROI methods by some of the 
studies (Mostofsky et al., 2006; Mulder et al., 2008; Vloet et al., 2010); the relatively 
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small sample sizes (Mostofsky et al., 2006; Mulder et al., 2008; Rubia, Halari, 
Christakou, et al., 2009; Rubia, Overmeyer, et al., 1999; Vloet et al., 2010) and the 
crucial confound which is the inclusion of previously medicated participants in some 
of the studies (Mostofsky et al., 2006; Mulder et al., 2008; Vloet et al., 2010). Thus, 
especially relevant is the evidence from studies on medication-naïve samples, which 
used whole brain analysis methods (Rubia, Halari, Christakou, et al., 2009; Smith et 
al., 2008). 
 
2.3.5 Reward and motivation-related deficits 
It is interesting that despite the fact that it has been hypothesised that abnormal 
reinforcement processing is key to ADHD (Luman et al., 2005; Luman et al., 2010; 
Sagvolden et al., 2005), there are very few studies that have tested for evidence on 
their potential neural underpinnings in children with ADHD. Thus, during the reward 
condition of a sustained attention task reduced activation has been reported in children 
with ADHD compared to controls in left PCC and precuneus (which was furthermore 
specific to children with ADHD when compared to children with CD) (Rubia, Smith, 
et al., 2009) and cerebellum (Rubia, Halari, Cubillo, et al., 2009). Enhanced activation 
in patients compared to controls has also been reported in a different sample of 
ADHD children, in OFC and temporal regions (Rubia, Halari, Cubillo, et al., 2009), 
which according to the authors was suggestive of enhanced sensitivity to rewards. 
Furthermore, reduced activation in children with ADHD relative to controls has been 
reported in right VS during reward anticipation (Scheres, Milham, Knutson, & 
Castellanos, 2007).  
Thus, despite the reduced number of studies, the evidence is suggestive of 
abnormalities is OFC-striatal, PCC and cerebellar regions during reward-related 
processes in children with ADHD. However, more studies are needed.   
 
2.4. ADHD and functional connectivity 
Recent fMRI studies in ADHD have focused not only on the abnormalities 
observed in brain activation in specific brain regions, but also in the disrupted 
functional connectivity between these regions, both during the resting state and in the 
context of cognitive tasks.  
During the resting state, reduced functional connectivity has been reported in 
children with ADHD compared to healthy controls in fronto-striatal, cingulate, fronto-
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parietal, temporo-parietal and fronto-cerebellar networks, although some studies have 
also reported increased inter-regional connectivity between ACC, striatum and 
temporo-cerebellar regions (for reviews see (Konrad & Eickhoff, 2010; Liston et al., 
2011)). Additionally, abnormalities in the default mode network (DMN) have also 
been reported. The DMN comprises midline structures including the ventromedial 
prefrontal cortex, PCC, and precuneus, is characterised by low-frequency oscillations 
of BOLD signal at rest (Raichle et al., 2001) and is typically anti-correlated with 
networks engaged by effortful cognitive tasks (Fox et al., 2005; Sonuga-Barke & 
Castellanos, 2007). Children with ADHD compared to healthy developing children 
showed decreased integration of the components of the DMN (Fair et al., 2009). 
Furthermore, problems with deactivation of the DMN have been linked to attention 
lapses in ADHD (Fassbender et al., 2009; Sonuga-Barke & Castellanos, 2007). 
 As mentioned above, few fMRI studies have focused so far on the 
abnormalities observed in functional connectivity in children with ADHD compared 
to healthy controls in the context of cognitive tasks. Thus, ADHD patients relative to 
healthy controls have shown reduced functional connectivity during sustained 
attention between IFC, basal ganglia, parietal cortices and cerebellum (Rubia, Halari, 
Cubillo, et al., 2009), during a TD task between right IFC and left cerebellum, and 
during interference inhibition between IFC and SPL (Vloet et al., 2010).  
Therefore, children with ADHD show not only brain dysfunctions in isolated 
brain regions during disorder-relevant cognitive tasks but also reduced functional 
connectivity both during the resting state and in the context of cognitive tasks.  
 
2.5 Findings from structural and functional studies in adults with ADHD  
 As a neurodevelopmental disorder, ADHD was considered until recent times a 
childhood disorder that resolved in late adolescence, hence the focus of imaging 
studies of ADHD was mostly in children. However, evidence has shown that 
symptoms of ADHD persist until adulthood in up to 65 % of the cases (Barkley et al., 
2002; Biederman et al., 2006).  
 The evidence of structural and functional abnormalities in adult ADHD 
populations is less numerous, although suggestive of similar abnormalities as those 
described in children with the disorder. Thus, sMRI and DTI studies have provided 
evidence for structural abnormalities (reduced cortical thickness, volumes or grey and 
white matter volumes) in subcortical structures, as well as in DLPFC/IFC, ACC and 
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PCC, and temporo-parietal regions (see (Cubillo et al., 2012) and (Cubillo & Rubia, 
2010) for reviews).  
 However, meta-analytic structural imaging studies as well as longitudinal 
imaging studies in children with ADHD have shown the normalisation of the reduced 
basal ganglia grey matter volumes with age, so that adults no longer showed deficits 
(Castellanos et al., 2002; Frodl & Skokauskas, 2012; Nakao et al., 2011). Therefore, 
there is evidence that basal ganglia deficits normalise in adult ADHD. Whether 
abnormalities normalise with age is a highly relevant issue that can only be studied 
with large samples in adequately designed prospective longitudinal studies.  
 It can therefore be concluded that patients whose symptoms of ADHD persist 
into adulthood show abnormalities in their brain structure that are similar to those 
reported in children with ADHD, most consistently in prefrontal, cingulate and 
temporo-parietal regions, as well as in subcortical structures with the exception of the 
basal ganglia (Cubillo et al., 2012; Cubillo & Rubia, 2010). However, prospective 
longitudinal follow-up studies into adulthood are needed to disentangle the 
association between brain structure abnormalities and symptomatic improvement or 
remission, as well as the influence of comorbid disorders, medication administration 
or different subtypes of ADHD into the persistence or severity of those structural 
abnormalities.   
 FMRI studies have also shown that, similarly to the evidence in childhood, 
adults with ADHD show reduced functioning during disorder-relevant cognitive tasks. 
Thus, adults with ADHD have shown reduced function compared to healthy control 
subjects in IFC and striatum during motor inhibition tasks, in ACC and fronto-striatal 
regions during interference inhibition, in dorsal/inferior prefrontal, temporo-parietal 
regions and subcortical structures (striatum/thalamus) during attention processes and 
in medial prefrontal and temporo-parietal regions during WM processes (for reviews, 
see Cubillo et al., 2012; Cubillo & Rubia, 2010).  Some inconsistent results have also 
been reported, with enhanced activation during some tasks which may be potentially 
compensatory for the underactivated regions necessary to perform some cognitive 
processes, as it is the case with the enhanced occipital and cerebellar activation 
observed in Cubillo et al (Cubillo et al., 2012). However, from the review of the 
literature there seem to be a number of confounds that may complicate the integration 
and replication of findings (see Cubillo & Rubia, 2010 for a more detailed discussion 
on this issue). Some of these confounds are shared with the studies conducted in 
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children with ADHD, such as the small sample sizes, the presence of a significant 
number of participants with comorbid disorders or a previous history of stimulant 
medication, as well as the recruitment of mixed-gender samples. Furthermore, studies 
in adults typically include participants within a very wide age range (of up to 30 
years), whose diagnosis of ADHD in childhood has been done retrospectively, which 
may be associated to recall bias (Cubillo et al., 2010). Thus, especially relevant are 
those studies where medication-naïve adults with ADHD have a confirmed childhood 
diagnosis of ADHD (Cubillo, Halari, Giampietro, Taylor, & Rubia, 2011; Cubillo et 
al., 2012; Cubillo & Rubia, 2010; Makris et al., 2010). In these cases, the findings 
from adult and children patients with ADHD are remarkably similar, with reduced 
activation in dorsolateral fronto-striatal networks during cognitive switching and 
selective attention tasks, in ventromedial orbitofrontal regions during reward-related 
processing and in inferior frontal cortices and striatum during motor inhibition tasks 
(Cubillo et al., 2012; Cubillo & Rubia, 2010). 
 
2.6. Summary and conclusions  
 As reviewed in the previous chapter, children with ADHD show deficits in a 
range of cognitive processes, most prominently during motor response inhibition, 
sustained attention, temporal processes, reward-related tasks and WM.  
 FMRI studies have provided compelling evidence of dysfunctions in children 
with ADHD in neural circuits underlying motor response inhibition, including right 
and left IFC, caudate and SMA/ACC, which in prefrontal regions has shown to be 
disorder-specific when compared to other paediatric disorders such as CD and OCD 
(Rubia, Cubillo, et al., 2010; Rubia et al., 2008).  
 Comparatively fewer studies have used attention-related paradigms, with 
particularly consistent evidence for underactivation in children with ADHD in 
temporo-parietal regions and the PCC across attention tasks. Disorder-specific 
dysfunctions for ADHD have also been described during attention allocation 
processes, in PCC when compared to OCD which was furthermore associated with 
ADHD symptoms (Rubia, Cubillo, et al., 2011), and in left IFC when compared to 
CD (Rubia, Halari, Smith, et al., 2009). Similarly, during sustained attention, 
ventrolateral prefrontal underactivation and enhanced activation in cerebellum and 
posterior brain regions were specific for ADHD compared to CD (Rubia, Smith, et al., 
2009).  
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Also, relatively consistent deficits have been reported during WM tasks, 
especially when findings from visuo-spatial and verbal-auditory WM studies are 
considered together, the evidence suggests most consistently a pattern of 
underactivation in medial frontal regions and temporo-parietal cortices. However, 
given the impact that attention and verbal WM deficits may have in academic and 
school performance (Gathercole & Alloway, 2006), further research would be needed 
to clarify the brain function abnormalities underlying these deficits.  
 The evidence of dysfunction during temporal processes in ADHD patients is 
also relatively consistent, in particular during TD tasks, showing underactivation in 
children with ADHD relative to healthy controls in all the key areas within TD 
networks including bilateral IFC, SMA/ACC and cerebellum.  
 As reviewed above, the number of studies conducted on reward-related 
processing so far is very limited, but shows deficits in VS, PCC/precuneus and 
cerebellum and enhanced activation in OFC and temporal regions.   
Despite the consistency of the findings, there are caveats that cannot be 
overlooked when reviewing the studies, including the small sample sizes, the 
recruitment of previously medicated children, the inclusion of patients with comorbid 
conditions, as well as mixed gender and mixed subtypes of ADHD samples. 
Furthermore, variations in the paradigms or methods used (such as the use of ROI or 
VBM methods) complicate the integration of the findings. These factors will be now 
separately reviewed.  
It is recommended that for neuroimaging studies at least 20 subjects per group 
should be included to observe significant confident and replicable results (Thirion et 
al., 2007). However, there are few studies that included subjects of this or larger 
sample sizes, i.e. during motor inhibition (Rubia et al., 2008; Suskauer et al., 2008), 
attention (Rubia, Halari, Smith, et al., 2009; Stevens, Pearlson, et al., 2007) or TD 
paradigms (Smith et al., 2008). Only a few have included more than 15 subjects in 
each group during motor inhibition (Pliszka, Glahn, et al., 2006; Rubia, Cubillo, et al., 
2010; Rubia et al., 2005; Smith, Taylor, et al., 2006), interference inhibition (Konrad 
et al., 2006; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Smith, et al., 2009; 
Smith, Taylor, et al., 2006), attention allocation (Rubia, Cubillo, et al., 2011; Rubia, 
Smith, et al., 2007b) or reward-related processes (Rubia, Smith, et al., 2009). Thus, 
the small samples sizes of the vast majority of the functional imaging literature needs 
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to be considered when interpreting the findings, and highlights the relevance of meta-
analytic studies to integrate and provide consistent findings.  
One of the most important factors in which studies differ is the inclusion of 
subjects with a previous history of stimulant medication. This is present in many of 
the reviewed studies (Booth et al., 2005; Durston et al., 2006; Durston et al., 2003; 
Epstein et al., 2007; Fassbender et al., 2011; Kobel et al., 2009; Mostofsky et al., 
2006; Mulder et al., 2008; Pliszka, Glahn, et al., 2006; Prehn-Kristensen et al., 2011; 
Rubia, Halari, Christakou, et al., 2009; Scheres et al., 2007; Schulz et al., 2004; 
Schulz et al., 2005; Sheridan et al., 2007; Stevens, Pearlson, et al., 2007; Suskauer et 
al., 2008; Tamm et al., 2006; Tamm et al., 2004; Vaidya et al., 2005; Vloet et al., 
2010). Stimulant administration has shown long-term effects both on brain structure 
and function (Frodl & Skokauskas, 2012; Konrad et al., 2007; Nakao et al., 2011; 
Shaw, Sharp, et al., 2009). This constitutes the most important confound in brain 
imaging studies in ADHD, since the observed abnormalities cannot be unequivocally 
attributed to the disorder, due to the potentially compensatory or other mechanisms 
triggered by the prescribed drug. Thus, specially valuable are those findings from the 
few studies where only medication-naïve children have been included (Konrad et al., 
2006; Rubia, Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2009; Rubia, Halari, 
Mohammad, et al., 2011; Rubia, Cubillo, et al., 2010; Rubia, Halari, Christakou, et al., 
2009; Rubia, Halari, et al., 2010; Rubia, Halari, Smith, et al., 2009; Rubia et al., 2008; 
Rubia, Overmeyer, et al., 1999; Rubia, Smith, et al., 2007b; Rubia et al., 2005; Rubia, 
Smith, et al., 2009; Silk et al., 2005; Smith et al., 2008; Smith, Taylor, et al., 2006; 
Vance et al., 2007). 
The integration and replication of the findings are also complicated by factors 
that increase the heterogeneity of the samples. One of these factors is the inclusion of 
patients with comorbid disorders in these small samples (at least 1/3 of the sample) 
(Kobel et al., 2009; Konrad et al., 2006; Mulder et al., 2008; Pliszka, Glahn, et al., 
2006; Sheridan et al., 2007; Suskauer et al., 2008). Despite the well-known high rate 
of comorbid disorders (up to 75-85% in children with ADHD) (Biederman et al., 
1991; Spencer, 2006; Wilens et al., 2002), the inclusion of patients with comorbid 
diagnosis should be avoided as it complicates the interpretation of the findings, 
especially in studies with such small sample sizes. Ideally, this should be avoided 
even in the case of the highly frequent comorbid diagnosis of ODD/CD, as it has 
recently observed the presence of shared but also disorder-specific dysfunctions 
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between these two disorders (Rubia, Halari, et al., 2010; Rubia et al., 2008; Rubia, 
Smith, et al., 2009)(for a review, see (Rubia, 2011)).  
Furthermore, although most of the studies included only the combined subtype 
of the disorder, it is not unusual to find that studies have included different subtypes 
of the disorder in the already small ADHD samples, which increases their 
heterogeneity (Booth et al., 2005; Durston et al., 2007; Durston et al., 2003; Epstein et 
al., 2007; Kobel et al., 2009; Konrad et al., 2006; Mostofsky et al., 2006; Mulder et 
al., 2008; Schulz et al., 2004; Schulz et al., 2005; Sheridan et al., 2007; Suskauer et 
al., 2008; Vloet et al., 2010).   
Similarly, the inclusion of males and females in the same sample group is a 
potential confound, given the gender-related differences in brain function, 
presentation of the disorder and brain maturation (Balint et al., 2009; De Bellis et al., 
2001; Gershon, 2002; Mahone & Wodka, 2008; Rubia, Hyde, et al., 2010). It has also 
recently been reported that brain deficits were far more pronounced in males than 
females suggesting that mixed gender studies show reduced activation due to females 
overshadowing male deficits (Valera et al., 2010). Therefore, the inclusion of males 
and females conducted by some studies (Scheres et al., 2007) (Pliszka, Glahn, et al., 
2006) (Booth et al., 2005; Durston et al., 2007; Durston et al., 2003; Epstein et al., 
2007; Fassbender et al., 2011; Konrad et al., 2006; Mostofsky et al., 2006; Suskauer et 
al., 2008; Vaidya et al., 2005) may have masked or attenuated differences that, should 
the samples have been gender-homogeneous, would have been present.  
We also need to take into account that although many studies have used whole 
brain methods to conduct the between-group comparisons, some have used a region of 
interest (ROI) approach (Durston et al., 2007; Durston et al., 2006; Epstein et al., 
2007; Mostofsky et al., 2006; Mulder et al., 2008; Pliszka, Glahn, et al., 2006; Scheres 
et al., 2007; Schulz et al., 2004; Schulz et al., 2005; Suskauer et al., 2008; Vaidya et 
al., 2005; Vloet et al., 2010). Although justified when there is a strong apriori 
hypothesis, this approach may bias the results as it increases the statistical power to 
detect differences within those areas of interest, but it leaves aside other regions that 
may be playing a role in the disorder and have not been initially hypothesised as such 
(Friston et al., 2006).  
Finally, another aspect that merits further attention is the presence of potential 
differences in IQ scores between children with ADHD and healthy participants, and 
how these differences are related to brain activation. To identify the role of IQ 
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differences between groups on cognition and brain activation two approaches are most 
commonly used.  
On the one hand, groups can be matched for IQ scores, so that there are no 
significant differences between them. However, IQ scores have consistently been 
shown to be lower in patients with ADHD than in age-matched healthy controls 
(Bridgett & Walker, 2006; Kuntsi et al., 2004). Matching both groups according to 
their IQ would potentially recruit less impaired patients, not representative of the 
population studied, as they may show less pronounced cognitive and brain activation 
differences when compared to healthy subjects.  
On the other hand, when groups differ in their IQ scores, those IQ scores are in 
many occasions used as a covariate, in an attempt to identify the role of IQ on the 
differences observed in brain activation between groups. However, this is 
controverted from the statistical point of view, as it is statistically inadequate. 
ANCOVA analyses should not be used to correct a between-group finding for a 
covariate that replicates the distribution of the classification variable, as it is the case 
in case-control studies, where participants are not randomly assigned to the groups.  
Given that patients with ADHD have shown to have lower IQ scores than healthy 
controls, this makes it inadequate the use of IQ as a covariate to rule out the effect of 
such differences in IQ on the brain activation differences observed between the two 
groups (Miller & Chapman 2001, Evans & Anastasio 2001, Dennis et al., 2009).  
However, the findings from fMRI studies that do not control for the observed 
differences in IQ between-groups (Rubia, Halari, Mohammad, et al., 2011; Vaidya et 
al., 2005) or where IQ has been used as a covariate (Rubia, Cubillo, et al., 2011; 
Rubia, Halari, Cubillo, et al., 2009; Rubia, Halari, Mohammad, et al., 2011; Rubia, 
Halari, Christakou, et al., 2009; Rubia, Smith, et al., 2009), are similar to those from 
studies where patients and healthy controls did not differ in IQ scores (Booth et al., 
2005; Durston et al., 2007; Durston et al., 2006; Konrad et al., 2006; Mulder et al., 
2008; Pliszka, Glahn, et al., 2006; Rubia, Cubillo, et al., 2011; Rubia, Cubillo, et al., 
2010; Rubia, Halari, Smith, et al., 2009; Rubia et al., 2008; Rubia, Overmeyer, et al., 
1999; Rubia, Smith, et al., 2007b; Rubia et al., 2005; Scheres et al., 2007; Schulz et 
al., 2004; Schulz et al., 2005; Smith et al., 2008; Smith, Taylor, et al., 2006; Stevens, 
Pearlson, & Kiehl, 2007; Suskauer et al., 2008; Tamm, Menon, & Reiss, 2006; Tamm 
et al., 2004; Vloet et al., 2010). Thus, the evidence suggests that the differences 
observed between children with ADHD and healthy controls in brain activation are 
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unlikely to be explained by the differences in IQ scores. However, it is perhaps 
necessary to incorporate the evidence from neuropsychological studies when 
considering the effects of IQ differences on cognitive function and brain activation, as 
these have shown that the role of IQ on the cognitive deficits observed in ADHD may 
differ depending on the cognitive function studied.  
Thus, IQ has been shown to be moderately associated with inhibitory 
measures (Mahone et al., 2002), and the evidence from meta-analytic studies suggests 
this association may only partially underlie the deficits reported in children with 
ADHD during inhibitory functions, with IQ being only a borderline moderator of the 
differences observed during motor inhibition tasks (Lipszyc & Schachar, 2010; 
Willcutt et al., 2005). In line with this, the findings from fMRI studies using motor 
inhibition and interference inhibition tasks that do not control for the observed 
differences in IQ between-groups (Rubia, Halari, Mohammad, et al., 2011; Vaidya et 
al., 2005) or where IQ has been used as a covariate (Rubia, Halari, Cubillo, et al., 
2011; Rubia, Cubillo, et al., 2010) , are very similar to those from studies where 
patients and healthy controls did not differ in IQ scores (Booth et al., 2005; Durston et 
al., 2007; Durston et al., 2006; Konrad et al., 2006; Mulder et al., 2008; Pliszka, 
Glahn, et al., 2006; Rubia, Cubillo, et al., 2010; Rubia, Halari, Smith, et al., 2009; 
Rubia et al., 2008; Rubia, Overmeyer, et al., 1999; Rubia et al., 2005; Schulz et al., 
2004; Schulz et al., 2005; Smith, Taylor, et al., 2006; Suskauer et al., 2008; Tamm et 
al., 2004; Vloet et al., 2010), with reduced activation in key inhibitory areas, including 
the right VLPFC and striatum, but also in left VLPFC, ACC and SMA. Furthermore, 
some of the studies have reported their findings with and without using IQ as a 
covariate, and their results did not significantly differ (Liddle et al., 2010; Peterson et 
al., 2009; Rubia, Halari, Mohammad, et al., 2011). Thus, the evidence suggests that 
the differences observed between children with ADHD and healthy controls in brain 
activation during motor and interference inhibition tasks are unlikely to be explained 
by the differences in IQ scores.   
On the other hand, measures of perceptual timing have been shown to vary 
with IQ scores (Paule, Chelonis, Buffalo, Blake, & Casey, 1999; Wearden, Wearden, 
& Rabbitt, 1997), suggesting that abnormal timing functions in ADHD might be 
associated with low IQ. This has been shown in children with ADHD during duration 
reproduction (Smith et al., 2002; Toplak et al., 2003), time estimation (Barkley, 
Edwards, Laneri, Fletcher, & Metevia, 2001), and temporal discounting tasks 
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(Bitsakou et al., 2009; Kuntsi, Stevenson, Oosterlaan, & Sonuga-Barke, 2001; Marco 
et al., 2009). While fMRI studies using time discrimination tasks have been conducted 
on samples where no differences in IQ scores were observed between healthy 
participants and ADHD patients (Mulder et al., 2008; Rubia, Halari, Christakou, et al., 
2009; Rubia, Overmeyer, et al., 1999; Smith et al., 2008; Vloet et al., 2010), during 
the only fMRI study using a temporal discounting task, participants differed in their 
IQ scores and IQ was entered as a covariate in the analysis (Rubia, Halari, Christakou, 
et al., 2009). Reduced activation was in key areas for temporal foresight, including 
IFC/OFC, putamen, thalamus, PCC, parietal regions and cerebellum (Rubia, Halari, 
Christakou, et al., 2009), and the reduced activation was furthermore associated with 
symptoms of ADHD, which suggests those deficits were not associated with IQ but 
with ADHD (Rubia, Halari, Christakou, et al., 2009). 
In contrast, WM tasks have shown to be closely associated with IQ measures, 
with indirect evidence suggesting they may share a common neurological basis, with 
the DLPFC being a key region (Conway, Kane, & Engle, 2003). WM is typically one 
of the factors obtained in tests of general intelligence and therefore covarying for IQ 
during this task would indeed mean covarying for any differences in WM that may 
exist between the groups. fMRI studies in ADHD samples have used a variety of WM 
tasks, and differ in their  sample characteristics and medication status of the patients, 
which complicates the comparison of the data. However, in the only study where 
groups differing in IQ scores were recruited, IQ was used as a covariate in the 
analyses (Sheridan et al., 2007). However, the authors found reduced activation in 
prefrontal and parietal regions in ADHD patients relative to healthy controls 
(Sheridan et al., 2007), which parallels those findings from fMRI studies where no 
differences in IQ were reported between groups (Fassbender et al., 2011; Kobel et al., 
2009; Silk et al., 2005; Vance et al., 2007).   
 Therefore, although the evidence suggests that generally the findings from 
fMRI studies in ADHD are not due to the potential differences in IQ scores between 
participants with ADHD and healthy controls, the role of the presence of IQ 
differences between groups on brain activation may vary depending on the cognitive 
process targeted by the study, which needs to be taken into consideration in the design 




2.7. Final remarks on structural and functional neuroimaging of ADHD 
Despite the limitations of the available evidence, when considering the 
findings from neuropsychological and functional imaging finding together, it can be 
concluded that children with ADHD compared to healthy controls sho w cognitive 
deficits in EF and in the key regions underlying these deficits, which include:  
a) deficits in motor response inhibition as measured by the SST and GNG 
tasks, with underfunctioning IFC, basal ganglia (mostly caudate) and ACC/SMA;  
b) deficits during working memory processes, with reduced functioning in 
medial PFC and temporo-parietal regions; 
c) deficits during temporal discrimination tasks, with underfunctioning of 
DLPFC/IFC, ACC/SMA and cerebellum. 
The disorder-specific character of some of these dysfunctions in key inferior 
frontal and striatal regions in ADHD (Rubia, Cubillo, et al., 2011; Rubia, Cubillo, et 
al., 2010; Rubia, Halari, et al., 2010; Rubia, Halari, Smith, et al., 2009; Rubia et al., 
2008; Rubia, Smith, et al., 2009) constitutes an important step towards the 
identification of the underlying differential aetiology of the disorder. However, it will 
only be with the study of large homogeneous, comorbid-free, medication-naïve 
samples that a more precise delineation of the underlying brain dysfunctions 
associated with the cognitive deficits and symptoms of ADHD will be obtained.  
Thus, for this study a group of 20 medication-naïve boys with ADHD 
combined subtype was recruited, without additional comorbid diagnoses, with the 
only exception of CD/ODD, present in 2 participants. The selection of boys with only 
the combined subtype reduced the heterogeneity of the sample. Differences in bra in 
activation would be more difficult to detect with heterogeneous samples, with a high 
proportion of participants with additional comorbid disorders diagnoses or including 
males and females, as gender-related differences have been reported in brain function, 
presentation of the disorder and brain maturation (De Bellis et al., 2001; Gershon, 
2002; Mahone & Wodka, 2008; Rubia, Hyde, et al., 2010; Valera et al., 2010). 
Furthermore, and most importantly, this study avoided any confounds related to long-
term effects of stimulant medication by recruiting children with ADHD who have 
never received stimulant treatment, which is highly relevant as long-term effects of 
stimulant medication have been described on brain structure and function (Frodl & 
Skokauskas, 2012; Konrad et al., 2006; Nakao et al., 2011; Shaw, Sharp, et al., 2009). 
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 We selected 3 paradigms where the evidence of cognitive deficits and reduced 
function of the underlying neural networks is consistent: the motor response inhibition 
















CHAPTER 3. EFFICACY AND MECHANISMS OF ACTION OF 
METHYLPHENIDATE AND ATOMOXETINE  
 
 In 1937, Charles Bradley was the director of the Emma Pendleton Bradley 
House, a neuropsychiatric hospital for children. To identify the neural basis of the 
disorders presented by patients, he performed pneumoencephalograms, which involve 
gas or air that is introduced into the spinal cord, producing severe headaches to his 
patients. In an attempt to improve these headaches, he administered Benzedrine to the 
children, an amphetamine-based drug, which had not effects on their headaches, 
however, they experienced significant improvements in their behaviour and school 
work, which they performed more readily and accurately (Bradley, 1937, 1950; 
Strohl, 2011). These studies were the basis for the development of the most 
commonly prescribed stimulant drug nowadays, Ritalin (Strohl, 2011). Ritalin 
(Methylphenidate - MPH) was first synthesised by Leandro Pannizzoni in 1944, 
marketed in 1954 (Lange et al., 2010) and approved for its use in children with 
ADHD by the Food and Drug Administration (FDA) in 1955, when the legal 
requirements of the knowledge of pharmacokinetics of the drugs was significantly 
lenient (Swanson & Volkow, 1998). Thus, relatively little is known about its 
mechanism of action in ADHD. 
 Atomoxetine (ATX) is the first non-stimulant medication licensed in 2002 by 
the Food and Drug Agency (FDA) for the treatment of ADHD patients. The history of 
ATX, although shorter, shows some parallels with that of MPH. As with MPH, ATX 
was initially intended for a different use, in this case as an antidepressant (Zerbe et al., 
1985), although it was finally used for the treatment of ADHD patients. Although 
known to be a selective presynaptic norepinephrine transporter blocker (NET), its 
mechanism of action in ADHD is also relatively unknown, as was the case with MPH.  
 A number of studies have focused on the efficacy of ATX in ADHD patients. 
Thus, initial research showed the positive effect of Tomoxetine (later the name 
changed because of potential confusion with the cancer drug Tamoxifen) on ADHD 
symptoms described by adult patients (Spencer et al., 1998). Since then, studies have 
shown the effectiveness of ATX both in children and adults with ADHD. However, a 
longer time course is required for the positive behavioural effects to be observed, as 
while the effects of MPH are typically observed within 1-2 hours of administration 
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(Swanson & Volkow, 2002), ATX reaches its maximal clinical efficacy only after 10-
12 weeks (Hazell et al., 2010; Montoya et al., 2009).  
 
3. 1. Compared efficacy of MPH and ATX 
 The beneficial effects of MPH have long been described, and have shown to 
be relatively fast, with clinical effects observable after 1 hour and lasting between 4-5 
hours (Greenhill et al., 2001; Swanson & Volkow, 2002). Studies of drug efficacy 
typically report either the number of subjects that show a decrease in symptoms 
(usually of >25% with respect to their baseline measures) as measured by a 
determined ADHD symptom scale (Hazell et al., 2010), or report the effect size of the 
decrease in symptoms (Greenhill et al., 2001; Hanwella, Senanayake, & de Silva, 
2011). MPH has shown to significantly reduce symptoms in the 
hyperactivity/impulsivity and inattention domains, as well as oppositional and 
aggressive behaviours in >75 % of the patients, with moderate to large effect sizes 
(Greenhill et al., 2001) (The MTA Cooperative Group, 1999). However, the relatively 
short life of its effects means it is necessary to administer MPH several times a day, 
which may affect compliance due to potential missing doses. The development of 
long-acting stimulants, which have shown to be as effective as immediate release 
formulations (Wolraich et al., 2001), allowed for the patients to overcome these 
issues.  
 ATX has shown to peak at plasma levels after 1-2 hours of dosing (Farid, 
Bergstrom, Ziege, Parli, & Lemberger, 1985; Witcher et al., 2003). Taken once daily, 
ATX has shown to improve behaviours not only in the morning but also in the 
evening, which persisted after 24 weeks (Wehmeier, Dittmann, Schacht, Helsberg, & 
Lehmkuhl, 2009). ATX has shown to reduce symptoms of both inattention and 
hyperactivity/impulsivity however, full clinical efficacy defined as the reported 
improvement of 25% of the initial ADHD symptoms at presentation, measured using 
the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored 
(ADHD-RS) is reached in approximately 75% of the cases at 10-12 weeks (Hazell et 
al., 2010; Montoya et al., 2009). This is in many occasions a difficult period of time 
for parents, teachers and the child, and has the potential negative effect of reducing 
compliance. This reduced compliance may be a contributing factor for the impression 
reported by clinicians that ATX may be less effective than MPH.  
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 However, the evidence suggests that both drugs are equally effective in 
ADHD. A recent meta-analytic study reviewed those randomized clinical trials that 
had directly compared MPH (both long-acting and immediate release) and ATX 
administration (Hanwella et al., 2011). Given the different definitions of response 
rates used by the studies included, which varied between 25-50% reduction in scores 
in ADHD-RS and the Turgay DSM-IV Screening and rating Scale (T-DSM-IV-S), the 
authors used the standardized mean difference in ADHD-RS scale as a measure of 
effect size and report no significant differences between the effect sizes of MPH and 
ATX (Hanwella et al., 2011). However, when different formulae were considered 
separately, long-acting but not immediate release MPH seemed to be superior to ATX 
(Hanwella et al., 2011). Nevertheless, it is important to consider that this study 
included a large randomized controlled trial which followed up subjects only for 3 
weeks (Kemner, Starr, Ciccone, Hooper-Wood, & Crockett, 2005), and given the 
above mentioned time course of the clinical efficacy of ATX (Hazell et al., 2010; 
Montoya et al., 2009), this may have resulted in an underestimation of its compared 
effectiveness. Another meta-analysis took this aspect into account and only included 
those trials that used sufficiently long durations as to observe clinical effects of ATX 
(Hazell et al., 2010). Similar clinically meaningful responses, defined as the reported 
improvement of 25% of the initial ADHD symptoms at presentation measured using 
the ADHD-RS scale, were reported for both MPH and ATX, with 70% of patients 
showing positive responses at 6 weeks and 77% at 10 weeks (Hazell et al., 2010 
4342). Furthermore, when efficacy was defined at a more stringent level of >40% 
improvement in core symptoms compared to the baseline symptoms score on the 
ADHD-RS scale, similar improvements were reported for both ATX and MPH, with 
54% of the cases showing positive responses, with a slightly higher proportion of 
responders for ATX at 10 weeks (67% vs 60% for MPH). These results were 
furthermore not affected by the inclusion/exclusion of patients with comorbid ODD, 
that is, comorbid ODD did not change the comparable efficacy rate for MPH and 
ATX (van Wyk, Hazell, Kohn, Granger, & Walton, 2012).  
 A negative aspect of ATX (shared by long-acting MPH) is its comparatively 
higher price relative to that of immediate-release MPH. The technical appraisal 
(TA98) from the National Institute for Clinical Excellence (NICE) on the use of MPH 
and ATX for the treatment of ADHD concluded that both drugs share a similar cost-
effectiveness, however, it also highlighted the difficulty to make direct comparisons 
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(http://publications.nice.org.uk). A more recent UK-based study showed that the 
longer- lasting and more stable responses to ATX than MPH make ATX an adequate 
cost-effective drug, at least in the UK (Cottrell et al., 2008).  
 However, adverse events have been described both after MPH and ATX 
treatment. MPH has been associated with potential cardiac adverse events, including 
hypertension or sudden death cases (Graham et al., 2011). These have also been 
described with ATX, although to a lesser extent (Kelly et al., 2005). Thus, careful 
monitoring of risk factors and frequent cardiac reviews are recommended when MPH 
and ATX are prescribed (Graham et al., 2011). Another controversial area with 
regards to MPH administration is the potential for drug diversion, or the increased risk 
for potential substance use/abuse disorders (Biederman et al., 2008; Faraone, 
Biederman, Wilens, & Adamson, 2007), although this has shown to be possibly 
mediated by the presence of a comorbid diagnosis of conduct disorder (Barkley, 
Fischer, Smallish, & Fletcher, 2003). Nevertheless, the evidence is not conclusive and 
it is recommended that a non-stimulant medication like Atomoxetine is prescribed in 
high-risk cases (Graham et al., 2011).  
 Other adverse events that have been reported in the literature are the increase 
or first-appearance of tics after treatment with MPH or ATX, or sleep disturbances 
after MPH dosing (Graham et al., 2011). The NICE guidelines suggest that ATX may 
be preferred to stimulant medications in the case of pre-existing tics or Tourette 
Syndrome. However, given the inconclusive evidence, close follow-up of the patients 
has been recommended, independently of the medication prescribed (Graham et al., 
2011).  
 Furthermore, although with pronounced individual variability, there is 
evidence of an effect of MPH on growth (1cm/year height, 1kg/year weight) at least 
during the 1-3 initial years of treatment (for reviews see (Pliszka, 2007) or (Graham et 
al., 2011)).  
 Finally, despite the positive results of ATX on patients with comorbid anxiety 
or depressive symptoms (Kratochvil et al., 2005), the FDA included in 2005 a black 
box warning for ATX, which informs about the risk of increased suicidality in 
children with ADHD taking ATX, which needs to be carefully monitored 
(www.fda.gov). In addition to the already mentioned potential cardiac adverse events, 
the most commonly reported side effects of ATX are decreased appetite, dizziness and 
dyspepsia (Kratochvil, Vaughan, Harrington, & Burke, 2003), which are typically 
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transient and can be managed with adequate titration procedures (Kratochvil et al., 
2003). Although some cases of liver failure have been described, the evidence is not 
conclusive and therefore the recommendation is of close vigilance (Graham et al., 
2011). 
 In conclusion, both drugs have shown similar efficacy in the treatment of 
ADHD symptoms in children with ADHD, reducing >25 % of the core symptoms of 
inattention and hyperactivity/impulsivity in 65-75% of ADHD patients (Hanwella et 
al., 2011; Hazell et al., 2010). However, their time courses significantly differ: while 
behavioural effects of MPH are observed shortly after administration (Swanson & 
Volkow, 2002), ATX reaches its maximal clinical efficacy after 10-12 weeks 
(Hanwella et al., 2011; Montoya et al., 2009). In both cases, a close monitoring of 
their potential adverse effects is required. The next sections of this chapter will review 
the evidence on their potential mechanisms of action on brain systems in ADHD, 
which are still relatively unknown. 
 
3.2. Dopaminergic and noradrenergic abnormalities in ADHD 
 
3.2.1. Catecholaminergic systems in the human brain 
 Dopamine (DA) and noradrenaline (NE) are catecholaminergic 
neurotransmitters with most prominently modulatory function on other 
neurotransmitter systems (Aston-Jones & Cohen, 2005). DA and NE are synthesised 
from the amino acid tyrosine and share a common biosynthetic pathway (Schwartz, 
2000). Tyrosine is converted into L-Dopa by the enzyme tyrosine hydroxylase, which 
is present in limited amounts in the brain and therefore rate-limiting in the production 
of DA and NE (Figure 1). L-Dopa is then converted by the enzyme dopa-
decarboxylase into DA, and this by the enzyme β-hydroxylase into NE. Finally, NE is 
converted by phenylethanolamine-N-methyltransferase into epinephrine (Figure 3.1).    
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 However, not all the catecholaminergic cells express all the enzymes and thus 
do not produce all the neurotransmitters. Thus, DA is synthesised in group s of 
midbrain neurons located mostly in the ventral tegmental area (VTA), the substantia 
nigra (pars compacta) (SN) and retrorubral area (Gerfen, 2010). There are four major 
dopaminergic tracts: 1) the nigrostriatal projection, formed by dopaminergic axons 
(mostly, but not only) which projects from the SN to caudate, putamen and nucleus 
accumbens (Moore & Bloom, 1978) and is involved in movement control (Robbins, 
2010; Schwartz, 2000). 2) Dopaminergic neurons in the mesocortical tract project 
from the SN and VTA to cortical regions (Moore & Bloom, 1978). 3) The mesolimbic 
tract is formed by dopaminergic neurons from the SN and VTA which project to the 
amygdala and hippocampus, and both mesocortical and mesolimbic tracts are 
involved in EF, affect, emotion and motivation regulation (Robbins, 2010; Schwartz, 
2000). Furthermore, some mesolimbic DA projections have been described in the 
thalamus and cerebellar vermis, regions traditionally considered as lacking 
dopaminergic projections (Melchitzky & Lewis, 2009). 4) The last dopaminergic tract 
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projects from the arcuate nucleus of the hypothalamus to the pituitary gland and 
regulates hormone secretion (Moore & Bloom, 1978; Schwartz, 2000) (Figure 3.2).  
  
 Dopaminergic receptors can be grouped into two families according to their 
ligand-binding affinities and signal transduction mechanisms: D2/D3/D4 and D1/D5 
receptors (Missale, Nash, Robinson, Jaber, & Caron, 1998). These have shown to be 
unevenly distributed in the brain. Thus, D1 receptors are present in the caudate, 
putamen, nucleus accumbens, and at lower levels in cerebral cortex, hippocampus, 
amygdala, thalamus and cerebellum (Hall et al., 1994; Melchitzky & Lewis, 2009). 
D2 receptors are highly present in the striatum, VTA and SN (Hall et al., 1994; 
Melchitzky & Lewis, 2009). D3 receptors are present mostly in limbic regions, such 
as the accumbens, and at much lower levels in the SN, VTA, thalamus, cortex and 
cerebellum, which have moderate to low levels of this receptor. In VTA and SN 
D2/D3 receptors are localised presynaptically, so their function involves the 
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regulation of DA synthesis and release of DA. On the other hand, D4 and D5 are 
much less expressed in the brain, with D4 detected in the SN, VTA, nucleus 
accumbens, hippocampus, amygdala and cortex, and D5 being the least expressed of 
all dopaminergic receptors, and located mostly in hippocampus, cerebellum and 
thalamus at low levels (Melchitzky & Lewis, 2009) (Table 3.1). 
  
 Norepinephrine is synthesised in the locus coeruleus (LC), which projects 
mostly to the cerebral cortex and dorsal thalamus (Melchitzky & Lewis, 2009; Moore 
& Bloom, 1979; Ramos & Arnsten, 2007), as well as to the cerebellum (Moore & 
Bloom, 1979), limbic system and spinal cord (Moore & Bloom, 1979). However, 
noradrenergic innervation in the cortex is uneven, and prefrontal regions are less 
heavily noradrenergically innervated than primary somatosensory or visual cortices 
(Melchitzky & Lewis, 2009). Also other areas receive noradrenergic projections, with 
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heavy innervation in amygdala and hypothalamus, and more moderate in the 
cerebellar cortex (Melchitzky & Lewis, 2009; Moore & Bloom, 1979)(Figure 3.2).  
 Two groups of noradrenergic receptors have been described, α and β, which at 
the same time are divided in two subgroups each α1 and α2, as well as β1 and β2 (each 
of them is divided into different subtypes (for reviews, see Koziek & Bylund, 2007; 
Ramos, Stark, Verduzco, van Dyck, & Arnsten, 2006). Norepinephrine has the highest 
affinity for the α2 receptor, lower affinity for the family of α1 receptors, and even 
lower still for β-receptors. α2a is the most common NE receptor in PFC (Ramos & 
Arnsten, 2007). 
 The LC-NE system has been associated with arousal and stimuli 
responsiveness (Aston-Jones & Cohen, 2005). Both noradrenergic and dopaminergic 
systems have shown an inverted-U mode of functioning, with too low or too high 
levels of DA and/or NE impairing cognitive function (Arnsten, 2009; Berridge et al., 
2011; Robbins, 2010), which varies depending on the different cognitive function 
studied as different levels of neurotransmitters may be necessary (Arnsten, 2009; 
Cools & D'Esposito, 2011; Gamo, Wang, & Arnsten, 2010; Robbins, 2010).  
 Fronto-striatal dopaminergic systems show a stability/flexibility trade-off in 
the brain (Cools & D'Esposito, 2011). Optimal levels of DA on PFC (via their action 
on D1 receptors) allow for the stability of representations withheld in WM by 
inhibiting neural firing to irrelevant stimuli (Arnsten & Pliszka, 2011; Cools & 
D'Esposito, 2011), while these levels seem to be too low to engage dopaminergic 
activity in the striatum via D2 receptors. However, with higher extracellular DA 
levels, D2 receptors stimulation in the striatum facilitates flexibility and rapid 
updating of information (Cools & D'Esposito, 2011), while excessive D1 stimulation 
in the PFC suppresses firing both to relevant and irrelevant stimuli (Arnsten & 
Pliszka, 2011; Cools & D'Esposito, 2011).  
 Phasic responses of the LC-NE system have been associated with task-related 
behavioural responses, by acting as an attentional filter that selectively modulates the 
responsiveness of task-related cortical circuits (Aston-Jones & Cohen, 2005). Thus, 
moderate levels of NE on prefrontal regions improve cognitive functions via α2 
receptors stimulation (Arnsten, 2009; Arnsten & Pliszka, 2011; Ramos & Arnsten, 
2007). However, at high NE levels (as happens under highly stressful conditions), 
there is an increase in the noradrenergic tone and an attenuation of phasic NE 
responses (Aston-Jones & Cohen, 2005), and the excess of extracellular NE engages 
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α1 and β-adrenergic receptors that impairs PFC function (Arnsten, 2009; Ramos & 
Arnsten, 2007). However, this allows for posterior brain regions to control behaviour, 
mechanism that may have originally had a survival value (Ramos & Arnsten, 2007), 
as it facilitates highly distractible activity oriented to exploration (Aston-Jones & 
Cohen, 2005) 
 Dopaminergic and noradrenergic transmission are terminated in several ways. 
Dopamine and norepinephrine transporters (DAT and NET, respectively) are 
membrane transporters that control extracellular levels of DA and/or NE by their 
reuptake from the synaptic space into the presynaptic neuron (Gainetdinov & Caron, 
2003). In prefrontal regions, given the much higher proportion of NET and the almost 
absent presence of DAT, NET reuptakes both DA and NE into the presynaptic neuron 
(Moron, Brockington, Wise, Rocha, & Hope, 2002; Yamamoto & Novotney, 1998). 
Furthermore, DA and NE are also removed from the synaptic space by enzymat ic 
metabolism via catechol O-methyltransferase (COMT) or monoamine-oxidase (MAO) 
(Gainetdinov & Caron, 2003; Gerfen, 2010; Mannisto et al., 1992; Melchitzky & 
Lewis, 2009; for more extensive reviews of dopaminergic and noradrenergic systems 
and monoamine transporters, see Torres, Gainetdinov, & Caron, 2003). 
 As both systems regulate neural circuits underlying critical higher cognitive 
functions typically impaired in ADHD patients, including inhibition, attention or time 
processing,  abnormalities in these catecholaminergic systems have been hypothesized 
to underlie or at least contribute to the disorder (Biederman & Spencer, 1999; Frank, 
Santamaria, O'Reilly, & Willcutt, 2007; Gonon, 2009; Prince, 2008; Sagvolden et al., 
2005; Sergeant, 2000; Staller & Faraone, 2007; Tripp & Wickens, 2008). Dysfunction 
in these systems may involve reduced neurotransmitter synthesis or release, or 
abnormally early or late termination of the catecholaminergic transmission, which 
may be due to reduced/enhanced levels of reuptake transporters or altered 
sensitivity/density of the pre/postsynaptic receptors, and may in turn regulate 
dopaminergic and noradrenergic transmission.  
 As reviewed by Madras et al (Madras, Miller, & Fischman, 2005), the DAT is 
present perisynaptically in the neuron (cell bodies, dendrites and axons) rather than in 
the immediate synapse. The DAT not only reuptakes DA, but also regulates DA 
release, as has been reported in the SN (Madras et al., 2005). Thus, abnormally high 
levels of reuptake transporters would clear DA in excess and lead to a reduced 
dopaminergic tone (Madras et al., 2005). Furthermore, reduced synthesis and release 
 98 
to the synaptic cleft, reduced sensitivity or availability of the receptors or increased 
levels of DAT in the synaptic cleft would reduce catecholaminergic transmission.  
 
3.2.2. Dopaminergic and noradrenergic dysfunctions in ADHD 
 The study of dysfunctions in dopaminergic systems in ADHD has focused 
mostly on the striatum, as there are no tracers that are adequate for the study of DA or 
NE in cortical regions (Arnsten, 2009). Most of the studies have focused on the level 
or availability of DAT in patients with ADHD. As recently reviewed by del Campo 
et al (Del Campo, Chamberlain, Sahakian, & Robbins, 2011) PET studies have 
provided evidence of abnormalities in striatal DAT in ADHD patients, with initial 
results supporting the hypothesized high levels of DAT in basal ganglia/striatum 
(Cheon et al., 2003; Dougherty et al., 1999; Dresel et al., 2000; Krause, Dresel, 
Krause, Kung, & Tatsch, 2000; la Fougere et al., 2006; Larisch et al., 2006; Spencer 
et al., 2007; Spencer et al., 2005). However, more recent studies do not support this 
hypothesis. In fact, these studies have shown reduced striatal DAT availability in 
medication-naïve adults with ADHD compared to controls (Hesse, Ballaschke, 
Barthel, & Sabri, 2009; Volkow et al., 2009; Volkow, Wang, Newcorn, Fowler, et al., 
2007), in the midbrain in adolescents with ADHD (Jucaite, Fernell, Halldin, 
Forssberg, & Farde, 2005), or no differences when compared to healthy control 
subjects (Jucaite et al., 2005; van Dyck et al., 2002) (for reviews, see Del Campo et 
al., 2011; Krause, 2008)  (for a meta-analysis, see Fusar-Poli, Rubia, Rossi, Sartori, & 
Balottin, 2012). These differences in the findings may have been influenced by a 
number of confounds, such as the different composition and sizes of the samples, age 
differences or the use of radiotracers with different specificities (Del Campo et al., 
2011).  Most importantly, there is evidence that the previous history of stimulant 
medication may be an important confounder: a recent meta-analysis conducted in PET 
and SPECT studies in ADHD patients is particularly relevant (Fusar-Poli et al., 2012). 
This study reports an increased density of striatal DAT in ADHD patients compared 
to those of healthy controls. However, a meta-regression analysis showed that patients 
without a history of medication had significantly lower striatal DAT levels than 
healthy subjects, while long-term medicated patients had significantly higher levels of 
DAT relative to controls (Fusar-Poli et al., 2012), with the presence of medication 
accounting for 48% of the variance of the results. The findings suggest that long-term 
medication may lead to an upregulation of DAT levels in the basal ganglia. The 
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potential effect of MPH of increasing DAT density with continued exposure had been 
previously hypothesised (Madras et al., 2005). The results of the meta-analytic study 
are thus of particular relevance as they suggest that the high levels of DAT reported 
by some studies may be an adaptive response of the brain to a long-term history of 
medication which, as the authors highlight, is in line with the clinical evidence of the 
need of progressively higher doses of stimulant to maintain the clinical efficacy 
(Fusar-Poli et al., 2012). However, given that the study was cross-sectional, 
longitudinal studies within patients are needed to provide conclusive evidence about 
this potential causality mechanism.  
 However, abnormal striatal DAT levels “per se” are unlikely to be the primary 
dopaminergic disruption in ADHD (Volkow, Wang, Newcorn, Fowler, et al., 2007). 
Using PET, reduced availability of D2/D3 receptors in adults ADHD patients has 
been reported in left lateralised regions including the left caudate (Volkow et al., 
2009; Volkow, Wang, Newcorn, Telang, et al., 2007), as well as the left nucleus 
accumbens, midbrain and hypothalamic regions, which were furthermore negatively 
correlated to inattention symptoms (Volkow et al., 2009). However, these results are 
not consistent with those reported in children and adolescents with the disorder, as 
studies have reported either no differences (Jucaite et al., 2005), or increased D2/D3 
availability (Ilgin, Senol, Gucuyener, Gokcora, & Sener, 2001; Lou et al., 2004) 
relative to healthy controls. Furthermore, Ilgin et al (Ilgin et al., 2001) reported an 
association between high levels of D2 receptors available at baseline and a) 
symptomatic improvement after MPH and b) the degree of down-regulation by MPH 
(Ilgin et al., 2001), suggesting more pronounced effects of MPH in those subjects with 
more abnormal levels of striatal dopaminergic receptor availability.  
 Measures of DA synthesis can be obtained using  [18F]DOPA or [11C]DOPA 
as radiotracers, as these are taken by the L-aminoacid transporter (located in the 
dopaminergic presynaptic neurons) as an analogue of DOPA and stored in storage 
vesicles, a step necessary and part of the DA synthesis process (Ernst, Zametkin, 
Matochik, Jons, & Cohen, 1998; Fusar-Poli et al., 2012) (Figure 3.1). Decreased DA 
synthesis in the midbrain observed in medicated children with ADHD compared to 
healthy adolescents has also been reported, which was furthermore associated with 
increased symptoms of inattention (Forssberg, Fernell, Waters, Waters, & Tedroff,  
2006). Also in adults with ADHD, reduced presynaptic dopaminergic function was 
reported in prefrontal regions, more markedly in medial and left PFC, and also 
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associated with childhood symptoms of ADHD retrospectively reported (Ernst et al., 
1998). In a study using parallel groups, a downregulation in dopamine turno ver was 
reported in ACC, putamen, amygdala and midbrain, with medication-naïve adults 
with ADHD showing lower DA synthesis than controls and long-term treated ADHD 
patients in bilateral striatum, insula and amygdala (Ludolph et al., 2008). However, 
some controversial results have been reported, with increased DA storage in the 
midbrain of previously medicated adolescents with ADHD (after 2 weeks off their 
usual psychostimulant medication) compared to those in healthy controls (Ernst et al., 
1999). Reduced DAT function has shown to downregulate presynaptic DA storage 
and synthesis (Gainetdinov & Caron, 2003). Thus, if as suggested by the recent meta-
analysis mentioned above (Fusar-Poli et al., 2012) long-term stimulant administration 
may increase DAT levels, it can be hypothesized that this would lead to an increase in 
presynaptic DA synthesis and storage. Thus, the small sample sizes of these studies 
make it necessary to replicate their results in larger samples.  
 So far, there are no studies on NE transmission in ADHD, given the lack of 
suitable radiotracers with adequate binding specificity characteristics (Logan et al., 
2007), thus hampering the study of the potential abnormalities on the NE system in 
patients with the disorder. However, promising advances have recently been made in 
studies in non-human primates (Gallezot et al., 2011; Seneca et al., 2006; Takano, 
Gulyas, Varrone, Maguire, & Halldin, 2009) and in humans (Hannestad et al., 2010), 
which may help to the future advance in this field.  
 
3.3 Mechanisms of action of methylphenidate and atomoxetine 
 
3.3.1. Methylphenidate  
 
3.3.1.1 Pharmacokinetics  
 MPH (dl-threo-methylphenidate) is a 50:50 racemic mixture of two 
enantiomers, d-threo-methylphenidate and l-threo-methylphenidate (Swanson & 
Volkow, 2002). While d-threo-methylphenidate has shown specific binding in the 
striatum, l-threo-methylphenidate binding has been shown to be non-specific (Ding et 
al., 1997). The evidence shows that the therapeutic effects of MPH are due to the 
effects of the d-threo-methylphenidate enantiomer (Ding et al., 1997; Markowitz & 
Patrick, 2008; Srinivas, Hubbard, Quinn, & Midha, 1992). MPH is metabolised into 
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ritalinic acid (inactive metabolite), and it has been shown to reach its peak plasma and 
serum levels 1-1.5 hours after oral administration (Chan et al., 1983; Swanson & 
Volkow, 2002), with a half- life of 3 hours (Swanson & Volkow, 2002). This relatively 
short half- life means it is necessary either to be administered two or three times a day, 
or sustained release formulations to be used. The usual dose for MPH is 0.3-0.7 
mg/kg, rounded to the nearest 2.5/5 mg (Santosh & Taylor, 2000). Peak brain 
concentrations of MPH occurring between 1-2h after its administration (Swanson & 
Volkow, 2002; Volkow, Wang, Fowler, Gatley, et al., 1998), which corresponds with 
the time to reach behavioural effects (Volkow, Wang, Fowler, Gatley, et al., 1998). 
 
3.3.1.2 Effects on extracellular levels of DA and NE: rodent studies 
 MPH has shown to block the DAT and NET at therapeutic doses (Hannestad 
et al., 2010; Volkow, Wang, Fowler, Gatley, et al., 1998). In vitro studies show that 
MPH has high affinity for the dopamine transporter (DAT), lower affinity for the 
norepinephrine transporter (NET) and minimum affinity for the serotonin transporter 
(SERT) (Bymaster et al., 2002; Gatley, Pan, Chen, Chaturvedi, & Ding, 1996).  
   
3.3.1.2.1 Effects on extracellular levels of DA 
 Microdyalises studies in rats have shown the effects of MPH administration on 
extracellular levels of DA and NE in different brain regions. Thus, dose-dependent 
enhanced levels of extracellular DA in prefrontal cortex (PFC) have been reported 
after administration of MPH in rats (0.25-1mg/kg intra-peritoneal -i.p.-, 2 mg/kg 
orally) (Berridge et al., 2006), as well as in the striatum (caudate/putamen) (10, 20, 30 
mg/kg, orally)(Kuczenski & Segal, 1997), and in PFC, nucleus accumbens and 
striatum (3mg/kg, i.p.) (Bymaster et al., 2002). However, MPH seems to enhance 
extracellular levels of DA in the nucleus accumbens only at high dosage. Thus, 
different studies have shown no effects on DA levels in the nucleus accumbens at low 
doses (0.25 mg/kg i.p) (Berridge et al., 2006; Kuczenski & Segal, 2001, 2002), while 
higher doses produced a significant increase in DA levels in the nucleus accumbens 
(0.5 mg/kg i.p., 2.5 mg/kg orally) (Berridge et al., 2006; Kuczenski & Segal, 1997, 
2001, 2002; Schiffer et al., 2006). 
 Furthermore, MPH (up to 50 mg/kg, i.p.) administration to rats had no effect 
on the biosynthesis of DA in striatal synaptosomal DA (Kuczenski & Segal, 1975). 
PET studies in rats have shown decreased radioligand DAT binding in the str iatum 
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(suggestive of increased synaptic DA) after MPH administration (5 mg/kg, i.p.) both 
in rats and primates (Schiffer et al., 2006), without changes in binding in cerebellum 
(Schiffer et al., 2006). 
 Similarly in mice, both a single dose (1,3, 10 mg/kg, i.p.) and chronic (3 
mg/kg i.p.) MPH administration increased extracellular levels of DA in PFC (Koda et 
al., 2010), without effects on 5-HT extracellular levels in these regions (Koda et al., 
2010). However, in the striatum, only the high dose (10 mg/kg) administered acutely 
increased extracellular levels of DA (Koda et al., 2010).  
 
3.3.1.2.2 Effects on extracellular levels of NE  
 MPH has shown effects not only on extracellular DA levels, but also on NE 
levels, which may be of particular relevance to the therapeutic effect of MPH in 
ADHD. Thus, after intra-peritoneal administration of MPH in rats, dose-dependent 
enhanced levels of extracellular NE in PFC have been reported  (Bymaster et al., 
2002), which were larger than those of extracellular DA (Berridge et al., 2006). MPH 
(3mg/kg, i.p.) as well as in primary sensory cortical regions (1mg/kg, 5 mg/kg, 
i.p)(Drouin, Page, & Waterhouse, 2006). Similarly, in the medial septal area, MPH at 
high doses (0.5 mg/kg) increased NE levels (Berridge et al., 2006).  
 MPH in enhanced extracellular levels of NE in the hippocampus in a dose-
dependent manner rats (10, 20, 30 mg/kg, i.p.) (Kuczenski & Segal, 1997)(0.5 
mg/kg/2.5 mg/kg, i.p.)(Kuczenski & Segal, 2001) (1, 2.5, 5 mg/kg, oral)(Kuczenski & 
Segal, 2002), without changes in extracellular concentrations of 5-HT in the 
accumbens/striatum (Kuczenski & Segal, 1997, 2001).  
 In mice, a single dose (1, 3, 10 mg/kg, i.p.) and chronic (3 mg/kg i.p.) MPH 
administration increased extracellular levels of NE in PFC (Koda et al., 2010), and 
only at high doses in the striatum, without effects on 5-HT extracellular levels (Koda 
et al., 2010).  
 In conclusion, studies in rodents show that MPH enhances extracellular levels 
of DA and NE in PFC, DA in the striatum and NE in the hippocampus in a dose-
dependent manner, with effects on extracellular DA in the nucleus accumbens and on 
NE in the medial septal area only at higher doses.   
 
 
3.3.1.3 PET studies in healthy adults and non-human primates  
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 PET studies have typically been used to observe the effects of MPH on the 
dopaminergic system. The radiotracers used compete with endogenous DA to block 
the DAT, or to occupy dopaminergic receptors. Thus, a reduction in radiotracer 
binding after MPH administration is typically interpreted as an increase of 
extracellular DA, which competes with the radioligand to occupy DAT or D2/D3 
receptors (Laruelle, 2000).  
 PET studies in baboons have shown that MPH infusion (0.5 mg/kg) reduced 
radioligand binding in the striatum but not in the cerebellum (Ding et al., 1994). In 
healthy adults, a single dose of MPH showed that administered at therapeutic doses 
(0.25 mg/kg –1 mg/kg, orally), blocks striatal DAT significantly in a dose-dependent 
fashion, with therapeutic doses (0.25 mg/kg) blocking 50% DAT in striatum (Volkow, 
Wang, Fowler, Gatley, et al., 1998). Furthermore, MPH (0.5mg/kg, ip) significantly 
blocked striatal DAT without effects in the cerebellum (Volkow et al., 1996). In 
addition, MPH has recently been shown to block significantly the NET in the LC, 
raphe nuclei as well as in the hypothalamus (Hannestad et al., 2010).   
 However, as mentioned above, the difficulties to find a suitable radiotracer 
have limited the research on how NET-blockade by MPH may affect the 
noradrenergic system in humans (Logan et al., 2007).  
 It has been hypothesized that by blocking DAT, MPH increases extracellular 
DA (Volkow et al., 2001), which acts on the presynaptic dopaminergic D2 receptors, 
decreasing the phasic release of DA by the neuron (Seeman & Madras, 1998; Seeman 
& Madras, 2002). It has also been postulated that MPH would enhance task-specific 
signalling, improve attention and performance in cognitive tasks by increasing signal-
to-noise ratio on target neurons, due to decreased background firing rates of 
dopaminergic cells (Volkow et al., 2001). Furthermore, as DA is involved in detecting 
the saliency of stimuli (Horvitz, 2000), as well as in motivation and reward processes 
(Schultz, 1998; Tobler, Fiorillo, & Schultz, 2005), by increasing DA signalling, MPH 
would also enhance the salience of the stimuli and improve reward and motivation-
related processing (Volkow et al., 2001; Volkow, Wang, Fowler, & Ding, 2005). 
 
3.3.1.3.1. Effects on DAT and D2/D3 receptor availability  
 In ADHD patients, prolonged treatment with MPH has been shown to affect 
DAT density and availability. In untreated, newly diagnosed adults with ADHD 
SPECT studies have shown that prolonged treatment (3x5mg/day) with MPH reduced 
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the specific binding of the radiotracer in the DAT striatum (suggestive of reduced 
availability/density of DAT, as there is a reduced number of DAT sites) when 
compared to baseline (Dresel et al., 2000). Unfortunately, the authors did not report 
the length of the treatment in this study (Dresel et al., 2000). Similar results were 
described by Krause et al using SPECT in medication-naïve adults with ADHD after 4 
weeks of MPH treatment (3x5mg/day) (Krause et al., 2000), as also in a SPECT study 
in medication-naïve children with ADHD after 3 months therapy with MPH  (0.25-0.6 
mg/kg/day) (Vles et al., 2003). A SPECT study in medication-naive adolescents with 
ADHD and comorbid substance use disorder showed that 3 weeks treatment with 
MPH (week 1: 0.3 mg/kg/day; week 2: 0.7 mg/kg/day; week 3: 1.2 mg/kg/day) 
reduced DAT availability compared to baseline levels in caudate and putamen 
(reduced binding of the radiotracer) (Szobot et al., 2008), which was concomitant to 
the reported symptomatic improvement. A small (N=5) group of medication-naïve 
children with ADHD showed a reduction in DAT availability compared to baseline 
levels following 3 months of treatment with MPH (0.25-0.6 mg/kg/day) (Feron et al., 
2005). After 9-20 months of treatment, MPH was withdrawn, and after 4 weeks off-
MPH, DAT activity levels returned to baseline levels, which suggested is no long-
term effect of MPH on DAT availability (Feron et al., 2005).  
 Thus, the findings suggest that short-term treatment with MPH reduced DAT 
levels in medication-naïve children and adults with ADHD. However, results from 
recent meta-analysis conducted by Fusar-Poli et al (Fusar-Poli et al., 2012) using a 
meta-regression analysis showed that long-term medication history was associated 
with increased DAT levels. Therefore, differences between long-term and short-term 
effects of stimulant medication administration on DA system in ADHD patients that 
need to be further investigated.  
 The ability of MPH to reduce DAT availability has furthermore been 
associated with symptomatic improvement in several SPECT studies. In medication-
naïve adults with ADHD, increased DAT availability compared to healthy subjects at 
baseline was associated with symptomatic improvement after 10 weeks of treatment 
with MPH (as measured by the Clinical Global Impression Scale – CGI, MPH was 
titrated up to 60 mg/day), which was taken as a proxy for response to MPH (Krause, 
la Fougere, Krause, Ackenheil, & Dresel, 2005; la Fougere et al., 2006). Thus, 
increased DAT availability at baseline seems to be a predictor of good response to 
MPH (Krause, 2008). However, Cheon et al (Cheon, Ryu, Kim, & Cho, 2005) 
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observed that, in a group of medication-naïve children with ADHD, those responsive 
to 8 weeks of MPH treatment (0.3-0.7mg/kg/day)(defined at 50% reduction in the 
ADHD Rating Scale) presented with lower striatal DAT levels at baseline (Cheon et 
al., 2005). 
 It has been shown the lack of association between the reduced binding of 
radioligands in DAT after single dose MPH challenge (60mg, orally) and the increase 
in extracellular DA levels (Volkow, Wang, Fowler, Logan, Franceschi, et al., 2002). 
The effects of MPH may not depend exclusively on DAT blockade, but also on other 
factors such as baseline levels of DA release (Volkow et al., 2001; Volkow, Wang, 
Fowler, Logan, Franceschi, et al., 2002). It has therefore been suggested that at a 
given DAT blockade level, MPH effects would be more significant in those subjects 
with higher activity in DA cells (releasing more DA) than in those with lower DA cell 
activity (Volkow, Wang, Fowler, Logan, Franceschi, et al., 2002). 
 PET studies using the radiotracer [11C]Raclopride focus on the effects of MPH 
on extracellular levels of DA by measuring changes in striatal D2/D3 receptor 
availability. Post-stimulant administration decline in radioligand receptor-binding is 
indicative of reduced receptor availability, which suggests a pharmacologically 
evoked increase in extracellular DA. Thus, single dose MPH administration in healthy 
adults (60 mg, orally) (Volkow et al., 2001) and prolonged (12-months) treatment 
with MPH (~1 mg/kg/day, orally) in medication-naïve adults with ADHD (Volkow et 
al., 2012), have been shown to reduce the availability of striatal D2 receptors. 
Similarly, in medication-naïve children with ADHD, a single dose MPH challenge 
(0.3 mg/kg, orally) reduced the striatal binding of the radioligand (Rosa Neto, Lou, 
Cumming, Pryds, & Gjedde, 2002; Rosa-Neto et al., 2005). However, in adults with 
ADHD, a blunted response of the dopaminergic system has also been observed, with 
reductions in availability of striatal D2/D3 receptors after a single dose of MPH (0.5 
mg/kg, i.p.) that were less pronounced than those in healthy controls (Volkow, Wang, 
Newcorn, Telang, et al., 2007). 
 PET studies in humans have also shown some effects of MPH on cortical 
regions. Thus, prolonged MPH treatment (1 mg/kg/day, orally) in adults with ADHD 
has been shown to increase extracellular DA in frontal and temporal regions (Volkow 
et al., 2012), while single dose MPH administration (40-60 mg, orally) in healthy 
adults reduced binding of the radioligand in a dose-dependent manner in frontal lobe, 
temporal cortex and thalamus, without significant changes in the 
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amygdala/hippocampus, ACC and cerebellum (Montgomery, Asselin, Farde, & 
Grasby, 2007).  
 Like with DAT levels, the changes induced by MPH administration in D2/D3 
receptor availability have also been associated with symptomatic improvement.  
Medication-naïve adults with ADHD showed blunted responses to a single dose of 
MPH (0.5 mg/kg, i.p.) compared to controls (as measured by the occupancy of striatal 
D2/D3 receptors in the caudate by a radioligand), which were associated with more 
inattention symptoms in the Conners Adult Attention Rating Scale (CAARS) 
(Volkow, Wang, Newcorn, Telang, et al., 2007). Similarly, increases in extracellular 
DA levels after a single dose MPH challenge in the striatum in adults with ADHD 
who had undergone 12-months of treatment with MPH (~1mg/day, orally) were 
associated with symptomatic improvement in the inattention domain (Volkow et al., 
2012). 
 Changes in striatal D2/D3 receptor availability have also been associated with 
performance during cognitive tasks. Thus, the reported reductions in D2/D3 receptor 
availability in the striatum in medication-naïve children with ADHD after a single-
dose of MPH (0.3 mg/kg, orally)  were positively associated with the baseline number 
of omission and commission errors, RT and SD of RT in a CPT-like task, suggestive 
of a stronger effect of MPH on blocking DAT in those patients who were more 
inattentive and impulsive (Rosa Neto et al., 2002; Rosa-Neto et al., 2005). According 
to the authors, these findings suggest that the effects of MPH on increasing striatal 
extracellular DA levels are more pronounced on those subjects with higher 
impulsivity levels as shown by their performance on the attention task. Furthermore, 
in healthy adults, the reduced availability in D2/D3 receptors in the striatum after a 
single dose of MPH (60 mg, orally) was associated with better performance during a 
spatial WM task and with poorer performance in a reversal learning task (Clatworthy 
et al., 2009).   
 It is therefore suggested that MPH would have stronger effects in those 
subjects where baseline activity in dopaminergic cells is high than in those where the 
activity in dopaminergic cells is low (Volkow, Wang, Fowler, Logan, Franceschi, et 
al., 2002). The increase of extracellular DA levels as a result of DAT blockade 
stimulates DA autoreceptors that attenuate DA release, thus decreasing dopaminergic 
background firing (noise), and improving signal-to-noise ratio in target neurons 
(Volkow et al., 2001). The amplification of weak DA signals experienced by ADHD 
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patients after MPH administration would enhance the saliency of the stimuli by 
enhancing task-specific signals, thus improving attention and performance (Volkow et 
al., 2001). In line with this, a single dose of MPH (20 mg, orally) in healthy adults  
enhanced extracellular DA levels in the striatum only during the performance of a 
remunerated mathematical task but not during a non-remunerated passive neutral task 
(Volkow et al., 2004), which was also found during presentation of food stimuli 
compared with presentation of neutral stimuli (20 mg, orally) (Volkow, Wang, 
Fowler, Logan, Jayne, et al., 2002). These DA increases were furthermore 
accompanied by the perception of increased saliency of both the food as well as the 
mathematical task (Volkow, Wang, Fowler, Logan, Jayne, et al., 2002; Volkow et al., 
2004). 
 
3.3.1.3.2 MPH and blood flow and metabolism in healthy subjects  
 PET studies in healthy adults have shown that MPH administration (two 
sequential doses: 1st 0.5 mg/kg, 2nd 90 minutes later, 0.25 mg/kg, both i.p.) has an 
effect on glucose metabolism in the brain, increasing cerebellar metabolism and 
decreasing glucose metabolism in the basal ganglia relative to the whole brain 
(Volkow, Wang, et al., 1997). It was furthermore observed that regional glucose 
metabolism changes in frontal and temporal cortices, as well as in cerebellum were 
associated with D2 receptor  availability, with increased metabolism in those subjects 
with high D2 receptor availability and decreased metabolism in those adults with low 
D2 receptor availability (Volkow, Wang, et al., 1997).  
 A recent study using pattern recognition analyses has furthermore shown the 
compared effects of single doses of MPH (30 mg, orally) and ATX (60 mg, orally) on 
rCBF in healthy adults at rest (Marquand et al., 2012). The results suggest that MPH 
and ATX had effects in line with the DAT and NET distributions in the brain. Thus, 
compared to each other, MPH showed differential effects on rCBF in areas that are 
rich in DAT distribution such as the caudate, midbrain and SN, thalamus, 
ventromedial prefrontal cortex (VMPFC), cingulate cortex, insula and temporal lobes 
(Marquand et al., 2012). ATX on the other hand, showed differential effects on rCBF 
relative to MPH in areas that are rich in NET such as cerebellum, parahippocampal 
gyrus, posterior insula, inferior and medial frontal regions, sensorimotor and middle 
temporal cortices (Marquand et al., 2012). 
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 The effects of MPH on task-related blood flow have also been studied in 
ADHD patients using PET. These studies will be reviewed in the next chapter, which 
gathers the available evidence on the effects of MPH and ATX on brain function in 




3.3.2.1 Pharmacokinetics  
 ATX is highly bound to plasma protein (Sauer et al., 2003), and is metabolised 
by the CYP2D6 enzyme into 2 metabolites: the active metabolite 4-
hydroxyatomoxetine and the inactive metabolite N-desmethylatomoxetine (Ring, 
Gillespie, Eckstein, & Wrighton, 2002). The main metabolite 4-hydroxyatomoxetine, 
which has been described as pharmacologically active as the parent compound, has 
also a selective effect on blocking the NET, and may therefore contribute to the 
effects of ATX. However, in children, plasma concentration of this metabolite has 
been shown to be significantly lower compared to those of ATX (parent-to-metabolite 
ratio)(Witcher et al., 2003).  
 In children with ADHD, ATX has shown a similar pharmacokinetic profile 
both after a single dose and repeated administration of ATX (Witcher et al., 2003). 
Peak plasma levels of ATX are dose-dependent and reached after 1-2 hours of dosing 
(Farid et al., 1985; Witcher et al., 2003) with a plasma half- life of 3-4 hours (Witcher 
et al., 2003). ATX has shown similar pharmacokinetic profiles both in children and 
adults (Sauer et al., 2003; Witcher et al., 2003). Two polymorphic forms exist for the 
enzyme CYP2D6, and thus subjects can be subgrouped as rapid/extensive or slow 
metabolizers, which has shown to have an impact of the half- life of the drug (which 
may vary between the 5 hours described in extensive metabolizers to 22 hours in poor 
metabolizers) (Farid et al., 1985; Ring et al., 2002; Sauer et al., 2003). However, there 
is no clear evidence about differences in efficacy depending on the CYP2D6 
polymorphism.    
 
3.3.2.2 Effects on extracellular levels of DA and NE: rodent studies 
 ATX is a selective presynaptic NET blocker, with higher affinity for the NET 
than for SERT or DAT (Bymaster et al., 2002), and which blocks the NET almost 
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completely in the ACC, thalamus, brain stem, midbrain, LC and cerebellum (Ding et 
al., 2009; Gallezot et al., 2011; Takano et al., 2009).  
 In the PFC, the NET takes up DA into NE neurons, given the low density of 
DAT in this region and the high affinity of DA for NET (Moron et al., 2002; Sesack, 
Hawrylak, Matus, Guido, & Levey, 1998; Yamamoto & Novotney, 1998). Therefore, 
a noradrenergic reuptake inhibitor will also have enhancing dopaminergic effect in 
this region, but not in other DA-rich regions like the striatum, where DA is reuptaken 
by DAT.  
 
3.3.2.2.1 Effects on extracellular levels of DA 
 Microdyalisis studies in rats have shown that ATX (0.3-3mg/kg i.p.) increases 
extracellular levels of DA in PFC (Bymaster et al., 2002; Swanson et al., 2006), but 
not in the nucleus accumbens, striatum (Bymaster et al., 2002; Swanson et al., 2006), 
lateral hypothalamus or occipital cortex (Swanson et al., 2006). Furthermore, no 
effects on extracellular levels of 5-HT in the PFC were reported (Bymaster et al., 
2002). Similarly in mice, a single dose (0.3, 1, 3 mg./kg, i.p.) and chronic (1 mg/kg 
i.p.) ATX administration increased extracellular levels of DA in the PFC (Koda et al., 
2010), without effects in the striatum (Koda et al., 2010).  
 
3.3.2.2.2 Effects on extracellular levels of NE 
 Microdyalisis studies in rats have shown that ATX (0.3-3mg/kg i.p.) increases 
extracellular levels of NE in PFC (Bymaster et al., 2002; Swanson et al., 2006), as 
well as in the lateral hypothalamus, hippocampus and cerebellum (Swanson et al., 
2006), without increasing extracellular levels of 5-HT in the PFC (Bymaster et al., 
2002). Similarly, a single dose (0.3, 1, 3 mg./kg, i.p.) and chronic (1 mg/kg i.p.) ATX 
administration in mice increased extracellular levels of NE in the PFC (Koda et al., 
2010), without effects in the striatum (Koda et al., 2010) or on 5-HT levels on these 
regions. Furthermore, the authors report a decrease in baseline extracellular levels of 
NE but not of DA in PFC after 21 days treatment with ATX, suggestive of adaptive 
processes in the brain to prolonged ATX administration (Koda et al., 2010). 
 In conclusion, rodent studies have shown that ATX increases extracellular 




3.3.2.3 PET studies in healthy adults and non-human primates  
 As previously mentioned, PET studies on the effect of MPH and ATX on 
noradrenergic transporters have been hampered due to the lack of a suitable 
radioligand (Del Campo et al., 2011; Logan et al., 2007). However, some preliminary 
evidence of the effects of ATX on NET-rich areas has been provided by studies using 
sub-optimal radioligands in human and non-human primates, which will be reviewed 
below. 
 Studies in non-human primates have shown that clinical doses of ATX 
significantly occupy the NET almost completely in a dose-dependent manner in 
monkeys (Ding et al., 2009). Dose-dependent occupancy of ATX has also been 
reported in a PET study in monkeys in the thalamus, brainstem and anterior cingulate, 
where clinical doses of ATX occupy the NET almost completely (Takano et al., 
2009). Similarly, a study focused on the use of a new radioligand to assess NET 
occupancy by ATX in non-human primates, showed that ATX blocks NET 
significantly in the ACC, thalamus, midbrain or brain stem, and furthermore 
suggested the use of the caudate as a reference region given the low NET binding 
(Gallezot et al., 2011).  
 A recent study using single-unit recording techniques in the DLPFC of 
monkeys while performing a spatial WM task showed that ATX enhanced activity in 
a inverted-U dose-dependent response fashion, by enhancing neuron firing for the 
preferred direction via α2-adrenoreceptors and, to a lessen extent, also by decreasing 
neuronal firing for non-preferred directions (via D1 receptors). Thus, it increases 
“signal-to-noise” signal in DLPFC (Gamo et al., 2010).  
 The evidence of the effect of ATX in humans using PET is very limited. ATX 
has been shown to block NET in midbrain/locus coeruleus, brain stem, hypothalamus, 
thalamus, cingulate gyrus and cerebellum (Logan et al., 2007). However, the authors 
were not able to detect differences between the doses of ATX administered (25mg, 
50mg or 100 mg). They suggest this might be due to non-specific NET background 
binding of the ligand used, highlighting the importance of the radioligand used (Logan 
et al., 2007). Another inconsistency of PET studies on NET is the use of an 
appropriate reference region with low NET density, which is crucial for the accuracy 
and replicability of the findings, with suggestions for the use of caudate or 
caudate+putamen (Logan et al., 2007), or the composite reference region of basal 
ganglia and occipital cortex (Logan et al., 2005).  
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 Finally, the study from Marquand et al (Marquand et al., 2012) needs to be 
mentioned briefly again. As described above, the authors used pattern recognition 
analyses and showed differential effects of a single dose MPH (30 mg, orally) and 
ATX (60 mg, orally) on rCBF in healthy adults at rest (Marquand et al., 2012). While 
MPH showed differential effects on rCBF in the caudate, midbrain and SN, thalamus, 
VMPFC, cingulate cortex, insula and temporal cortices, ATX showed differential 
effects in cerebellum, parahippocampal gyrus, posterior insula, inferior and medial 
frontal regions, sensorimotor and middle temporal cortices (Marquand et al., 2012). 
 
3.4 Conclusions 
 This chapter has shown the evidence for the comparable efficacy of both MPH 
and ATX in the treatment of ADHD symptoms, reducing >25% of the core symptoms 
of inattention and hyperactivity/impulsivity in 65-75% of ADHD patients (Hanwella 
et al., 2011; Hazell et al., 2010). Despite the fact that both are routinely prescribed for 
the treatment of ADHD, their mechanisms of action are still relatively unknown. 
From the evidence reviewed above, it can be concluded that MPH blocks the DAT in 
the striatum in a dose-dependent manner, as well as NET in the PFC, hippocampus, 
primary sensory regions, LC, raphe nuclei and hypothalamus. Meanwhile, ATX 
significantly blocks NET in PFC, hypothalamus, hippocampus, cerebellum, thalamus, 
brain stem, anterior cingulate and midbrain.  
 However, how the DAT and NET blockade improves or normalises 
catecholaminergic abnormalities and ADHD symptoms is still under study. The 
evidence on the dysfunctions of the dopaminergic system in ADHD is inconsistent. 
Initial studies showed that ADHD patients had higher levels of striatal DAT 
(Dougherty et al., 1999; Dresel et al., 2000; Krause et al., 2000; la Fougere et al., 
2006; Larisch et al., 2006; Spencer et al., 2007; Spencer et al., 2005), which would 
reuptake DA from the synaptic space in excess, leading to a reduced dopaminergic 
tone. However, a large body of evidence does not support this statement, and reduced 
DAT levels have been described, in particular in larger sampled, better defined, 
medication-naïve and non-comorbid samples (Hesse et al., 2009; Jucaite et al., 2005; 
van Dyck et al., 2002; Volkow et al., 2009; Volkow, Wang, Newcorn, Fowler, et al., 
2007). As reviewed above, a recent meta-analytic study provides evidence that the 
DAT levels may be dependent on long-term stimulant medication, being reduced in 
medication-naive but enhanced in previously medicated ADHD patients. This 
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suggests potential mediating effects of previous MPH administration on the reported 
increase on DAT levels (Fusar-Poli et al., 2012), potentially as an adaptive response 
of the brain. It is important to note that in addition to the potential effects of long-term 
stimulant treatment other environmental factors may influence DAT levels and need 
to be considered in studies in children and adults with ADHD, such as smoking habits 
(Krause, 2008) or age-related changes in the dopaminergic system (Volkow, Wang, 
Fowler, Ding, et al., 1998; Wong, Young, Wilson, Meltzer, & Gjedde, 1997). 
 In addition, if MPH acts by blocking the DAT in the striatum, one can expect 
that to be directly associated to the increased level of extracellular DA. However, the 
available evidence suggests this is not the case (Volkow, Wang, Fowler, Logan, 
Franceschi, et al., 2002), and therefore other factors such as the rate of DA release or 
the availability or density of dopaminergic receptors may play a role on the effects of 
MPH on the dopaminergic system.  
 Furthermore, the evidence seems to suggest an association between the 
increase in extracellular DA levels as a consequence of DAT blockade by MPH and 
the symptomatic improvement in ADHD patients (Krause et al., 2000; la Fougere et 
al., 2006; Szobot et al., 2008; Volkow, Wang, Newcorn, Telang, et al., 2007; Volkow 
et al., 2012).  
 A different question is the effect of the enhanced extracellular dopaminergic 
levels in the brain. The elevated extracellular DA may reduce the phasic discharge in 
DA pathways (Seeman & Madras, 2002). Follow-up studies have shown that 
prolonged MPH administration in medication-naïve ADHD patients significantly 
reduces DAT availability levels, which were furthermore associated with 
symptomatic improvement. It may be that this reduced availability triggers adaptive 
processes in the brain, leading to an increase in DAT levels as a result of such 
processes, which would be in line with recent evidence from a meta-analytic study 
(Fusar-Poli et al., 2012). Furthermore, in medication-naïve ADHD patients reduced 
DA storage and synthesis have been reported, which may be linked to the known 
association between reduced DAT function that downregulates presynaptic DA 
storage and synthesis (Gainetdinov & Caron, 2003). Thus, if MPH significantly 
blocks DAT and the brain responds by increasing DAT levels in an attempt to 
regulate, that would lead to upregulated DA storage and synthesis, as reported by 
studies in adults and adolescents with ADHD (Ernst et al., 1999). 
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 However, as suggested by the studies from Volkow et al, the effects of MPH 
may be context-dependent, as the enhanced DA levels would reduce background DA 
firing thus reducing noise and making relevant stimuli more salient, leading to 
enhanced salience of stimuli by increasing signal-to-noise ratio (Volkow, Wang, 
Fowler, Logan, Jayne, et al., 2002; Volkow et al., 2004). Thus, the beneficial effects 
of MPH may be due to the improved efficiency of the dopaminergic system in those 
contexts (whether these are classroom work or cognitive tasks in the lab) where the 
dopaminergic system of ADHD patients was previously dysfunctional (Volkow et al., 
2005).  
 It is important at this time to note that MPH not only acts on dopaminergic but 
also on noradrenergic systems. Studies in animals suggest a combined action of MPH 
and ATX on both dopaminergic and noradrenergic systems as underlying the 
increased “signal-to-noise” ratio reported in the PFC during WM processes (Gamo et 
al., 2010). However, the field is greatly limited at the moment. Imaging the NET has 
shown to be complicated given the difficulties to develop adequate radioligands 
(Logan et al., 2007), with some recent success (Ding et al., 2009; Gallezot et al., 
2011; Seneca et al., 2006; Takano et al., 2009). Similarly, only D2/D3 receptors in the 
striatum can be confidently studied due to lack of specific radioligands for other 
dopaminergic receptors, present in cortical regions (Melchitzky & Lewis, 2009). 
Furthermore, different radioligands used in different studies may have different 
binding-specificities and therefore may differ in their findings (Del Campo et al., 
2011).  
 The evidence on the effects of ATX on the dopaminergic and noradrenergic 
systems is scarce. From rodent studies, we know that ATX enhances DA and NE in 
PFC, and NE in lateral hypothalamus, hippocampus and cerebellum. Also, PET 
studies in non-human primates and healthy adults have shown that ATX blocks the 
NET in NET-rich areas including thalamus, hypothalamus, ACC, brain stem/ 
midbrain and cerebellum.  
 However, it is not known whether patients with ADHD present with 
abnormalities in the NE system which may be ameliorated by the administration of 
MPH or ATX, what are their differential effects or how the effects of ATX on 
dopaminergic or noradrenergic systems in the brain are associated with symptomatic 
improvement. The development of a radioligand with highly specific binding 
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characteristics for the NET will allow for the accurate measure of variations in the NE 
system after administration of MPH and ATX, which is crucial to clarify this area.  
 Furthermore, only one study comparing the effects of the two compounds on 
rCBF in healthy adults has been conducted. Studies focused on the compared effects 
of MPH and ATX on the dopaminergic and noardrenergic systems in ADHD patients 
would be crucial to help clarify their mechanisms of action, and their compared 
effects on symptomatic improvement. The recruitment of medication-naïve patients is 
crucial in this case given the long-term effects of MPH administration in the striatal 
dopaminergic system, as reviewed in this chapter. Furthermore, the homogeneity of 
the samples is also essential to identify the abnormalities associated to ADHD. 
Therefore, PET studies comparing the effects of the two drugs are needed in healthy 
adults but also in well-defined large samples of ADHD patients, who should ideally 
be medication-naïve and free of comorbid disorders.  
 Thus, one of the main limitations to the field is the lack of adequate NET 
radioligands. However, other aspects need also to be considered, such as the fact that 
changes in DA and NE systems do not happen in isolation in the brain, but there are 
interactions between the different neurotransmitter systems.  
 Therefore, at present, suitable techniques to study the compared effects of 
MPH or ATX on cortical regions are either the use of single-cell recordings in 
animals as recently done by Gamo et al (Gamo et al., 2010) or studies on blood flow 
in humans as recently conducted by Marquand et al (Marquand et al., 2012), which 
furthermore allow for the study of the effects on subcortical structures, known to be 
crucial in the brain dysfunctions presented by ADHD patients. PET is the best method 
to study the compared effects of drugs when the focus of the study is on drug-related 
changes on neurotransmitter systems, either by using radioligands that bind to the 
reuptake transporter or to neurotransmitter receptors. It is also the best method to use 
when the main focus of the study is on drug-related changes on blood flow at rest, 
although other techniques such as fMRI arterial spin- labelling can also be used, as 
shown by Marquand et al (Marquand et al., 2012). However this method can not be 
used in children. 
 Both PET and fMRI are adequate techniques when the focus of the study is on 
drug-related effects on brain activation during cognitive tasks. This is particularly 
relevant in children with ADHD, since PET cannot be used in children for ethical 
reasons, as it requires the injection of a radioactive substance into the blood stream. 
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Furthermore, fMRI and PET allow for the study of brain function in networks 
including both cortical and subcortical structures which, as reviewed in previous 
chapters, underlie the cognitive deficits presented by children with ADHD.  
 In this study, fMRI was used as it is the most adequate of the available 
techniques to be used in children with ADHD. The use of fMRI thus allows for the 
detection of dysfunctions in cognitive networks in patients when under placebo during 
cognitive tasks, and the changes in those in networks after administration of a single 
dose challenge of MPH and ATX in children with ADHD.  
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CHAPTER 4. EFFECTS OF MPH AND ATX ON COGNITIVE FUNCTIONS, 
BRAIN STRUCTURE AND FUNCION  
 
 MPH and ATX have shown to be safe and effective treatments for the 
symptoms of ADHD, both in children and adults (Hanwella et al., 2011; Hazell et al., 
2010). In the case of MPH, the beneficial effects on behaviour are observable within 
hours whereas the effects of ATX are typically observable only after 4-6 weeks 
(Greenhill et al., 2001; Montoya et al., 2009; Swanson & Volkow, 2002).  
 Studies have focused not only on their efficacy as measured by behavioural 
function but also on the effects on cognitive functions. The number of studies on the 
effects of MPH and ATX on cognitive and brain function in children with ADHD is 
related to the time each medication has been prescribed for the disorder. Thus, as 
reviewed in the previous chapter, MPH has been used for decades for the treatment of 
ADHD and there is a substantial body of evidence about its effects on cognitive 
functions. Conversely, ATX has only been marketed and approved for the use in 
ADHD patients during the last decade, hence the comparatively reduced number of 
studies about its cognitive effects. However, the fact that MPH has consistently been 
the first- line treatment for decades does not mean that its mechanisms of ac tion are 
well described: far from that, they are not yet known.  
 As reviewed in the previous chapter, MPH has dopaminergic effects in the 
striatum and it enhances both DA and NE in prefrontal regions. However, a recent 
study has provided evidence that its therapeutic effects are not only mediated by the 
dopaminergic but also noradrenergic system, as it has been shown to block 
norepinephrine transporters (NET) in other regions (Hannestad et al., 2010). ATX on 
the other hand is a more selective presynaptic NET blocker that has shown to block 
the NET almost completely in NET-rich areas including the LC, raphe nuclei and 
hypothalamus, and more moderately in the thalamus and subthalamic nuclei 
(Hannestad et al., 2010). However, their compared effects on cognitive functions in 
ADHD have not yet been studied. This chapter will review the available evidence of 
the effects of both drugs from neuropsychological and functional imaging studies. It 
should be noted that given the reduced number of studies on the effects of ATX, this 




4.1 Effects on cognitive tasks 
 The effects of MPH have been studied across a number of cognitive functions, 
largely on cognitive control but also on attention, inhibition, reward or temporal 
processing. As reviewed in Chapter 1, children with ADHD have shown consistent 
deficits during sustained attention, temporal processing and WM; however, the most 
consistent evidence is that of deficits during motor response inhibition tasks (Willcutt 
et al., 2005). This, together with symptomatic improvement in hyperactive and 
impulsive behaviours after MPH administration, has led to the majority of 
neuropsychological studies on the cognitive effects of MPH in ADHD patients 
focussing upon on its effects during inhibitory functions (for reviews, see 
Chamberlain et al., 2011; Pietrzak, Mollica, Maruff, & Snyder, 2006; Swanson, Baler, 
& Volkow, 2010). Although the evidence on the effects of ATX is more limited, 
recently several studies on the effects of ATX on inhibition in children with ADHD 
have also been conducted.  
 However, before proceeding to the review of the literature, it is of note that 
many of the studies included subjects with a previous history of stimulant medication. 
Many studies compared the performance of children with ADHD when on MPH to 
that reported when they are off-MPH (or on placebo) after a washout period to ensure 
performance is not affected by previous MPH intake. However, this introduces a 
significant confound as there is evidence of the long-term effects of persistent 
stimulant administration both on brain activation and brain structure (Frodl & 
Skokauskas, 2012; Konrad et al., 2007; Nakao et al., 2011; Shaw, Sharp, et al., 2009). 
Thus, this review will emphasize those studies where medication-naïve children with 
ADHD have been recruited, both during neuropsychological and imaging studies.  
 This chapter will review in detail the effects of MPH and ATX on inhibition, 
WM and temporal processing, as these are the aspects where children with ADHD 
have shown most consistent deficits, and constitute the focus of this PhD. The effects 
of MPH and ATX on other cognitive tasks will only be succinctly summarised at the 







4.1.1. Effect on inhibition tasks 
 
4.1.1.1. Methylphenidate  
 The evidence is relatively consistent with regards to the enhanced inhibitory 
functions, in particular motor response inhibition, after MPH administration in ADHD 
patients. MPH has shown to improve performance of children (DeVito et al., 2009; 
Lijffijt et al., 2006; Schachar et al., 2008; Scheres et al., 2003) and adults with ADHD 
(Overtoom et al., 2009) during motor inhibition tasks both after a single dose (DeVito 
et al., 2009; Lijffijt et al., 2006; Overtoom et al., 2009) and repeated/chronic (Coghill, 
Rhodes, & Matthews, 2007; Schachar et al., 2008; Scheres et al., 2003) 
administration.  
 Using the SST, and compared to healthy controls, a single dose challenge of 
MPH normalised the deficits observed in previously medicated children with ADHD 
under placebo in the main inhibitory index, SSRT, coupled with relatively slower RT 
(DeVito et al., 2009). However, most of the studies have compared the performance 
within ADHD patients to their own performance without medication (either off-MPH 
or under placebo). Thus, shortened SSRTs, have also been described in children with 
ADHD under MPH when compared to the off-medication or placebo condition, 
whether they were previously medicated (DeVito et al., 2009; Konrad, Gunther, 
Hanisch, & Herpertz-Dahlmann, 2004; Lijffijt et al., 2006; Tannock, Schachar, Carr, 
Chajczyk, & Logan, 1989; Tannock, Schachar, & Logan, 1995) or, most importantly, 
medication-naïve children (Bedard et al., 2003; Scheres et al., 2003) and adults with 
ADHD (Overtoom et al., 2009), as well as a reduced number of commission errors 
(Lijffijt et al., 2006).  
 A single dose of MPH has also shown an effect on other performance 
measures that are not related to inhibitory processes during motor inhibition tasks. 
Thus, compared to placebo or off-MPH conditions, previously medicated children 
with ADHD under MPH have shown reduced MRT (Lijffijt et al., 2006; Tannock et 
al., 1989), intra- individual SD of RT (DeVito et al., 2009; Lijffijt et al., 2006; 
Tannock et al., 1989) and reduced number of omission errors (Lijffijt et al., 2006; 
Tannock et al., 1989). This was also observed in medication-naïve children with 
ADHD, where a single dose MPH challenge reduced MRT and SD of RT (Bedard et 
al., 2003).  
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 Although there are fewer studies on the effects of prolonged MPH 
administration, similar findings have been reported, with improved inhibitory function 
after 1 week of treatment with MPH (Schachar et al., 2008), reducing typically longer 
MRTs both in previously medicated (Schachar et al., 2008) and medication-naïve 
children (Coghill et al., 2007; van der Meere, Shalev, Borger, & Wiersema, 2009), 
and reducing during GNG tasks the number of commission errors (Coghill et al., 
2007), and intra- individual SD of RT (after 4 weeks of treatment) (Epstein, Brinkman, 
et al., 2011). However, some negative results have also been reported. Thus, 4 weeks 
of treatment with MPH in medication-naïve children with ADHD showed no effect on 
SSRT or MRT (Epstein, Brinkman, et al., 2011).  
 However, aside from the findings reported by Coghill et al (Coghill et al., 
2007), results seem to be less positive for the GNG task compared with those reported 
in studies using the SST. A single dose challenge of MPH in medication-naïve 
children with ADHD showed no effect on performance during a GNG task (Rhodes, 
Coghill, & Matthews, 2006). In a recent study using incentivised and non- incentivised 
version of the GNG task, medication-naive children with ADHD under placebo 
showed shorter RT when incentive was present compared to when it was not, 
however, the difference in RT between incentivised and non-incentivised disappeared 
after 4-weeks of treatment with MPH (Epstein, Brinkman, et al., 2011). MPH 
furthermore shortened SD of RT for both versions of the task and increased 
percentage of accuracy in the GNG task (independently of incentive) (Epstein, 
Brinkman, et al., 2011). After 4 weeks of MPH treatment, medication-naïve children 
with ADHD were tested under MPH and placebo during a GNG task, and depending 
on the characteristics of the task differential effects of MPH were observed: with short 
Inter-Stimuli Intervals (ISIs), performance was worse under MPH than under placebo, 
with more commission errors, but with long ISIs they made less commission errors 
under MPH than under placebo. According to the authors, these results suggest MPH 
worsens performance in a task where children with ADHD have previously done well 
(van der Meere et al., 2009).  
 Thus, the results during different motor response inhibition tasks suggest that 
either the SST is a more sensitive paradigm to detect the beneficial effects of MPH on 
this cognitive function, or that MPH has specific effects on different aspects of motor 
response inhibition processes. The SSRT is a measure of the speed of the motor 
inhibition process that differs from the percentage of commission errors, which is 
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typically taken as the main inhibitory measure in GNG tasks. Furthermore, it may be 
that MPH improves motor response inhibition of those responses that have already 
been triggered by the stimuli, as happens during the SST, and has less significant 
effect on the inhibition of a prepotent response which has not started by the time the 
NoGo stimuli is presented, as happens in the GNG task (Eagle et al., 2008; Rubia, 
Russell, et al., 2001). On the other hand, as suggested by some authors (Bedard et al., 
2003; Tannock et al., 1989; Tannock, Schachar, et al., 1995), MPH may improve 
performance during inhibitory tasks not by affecting inhibitory function per se but by 
improving other processes, in particular motor response execution, as it consistently 
reduces MRT and SD of MRT in this task. This could affect the SSRT since it is 
dependent on the MRT, which is also reduced by MPH. 
 MPH seem to have therefore a positive effect on the speed of inhibitory 
processes as measured by the SSRT, as well as improved motor execution as 
measured by the shortened MRT and SD of RT although these effects seem to be 
mostly observed in previously medicated patients.  
 Less consistent is the evidence with regards to the effects of MPH 
administration during interference inhibition tasks.  
 Compared to the off-MPH condition, a single dose MPH challenge in 
previously medicated children with ADHD (but not in healthy children) has shown to 
improve interference inhibition during the Colour-Word Stroop task (Langleben et al., 
2006), as well as during a modified version of the Stroop task (Brackenridge, 
McKenzie, Murray, & Quigley, 2011) and a Flanker task (Tucha et al., 2006). 
Similarly, repeated MPH administration in medication-naïve children with ADHD 
showed to improve accuracy and SD of RT during interference inhibition in children 
with ADHD (Epstein, Brinkman, et al., 2011). However, children with ADHD under a 
single dose of MPH compared to placebo showed no effect on interference inhibition 
conditions during Stroop or Eriksen Flanker tasks, both in medication-naïve (Bedard, 
Ickowicz, & Tannock, 2002; Ridderinkhof, Scheres, Oosterlaan, & Sergeant, 2005; 
Scheres et al., 2003), or previously medicated children with ADHD (Jonkman et al., 
1999), although it improved naming speed during the Stroop task (Bedard et al., 2002) 
and RT during a Flanker task (Ridderinkhof et al., 2005). 
 Other tasks involving inhibitory processes are cognitive flexibility tasks, like 
switching, change tasks or set-shifting tasks (also defined in Chapter 1). During these, 
MPH effects have also shown to be inconsistent. During change tasks (Tannock, 
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Schachar, et al., 1995) and switching tasks (Cepeda, Cepeda, & Kramer, 2000; 
Kramer, Cepeda, & Cepeda, 2001), previously medicated children with ADHD under 
a single dose challenge of MPH have shown improved accuracy and shortened RT 
during switching trials than when under placebo (Cepeda et al., 2000; Kramer et al., 
2001; Tannock, Schachar, et al., 1995). Similarly, during set-shifting tasks like the 
ID/ED from the CANTAB battery (described in Chapter 1) previously medicated 
children with ADHD under a single dose of MPH, successfully passed more stages in 
the ED dimension than when unmedicated (Mehta, Goodyer, & Sahakian, 2004). The 
findings from studies in medication-naïve patients are more inconsistent. Reduced 
MRT and SD during a set-shifting task have been reported under a single dose of 
MPH compared to placebo in medication naïve children with ADHD (Gunther, 
Herpertz-Dahlmann, & Konrad, 2010). However, other authors have shown no effects 
of MPH during the ID/ED from the CANTAB battery in medication-naïve children 
with ADHD, either after a single dose (Rhodes et al., 2005) or chronic administration 
(Coghill et al., 2007).  
 
4.1.1.2. Atomoxetine 
 The data about ATX effects on response inhibition are much more scarce. It is 
only very recently that studies about the effects of ATX in children with ADHD have 
been conducted. Only one study has so far been conducted in children with ADHD 
under prolonged ATX treatment during a motor response inhibition task. Four weeks 
of ATX treatment in previously medicated children with pure ADHD showed no 
effects, although children with ADHD and comorbid RD showed shorter SSRT than 
at baseline (de Jong et al., 2009). Given the limited evidence available, studies in 
adult patients and healthy subjects will also be reviewed, as these are the only 
indications available of the potential effect of ATX on different cognitive functions.  
 Thus, compared to their own performance under placebo, previously 
medicated adults with ADHD under a single dose of ATX showed shorter SSRT 
(Chamberlain et al., 2007). Healthy adults under a single dose ATX challenge have 
shown shorter SSRT without effects on MRT to Go responses when compared to 
adults under placebo or the selective serotoninergic reuptake inhibitor citalopram 
(Chamberlain, Muller, Blackwell, Clark, et al., 2006), which suggests that ATX had 
an specific effect on the inhibitory function without affecting the motor response 
execution process. Interestingly, a recent placebo-controlled, crossover study in 
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healthy adults that compared the effects of single doses of MPH and ATX on motor 
response inhibition (Nandam et al., 2011) showed that only MPH compared to ATX, 
citalopram or placebo shortened SSRT and SD of RT, thus suggestive of improved 
motor response inhibition after a single dose challenge of MPH challenge but not of 
ATX (Nandam et al., 2011). 
 During interference inhibition tasks such as the Stroop task, 3 weeks of 
treatment with ATX in adults with ADHD showed to improve interference scores 
compared to those of a parallel group under placebo (Spencer et al., 1998). Similarly, 
10 weeks of treatment with ATX in adults with ADHD improved interference 
inhibition, as measured by the colour-word score, although only for those cases with a 
low baseline performance (Faraone et al., 2005). Other inhibitory tasks have been 
used to assess the effects of prolonged administration of ATX on medication-naïve 
children with ADHD. Thus, 4 weeks of treatment with ATX reduced the number of 
errors during set-shifting tasks, which was still observed at 12 weeks of treatment 
(Gau & Shang, 2010b). 
 
4.1.1.3 Summary 
 The available evidence therefore supports the positive effect of MPH on 
inhibitory functions, with the most consistent findings supporting the positive impact 
of MPH administration on motor response inhibition, as measured by the SSRT in the 
SST. However, evidence is also suggestive of improvement in MRT and the reduced 
SD of MRT not only in the SST but also during cognitive inhibition and interference 
inhibition tasks, which has led some authors to suggest that MPH may have an effect 
on other processes underlying the task, such as motor response execution (Bedard et 
al., 2003; Tannock et al., 1989; Tannock, Schachar, et al., 1995). On the other hand, 
the few existing studies on the effects of ATX in ADHD patients (children and adults) 
provide evidence of its positive effects on motor response inhibition as measured by 
the SSRT. In opposition to this, the findings from the only study that has compared 
the effect of both compounds during motor response inhibition in healthy adults are 
intriguing, as the authors reported marked positive effects under MPH but not under 
ATX (Nandam et al., 2011). This highlights the need for comparison studies to 
observe the shared and differential effects of both compounds in ADHD patients.  
 However, the effects of MPH appear to be restricted to motor response 
inhibition tasks, as findings are not so consistent in other cognitive control tasks, such 
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as interference inhibition, change or set-shifting tasks. ATX has shown positive 
effects on interference inhibition, but the number of conducted studies is still very 
small.  
 The inclusion of previously medicated subjects in studies of single dose 
challenges of MPH or ATX cannot be understated as one of the most significant 
confounds in neuropsychological and functional imaging studies in ADHD, and this 
acquires potentially utmost relevance when we attempt to disentangle the effects of 
MPH and ATX on cognitive function and brain activation during cognitive tasks, as  
MPH has shown to have an effect on brain structure (Frodl & Skokauskas, 2012; 
Nakao et al., 2011) and brain function (Konrad et al., 2007). For this reason, those 
findings from studies recruiting pure medication-naïve samples (Bedard et al., 2003; 
Coghill et al., 2007; Epstein, Brinkman, et al., 2011; Rhodes et al., 2006; Scheres et 
al., 2003) are particularly relevant.  
 Furthermore, these studies suffer from the same limitations as previously 
reviewed in Chapter 1: many of them have included both males and females (Bedard 
et al., 2003; Bedard et al., 2002; Brackenridge et al., 2011; Epstein, Brinkman, et al., 
2011; Jonkman et al., 1999; Konrad et al., 2004; Lijffijt et al., 2006; Schachar et al., 
2008; Tannock et al., 1989; van der Meere et al., 2009), patients with comorbid 
conditions (Bedard et al., 2003; Bedard et al., 2002; Konrad et al., 2004; Lijffijt et al., 
2006; Scheres et al., 2003; Tannock et al., 1989) or different subtypes of the disorder 
(Bedard et al., 2003; Bedard et al., 2002; Epstein, Brinkman, et al., 2011; Konrad et 
al., 2004; Lijffijt et al., 2006; Scheres et al., 2003) that will increase the heterogeneity 
of the sample, typically small per se (Jonkman et al., 1999; Lijffijt et al., 2006; 
Tannock et al., 1989), and therefore reduce the possibility of providing the field with 
replicable and consistent evidence.  
 
4.1.2. Effects on attention tasks 
 
4.1.2.1. Methylphenidate  
 An early meta-analytic review of studies using sustained attention measures 
such as the Continuous Performance Test (CPT) (Losier et al., 1996) showed that 
MPH administration compared to placebo significantly improved the number of 
omission errors and, to a lesser extent the number of commission errors (Losier et al., 
1996). This has also been shown in later studies. Thus, in previously medicated 
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children with ADHD, single doses of MPH reduced the number of omissions errors 
(Hanisch, Konrad, Gunther, & Herpertz-Dahlmann, 2004; Konrad et al., 2004; 
Spencer et al., 2009; Teicher, Lowen, Polcari, Foley, & McGreenery, 2004; Tucha et 
al., 2006), commission errors (Huang, Chao, Wu, Chen, & Chen, 2007; Rosa-Neto et 
al., 2005; Spencer et al., 2009; Teicher et al., 2004), latency of responses and SD of 
RT (Huang et al., 2007; Konrad et al., 2004; Rosa-Neto et al., 2005; Spencer et al., 
2009; Teicher et al., 2004).  Importantly, reduced numbers of omission, commission 
errors and variability of responses have been reported also in medication-naïve 
children with ADHD after single dose MPH challenge (Gunther et al., 2010). 
 Positive effects have also been reported after repeated administration of MPH. 
Thus, 1-week of treatment reduced the number of omission errors in previously 
medicated children with ADHD (Schachar et al., 2008). Six-weeks of treatment with 
MPH reduced the number of commission errors and variability of responses in 
medication-naïve children with ADHD (Johnson, Barry, et al., 2008). Similarly, after 
1 year of treatment with MPH reduced commission errors were reported in children 
with ADHD (Aggarwal & Lillystone, 2000). 
 Some normalising effects have also been reported for MPH during sustained 
attention tasks. A single dose MPH challenge in previously medicated children with 
ADHD normalised the deficits observed when they were under placebo relative to 
healthy participants for time on task and attention shifts (Teicher et al., 2004), and in 
the SD of RT during a vigilance task (Tucha et al., 2006). Six-weeks of treatment with 
MPH reduced and normalised the enhanced number of commission errors observed in 
medication-naïve children with ADHD under placebo as compared to healthy controls 
during the Sustained Attention to Response task (SART, defined in Chapter 1), and 
also reduced fast moment to moment variability of responses (Johnson, Barry, et al., 
2008).  
 During other attention tasks single doses of MPH have also shown to have a 
positive effect in children with ADHD. Thus, compared to the placebo condition, a 
single dose MPH challenge in previously medicated children with ADHD has shown 
to reduce intra- individual SD during alerting and focused attention (Konrad et al., 
2004),  MRT, omission and commission errors during focused and divided attention 
tasks (Konrad et al., 2004; Tucha et al., 2006). However, no effects have been 




 Very little evidence is available with regards to ATX. Prolonged ATX 
administration in medication-naïve children with ADHD has shown to reduce latency 
of responses and omission errors, after both 4 and 12 weeks of treatment (Gau & 
Shang, 2010b). Similarly, a single dose of ATX administration reduced the number of 
commission errors during a sustained attention task in previously medicated adults 
with ADHD (Chamberlain et al., 2007).  
 
4.1.2.3. Summary 
 The evidence provides support for the positive effects of MPH on sustained 
attention tasks, as well as preliminarily also for ATX. Unfortunately, the evidence 
from studies recruiting medication-naïve patients is very limited (Gau & Shang, 
2010b; Gunther et al., 2010; Johnson, Barry, et al., 2008). It is interesting that there 
seem to be no clear indicator of which is the most sensitive measure of the effects on 
attention by MPH on these tasks whether omission errors or commission errors. 
Whether MPH improves performance during sustained attention tasks due to reduced 
impulsiveness, to improved efficiency of attention processes or both is still therefore 
to be elucidated. 
 
4.1.3. Effect on WM tasks 
 
4.1.3.1. Methylphenidate  
 Different effects have been reported during WM tasks, depending on the type 
of WM paradigms used. The most consistent evidence is for improved performance 
during visuo-spatial WM tasks, as will be reviewed below.  
 A single dose MPH challenge in children with ADHD has shown to improve 
performance during visuo-spatial WM tasks: previously medicated children with 
ADHD under MPH compared to their own performance under placebo have shown a 
reduced number of errors (Mehta et al., 2004), and improved storage and spatial 
manipulation (McInnes, Bedard, Hogg-Johnson, & Tannock, 2007). Studies on 
medication naïve samples have also reported some positive results, with single dose 
challenges of MPH improving accuracy (Bedard, Martinussen, Ickowicz, & Tannock, 
2004), storage and spatial manipulation (Bedard & Tannock, 2008). However, a lack 
of effects of MPH on visuo-spatial WM tasks has also been reported, both in 
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medication-naïve samples after a single dose (Rhodes et al., 2006) or prolonged MPH 
administration (Coghill et al., 2007), as well as in previously medicated children with 
ADHD compared to placebo, although in this case there was an increased latency of 
responses (Tannock et al., 1989). 
 Some studies have compared parallel groups, that is, a group of healthy 
controls, a group of medication-naïve or unmedicated children with ADHD and a 
third group of medicated children with ADHD. In these studies, medication-naïve 
children with ADHD compared to healthy controls showed a reduced number of 
errors than children with ADHD who were under their usual dose of MPH, whose 
performance did not differ from that of healthy control children (Barnett et al., 2001; 
Kempton et al., 1999; Vance, Maruff, & Barnett, 2003).  
 The few studies that have focused on verbal-auditory WM tasks have shown 
inconsistent results, with a single dose MPH challenge in previously medicated 
children with ADHD showing no effects when compared to their own performance 
under placebo (McInnes et al., 2007). Similarly, a recent study using a verbal N-Back 
task showed no effects of prolonged MPH administration in medication-naïve 
children with ADHD (Epstein, Brinkman, et al., 2011). However, a single dose of 
MPH at medium dose (0.45 mg/kg) in medication-naïve children with ADHD 
improved their performance on the manipulation component of a verbal-auditory WM 
task compared to placebo (Bedard & Tannock, 2008).  
 
4.1.3.2. Atomoxetine 
 Studies using WM tasks with ATX are scarce and results are inconsistent. 
Previously medicated adults with ADHD under placebo were less accurate than 
healthy controls in a visuo-spatial WM task, which persisted after ATX challenge 
(Chamberlain et al., 2007). However, these adults showed improved strategy 
utilization (Chamberlain et al., 2007), which has also been recently reported after 
repeated ATX administration in medication-naïve children with ADHD during a 
visuo-spatial WM task, although this was observed after 12 weeks of treatment rather 
than 4 weeks of treatment (Gau & Shang, 2010b). However, another study showed 
that after 4 weeks of treatment with ADHD, previously medicated children with 
ADHD improved performance (normalisation of deficits observed under placebo 
compared to controls) in a visuo-spatial WM task only in those cases with comorbid 




 Thus, there is some evidence for the positive effects of both compounds on 
visuo-spatial WM processes. However, given the relevance of the role of verbal-
auditory WM during academic and daily life (Gathercole & Alloway, 2006), the 
potential impact of the treatments routinely prescribed for the disorder seems 
understudied.  
 
4.1.4. Effects on temporal processing tasks 
 
4.1.4.1. Methylphenidate  
 The evidence of the effects of MPH on temporal processing tasks is scarce, 
and non-existent in the case of ATX. In previously medicated children with ADHD, 
single doses of MPH compared to the off-MPH or placebo condition have shown to 
improve sub-seconds synchronization (Ben-Pazi, Shalev, Gross-Tsur, & Bergman, 
2006), and to reduce their variability of responses during a time production task 
(without effects on accuracy or MRT) (Baldwin et al., 2004). 
 A single dose MPH challenge in medication-naïve children with ADHD 
showed no effect on performance during sensorimotor anticipation, synchronization 
and a TD task of seconds (Rubia, Noorloos, et al., 2003). On the other hand, 
prolonged MPH administration in medication-naïve children during 4 weeks has been 
associated with reduced variability and increased speed of responses during 
sensorimotor synchronization and a reduction in variability and impulsive errors in an 
anticipation task (Rubia, Noorloos, et al., 2003). However, 4-weeks of treatment with 
MPH showed no effects on their performance during a TD task of seconds (Rubia, 
Noorloos, et al., 2003). Similarly, 4-weeks of treatment with MPH (with a different 
condition each week: either placebo or 5, 10, 15 mg of MPH) showed no effects on 
the performance of children with ADHD during a time reproduction task (Barkley, 
Koplowitz, Anderson, & McMurray, 1997). 
 During temporal discounting tasks measuring temporal foresight, previously 
medicated children with ADHD after a single dose of MPH relative to their own 
performance under placebo have shown a reduced delay discounting rate during an 
experiential discounting task but not when the discounting task was hypothetical 




 So far, however, there are no studies that have examined the effects of ATX 
on temporal processes, either in patients with ADHD (neither children nor adults) or 
healthy subjects.  
 
4.1.4.3. Summary 
 Thus, the reduced number of studies on the effects of MPH on temporal 
processing functions supports a positive impact of the drug during sensorimotor 
synchronization. The evidence in healthy subjects suggest that time perception is 
mediated by dopaminergic networks (Rubia et al., 2006; Wiener et al., 2010) and it 
can therefore be expected that stimulant medications would enhance time perception 
processing. Thus, given the limited evidence on the effects of MPH in patients with 
ADHD, more studies are needed on this field.  
 
4.1.5. Effects of MPH and ATX on other cognitive functions 
 Some studies have also shown the effects of MPH on cognitive tasks in 
children with ADHD, with mounting evidence for positive effects during rewarded 
tasks. Thus, previously medicated children with ADHD have shown improved 
performance under a single dose of MPH than under placebo in a rewarded 
sensorimotor task that required progressively increased button-pressings to receive the 
rewards (Wilkison, Kircher, McMahon, & Sloane, 1995). Children with ADHD 
showed improved performance during motor response inhibition and visual attention 
tasks which involve contingencies manipulations (reward and response cost) under a 
single dose of MPH than under placebo (Tamm & Carlson, 2007). Similarly, other 
studies had shown improved performance in children with ADHD under stimulant 
medication compared to placebo during a rewarded signal detection task (Tripp & 
Alsop, 1999). During a gambling task, previously medicated children under a single 
dose of MPH have shown to make more conservative bets than when under placebo 
(DeVito et al., 2008). 
 
4.1.6. Dose-related effects of Methylphenidate 
  Some studies have furthermore studied the potential association between 
different doses of MPH and performance improvement in ADHD. Typically, studies 
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on the effects of a single dose of MPH have used either two or three different dosages 
with low (0.25-0.30 mg/kg), medium (0.45-0.6 mg/kg) and high dosages (0.9-1 
mg/kg). Although some studies report no differences between the different doses used 
(Bedard et al., 2002; Scheres et al., 2003; Shiels et al., 2009; Tannock, Ickowicz, & 
Schachar, 1995), the findings from those that report an effect suggest that these may 
be task-dependent. Thus, linear effects with more pronounced improvements at higher 
doses have been reported during fast trials in WM (Tannock, Ickowicz, et al., 1995), 
change-RT (Tannock, Schachar, et al., 1995) and attention tasks (Gunther et al., 2010; 
Konrad et al., 2004). Also linear effects were found for MRT and SD of RT (Spencer 
et al., 2009) or in MRT during inhibition processes (Ridderinkhof et al., 2005; 
Tannock et al., 1989), as well as in SSRT during inhibitory tasks (Lijffijt et al., 2006). 
However, an inverted-U effect has also been described for the SSRT during motor 
inhibition (Konrad et al., 2004), as well as during focused attention or variability of 
responses during sustained attention tasks (Gunther et al., 2010), and during auditory-
verbal memory tasks (Bedard & Tannock, 2008). Another study using slightly lower 
doses (0.21, 0.31, 0.41 mg/kg) found a linear relationship with improvement in visuo-
spatial and verbal-auditory WM tasks (McInnes et al., 2007). However, this could be 
due to the lower doses, and had they included a higher dose condition they may have 
found the inverted-U effect described by Bedard et al (Bedard & Tannock, 2008).  
 Similarly, a study on the effects of chronic MPH administration at fixed doses 
(0.3mg/kg, 0.6 mg/kg) showed very little differences between the effects of these, 
with only higher doses shortening RT during motor response inhibition tasks (Coghill 
et al., 2007).  
 Some of these dose-related effects may be affected by the inverted U-shape 
relationship between neurotransmitter levels and cognitive performance which varies 
depending on each cognitive function, as different levels of neurotransmitters may be 
necessary (Arnsten, 2009; Cools & D'Esposito, 2011; Gamo et al., 2010; Robbins, 
2010). Fronto-striatal dopaminergic systems show a stability/flexibility trade-off in 
the brain (Cools & D'Esposito, 2011). Optimal levels of DA on PFC (via their action 
on D1 receptors) allow for the stability of representations withheld in WM by 
inhibiting neural firing to irrelevant stimuli (Arnsten & Pliszka, 2011; Cools & 
D'Esposito, 2011), while these levels seem to be too low to engage dopaminergic 
activity in the striatum via D2 receptors. However, with higher DA levels, D2 
receptors stimulation in the striatum facilitates flexibility and rapid updating of 
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information (Cools & D'Esposito, 2011), while excessive D1 stimulation in the PFC 
suppresses firing both to relevant and irrelevant stimuli (Arnsten & Pliszka, 2011; 
Cools & D'Esposito, 2011).  
 
4.1.7. Findings from neuropsychological studies: summary and conclusions  
 Most of the evidence on effects of MPH and ATX during neuropsychological 
studies supports the positive effects of MPH on inhibitory processes, in particular 
during motor response inhibition tasks, mostly when measured using the SST. There 
is consistent evidence for a shortened SSRT, suggestive of improved speed of the 
inhibitory function. However, the limited evidence for a reduction in the number of 
commission errors during motor response inhibition is intriguing and suggests that the 
effect of MPH is more on the speed of the inhibitory process rather than the likelihood 
to inhibit. This may be indicative of a higher sensitivity of the SSRT to detect the 
effects of MPH on motor response inhibition processes. There is some consistent 
evidence of effects on other measures of the task under single doses or chronic MPH 
administration like shortened MRT and reduced intrasubject SD of RT, suggesting 
that the effect is not specific to the inhibitory process but also motor execution 
processes. However, this evidence is mostly coming from studies that recruited 
previously medicated ADHD children. Nevertheless, this has led to the suggestion 
that MPH may not improve inhibitory processes per se, but may improve the speed of 
motor execution processes and the speed of the inhibitory process (Bedard et al., 
2003; Tannock et al., 1989; Tannock, Schachar, et al., 1995).  
 On the other hand, with regards to ATX very little is known. Studies in both 
healthy adults and those with ADHD show that ATX administration shortens SSRT, 
indicative of improved inhibitory function, as well as improved interference inhibition 
(although only in those cases of impaired performance at baseline), and improved 
performance in change or set-shifting tasks in children with ADHD. The lack of 
effects on MRT of Go responses in these tasks, suggests that its effects are more 
specific on inhibitory processes without affecting motor response execution process, 
as opposed to the effects described for MPH.  
 However, contrary to this interpretation, a recent study comparing a single 
dose of ATX and MPH on healthy adults has shown that only MPH improved SSRT 
(Nandam et al., 2011), and in children with ADHD chronic ATX only improved 
SSRT in those cases with comorbid reading disorder (de Jong et al., 2009). Given the 
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very limited evidence available, more studies are needed to get more conclusive 
results about the exact nature of the effects of ATX on motor inhibition processes.  
 MPH also showed positive effects during sustained attention tasks, with 
reduced number of omission errors, commission errors, MRT, SD of RT and time on 
task. On the other hand, ATX has also shown some positive effects both in children 
and adults with ADHD, such as a reduced number of omission and commission errors 
and latency of responses. Nevertheless, given the reduced number of studies 
addressing these tasks, the findings can only be considered as preliminary and more 
research is needed. 
 During temporal processing paradigms, only studies of the effects of MPH 
exist. In this case, the evidence supports the positive effects on time processes, 
although not consistently, with mixed results. Whether this may be due to the design 
of the tasks, and whether the tasks are not sensitive enough to detect the effects of the 
drugs is something to consider.  
 During WM tasks the little evidence available seems to support the positive 
effect of MPH on visuo-spatial WM tasks, and not that clearly during verbal-auditory 
WM tasks. Single doses of ATX meanwhile have shown no effects on visuo-spatial 
WM tasks neither in adults with ADHD, nor in children with ADHD after 4 weeks of 
treatment. However, there is evidence of positive effects when the treatment is 
continued during 12 weeks. This results are in line with the time course shown for 
behavioural effects, as ATX has been reported to reach its maximum clinical efficacy 
only after 12 weeks of treatment (Montoya et al., 2009), and therefore may suggest 
that its beneficial effect on WM processes may only be observed after chronic 
administration.  
 Only few studies have tested the association between the reported effects of 
MPH on cognitive measures and symptomatic profile with, however, little success 
(Barnett et al., 2001; Mehta et al., 2004). Nevertheless, it needs to be highlighted that 
these studies suffer in their majority from the same limitations as those reviewed in 
chapter 1, when describing the evidence from neuropsychological studies in ADHD. 
These comprise the inclusion of small samples of subjects with different subtypes of 
ADHD, of males and females, or the presence of subjects with comorbid conditions, 
which increase the heterogeneity of the sample. Most importantly, as mentioned at the 
beginning of this chapter, the inclusion of subjects with a previous history of 
stimulant medication constitutes possibly the most significant confound in the studies 
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reviewed. These factors were extensively discussed in chapter 1, and therefore they 
will not be further discussed here.  
 Thus, additional evidence on the effects of ATX during different cognitive 
functions in ADHD patients is urgently needed. Furthermore, studies comparing the 
effects of both drugs in homogeneous samples would allow to elucidate the 
commonalities and differences of the cognitive effects of these drugs on medication-
naïve children with ADHD.   
 Whether the observed improvements are associated with the presence of 
previous deficits in children with ADHD merits further discussion. Some of the 
studies have reported differential effects depending on the baseline performance 
levels, with significant improvements after medication in those cases with impaired 
baseline performance levels (Faraone et al., 2005; Hanisch et al., 2004). This is 
consistent with the results from other studies, reviewed in chapter 3, where responders 
to MPH behaviourally were those who presented with more severe abnormalities in 
the dopaminergic system at baseline (Krause et al., 2005; la Fougere et al., 2006). 
Furthermore, as reported in chapter 2, the evidence for the presence of abnormalities 
or deficits during interference inhibition tasks in children with ADHD is not as 
consistent as that for motor response inhibition processes. Thus, it is possible that 
MPH has stronger effects on those cases where the deficits both at the cognitive and 
catecholaminergic neurotransmitter systems levels are more pronounced, and the re is 
therefore more room for improvement. However, some evidence in the opposite 
direction has also been provided, with larger improvements in those children with 
ADHD with better baseline performance (Mehta et al., 2004).  
 The effects of MPH and ATX should ideally be compared not only using a 
single cognitive function, but using a range of tasks loading on executive and non-
executive cognitive functions, so as to provide more details on their compared e ffects 
on cognition. However, only few studies have used neuropsychological batteries to 
assess the effect of MPH or ATX on cognitive processes (Coghill et al., 2007; Gau & 
Shang, 2010b; Rhodes et al., 2006), and therefore more studies are needed. These 
studies would furthermore help to identify whether there are specific beneficial effects 
on specific cognitive functions for the drugs studied, which at present is unknown.  
 Furthermore, the doses required for positive behavioural effects may be higher 
than those for positive cognitive effects (Sprague & Sleator, 1977; Swanson et al., 
2010). However, the majority of the studies have used a single dose, and there fore 
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more studies on the compared effects of different dosages both of MPH and ATX are 
needed.  
 Results from the MTA study showed a dissipation of the superior effects of 
stimulant treatment relative to other behavioural treatment options after approximately 
3 years (for a review, see Swanson et al., 2010). How and whether this occurs also at a 
cognitive function level would merit further investigation, and whe ther this 
dissipation of effects long-term also occurs with ATX. Therefore, studies on the 
compared effects of a single dose and chronic administration of MPH and ATX are 
strongly needed.  
 
4.2 Effects of MPH and ATX on brain structure and function 
 The study of the effects of MPH and ATX cannot be limited to the study of 
their effects on cognitive functions, but the neural underpinnings of these effects on 
cognition need to be clarified. Functional imaging studies on the effects of the 
different medications during cognitive tasks not only provide this evidence, but also 
help to increase our knowledge about the mechanisms of action underlying the 
observed cognitive changes.  
 
4.2.1. Indirect evidence for the effects of MPH on brain development/structure  
 At present, there is not a single prospective longitudinal imaging study within 
randomised clinical trials with a focus on the effects of MPH on brain structure, and 
only indirect evidence of its potential effects from small studies conducting mostly 
cross-sectional comparisons between medicated and unmedicated groups of children 
with ADHD is available. Thus, given the severe limitations of most of the existent 
studies, the evidence will be succinctly summarised here. This is only applicable to 
MPH, as there are no such studies for ATX as yet.  
 Only one longitudinal study has so far focused on the effects of MPH on brain 
structure in a very small subgroup of children of their original sample. This study 
showed that those children who had received long-term psychostimulants during a 4-
years period (N=24) had more normal cortical thickness in the right precentral gyrus, 
left middle/inferior frontal gyrus and in right parieto-occipital regions, due to a more 
rapid cortical thinning rate in the non-medicated group (N=19) (Shaw, Sharp, et al., 
2009).  
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 A longitudinal study conducted a cross-sectional post-hoc comparison 
between medicated and unmedicated patients, as well as with healthy controls 
(Castellanos et al., 2002). The authors reported significantly reduced white matter 
volumes in unmedicated patients (N=49) compared to both long-term treated patients 
(N=103) and healthy controls (N=139) (Castellanos et al., 2002). However, the cross-
sectional nature of the comparison and the reduced number of cases included in the 
post-doc comparison limit the interpretation of this finding.  
 In addition, some small-numbered cross-sectional studies found more normal 
structure in the posterior inferior vermis of the cerebellum and in right ACC volume 
compared to healthy controls in long-term medicated (Pliszka et al N=16; Bledsoe et 
al N=18) compared to unmedicated children with ADHD (Pliszka et al N=14; Bledsoe 
et al N=14), who had smaller volumes compared to healthy controls (Pliszka et al 
N=21; Bledsoe et al N=15)  (Bledsoe et al., 2009; Pliszka, Lancaster, Liotti, & 
Semrud-Clikeman, 2006).  
 As reviewed in chapter 2, meta-analytic studies of findings from VBM studies 
in children with ADHD have shown that the most significant volumetric grey matter 
reductions are in the right basal ganglia (Frodl & Skokauskas, 2012; Nakao et al., 
2011). Furthermore, those studies with a higher proportion of long-term medicated 
patients no longer showed striatal grey matter volumetric abnormalities (Frodl & 
Skokauskas, 2012; Nakao et al., 2011). Similarly, a cross-sectional study showed that 
children with ADHD presented with inwards deformations in the basal ganglia that 
were associated to ADHD symptom severity (Sobel et al., 2010). However, when 
their medication status was taken into account, the group not taking stimulant 
medication showed exacerbated inward deformations compared to controls, whereas 
the group taking long-term stimulant medication showed outwards deformations that 
attenuated the differences relative to the healthy control group (Sobel et al., 2010).  
 A limitation of all these studies is their cross-sectional nature, and the presence 
of a potential selection bias. To assess adequately the potential effects of stimulant 
medication on brain structure, prospective longitudinal imaging studies within 
randomised clinical trials are needed. However, all studies seem to be in the same 
direction and there is thus some indication that long-term stimulant-treated children 
may have more normal brain structure than untreated children, which could 
potentially point towards a protective effect of MPH. However, this needs to be 
confirmed in well-controlled longitudinal randomised longitudinal trials.   
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4.2.2. Effect on resting state 
 Some studies have tried to identify changes in cerebral blood flow (rCBF) 
during the resting state by using PET in ADHD patients. In this section, only the 
evidence for the effects of MPH on the dysfunctions reported during the resting state 
of patients will be succinctly summarised, as there is no such type of studies on the 
effects of ATX as yet.  
 Using fMRI relaxometry, 1-week of treatment with MPH has been shown to 
increase the function of the vermis of the cerebellum (Anderson, Polcari, Lowen, 
Renshaw, & Teicher, 2002). Furthermore, SPECT studies have shown the effect of 
MPH on rCBF both in medication naïve (Kim, Lee, Cho, & Lee, 2001; Lee et al., 
2005) and in previously medicated patients (Langleben et al., 2002; Lou, Henriksen, 
Bruhn, & Borner, 1989; Szobot et al., 2003), using a single dose of MPH (Lou et al., 
1989) or prolonged treatment (>1 week) (Kim et al., 2001; Lee et al., 2005; Szobot et 
al., 2008). Thus, MPH within children with ADHD upregulated rCBF in frontal 
regions (Kim et al., 2001), thalamus (Kim et al., 2001), striatum (Kim et al., 2001; 
Lou et al., 1989) and parietal cortices (Szobot et al., 2003) and decreased rCBF in 
sensorimotor regions (Lou et al., 1989). Also using SPECT, a single dose MPH 
challenge in previously medicated children with ADHD decreased rCBF in bilateral 
precentral (motor cortex) regions and the ACC compared to the off-medication 
condition (Langleben et al., 2002). Furthermore, MPH reduced the dysfunction in 
medication-naïve children with ADHD compared to healthy controls in frontal and 
occipital regions as well as in the striatum (Lee et al., 2005).  
 In adults with ADHD, similar improvements on the abnormal patterns of 
activation have been reported. Using PET, 3 weeks of treatment with MPH on 
previously medicated adult patients modulated baseline hyperactivity in precentral 
gyrus, caudate and claustrum, and increased activity (rCBF) in cerebellar vermis 
(Schweitzer et al., 2003). When compared to the off-medication condition, adults with 
ADHD under their usual stimulant medication showed a decrease in perfusion in the 
left caudate, IFC, parietal cortices and parahippocampal gyrus (O'Gorman et al., 
2008). On the other hand, there are also studies where negative results have been 
reported. Thus, a single dose (Matochik et al., 1993) or chronic (Matochik et al., 
1994) treatment with stimulant medication (methylphenidate and d-amphetamine) in 
adults with ADHD showed no effects on global glucose metabolism.  
 136 
 Thus, the evidence in children and adults with ADHD show mixed results. 
While in children with ADHD MPH has shown to have mostly enhancing effects on 
rCBF in predominantly frontal and subcortical regions, in adults with ADHD MPH 
treatment had either no effect or downregulated rCBF, with the only exception of 
Schweitzer et al (Schweitzer et al., 2003) who additionally reports enhanced rCBF in 
the cerebellum. Whether this is due to long-term adaptive responses of the brain to the 
dysfunctions they present with throughout their lives or a response to chronic MPH 
treatment can only be elucidated with long-term longitudinal randomised clinical 
studies.  
 There is some evidence of brain activation patterns in non-responder patients 
that suggests that clinical response to MPH may happen only when there is room for 
improvement on brain function. Thus, those subjects who did not response to MPH 
had higher baseline rCBF in midbrain, posterior cerebellum and middle frontal gyrus 
(Schweitzer et al., 2003) and ACC, claustrum and putamen (Cho et al., 2007), as well 
as reduced rCBF in the parietal lobe (Cho et al., 2007). However, given the small 
sample sizes and heterogeneity of the samples further studies are needed to clarify this 
aspect.   
 
4.2.3. PET studies during cognitive tasks 
 Some evidence from PET studies in healthy adults during cognitive tasks 
suggests increased efficiency of the neuronal networks after a single dose of MPH. In 
adults with ADHD, 3-weeks of treatment with MPH enhanced activation during a 
WM task under MPH compared to the unmedicated condition in the right thalamus 
and precentral gyrus (Schweitzer et al., 2004). Furthermore, there were no 
normalising effects when compared to healthy controls, as the reduced rCBF in left 
IFC, STG and ACC, and the enhanced activation in basal ganglia and cerebellum 
observed when unmedicated were not normalised after MPH. However, performance 
in the task was improved, with a reduction in MRT within patients, and a 
normalisation of the reduced accuracy observed when off-MPH compared to healthy 
subjects (Schweitzer et al., 2004).  
 In healthy subjects, blunted metabolic responses or reduced rCBF, suggestive 
of increased neural efficiency, have been reported in medial frontal and temporo-
parietal regions together with increased rCBF in cerebellum compared to placebo 
during a mathematical cognitive task  (20 mg, orally)(Volkow et al., 2008), working 
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memory (40 mg, orally)(Mehta et al., 2000) or sustained attention tasks (0.25 mg/kg, 
i.p.) (Udo de Haes, Maguire, Jager, Paans, & den Boer, 2007). The findings are less 
consistent on other regions, with rCBF in the cingulate being increased (Udo de Haes 
et al., 2007) or decreased (Volkow et al., 2008) after MPH administration compared to 
placebo during sustained attention and mathematical cognitive tasks, respectively. 
This suggests the presence of context-dependent effects of MPH, in line with previous 
evidence of increased saliency of stimuli after MPH administration (Volkow, Wang, 
Fowler, Logan, Jayne, et al., 2002; Volkow et al., 2004).  
 
4.2.4. Effect on brain function during inhibitory tasks 
 Given the key role of the striatum in inhibitory processes, these have been 
typically considered as dopaminergically innervated. However, there is evidence 
supporting the positive effects on inhibitory processes of predominantly noradrenergic 
drugs, like ATX both in animal studies (Bari, Eagle, Mar, Robinson, & Robbins, 
2009; Eagle et al., 2008) and in neuropsychological studies in humans as reviewed in 
section 4.1. It seems therefore plausible that both drugs have an enhancing effect in 
PFC activation during inhibitory processes, since in Chapter 3 it has been reviewed 
that both MPH and ATX enhanced the levels of both catecholamines in this region 
(Berridge et al., 2006; Bymaster et al., 2002; Swanson et al., 2006), and that only 
MPH will have an effect on the striatum (Berridge et al., 2006; Bymaster et al., 2002; 
Koda et al., 2010; Swanson et al., 2006; Volkow, Wang, Fowler, Gatley, et al., 1998; 
Volkow, Wang, Fowler, Logan, Franceschi, et al., 2002).  
 
4.2.4.1. Methylphenidate  
 MPH enhances or normalises inhibitory performance in children with ADHD, 
as has been reviewed in a previous section of this chapter. Furthermore, performance 
improvements during inhibitory tasks in children with ADHD under MPH have been 
associated not only with enhanced activation in inhibition-related networks, but also 
with modulatory effects on other neural circuits.  
 During successful inhibitory trials in the SST, a single dose challenge of MPH 
in medication-naïve children with ADHD normalised the underactivation when under 
placebo compared to healthy controls in temporo-parietal cortices and cerebellum 
(Rubia, Halari, Mohammad, et al., 2011).  
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 Similarly, during GNG tasks, a single dose MPH challenge in previously 
medicated children with ADHD has shown to enhance activation compared to a 
placebo (Epstein et al., 2007) or off-MPH conditions (Vaidya et al., 1998) in key 
inhibitory regions, including IFC and MFC, as well as striatal regions (Epstein et al., 
2007; Vaidya et al., 1998). Further upregulating effects have been reported in the 
ACC, IPL and cerebellum (Epstein et al., 2007). Although patients showed an 
improved performance in the task, with shorter SD of RT and improved target 
stimulus discrimination, this was not associated to the changes in bra in activation 
(Epstein et al., 2007).   
 During an incentivised GNG task, previously medicated children with ADHD 
showed reduced task-related deactivation in the DMN (including medial prefrontal 
cortex, PCC, inferior parietal and lateral temporal cortices) under the low incentive 
condition, which was normalised under a single dose MPH challenge (Liddle et al., 
2010). The authors report reduced sensitivity (d prime) and enhanced omission errors 
in children with ADHD off-MPH, which disappeared under a single dose of MPH 
(Liddle et al., 2010).  
 A study used fNIRS (described in Chapter 2), finding enhanced activation in 
the right lateral prefrontal cortex during a Go/No Go task after a single dose MPH 
challenge in previously medicated children with ADHD compared to the off-MPH 
condition, which was associated with improved accuracy during NoGo trials (Monden 
et al., 2011).  
 Finally, in previously medicated children with ADHD during the motor 
response inhibitory trials of a modified version of the Flanker task which included a 
NoGo component, no effect of a single dose MPH challenge was observed (Lee, Han, 
Lee, & Choi, 2010).  
 There is also some evidence that MPH improves brain function associated 
with performance monitoring or error monitoring. In the only study conducted using 
the SST and recruiting a medication-naïve sample of children with ADHD, a single 
dose MPH challenge compared to placebo upregulated activation in left MFC, 
bilateral IFC and lenticular nucleus and right parietal regions only during failed 
inhibitory trials (Rubia, Halari, Mohammad, et al., 2011). These upregulation effects 
were furthermore associated with performance during the task, thus, enhanced 
activation in bilateral IFC was associated with longer post-error RT, the upregulation 
in right IFC  was associated with longer MRT to go responses and the SD of RT was 
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associated with enhanced parietal activation. Also, when compared to healthy boys, 
children with ADHD under placebo showed underactivation in an error monitoring 
network involving left IFC, right dorsomedial prefrontal, pre-SMA, bilateral 
thalamus, PCC, temporo-parietal and occipital cortices (Rubia, Halari, Mohammad, et 
al., 2011), that was associated with post-error slowing (reduced at a trend level) in 
ADHD patients under placebo. When patients were under a single dose MPH 
challenge they no longer differed from healthy boys (Rubia, Halari, Mohammad, et 
al., 2011).  
 Other inhibitory tasks used to assess the effect of MPH during interference 
inhibition processes do not produce consistent findings. Using the Attention Network 
Test (ANT), in which one of the conditions is a variation of a Flanker task, Konrad et 
al (Konrad et al., 2007) observed that one year of treatment with MPH did not 
normalise the reduced function in the ACC in ADHD children compared to healthy 
children during interference inhibition processes.  
 Conversely, using a Simon task in a medication-naïve sample of children with 
ADHD, a single dose MPH challenge compared to the placebo condition enhanced 
activation in right IFC, premotor cortices, temporo-parietal lobes as well as in 
cerebellum, without significant effects on task performance (Rubia, Halari, Cubillo, et 
al., 2011). Furthermore, when compared to healthy boys, a single dose of MPH 
normalised the reduced function under placebo in left VMPFC and right IFC, as well 
as in basal ganglia and thalamus. However, MPH administration did not modify the 
underactivation observed in other key regions for conflict monitoring and interference 
suppression as the SMA, ACC and PCC and left temporo-occipital regions (Rubia, 
Halari, Cubillo, et al., 2011). The longer RT in ADHD under placebo compared to 
controls were furthermore not normalised by MPH.  
 Using a Stroop task, a single dose of MPH in previously medicated 
(responders) children with ADHD has shown to enhance activation in the control 
condition of the task in the ventral ACC and PCC, which according to the authors 
may represent the enhanced deactivation of the DMN during the condition of interest 
(interference inhibition) (Peterson et al., 2009). Furthermore, it was observed that the 
connectivity between left inferolateral prefrontal cortex and ventral ACC was also 
enhanced when under MPH compared to the off-MPH condition. However, this study 
did not have a placebo condition, and therefore cannot rule out the influence of 
subjects’ expectations on the results.  
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 Other studies have used modified versions of interference inhibitory 
paradigms. Thus, previously medicated children with ADHD were administered a 
single dose of MPH during a modified version of the Flanker task that included a 
component of motor response inhibition (no-go stimuli) (Lee et al., 2010). A single 
dose MPH challenge elongated MRT during incongruent trials and enhanced 
activation in right IFC, DLPFC, SFC and premotor regions (Lee et al., 2010).  
 During a emotional Stroop task, previously medicated children with ADHD  
off their daily medication compared to healthy controls showed greater reactivity in 
MFC to emotional stimuli, which was associated with greater levels of hyperactivity 
symptoms as measured by the Conners’ Parent Rating Scale (at the time of their first 
scan) and normalised when on their usual dose of stimulant medication (Posner et al., 
2011).  
 In a study using a parallel groups design in adults with ADHD, 6 weeks of 
treatment with MPH increased activation compared to that of a placebo group in the 
dorsal anterior midcingulate, DLPFC, premotor and parietal cortices, caudate, 
thalamus and cerebellum during interference inhibition, despite a lack of performance 
differences (Bush et al., 2008)Therefore, the evidence suggests beneficial effects of 
single dose MPH on brain activation during inhibition tasks which, as in 
neuropsychological studies, are more consistent for motor response inhibition than for 
interference inhibition tasks. MPH has shown to upregulate most consistently IFC and 
striatal regions in children with ADHD during tasks of motor and interference 
inhibition, with additional upregulating effects on temporo-parietal cortices. 
 
4.2.4.2. Atomoxetine 
 Although no functional imaging study has focused so far on the effects of 
ATX during inhibitory processes in ADHD patients, two studies have tested healthy 
adults after a single dose of ATX compared to placebo using motor response 
inhibition tasks combined with fMRI. Both studies found upregulating effects in IFC 
as well as right STG, left anterior insula and SMA (Chamberlain et al., 2009; Graf et 
al., 2011). During response inhibition, a single dose of ATX enhanced activation 
(irrespective of their success in the inhibition trial) in the right IFC, extending to the 
superior temporal cortex and insula as well as improved motor response inhibition 
(shorter SSRT) (Chamberlain et al., 2009). Furthermore, the authors observed a 
positive association between plasma levels of ATX and activation in right IFC and 
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STG during successful inhibition trials only (Chamberlain et al., 2009). During a 
combined Eriksen Flanker and GNG task, healthy adults under a single dose of ATX 
administration showed enhanced activation during errors in incongruent NoGo trials 
in bilateral IFC extending to left insula, SMA and SFC/pre-SMA as well as increased 
number of errors during the incongruent No-Go trials (significantly associated to 
blood serum levels of ATX, but not with brain activation changes)(Graf et al., 2011). 
Phasic alertness is a noradrenergically regulated process which shows an inverted-U 
dose-response and may have had a detrimental effect on the performance of the 
participants during the cognitive task by enhancing NE levels to the right end of the 
curve (Aston-Jones & Cohen, 2005). In line with this, the authors furthermore report 
an increase in phasic alertness, which may underlie the accompanying enhanced 
number of commission errors in incongruent nogo trials (which were furthermore 
correlated with blood serum levels of the drug) (Graf et al., 2011).  
 There is only one study so far that, using eletrophysiological methods, has 
focused on the compared effects of repeated ATX and MPH administration in 
children with ADHD, using Event Related Potentials (ERP, defined in Chapter 2, 
section 2.1)(Kratz et al., 2012). Using a crossover design, the authors show that 8 
weeks of treatment under each condition both equally improved MRT and errors 
during the conflict condition. In addition, both drugs reduced SD of RT, although 
MPH had significantly stronger effects than ATX. However, the ERPs associated to 
attention processes and stimulus evaluation (P3) did not differ from the reported at 
baseline, and only the Contingent Negative Variation (CNV), which is associated to 
anticipation and preparation, was significantly modulated only by MPH. The authors’ 
interpretation of this finding is that only MPH improved brain function in relation to 
the preparation and allocation of attention resources. At the same time, changes in the 
CNV were positively associated to changes in SD of RT only under MPH and not 
under ATX (Kratz et al., 2012). 
 
4.2.4.3. Summary 
 In conclusion, most studies report upregulating effects of MPH in children 
with ADHD on IFC, MFC and striatal regions, as well as improved downregulatio n in 
the DMN during inhibitory tasks (both GNG and Stroop). Furthermore, MPH has 
shown additional upregulating and normalising effects on motor execution and 
performance monitoring processes in IFC, striatal, pre-SMA and temporo-parietal 
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regions. On the other hand, there is no evidence for the effects of ATX on brain 
function during inhibitory processes in children or even adult ADHD patients. The 
only existing evidence from studies in healthy adults suggests enhancing effects of 
ATX in key regions during motor response inhibition tasks, most significantly the 
right IFC, as well as in other cortical regions including the right STG.  
 
4.2.5. Effect on brain function during attention tasks 
 Attention tasks typically engage right lateralised networks including the 
IFC/DLPFC, pre-SMA, thalamus, the temporo-parietal junction and cerebellum 
(Lawrence et al., 2003; Tucker & Williamson, 1984).  
 
4.2.5.1. Methylphenidate  
 The evidence on the effects of MPH or ATX on brain activation during 
attention functions is significantly more limited than that of inhibitory processes.  
Prolonged MPH administration in children with ADHD during reorienting attention 
processes did not normalise the underfunctioning temporo-parietal junction compared 
to healthy controls, but normalised the enhanced (potentially compensatory) 
activation at baseline relative to controls in insula and putamen (Konrad et al., 2007).  
 In a divided attention task, a single dose of MPH in previously medicated 
children with ADHD did not had any effect on performance and did not normalise the 
underactivation in right MTG, but showed some normalising effects on the 
underactivated baseline functioning of the left striatum compared to healthy controls 
(Shafritz, Marchione, Gore, Shaywitz, & Shaywitz, 2004). Furthermore, MPH 
enhanced activation in the basal ganglia both in children with ADHD and children 
with reading disorder during the divided attention task, which suggests that MPH has 
a general upregulating effect in the basal ganglia, independently of the presence of an 
attention disorder (Shafritz et al., 2004).  
 The only imaging study so far which has assessed the effects of MPH on 
sustained attention has shown that a single dose of MPH in medication-naïve children 
with ADHD enhanced activation in IFC, premotor cortex, PCC, precuneus and 
cerebellum, but only normalised the reduced functioning of temporo-parietal cortices. 
Enhanced activation compared to healthy boys was reported after MPH in 
DLPFC/IFC and right cerebellum. Omission errors, which were normalised under a 
single dose of MPH, were associated negatively with activation in right parietal 
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regions, and with the enhanced frontal and cerebellar activation, supporting thus the 
potential compensatory role of this enhanced activation (Rubia, Halari, Cubillo, et al., 
2009). Finally, a single dose of MPH also normalised the underfunctional patterns of 
inter-regional connectivity in fronto-striatal, fronto-cerebellar, and cerebello-striatal 
intercorrelations, although cerebello-parietal connectivity deficits persisted (Rubia, 
Halari, Cubillo, et al., 2009). Thus, this study suggests that the effects of MPH on 
sustained attention functions may be stronger in normalising the abnormal 
connectivity within sustained attention networks rather than by normalising 
underfunctioning isolated regions.  
 
4.2.5.2. Atomoxetine 
 No imaging studies have tested for the neurofunctional effect of ATX in 
ADHD patients or healthy subjects during attention tasks.  
 
4.2.5.3. Summary 
 Thus, in children with ADHD the effects of MPH on attention networks seem 
to be task-dependent, with upregulating and normalising effects in frontal regions, 
basal ganglia, temporo-parietal cortices and cerebellum during sustained attention, but 
no effects on temporo-parietal dysfunction during focused and divided attention. 
Furthermore, during sustained attention tasks, a single dose of MPH in medication-
naïve patients showed normalisation effects on most of the abnormal functional 
connectivity when under placebo relative to controls in fronto-striatal, fronto-
cerebellar, and cerebello-striatal networks, and facilitated the engagement of 
potentially compensatory activation in cerebellar regions.  
 
4.2.6. Effect on working memory tasks 
 As described in the previous chapters, WM is a higher cognitive process that 
involves the storage and manipulation of information, which typically engage the 
DLPFC and PL. Furthermore, it is known that WM is mediated by DA and NE in the 
PFC (Gamo et al., 2010), and that both drugs enhance the levels of both 
catecholamines in the PFC (Berridge et al., 2006; Bymaster et al., 2002; Swanson et 
al., 2006). Therefore, is seems reasonable to expect both drugs to have enhancing 





4.2.6.1. Methylphenidate  
 During a verbal-auditory WM task (N-Back), administration of their usual 
dose of MPH in previously treated children with ADHD improved their performance 
in the most difficult condition of the task (3-Back) compared to their own 
performance off-MPH, and normalised the performance deficits observed in the 2- 
and 3-Back when compared to controls. However, it showed no significant effect on 
brain activation compared to that observed when off-MPH (Kobel et al., 2009).  
 In a very small study including only 5 previously treated girls with ADHD, 
MPH compared to off-MPH improved accuracy in a visuo-spatial WM task (with data 
from only 4 of the participants) and reduced the enhanced brain activation in MFC as 
well as the functional connectivity between this region and basal ganglia (Sheridan, 
Hinshaw, & D'Esposito, 2010). The authors interpret these findings as a normalization 
of enhanced compensatory activation when off-MPH, given the cognitive demands on 
PFC during the task.  
 A single dose MPH challenge in previously medicated children with ADHD 
normalised the deficits observed when under placebo compared to healthy control 
children within IFC and MFC and improved the deficits observed in basal ganglia 
however, deficits in posterior temporo-occipital regions persisted (Prehn-Kristensen et 
al., 2011). The authors furthermore report improved and normalised the reduced 
accuracy when off-MPH compared to controls, although only in those trials when no 
distracters were present. 
 A recent study from Wong and Stevens (Wong & Stevens, 2012) showed the 
effects of a single dose MPH challenge in previously medicated children with ADHD 
during the Stenberg WM task. They report enhancing effects on activation and 
increased functional integration after MPH administration in the different WM 
networks identified, which involved most prominently (but were not limited to) left 
VLPFC, DLPFC and parietal network, as well as the ACC and PCC (Wong & 
Stevens, 2012). Although no significant effects on accuracy were reported, there was 
a shortened RT to targets, suggestive of decreased search time, with the highest effect 
at the lowest WM load. Furthermore, despite the lack of effects on accuracy, changes 
in functional connectivity patterns were linked to reductions in RT, with greater 





 There are no studies investigating the effects of ATX on brain activation in 
ADHD patients during WM tasks. A recent study comparing the effects of single dose 
challenges of MPH and ATX on brain activation of healthy adults during WM 
processes using multivariate pattern recognition analyses showed that MPH had a 
stronger effect on upregulating task-relevant networks (bilateral DLPFC and IPL), 
while ATX had relatively stronger effects on the suppression of the DMN (medial 
PFC, PCC/Precuneus) (Marquand et al., 2011). However, these findings were highly 
context-dependent as they were only observed during the delay component of 
rewarded trials. This would be in line with studies from Volkow et al  reviewed in the 
previous chapter (Volkow, Wang, Fowler, Logan, Jayne, et al., 2002; Volkow et al., 
2004), which suggest that MPH seems to mimic the effect of reward on upregulating 
other cognitive processes, increasing the salience of stimuli.  
 
4.2.6.3. Summary 
 In conclusion, the findings on WM tasks in children with ADHD seem to be 
relatively inconsistent, with some studies showing either no effects, downregulation 
of medial prefrontal regions or enhanced activation and functional integration of 
fronto-parietal WM networks. Whether this is due to the differences in the paradigms 
used, the previous medication history of the participants and/or the small sample sizes 
of the studies still need to be elucidated. The effects of ATX have only been studied in 
healthy adults, and ATX compared to MPH downregulated more strongly the DMN.  
 
4.2.7. Effect on timing tasks 
 Time perception processes are known to be mediated by fronto-striatal 
networks (Rubia, 2006; Wiener et al., 2010). Furthermore, as reviewed in the previous 
chapter, time perception networks are sensitive to dopaminergic manipulations 
(Baldwin et al., 2004; Rubia, Noorloos, et al., 2003) and accordingly there is 
consistent evidence that shows time perception deficits in ADHD patients, as 
reviewed in chapters 1 and 2.  
 
4.2.7.1. Methylphenidate  
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 Only one functional imaging study has so far tested the effects of MPH on 
brain activation during these cognitive functions in ADHD patients. Under a single 
dose of MPH compared to when under placebo, medication-naïve children with 
ADHD showed enhanced activation in left orbital and IFC, and at a more lenient 
threshold, also in key temporal discrimination regions comprising the right DLPFC, 
ACC and cerebellum, despite no differences in performance (Rubia, Halari, 
Christakou, et al., 2009). Furthermore, compared to healthy controls, a single dose 
MPH challenge normalised all areas of underactivation reported under placebo in 
OFC cortex, caudate and ACC and the enhanced activation in predominantly 
temporo-occipital cortices observed when ADHD boys were under placebo (Rubia, 
Halari, Christakou, et al., 2009).  
 
4.2.7.2. Atomoxetine 
 There are no studies as yet on the effect of ATX during timing tasks in ADHD 
or healthy subjects. 
 
4.2.7.3. Summary 
 The limited available evidence has shown that a single dose of MPH in 
medication-naïve children with ADHD normalises and upregulates key regions for 
TD, including IFC, ACC, basal ganglia and cerebellum. Both ATX and MPH have 
shown to enhance extracellular levels of DA in PFC, consequently shared effects may 
be shown in this region. Therefore, it would be interesting to compare the effects of 
both compounds during a TD task.  
 
4.2.8. Effects of MPH on other cognitive tasks 
 There is some evidence that single dose MPH administration has also positive 
effects on brain function during reward-related tasks in children with ADHD. Thus, as 
mentioned above, during an incentivised GNG task, a single dose MPH challenge 
normalised the reduced task-related deactivation in the DMN under low incentive 
condition in previously medicated children with ADHD (Liddle et al., 2010). 
Furthermore, during the rewarded trials of a sustained attention task, single dose MPH 
administration to medication-naïve children with ADHD showed upregulating effects 
within subjects in right VMPFC, ACC and caudate, and normalised the enhanced 
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activation under placebo relative to controls in OFC and temporal regions (Rubia, 
Halari, Cubillo, et al., 2009).  
 
4.2.9. Findings from imaging studies: summary and conclusions 
 Neuropsychological and functional imaging studies have thus provided 
consistent evidence of the effects of MPH on different cognitive functions and their 
underlying neural underpinnings respectively. More recently, studies have focussed 
upon the effects of ATX, although the evidence is much more limited.  
 The findings from functional imaging studies show that MPH has effects on 
inhibitory networks, most consistently upregulating key frontal and striatal regions, as 
well as other regions, like the improved downregulation in the DMN during inhibitory 
tasks (both GNG and Stroop). Furthermore, MPH has been shown to have 
upregulating and normalising effect on performance monitoring networks including 
IFC (most prominently left lateralised), basal ganglia, pre-SMA, thalamus, posterior 
cingulate and temporo-parietal regions.  
 On the other hand, the lack of studies on the effects of ATX on brain 
activation in children with ADHD during inhibitory tasks makes the comparison of 
the effects impossible. However, results are promising for ATX as well, as enhancing 
effects have been reported in healthy adults in the key inhibitory region, the right IFC, 
as well as in other cortical regions including the right superior temporal gyrus. 
Furthermore, enhanced activation in bilateral IFC and SMA, part of the performance 
monitoring network, have been reported during a mixed GNG/Flanker task. It is likely 
that both drugs share effects on prefrontal regions, given that both enhance DA and 
NE levels in prefrontal areas. However, how their effects will compare in ADHD 
patients in the PFC as well as in other regions of inhibitory networks still needs to be 
elucidated. As reviewed above, MPH has been shown to have effects on other 
networks, necessary to perform inhibitory tasks, such as the deactivation in the DMN, 
and the upregulation of performance and error monitoring networks. While ATX has 
also shown some effects on error monitoring networks in healthy adults, the effects of 
ATX on cognitive functions in patients with ADHD may differ from those on healthy 
subjects. Healthy adults with adequate NE levels would have these upregulated in 
excess by the administration of a single dose of ATX, which according to the reported 
inverted-U function of NE on cognitive performance may underlie the impaired 
performance in healthy adults (Graf et al., 2011). On the other hand, patients with 
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ADHD would show downregulated levels of NE, which would potentially be 
enhanced to an optimal level by the administration of a single dose challenge of ATX, 
improving their performance in the task.  
 There is only one study in time discrimination but the evidence of 
upregulating and normalising effects of MPH on key regions involved in these 
processes, including IFC, ACC and basal ganglia is consistent with the well-known 
role of DA in TD process.  
 Finally, during WM tasks, the little evidence for normalising effects on areas 
underactive compared to controls, suggests that MPH may work not by normalising 
regions typically involved in WM processes, but by upregulating prefrontal regions 
and basal ganglia, and by engaging and enhancing functional connectivity in 
widespread lateral prefrontal-cingulate-parietal networks. On the other hand, ATX 
compared to MPH in healthy adults has shown to downregulate more strongly the 
DMN during WM. However, whether these effects will be similar in ADHD patients 
still needs to be elucidated.  
 
4.3. Limitations of the literature reviewed 
 Having reviewed the evidence, a number of factors need to be considered. 
Both neuropsychological and functional imaging studies suffer from the same caveats 
as those reviewed in Chapter 2. The inclusion of subjects with different subtypes of 
the disorder, comorbid conditions and different genders increase the heterogeneity of 
the samples and complicate the integration of the findings. As these factors were 
already extensively discussed in chapter 2 and therefore will not be further discussed 
in this section. However, the inclusion of subjects with a previous history of 
medication is of particular relevance for this section. The evidence on the long-term 
effects of persistent stimulant administration on brain structure and function (Frodl & 
Skokauskas, 2012; Konrad et al., 2007; Nakao et al., 2011; Shaw, Sharp, et al., 2009) 
suggests that the recruitment of participants with a previous stimulant medication 
history introduces a major confounder. Thus, specially informative and valuable are 
those studies that have focused on medication naïve samples (Kratz et al., 2012; 
Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2009; Rubia, Halari, 
Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 2009). Apart from these, all 
the other fMRI studies reviewed recruited subjects with a long-term history of 
stimulant medication, and tested them after a washout period either off their usual 
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medication or under a placebo condition. By including subjects that are under 
treatment and assessing them off and on their usual treatment we may be detecting a 
rebound effect on brain function. Using long enough washout periods is necessary to 
ensure both the lack of medication effects as well as the potential withdrawal effects 
of the drug. However, the potential effects of long-term adaptations on neural 
structure and function cannot be ruled out.  
 An important confound when interpreting the findings is the use of ROI 
methods. As described in Chapter 2, these methods are adequate when there is a 
strong a priori hypothesis, as it allows to restrict the number of comparisons 
conducted and therefore increases the power to detect differences (Poldrack, 2007). 
However, it leaves aside the potential involvement of other areas. This is particularly 
relevant for the reviewed studies, in particular with regards to the effects of MPH on 
brain function during motor response inhibition. Out of the studies conducted using 
motor response inhibition tasks, only one has used whole brain analysis (Rubia, 
Halari, Mohammad, et al., 2011). Thus, the available evidence may show some bias, 
with studies reporting consistently enhanced activation mainly in fronto-striatal 
regions by using ROI methods (Epstein et al., 2007; Vaidya et al., 1998). However, 
when whole brain methods are used, there are no upregulating effects of MPH within 
patients with ADHD, but the effects are stronger on IFC, basal ganglia, pre-SMA and 
temporo-parietal performance monitoring networks (Rubia, Halari, Mohammad, et al., 
2011). As reviewed in a previous section of this chapter, MPH has been hypothesised 
to improve inhibitory performance not per se but by its effects on other processes such 
as motor execution (Bedard et al., 2003; Tannock et al., 1989; Tannock, Schachar, et 
al., 1995). Therefore, the study of the effects of MPH on brain activation seems to be 
at a stage where the use whole brain methods are needed to identify its true effects.  
 Ideally, a double blind design where neither the experimenter nor the subjects 
are aware of the condition they are being scanned under is desired. To do this, the use 
of a placebo condition is required. However, some studies have not used this placebo 
condition, but only tested their participants off-MPH, both in neuropsychological 
(Brackenridge et al., 2011; Langleben et al., 2006; Teicher et al., 2004) and fMRI 
studies (Kobel et al., 2009; Lee et al., 2010; Liddle et al., 2010; Peterson et al., 2009; 
Posner et al., 2011; Prehn-Kristensen et al., 2011; Vaidya et al., 1998). Although this 
is unavoidable in those cases where medication-naïve subjects are scanned at baseline 
and then again after long-term treatment, this is not appropriate for testing the effects 
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of a single dose of any of the drugs in patients that have been under treatment for 
some time. The lack of a placebo condition in these cases is a potential confound, as 
this makes it difficult to manage the potential expectations of the subjects about their 
performance in the tasks, and therefore on the brain activation observed. Placebo is a 
known medical phenomenon (Benedetti, 2005). Furthermore, the use of a placebo that 
appears identical to the medication helps to control the effects of expectation and 
masks the different conditions the patients are participating in, thus maintaining the 
blinding.   
 The presence of potential practice effects is another confound that the design 
of the studies typically have to try to minimise. In the case of within subjects studies, 
the randomisation of the conditions, the use of parallel versions of the tasks or a 
relatively long temporal lapse between sessions may have to dissipate or eliminate 
these potential effects. In the case of case-control studies, the testing of the healthy 
control group the same number of times so as to equalize the potential practise effects 
may be a solution. However, this is at a significant financial cost and ethical 
compromise.  Nevertheless, if it can be shown that practice effects do not occur in the 







CHAPTER 5. DESIGN AND AIMS OF THE PRESENT STUDY 
 
5.1. Introduction 
The evidence reviewed in chapters 1 and 2 demonstrates that ADHD is 
associated with neuropsychological deficits and reduced brain function during 
executive function processes, most consistently in tasks of motor response inhibition, 
working memory and additionally during temporal processes (Alderson et al., 2007; 
Cubillo et al., 2012; Lijffijt et al., 2005; Martinussen et al., 2005; Nigg et al., 2005; 
Rubia, 2011; Rubia, Smith, et al., 2007a; Rubia, Halari, Christakou, et al., 2009; 
Willcutt et al., 2005).  
Despite the significant caveats of the studies reviewed in chapter 4, the 
findings suggest that MPH upregulates frontal, striatal, ACC and parietal regions 
during motor inhibition and TD tasks (Epstein et al., 2007; Rubia, Halari, 
Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 2009; Vaidya et al., 1998), 
and enhances the deactivation of the DMN (including medial PFC and PCC regions) 
during different tasks (Liddle et al., 2010; Peterson et al., 2009). Furthermore, MPH 
has been shown to upregulate and normalise abnormally reduced activation in 
children with ADHD relative to controls in the IFC, ACC and basal ganglia during 
TD (Rubia, Halari, Christakou, et al., 2009). During WM tasks, however, the 
available evidence suggests that MPH may upregulate prefrontal regions and basal 
ganglia, and enhance functional connectivity in widespread fronto-cingulate-parietal 
cortical networks (Prehn-Kristensen et al., 2011; Wong & Stevens, 2012).  
However, no fMRI study has as yet investigated the effects of ATX on brain 
function in ADHD patients, or compared the effects of ATX and MPH during any 
cognitive function in ADHD. The only available evidence is from studies in healthy 
adults, where ATX has been shown to enhance activation in key inhibitory regions, 
including the right IFC and STG (Chamberlain et al., 2009), in bilateral IFC during 
error processing (Graf et al., 2011) and to have deactivating effects on the DMN 
during WM (Marquand et al., 2011).  
Taken together, neuropsychological and functional imaging studies show that 
MPH has important positive effects on cognition and brain activation in patients with 
ADHD. Furthermore, there is also emerging evidence from neuropsychological 
studies for the positive effects of ATX on performance in motor inhibition tasks in 
ADHD patients (Chamberlain et al., 2007; de Jong et al., 2009). However, more 
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studies have tested for potential positive effects of MPH on cognitive improvement 
than of ATX. Furthermore, the modulatory effects of ADHD medications on 
functional brain activation underlying cognitive performance has so far only been 
studied in patients with ADHD using MPH. Only a few fMRI studies have focused on 
the effects of MPH on brain activation in medication-naïve ADHD patients (Rubia, 
Halari, Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2009; Rubia, Halari, 
Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 2009). Most other studies 
were conducted in previously medicated patients. Consequently, the changes in brain 
activation may have been modulated by the previous stimulant medication and 
therefore any conclusions drawn from these studies can only be done so tentatively. 
Definite evidence on the compared effects of single dose challenges of MPH and 
ATX on brain networks can only be confidently concluded from studies on 
medication-naïve samples.  
 
5.2. Design of the present study 
This study investigates for the first time the compared effects of a single dose of 
MPH and ATX on brain activation in right-handed, non-comorbid, medication-naïve 
boys between 10 and 17 years of age with a clinical diagnosis of ADHD combined 
type during cognitive tasks where they typically present with cognitive deficits. These 
tasks are: a motor response inhibition task (SST), a parametric working memory task 
(N-Back) and a TD task.  
For this purpose, participants were scanned three times in a double-blind, 
randomised, placebo-controlled, crossover design, which avoided the potential 
influence of the expectations of the subjects on the effects of the drugs. Furthermore, 
the randomised order of the drug administration was equally distributed to prevent the 
potential presence of practice effects between the three conditions. In order to 
maintain the double-blind design, all three medications were over-encapsulated using 
the same opaque capsules by the pharmacist. The psychiatrist collaborating in the 
study administered the medication on each occasion. This administration was based 
on pharmacokinetic evidence as reviewed in chapter 3, 1.5 hours before the scan to 
allow for maximum absorption (Chan et al., 1983; Witcher et al., 2003). 
On each scanning session, they received a single dose of either placebo (Vitamin 
C, 50mg), MPH (Equasym, 0.3mg/kg, range 5−20mg) or ATX (Strattera, 1mg/kg, 
range 16-66mg), in a pseudo-randomized order, and remained medication-free 
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between scans. Dosages were determined following NICE guidelines of clinical 
efficacious dosages with minimal side effects at the time of the study (National 
Institute for Heath and Clinical Excellence, 2008).  
Brain activation under each drug condition was compared within patients to 
identify potential up- or down-regulation effects. To identify potential normalisation 
effects, an age-matched group of healthy control boys were recruited from the same 
South London geographical area, and they were scanned once, unmedicated. Brain 
activation in ADHD boys under each drug condition (placebo, MPH and ATX) was 
compared in each cognitive paradigm to that of the healthy control group, in order to 
identify abnormalities in brain function in ADHD boys when these were under 
placebo, and in order to test the potential normalisation effects of MPH and ATX on 
those brain dysfunctions. 
Exclusion criteria for all participants were IQ<70 on the Wechsler Abbreviated 
Scale of Intelligence (WASI)(Wechsler, 1999), history of substance abuse or 
neurological deficits, presence of psychiatric disorders (except for ADHD and  
CD/ODD in the ADHD group), learning disability, reading, speech or language 
disorder.  
 
5.3. Sample selection and methods 
The present study recruited only medication-naïve children with ADHD, in 
order to avoid the confound of the effects of a previous history of stimulant 
medication on brain activation. Chronic administration of stimulant medication is 
known to have long-term effects on brain structure and function (Frodl & Skokauskas, 
2012; Konrad et al., 2007; Nakao et al., 2011; Shaw, Sharp, et al., 2009), and is 
therefore a major confound in those studies aiming to identify the effects of MPH 
and/or ATX on cognition and brain function. The present study is therefore highly 
relevant and novel as the evidence from fMRI studies of the effects of ADHD 
medications on brain function during cognitive tasks in medication-naïve ADHD 
patients is scarce (Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 
2009; Rubia, Halari, Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 2009) 
and non-existent in the case of ATX.   
In this study, we recruited children with pure ADHD, without any comorbid 
disorders except for CD/ODD, which was present in 2 participants. The recruitment of 
patients with ADHD and comorbid disorders is an additional confound to previous 
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studies, even when the comorbid disorders are ODD/CD. These are highly comorbid 
with ADHD (30-50% of the cases) (Biederman et al., 1991; Spencer, 2006; Wilens et 
al., 2002), and it has been reported that children with pure ADHD compared to  
children with pure CD show shared and disorder specific abnormalities in brain 
activation (Rubia, Halari, et al., 2010; Rubia, Halari, Smith, et al., 2009; Rubia et al., 
2008; Rubia, Smith, et al., 2009). This is important because the only way to rule out 
that the differences between groups with regards to cognitive deficits, brain activation 
or the effects of drugs are not due to the presence of comorbid conditions is by 
excluding them from the study. Therefore, any effects observed can be more 
confidently attributed to the presence of ADHD or the effects of drug administration 
and not to comorbid disorders. 
In this study, only boys with ADHD were recruited, to increase the 
homogeneity of the sample and therefore the likelihood of detecting potential 
cognitive deficits, abnormal brain function and the effect of the two medications on 
these impairments. The inclusion of males and females in small samples reduces the 
homogeneity of the sample. Gender differences have been reported in ADHD patients 
in their cognitive profiles, brain function, presentation of the disorder and brain 
maturation (Balint et al., 2009; De Bellis et al., 2001; Gershon, 2002; Mahone & 
Wodka, 2008; Nigg et al., 2002; Rubia, Hyde, et al., 2010; Valera et al., 2010). In 
particular, the lack of brain dysfunction in females has been shown to overshadow 
brain deficits in males with ADHD (Valera et al., 2010). We therefore included only 
boys with the disorder, to increase the homogeneity of the sample. 
The inclusion of different subtypes of the disorder is another factor that 
increases the heterogeneity of the samples. Although the combined subtype is the 
most commonly studied it is not infrequent to find that studies have collapsed the 
results of participants with different subtypes of the disorder. However, as discussed 
in chapter 1, there is still a debate about whether or not the combined and 
predominantly inattentive subtypes are etiologically similar or distinct entities 
(Barkley, 2001; Hinshaw, 2001; Milich et al., 2001; Swanson et al., 2007). Therefore, 
only children with the combined subtype  of the disorder were recruited for the 
present study.  
The selection of whole-brain or ROI methods is a highly relevant factor. The 
selection of ROI methods may be adequate in the presence of strong apriori 
hypotheses; however, it may bias the results towards certain areas and would miss 
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other regions where the two compounds may have an effect. This study used a 
combination of ROI and whole brain methods. Whole brain analyses were used for 
the case-control comparisons. The use of whole brain methods enabled the study to 
identify those regions where patients under placebo showed abnormal brain activation 
relative to controls, which may have not been hypothesised, but play a relevant role in 
the disorder, without the restrictions imposed by ROI methods to certain a-priori 
selected regions. We thought that this was important as previous fMRI studies in 
ADHD rarely exceed sample sizes of 20 participants. By recruiting 20 children with 
ADHD and 20 healthy controls, this study was relatively high powered and we did not 
want to miss important deficit regions. Furthermore, this also allowed for the study of 
the modulatory effects of both compounds on brain activation in these regions.  
ROI analyses were conducted in the within patients contrasts. The main goal of 
this PhD was to study the compared effects of both drugs on those regions which are 
part of task-relevant neural networks and where children with ADHD typically 
present with reduced function.  Thus, a mask was created for each task, taking as a 
reference those regions that where children with ADHD under placebo relative to 
controls showed reduced activation, as identified by whole brain analyses. This 
maximised the power of the study to detect the compared effects of each drug within 
patients in restricted task-relevant regions, which showed abnormal function in the 
ADHD group. 
The use of a single dose of MPH and ATX avoids potential confounds 
associated to long-term treatment which may complicate the interpretation of the 
findings and the attribution of any changes in brain activation and performance to the 
drugs unequivocally. For example, the symptomatic improvement experienced by 
patients after prolonged administration of the drugs, the presence of side effects such 
as dizziness, nausea or sleepiness, and the potential chronic effects on brain structure 
and activation, which have so far only been described for MPH (Frodl & Skokauskas, 
2012; Konrad et al., 2007; Nakao et al., 2011; Shaw, Sharp, et al., 2009) are potential 
confounds associated with long-term treatment. Thus, the present study avoids such 
confounds by using a single dose of MPH and ATX.   
 
5.4. Paradigms used 
The selection of adequate paradigms also plays a highly relevant role. It is 
necessary to select tasks that have been shown to be sensitive both to the cognitive 
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deficits and underlying brain dysfunctions shown by children with ADHD, as also to 
the effects of single dose challenges of MPH and/or ATX. The evidence reviewed in 
chapters 1 and 2 allows to conclude that children with ADHD show deficits both in 
performance and brain activation in the underlying neural networks, most consistently 
during motor response inhibition processes as measured by the SST (Alderson et al., 
2007; Lijffijt et al., 2005; Rubia, Halari, Mohammad, et al., 2011; Rubia, Smith, et al., 
2007a; Rubia, Cubillo, et al., 2010; Rubia et al., 2008; Rubia, Overmeyer, et al., 1999; 
Rubia et al., 2005; Smith, Taylor, et al., 2006; Willcutt et al., 2005), during TD tasks 
(Rubia, Halari, Christakou, et al., 2009; Smith et al., 2008; Vloet et al., 2010) as well 
as in WM processes (Fassbender et al., 2011; Kobel et al., 2009; Sheridan et al., 2007; 
Silk et al., 2005; Vance et al., 2007). As reviewed in chapter 4, these deficits in 
performance and the underlying brain dysfunctions during these tasks have also 
shown to be sensitive to the administration of a single dose and prolonged MPH in 
ADHD patients, and also to the effects of ATX in the case of the SST in studies in 
healthy adults. Therefore, we selected a SST, and a TD task for use in this study.  
MPH has been shown to have upregulation effects on prefrontal and striatal 
brain activation within children with ADHD during motor inhibition tasks (Epstein et 
al., 2007; Rubia, Halari, Mohammad, et al., 2011; Vaidya et al., 1998), while a single 
dose of ATX has shown upregulation effects in healthy adults in the key inhibitory 
area of right IFC during the SST (Chamberlain et al., 2009). There is also evidence for 
the key role of the left IFC during motor inhibition (Nee et al., 2007; Swick, Ashley, 
& Turken, 2008) and evidence that this region is upregulated with ATX in healthy 
adults during SST. Therefore, we expected that single doses of ATX and MPH would 
show comparable effects in inhibitory regions including bilateral IFC, with drug-
specific effects for MPH on striatal activation, and perhaps slightly stronger effects 
for ATX given the evidence supporting the key role of noradrenaline during motor 
inhibition processes as measured by the SST (Bari et al., 2009; Eagle et al., 2008).  
On the other hand, there is consistent evidence that dopamine is involved in 
time perception processes and neural networks (Rammsayer, 1999; Rubia, 2006) and 
there is evidence of upregulation and normalisation effects of MPH in key TD regions 
including IFC, ACC, striatum and cerebellum in medication-naïve children with  
ADHD (Rubia, Halari, Christakou, et al., 2009). Thus, we expected that a single dose 
of MPH but not of ATX would upregulate and normalise brain activation in TD 
neural networks.  
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 Furthermore, as part of the Biomedical Research Centre program, the verbal 
N-Back Working Memory task is routinely administered. This is also a relevant task 
in the study of the effects of MPH and ATX in children with ADHD, given the 
relevance that verbal WM has in the academic achievement of these children 
(Gathercole & Alloway, 2006), which is frequently impaired. WM shown to be 
mediated by DA and NE in PFC (Gamo et al., 2010) and both MPH and ATX 
enhance NE and DA in PFC (Berridge et al., 2006; Bymaster et al., 2002; Swanson et 
al., 2006). Furthermore, MPH in children with ADHD has shown upregulation effects 
in PFC and striatum during WM tasks (Prehn-Kristensen et al., 2011; Sheridan et al., 
2010), while WM functions have shown to be sensitive to noradrenergic 
manipulations (Chamberlain, Muller, Blackwell, Robbins, & Sahakian, 2006). Hence, 
we hypothesized that both drugs would modulate brain activation in PFC and that 
MPH would additionally do so in basal ganglia activation.  
 
5.5 Conclusions 
The comparison of the effects of single dose challenges of the two compounds 
on brain function in ADHD during cognitive processes that are problematic in ADHD 
would shed some light on the shared and drug-specific mechanisms of action of the 
two drugs in ADHD. It is currently not known whether MPH and ATX have drug-
specific effects on cognitive functions that are typically impaired in ADHD or 
whether their modulatory effects on the underlying neural networks are similar or 
drug-specific. Although both drugs are routinely prescribed for the treatment of 
ADHD, it is not clear how they act on neural networks in ADHD patients.  Given the  
lack of knowledge on the compared mechanisms of action of these drugs, at present, 
clinicians have to go through a trial-and-error process to identify the most appropriate 
medication and dose for each patient, with the accompanying delay in symptomatic 
improvement. Therefore, the study of the compared effects of a single dose challenge 
of MPH and ATX on brain activation would be a pioneering step towards the first 
knowledge of their drug-specfic mechanisms of action, which would help to identify 
task-specific and shared effects of the two compounds on cognitive functions and the 
underlying neural networks. The use of a single dose instead of prolonged treatment 
avoids potential confounds of long-term treatment such as symptomatic improvement, 
and side effects of both drugs or their chronic effects on brain activation.  
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The differential effects of the two compounds on different cognitive functions 
and brain activation may eventually help to develop individually tailored treatment 
programs, based on the areas where a particular patient shows deficits and the specific 
action of the drugs.  
The presence of drug-specific effects would furthermore help to understand the 
differential contribution of the cathecolaminergic neurotransmitters DA and NE to the 
disorder. While both drugs share upregulation effects of DA and NE in PFC, only 
MPH has been shown to enhance DA availability in the basal ganglia. Whether the 
beneficial effects of ATX in ADHD are due to those shared prefrontal effects or 
whether it has differential effects on cognition and brain activation from those of 
MPH is not yet known. ATX is a selective pre-synaptic NET blocker (Bymaster et al., 
2002), while MPH blocks both DAT and NET (Hannestad et al., 2010; Volkow, 
Wang, Fowler, Gatley, et al., 1998). Differential drug-specific modulatory effects of 
MPH and ATX on brain activation during a given cognitive task may suggest 
differential effects on catecholaminergic systems. This would indirectly shed light on 
the implication of DA and NE on the brain activation changes observed in ADHD 
after each medication, as well as indirectly increase our understanding on the 
neurotransmitters abnormalities present in ADHD patients compared to controls.    
In conclusion, this study comparing the effects of MPH and ATX on brain 
activation of medication naïve children with ADHD during the performance of 
disorder-relevant tasks would lead to a first understanding of the compared 
mechanisms of action of the two compounds, and their differential effects may 
indirectly increase our knowledge of the underlying neurotransmitters involvement in 
ADHD during disorder-relevant tasks. Furthermore, a comparison of each drug’s 
effect on brain function in ADHD relative to healthy controls would help to increase 
our understanding about their potentially shared and drugs-specific normalisation 









CHAPTER 6: ATOMOXETINE AND METHYLPHENIDATE NORMALISE 




 Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental 
disorder characterised by age- inappropriate levels of impulsivity, inattention and 
hyperactivity (American Psychiatric Association, 2000). One of the most consistent 
findings are deficits in motor response inhibition, in particular during the SST 
(Alderson et al., 2007), underpinned by fMRI findings of reduced activation in key 
areas of motor response inhibition such as VLPFC, SMA and caudate (for reviews, 
see Cubillo et al., 2012; Rubia, 2011).  
 The stimulant MPH and the non-stimulant ATX are the most frequently 
prescribed drugs for the treatment of ADHD. However, their mechanisms of action in 
ADHD are relatively unknown. At therapeutic doses, MPH blocks 60-70% the 
dopamine transporter (DAT) in the striatum (Volkow, Wang, Fowler, Gatley, et al., 
1998) and 70-80% of the norepinephrine transporter (NET) in NET-rich regions 
(Hannestad et al., 2010) including PFC, where it enhances extracellular levels of both 
NE and DA (Bymaster et al., 2002). ATX is a selective presynaptic NET blocker, 
which at therapeutic doses occupies NET almost completely in the ACC, thalamus, 
brain stem, midbrain, locus coeruleus and cerebellum (Gallezot et al., 2011). 
 Single dose MPH challenges in previously medicated children with ADHD 
have shown to upregulate frontal, striatal, ACC and parietal activation during GNG 
tasks (Epstein et al., 2007; Vaidya et al., 1998) and to normalise all brain activation 
deficits in VLPFC, SMA, parieto-temporal and cerebellar regions in medication-naïve 
children with ADHD during a SST (Rubia, Halari, Mohammad, et al., 2011). During 
other cognitive control functions, single dose MPH challenges in ADHD children 
have shown to upregulate or normalise most prominently fronto-striatal, but also 
temporo-parietal, cingulate and cerebellar activations (Rubia, Halari, Cubillo, et al., 
2011; Shafritz et al., 2004).  
 In ADHD patients, no fMRI study has as yet investigated the effects of ATX 
or compared its effects with those of MPH during any cognitive function. In healthy 
adults, however, a single dose challenge of ATX upregulated VLPFC, STG and SMA 
activation during motor inhibition tasks (Chamberlain et al., 2009; Graf et al., 2011).  
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 The aim of this study was to compare the effects of a single dose of MPH and 
ATX in medication-naïve ADHD boys during a challenging SST task using a 
randomised, double-blind, placebo-controlled, crossover design. To identify potential 
normalization effects, brain activation in the ADHD group under each drug condition 
was compared with that of a group of age-matched healthy boys. Based on previous 
studies on the SST, we hypothesized that medication-naïve ADHD boys under 
placebo compared to healthy boys would show reduced activation in VLPFC, 
SMA/ACC and caudate during successful inhibition (Pliszka, Glahn, et al., 2006; 
Rubia, Cubillo, et al., 2010; Rubia et al., 2008; Rubia, Overmeyer, et al., 1999; Rubia 
et al., 2005). We furthermore hypothesized that MPH would enhance frontal, striatal, 
SMA/ACC and parietal activation (Epstein et al., 2007; Rubia, Halari, Cubillo, et al., 
2011; Rubia, Halari, Mohammad, et al., 2011; Vaidya et al., 1998), while ATX would 
enhance activation of VLPFC and STG (Chamberlain et al., 2009; Graf et al., 2011).  
 
6.2. Methods and materials 
 
6.2.1. Participants  
 Sixty right-handed boys in the age range between 10-17 years participated in 
the study. Thirty medication-naive right-handed boys were recruited from clinics. 
Patients had clinical diagnosis of ADHD, inattentive/hyperactive- impulsive combined 
subtype, as assessed by an experienced child psychiatrist using the standardized 
Maudsley diagnostic interview that assesses ADHD according to DSM-IV-TR criteria 
(Goldberg & Murray, 2002). A multidisciplinary clinical team participated in the 
assessment, which included information from semi-structured clinical assessment 
interviews with parents/carers, questionnaires from parents and teachers, school 
reports, developmental history, cognitive assessments and behavioural observation of 
the child. The presence of learning disability was concluded from the information 
provided by parents and school during the clinical and cognitive assessments, or by 
the presence of significant discrepancies between verbal and performance IQ 
subscores, which is considered as an indicator of potential learning difficulties.  
 ADHD boys scored above clinical threshold for hyperactive-
impulsive/inattentive symptoms on the Strengths and Difficulties Questionnaire for 
parents (SDQ)(Goodman & Scott, 1999), the Conners’ Parent Rating Scale (CPRS-
R)(Conners et al., 1998), and below clinical threshold on the Social Communication 
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Questionnaire (SCQ)(Rutter et al., 2003)(Table 6.1). Patients were scanned in a 
double-blind, placebo-controlled, crossover design. On each scanning session, they 
received a single dose of either placebo (Vitamin C, 50mg), MPH (Equasym, 
0.3mg/kg, range 5−20mg) or ATX (Strattera, 1mg/kg, range 16-66mg), in a pseudo-
randomized order, and remained medication-free between scans. NICE guidelines of 
clinical efficacious dosages with minimal side effects at the time of the study were 
followed (National Institute for Heath and Clinical Excellence, 2008). All three drug-
conditions were over-encapsulated using the same capsules by the pharmacist. Based 
on pharmacokinetic evidence, both medications were administered 1.5 hours before 
the scan to allow for maximum absorption (Chan et al., 1983; Witcher et al., 2003). 
The same or similar dosages and time lapses between drug administration and scan 
have been shown to be sufficient to observe changes in brain activation and 
performance in ADHD patients (MPH)(Rubia, Halari, Cubillo, et al., 2011; Rubia, 
Halari, Mohammad, et al., 2011) and healthy controls (ATX)(Chamberlain et al., 
2009).  
 Thirty healthy control boys were recruited through advertisement in the same 
geographical area and scanned once, unmedicated. They scored below clinical 
threshold on the SDQ, SCQ and CPRS-R (Table 6.1).  
 Exclusion criteria for all participants were IQ<70 on the Wechsler 
Abbreviated Scale of Intelligence (WASI)(Wechsler, 1999), history of substance 
abuse or neurological deficits, presence of learning disability, reading, speech or 
language disorder, or other psychiatric disorder (except for CD/ODD in the ADHD 
group). When parental reports for potential participants were suggestive of the 
presence of such difficulties, questions addressing each of the criteria for ODD/CD 
were included in the semi-structured interviews. Thus, despite the fact that the mean 
score in the ADHD group for oppositional problems in the CPRS-R and behavioural 
difficulties in the SDQ scales were above clinical cut-offs (Table 6.1), only two cases 
received the formal diagnosis of ODD/CD. 
 Twelve participants (1 control, 11 ADHD boys) were excluded due to: above 
clinical threshold on the CPRS-R score in one control subject, IQ <70 (N=1), 
neurological abnormalities detected at the scan (N=1), technical problems that led to 
loss of data (N=3), incorrect performance of the task (N=1); inability to tolerate the 
scanning situation (N=4) or braces (N=1). Thus, the final sample consisted of 29 
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healthy control boys (mean age(SD)=13.9 (2.6)) and 19 medication-naïve children 
with ADHD (mean age(SD)=13.1m (1.7))(Table 6.1).  
 One-way analyses of variance (ANOVAs) showed no between-group 
differences for age (F(1,46)=1.16;p=0.28) but for IQ (F(1,46)=28.07;p<0.001)(Table 
6.1).  IQ scores have consistently been shown as lower in individuals with ADHD 
than in age-matched healthy controls (Bridgett & Walker, 2006; Kuntsi et al., 2004). 
Furthermore, IQ has shown to be moderately associated with inhibitory measures 
(Mahone et al., 2002). However, evidence from meta-analytic studies suggests this 
association may only partially underlie the deficits reported in children with ADHD 
during inhibitory functions. Thus, a recent meta-analytic study conducted meta-
regression analyses and showed that IQ was not a moderator of the deficits observed 
in children with ADHD in the main performance variable of the SST, the SSRT, and 
was only a borderline moderator for the differences in mean reaction time of go 
responses (Lipszyc & Schachar, 2010). Similarly, another meta-analytic study 
reviewed the role of IQ in the differences reported by the different studies included in 
their meta-analyses, and concluded that differences in inhibitory measures may persist 
although weakened after controlling for IQ (Willcutt et al., 2005).  
 Hence, we conducted an exploratory analyses comparing brain activatio n 
between healthy controls and children with ADHD under placebo with and without 
using IQ as a covariate. When using IQ as a covariate, the resulting clusters of 
activation differences between groups included the same as when IQ was not used as 
a covariate, although at a higher p value (p<0.03), with the only exception of a small 
cerebellar/occipital cluster that was no longer observed. Hence, all the case-control 
comparisons for fMRI and performance data were conducted without using IQ as a 












Table 6.1.  Sample characteristics for healthy control boys and patients with ADHD.  




Age (years, months) 13y, 9m (2y, 6m) 13y, 1m (1y, 7m) 
Age range (years, months) 10y, 3m – 17y, 10m 10y, 1m–15y, 6m 
IQ 110 (12) 92 (11) 
SDQ Total  4 (4) 22 (7) 
SDQ Hyperactive-impulsive/ 
Inattentive Subscale 
1(2) 8 (3) 
SDQ Emotional difficulties subscale 
1 (2) 4 (3) 
SDQ Behavioural difficulties subscale 
1 (1) 6 (3) 
SDQ Getting along difficulties 
subscale 1 (1) 4 (3) 
SDQ Kind and helpful behaviours  
subscale 9 (2) 5 (2) 
SCQ Total 1 (1) 10 (5) 
CPRS-R (DSM-IV) Total T score 44 (5) 79 (11) 
CPRS-R oppositional T score  
45 (4) 78 (11) 
CPRS-R Cognitive/ inattention 
problems T Score 46 (4) 
69 (9) 
CPRS-R hyperactivity T score 
47 (5) 81 (13) 
CPRS-R anxious/shy T score 
49 (8) 60 (16) 
CPRS-R Perfectionism T score 
44 (5) 59 (17) 
CPRS-R social problems T score 
46 (2) 60 (14) 
CPRS-R Psychosomatic T score 
48 (7) 63 (16) 
CPRS-R Global Index: restless 
impulsive T score 45 (4) 78 (11) 
CPRS-R Global Index: emotional 
liability T score 46 (6) 74 (13) 
CPRS-R ADHD T score 
46 (5) 76 (8) 
Note: SDQ=Strengths and Difficul ties Questionnaire; CPRS-R: Conners’ Parent Rating 




 Participants received £50 per scanning session. Parental and child informed 
consent/assent and approval from the local Ethical Committee were obtained.  
 
 
6.2.2. Experimental fMRI design: Stop task 
 Participants practiced once the 9-minutes mixed-trials, event-related fMRI 
Stop task, which measures the ability to suppress an already triggered motor response 
(Rubia et al., 2008; Rubia, Smith, et al., 2003; Rubia et al., 2005; Rubia, Smith, 
Taylor, et al., 2007). The basic go task is a choice reaction time task with a mean ITI 
of 1.8s, where subjects have to respond to go arrows (80% of trials, 236 trials) 
pointing either right or left with a right or left button response with the right/left 
thumb. In 20% of trials (60 trials), the go-signals are followed (about 250ms later) by 
stop-signals and subjects have to inhibit their motor responses (Figure 6.2). A tracking 
algorithm changes the time interval between go-signal and stop-signal onsets 
according to each subject’s performance on previous trials based on the average 
percentage of inhibition over previous stop trials, recalculated after each stop trial, 





Figure 6.1. Stop task. Subjects have to respond to go arrows (79.6% of trials, 294 trials) that 
point either right or left with a right/left button response. In 20.4% of trials (60 trials), the go -signals 
were fo llowed (about 250ms later) by stop signals and subjects had to inhibit their motor responses. A 
tracking algorithm changed the time interval between go-signals and stop-signals according to each 
subject’s performance on previous trials (average percentage of inhibition over previous stop trials, 
recalculated after each stop trial), resulting in 50% successful and 50% unsuccessful inhibit ion trials.  
 
6.2.3. MRI image acquisition and analysis 
 Gradient-echo echoplanar MR imaging (EPI) data were acquired on a GE 
Signa 3T Horizon HDx system (General Electric, Milwaukee, WI, USA) at the Centre 
for Neuroimaging Sciences, Institute of Psychiatry, King’s College London, UK. A 
semi-automated quality control procedure ensured consistent image quality 
(Simmons, Moore, & Williams, 1999). A quadrature birdcage headcoil was used for 
RF transmission and reception. In each of 28 non-contiguous planes parallel to the 
anterior-posterior commissure, 296 T2*-weighted MR images depicting BOLD 
contrast covering the whole brain were acquired with TE=30ms, TR=1.8s, flip 
angle=75, in-plane resolution=3mm, slice thickness=5.5mm (including slice-
skip=0.5mm). This EPI dataset provided almost complete brain coverage.  
 For fMRI analysis, the software package of XBAM was used (Brain Image 
Analysis Unit, 2011; Brammer et al., 1997) that makes no normality assumptions 
(violated in fMRI data), but instead uses median statistics to control outlier effects and 
permutation rather than normal theory-based inference. Furthermore, the most 
common test statistic is computed by standardising for individual differences in 
residual noise before embarking on second- level, multi- subject testing using robust 
permutation-based methods. This allows a mixed effects approach to analysis, 
recommended for fMRI (Thirion et al., 2007). 
 fMRI data were first processed to minimise motion related artifacts (Bullmore, 
Brammer, et al., 1999). A 3D volume consisting of the average intensity at each voxel 
over the whole experiment was calculated and used as a template. The 3D image 
volume at each time point was then realigned to this template by computing the 
combination of rotations (around the x y and z axes) and translations (in x y and z) 
that maximised the correlation between the image intensities of the volume in 
question and the template (rigid body registration). Following realignment, data were 
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then smoothed using a Gaussian filter (FWHM, 7.2mm) to improve the signal to noise 
characteristics of the images.  
 After preprocessing, time series analysis for each subject was based on a 
wavelet-based data resampling method for functional MRI data (Bullmore et al., 
2001; Bullmore, Brammer, et al., 1999). At the individual subject level, a standard 
general linear modelling approach was used to obtain estimates of the response size 
(beta) to the SST conditions (successful and failed stop trials) against an implicit 
baseline (go trials). Briefly, we first convolved the main experimental condition 
(successful and failed inhibitory trials, each separately contrasted with Go trials) with 
two Poisson model functions (peaking at 4s and 8s) after motion correction, global 
detrending and spin-excitation history correction. We then calculated the weighted 
sum of these two convolutions that gave the best fit (least-squares) to the time series 
at each voxel. A goodness-of- fit statistic (the SSQ-ratio) was then computed at each 
voxel consisting of the ratio of the sum of squares of deviations from the mean 
intensity value due to the model (fitted time series) divided by the sum of squares due 
to the residuals (original time series minus model time series). The appropriate null 
distribution for assessing significance of any given SSQ-ratio was established using a 
wavelet-based data re-sampling method (Bullmore et al., 2001) and applying the 
model- fitting process to the re-sampled data. This process was repeated 20 times at 
each voxel and the data combined over all voxels, resulting in 20 null parametric 
maps of SSQ-ratio for each subject, which were combined to give the overall null 
distribution of SSQ-ratio. The same permutation strategy was applied at each voxel to 
preserve spatial correlation structure in the data.  
 After first- level analysis, the individual statistical maps were normalised into 
Talairach standard space (Bullmore et al., 2001). A group activation map was then 
produced for the experimental conditions by calculating the median SSQ-ratio over all 
subjects at each voxel in standard space and testing them against the null distribution 
of median SSQ-ratios computed from the identically transformed wavelet re-sampled 
data (Brammer et al., 1997). The voxel- level threshold was first set to p <0.05 to give 
maximum sensitivity and to avoid type II errors. Next, a cluster- level threshold was 
computed for the resulting 3D voxel clusters such that the final expected number of 
type I error clusters was <1 per whole brain. Cluster mass rather than a cluster extent 
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threshold was used, to minimise discrimination against possible small, strongly 
responding foci of activation (Bullmore, Suckling, et al., 1999). 
 ANOVAs were conducted using randomization-based tests for voxel or 
cluster-wise differences (Bullmore, Suckling, et al., 1999). Less than 1 false activated 
cluster was expected at a p-value of p<0.05 for voxel and p<0.01 for cluster 
comparisons. Thus, an expected cluster- level type I error rate of <1 per brain was 
achieved by first applying a voxel- level threshold of p<0.05 followed by thresholding 
the 3D clusters formed from the voxels that survived this initial step at a cluster- level 
threshold of p<0.01. The cluster level threshold of p<0.01, was therefore not applied 
to the whole brain (which would be lenient) but rather to the data previously 
thresholded at a voxel-wise level of p<0.05. The necessary combination of voxel and 
cluster level thresholds is not assumed from theory but rather determined by direct 
permutation for each data set. In large connected clusters, we identified local maxima 
that were farther apart than the upper bound of the likely Talairach mapping error (3 
voxel radius:10 mm) (Thirion et al., 2007). Voxels were then assigned to the nearest 
local maximum with a statistic value that exceeded that of the voxels. For each 
analysis, <1 false positive 3D cluster per map were expected at a p-value of <0.05 at 
the voxel- level and <0.01 at the cluster-level. 
 For between-group comparisons, three ANOVAs were conducted comparing 
controls with patients under a) Placebo; b) MPH; and c) ATX. Within-subjects, we 
wanted to focus on the potential upregulation effects of either drug on brain regions 
that have shown to be typically impaired in ADHD patients during motor response 
inhibition tasks. Therefore, we chose as regions of interest, those areas that have been 
shown to be underactivated in ADHD patients in a recent meta-analysis of fMRI 
studies of Go/NoGo and Stop tasks (Hart, Radua, Nakao, et al., 2012). The areas that 
were found to be consistently underactivated in Go/NoGo and Stop tasks across 15 
fMRI studies of motor response inhibition were the right VLPFC, SMA and ACC, left 
caudate and right thalamus (Hart, Radua, Nakao, et al., 2012). Based on these findings 
we therefore created an anatomical mask using the Talairach Client (Lancaster et al., 
1997; Lancaster et al., 2000) which included the frontal lobes, the basal ganglia, the 
thalamus, and the ACC/SMA. Statistical measures of BOLD response were extracted 
in each of the clusters of within-group drug effects and post-hoc analyses were 
conducted to clarify the direction of these effects. Within patients, repeated measures 
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ANOVAs on the extracted BOLD response measures were conducted to test for 
potential order effects. 
  
6.2.4. Performance data analysis 
 Multiple univariate ANOVAs were conducted between controls and patients 
under each drug condition (separately) in the main performance variables: the SSRT, 
calculated by subtracting the mean stop-signal delay (SSD: average time between go- 
and stop-signal, at which the subject inhibited 50% of stop trials) from the MRT to go 
trials, i.e. MRT-SSD (Rubia et al., 2008; Rubia, Smith, et al., 2003; Rubia et al., 2005; 
Rubia, Smith, Taylor, et al., 2007). Measures of the Go process of the task are the 
MRT to go trials and intra-subject standard deviation of MRT (SD of MRT). 
Repeated measures ANOVAs were conducted within patients to test for drug-




6.3.1. Task performance 
 There were no between-groups differences in the probability of inhibition 
(F(3,82)=1.25; p<0.3), demonstrating that the tracking algorithm was successful 
(Table 6.2). There were no significant performance differences between controls and 
patients under placebo. Patients under MPH showed a significantly shorter SSRT than 
controls (F(1,46)=5.32; p<0.026). Under ATX, patients relative to controls showed a 
reduced MRT to Go trials (F(1,46)=5.04; p<0.03) (Table 6.2).  
 Within-patients ANOVA showed a significant drug-condition effect on MRT 
to Go trials (F(2,36)=3.28; p<0.049), which was significantly reduced when patients 
were under ATX compared to placebo (p<0.009) (Table 6.2).  









Table 6.2. Performance data for 20 healthy control boys and 20 boys with ADHD under each 














Pi (%) 51 (3) 51 (4) 53 (4) 53 (10) 
MRT go trials (msec)  615 (117) 592 (77) 576 (79) 548 (71) 
SD go trials (msec)  163 (56) 166 (50) 152 (42) 155 (65) 
SSRT (msec)  165 (103) 126 (82) 93 (110) 133 (121) 
Note: Pi = Probability of inhibition; MRT = Mean Reaction Time; SD = Intra -subject 
Standard Deviation; SSRT = Stop Signal Reaction Time; ATX = Atomoxetine; MPH = 
Methylphenidate  
 
 The performance of ADHD under placebo and healthy controls did not 
significantly differ in the main variable of the task, the SSRT. The group of patients 
showed a slightly shorter SSRT than healthy controls. However, this was only 
significantly shorter when patients were under MPH.  
 Given that the non-significant findings of the SSRT are not in line with the 
majority of neuropsychological studies (Alderson et al., 2007; de Zeeuw et al., 
2008; Epstein, Langberg, et al., 2011; Lee et al., 2008; Lijffijt et al., 2005; Lipszyc 
& Schachar, 2010; Martel et al., 2007; Nigg et al., 2005; Rommelse et al., 2008; 
Rubia, Smith, et al., 2007a; Willcutt et al., 2005), we further explored SSRT 
performance in ADHD patients.  Table 6.3 shows the performance data of the group 
of ADHD boys depending on whether drug condition was administered during the 
first, second or third scanning session. In addition, Figure 6.2 shows the SSRTs for 










Table 6.3. Detailed performance data of the 19 boys with ADHD in the main variables of the 
task under each drug condition and according to whether it was their first, second or third 
scanning session. 
 FIRST SCAN SECOND SCAN THIRD SCAN 
ADHD PLACEBO SSRT: 177 (105) SSRT: 93 (74) SSRT: 122 (64) 
ADHD MPH SSRT: 60 (111) SSRT: 109 (116) SSRT: 116 (112) 
ADHD ATX SSRT: 139 (104) SSRT: 160 (138) SSRT: 99 (137) 
Note: SSRT = Stop Signal Reaction Time; ATX = Atomoxetine; MPH = Methylphenidate  
 
 The small number of subjects in each group precludes from having enough 
power to confidently test whether there were order effects of the scanning session 
within each condition or, what could be even more important, the potential presence of 
sequence effects. SSRT of patients under placebo was numerically larger during the 
first scan, and numerically but not significantly shorter during the second and third 
scanning sessions, suggestive of potential albeit not statistically significant practice 
effects. However, this was not the case when ADHD boys were under MPH or ATX 
(see also Figure 6.2 below). Therefore, while practice effects may have been present 
under placebo, it seems unlikely that the significant differences in SSRT between 
healthy controls and patients under MPH are solely explained by such potential 
practice effects.  
 We furthermore explored the data to test whether the presence of potential 
outliers in any group or scanning session may have affected the group performance in 
any direction. However, as it can be seen in Figure 6.2 below, the only two subjects 
who were outliers were present in the control group. Results in task performance did 
not change after the exclusion of those two subjects.  
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Figure 6.2. Mean and variability for each group in the main performance variable of the task 
(SSRT). On the top left, SSRT values and variability for each group (Controls, ADHD Placebo, ADHD 
MPH, ADHD ATX). On the top, right, SSRT values and variability within patients under placebo, 
depending on whether placebo was administered on the first, second or third scanning session. Down, 
on the left, SSRT values and variability within patients under MPH, depending on whether MPH was 
administered on the first, second or third scanning session. Finally, down on the right hand side, SSRT 
values and variability with in patients under ATX, depending on whether ATX was admin istered on the 
first, second or third scanning session. MPH= Methylphenidate; ATX= Atomoxetine, SSRT= Stop 
Signal Reaction Time    
 
6.3.2. Brain Activation 
 
6.3.2.1. Motion 
 A multivariate ANOVA showed no significant differences between controls 
and patients under each drug-condition in the extent of maximum rotation and 
translation movement parameters in the 3-dimensional Euclidean space 







6.3.2.2. Brain activation within groups 
 
6.3.2.2.1. Successful inhibition – Go trials contrast 
 In the contrast of successful inhibitory trials compared to go trials, healthy 
boys showed activation in bilateral VLPFC and premotor regions, ACC extending to 
SMA, thalamus and subthalamic nuclei, inferior and superior temporal and parietal 
cortices, as well as in medial occipital regions and cerebellum. Furthermore, they 
showed activation in the right PCC, right putamen, left medial frontal gyrus, as well as 
in right medial and superior frontal areas (Table 6.4, Figure 6.3).   
 Children with ADHD under placebo showed activation in similar but less 
extensive bilateral VLPFC and premotor regions, insula, ACC and SMA, right 
putamen, STG, inferior and superior parietal regions, in occipital and 
parahippocampal cortices as well as in the cerebellum (Table 6.4, Figure 6.3).  
 ADHD boys under MPH showed enhanced activation during successful 
inhibitory trials in the bilateral VLPFC, premotor regions, ACC, putamen, thalamus, 
PCC, medial and superior temporal cortices, inferior and superior parietal lobes, 
occipital cortices (including parahippocampal gyrus) and cerebellum (Table 6.4, 
Figure 6.3). 
 When under ATX, boys with ADHD showed activation in right medial and 
superior frontal areas, bilateral VLPFC, premotor regions, ACC, SMA, putamen, 
thalamus and subthalamic nuclei, PCC, medial and superior temporal regions, inferior 
and superior parietal cortices, occipital gyri and cerebellum (Table 6.4, Figure 6.3).  
 
6.3.2.2.2. Failed inhibition – Go trials contrast 
 During failed inhibitory trials compared to go trials, participants showed 
activation clusters that were very similar to those during the successful inhibition 
contrast, but less extended. This was the case in healthy controls, as seen in Figure 6.3 
and Table 6.4.  
 Boys with ADHD under placebo also showed similar but less extended 
activation to that observed during successful inhibitory trials, although in this contrast 
the activation did not reach medial or superior prefrontal regions, and was particularly 
less extensive in VLPFC, PCC and parietal regions (Table 6.4, Figure 6.3).  
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 The activation observed in children with ADHD when under MPH was again 
very similar to that showed during the successful inhibition contrast, although in this 
case it was slightly more extensive in posterior temporo-parietal and thalamic regions, 
less extended in VLPFC and no longer comprised the ACC (Table 6.4, Figure 6.3).  
Children with ADHD under ATX showed activation during inhibition failures 
in the same regions as during successful inhibition trials, although in this case it did 
no longer reach the left VLPFC, and was much less extended in the right VLPFC, 




Fig 6.3. Within-group activation for healthy control boys and boys with 
ADHD under either Placebo, Methylphenidate or Atomoxetine. Axial sections 
showing within-group brain activation for the healthy comparison boys and boys 
with ADHD under each condition (placebo, MPH, ATX) for the contrasts a) 
Successful Inhibition – Go trials, b) Failed inhibition – Go trials. Talairach z-
coordinates are indicated for slice distance (in mm) from the intercommissural 
line. The right side of the image corresponds to the right side of the brain. 
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Table 6.4. Brain Activation within each group for the contras ts a) Successful inhibition- Go trials and b) Failed inhibition – Go trials 









a) Successful inhibition- Go trials contrast 
Healthy control boys 
R inferior/medial/superior frontal/premotor gyri/insula/putamen 
L inferior frontal/premotor/insula/putamen 
L medial frontal gyrus 
R + L anterior cingulate/mesial prefrontal cortex/supplementary motor area/premotor gyri 
R suthalamic nuclei/globus pallidus/R+L thalamus  
R posterior cingulate/ postcentral/ medial/superior temporal/inferior/superior parietal/ 
cuneus/precuneus/occipital gyri/cerebellum 
L inferior/superior parietal gyri/cuneus/precuneus  
R medial occipital gyrus 
L inferior/medial/superior temporal/inferior parietal/occipital gyri/cerebellum 
Boys with ADHD under PLACEBO 
R inferior frontal/premotor/insula/putamen/superior temporal gyri 
L inferior frontal/premotor gyri/insula/putamen/medial frontal gyri 
R medial/superior frontal gyri 
R + L anterior cingulate/mesial prefrontal/supplementary motor area 
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L inferior/superior parietal gyri 
R posterior cingulate/postcentral/inferior/medial/superior temporal/inferior/superior 
parietal/cuneus/precuneus/occipital/parahippocampal gyri/cerebellum 
L hippocampus/parahippocampal/inferior/medial temporal/occipital gyri/cerebellum 
R + L cerebellum 
Boys with ADHD under MPH 
R inferior frontal/premotor gyri/insula/putamen/hippocampus/amygdala 
R inferior frontal/premotor gyri 
L inferior frontal gyrus/insula 
R + L anterior cingulate 
L pre/postcentral gyri 
L medial/superior temporal/inferior parietal gyri 
L hippocampus/parahippocampal/inferior temporal/occipital gyri/cerebellum 
R inferior/medial/superior temporal/postcentral/occipital gyri/cerebellum/ R + L 
thalamus/posterior cingulate/inferior/superior parietal gyri/cuneus/precuneus 
Boys with ADHD under ATX 
R inferior/medial/superior frontal/premotor gyri/insula/putamen 
L inferior frontal gyrus/insula/putamen 
R + L anterior cingulate/mesial frontal gyri/supplementary motor area  
R + L thalamus/subthalamic nuclei 
L premotor (precentral gyrus) 
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b) Failed inhibition – Go trials contrast 
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Healthy control boys 
R inferior/medial/superior frontal/premotor gyri/insula/putamen 
L inferior frontal/premotor gyri/insula/putamen 
R + L anterior cingulate/mesial prefrontal cortex/supplementary motor area/premotor gyri 
R thalamus/subthalamic nuclei 
R posterior cingulate/ postcentral/ medial/superior temporal/inferior/superior parietal/ 
cuneus/precuneus/occipital gyri/cerebellum 




Boys with ADHD under PLACEBO 
R inferior frontal/premotor/insula/putamen/superior temporal gyri 
L inferior frontal gyrus/insula 
R + L anterior cingulate/supplementary motor area 
R precental gyrus 
L postcentral gyrus 
L inferior/superior parietal gyri 
R posterior cingulate/postcentral/inferior/medial/superior temporal/inferior/superior 
parietal/cuneus/precuneus/occipital/parahippocampal gyri/cerebellum 
L inferior/medial temporal/occipital gyri/cerebellum  
R + L cerebellum 
Boys with ADHD under MPH 
R inferior frontal/premotor gyri/insula/putamen 
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L inferior frontal gyrus 
L pre/postcentral/superior frontal gyri 
R+ L thalamus/posterior cingulate/inferior/medial/superior temporal/postcentral/inferior/superior 
parietal/cuneus/precuneus/occipital gyri/cerebellum 
Boys with ADHD under ATX 
R inferior/premotor gyri/insula/putamen 
R inferior frontal/premotor gyri 
R + L anterior cingulate/mesial frontal gyri/supplementary motor area  
L premotor (precentral gyrus) 
R thalamus 
R precuneus 
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6.3.3. ANOVA comparisons between controls and ADHD boys under each drug 
condition 
 
6.3.3.1. Successful inhibition – Go trials contrast 
 
Controls compared to ADHD patients under placebo 
 Compared to healthy controls, ADHD boys showed underactivation in left and 
right VLPFC, left MTG and inferior temporal gyrus (ITG) reaching into IPL and right 
anterior cerebellum/fusiform gyrus (Table 6.5, Figure 6.4).  
 Patients showed enhanced activation compared to controls in a cluster 
comprising left posterior cerebellum/PCC, and in right STG, reaching into posterior 
insula and putamen (Table 6.5, Figure 6.4). Given prior evidence for enhanced 
posterior cerebellum/PCC activation in ADHD to compensate for reduced VLPFC 
activation (Cubillo et al., 2012; Rubia, Smith, et al., 2009) we used one-tailed Pearson 
correlations within patients on the BOLD response in these two enhanced activation 
clusters to test whether they were negatively correlated with the reduced VLPFC 
clusters. Only activation in the right STG-putamen, but not the cerebellum, was 
negatively correlated with that of left VLPFC (r= -0.39, p<0.05).  
  To test whether areas of group differences were associated with inhibitory 
function, one-tailed Pearson correlations were performed between BOLD responses in 
these regions and SSRTs within each group. Within healthy boys, the (enhanced) 
activation in right cerebellum was correlated with shorter SSRT (r=-0.45, p<0.007). 
Within patients, the (enhanced) activation in the right STG-putamen was negatively 
correlated with SSRT (r=-0.41, p<0.04).  
 Post-hoc analyses were conducted to examine the linear relationship between 
IQ and brain activation differences. There were no significant correlations between 
BOLD signal in any of the clusters of activation differences and IQ within patients 
(p>0.4) or controls (p>0.5).  
  
Controls compared to ADHD patients under MPH 
 ADHD boys under MPH compared to controls showed reduced activation in 
the same left MTG cluster (Table 6.5, Figure 6.4). All other previously reduced 
activation clusters were no longer observed. 
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 Patients under MPH showed enhanced activation compared to healthy boys in 
three clusters, 1) bilateral occipital cortex, PCC and precuneus, 2) left occipital cortex 
and cerebellum, and 3) left occipital and MTG/IPL (Table 6.5, Figure 6.4).  
 Within patients, the enhanced activation in left cerebellum was negatively 
correlated with SSRT (r=-0.44, p<0.03). Within controls, there were no significant 
associations between brain activation and SSRT.  
  
Controls compared to ADHD patients under ATX 
 After ATX, patients relative to controls showed reduced activation in the same 
left MTG cluster and, as with MPH, all other previously reduced activation clusters 
were no longer observed (Table 6.5, Figure 6.4). There were no areas of enhanced 
activation in patients and no significant associations between brain activation and 
SSRT within patients or controls.  
 
Figure 6.4. Between-group ANOVA comparisons between healthy control boys and boys with 
ADHD under either Placebo, Methylphenidate or Atomoxetine for the successful inhibition-Go 
trials contrast. Axial sections showing the ANOVA between-group differences in brain activation 
between healthy control boys and boys with ADHD under each drug condition (Placebo, MPH, ATX) 
during successful inhibition in the Stop task. Talairach z-coordinates are indicated for slice distance (in 
mm) from the intercommissural line. The right side of the image corresponds to the right side of the 
brain. 
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 In order to test for potential effects of IQ on group differences in brain 
activation, the analyses were repeated with IQ as a covariate. All findings remained 
significant at a more lenient p value (p<0.03) (See Appendix Figure A1).  
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Table 6.5. ANOVAs comparing controls and ADHD patients under each drug during successful motor response inhibition in the Stop task  












C > ADHD Plac R inferior frontal gyrus 
L inferior frontal gyrus 
L middle/inferior/temporal/parietal gyri 





32; 30; -10 
-22; 33; -13 
-43; -52; 0 













ADHD Plac> C L cerebellum/R + L posterior cingulate/occipital gyri 
R superior temporal/postcentral gyri/posterior insula/putamen 
29/30/31/18/19 
42/22/21/4 
-25; -70; -16 







C > ADHD MPH  L middle temporal gyri  21/37 -40; -59; -3 108 0.005 0.91 
ADHD MPH > C L cerebellum/parahippocampus/occipital gyri 
L occipital/middle temporal/precuneus  




-29; -37; -26 
-32; -70; 27 










C> ADHD ATX  L middle temporal gyrus 21/37 -40; -56; -7 156 0.003 1.23 
ADHD ATX > C Nil      
Note: N voxels = number of voxels. L = left; R = right; the maps are thresholded to give less than 1 Type I error 3D cluster per map. Talairach 
coordinates, number of voxels and areas are included underneath the corres ponding cluster. 
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6.3.3.2. Failed inhibition – Go trials contrast 
  
Controls compared to ADHD patients under placebo 
 Children with ADHD under placebo compared to healthy boys showed 
underactivation in the same regions as in the successful inhibition contrast, with some 
exception: there was no underactivation in left VLPFC, the reduced activation in 
temporal region was bilateral and reaching more dorsally parietal regions, and there 
was an additional cluster or reduced activation in children with ADHD relative to 
controls comprising the thalamus (Table 6.6, Figure 6.5).  
 There were no significant correlations between BOLD signal in any of the 
clusters of between-group activation differences and IQ within patients (p>0.1) and 
controls (p>0.5). 
 
Controls compared to ADHD patients under MPH 
The pattern of activation differences was almost identical to that observed in 
the successful inhibition contrast, with the exception of the cluster of reduced 
activation in left MTG in patients with ADHD under placebo, which was no longer 
observed in the failed inhibition contrast (Table 6.6, Figure 6.5).  
  
Controls compared to patients under ATX 
As in the successful inhibition contrast, children with ADHD under ATX 
relative to healthy boys only showed reduced activation in the same clusters when 
under placebo of reduced activation located in temporal regions, which in this contrast 
were bilateral (Table 6.6, Figure 6.5).  
When IQ was used as a covariate, most findings remained significant at a 
more lenient p value (p<0.03) with the exception of the clusters in the thalamus and 




Figure 6.5. Between-group ANOVA comparisons between healthy control boys and boys with 
ADHD under either Placebo, Methylphenidate or Atomoxetine for the contrast failed inhibitory – 
go trials. Axial sections showing the ANOVA between-group difference effects in brain activation 
between healthy control boys and boys with ADHD under each condition (placebo, MPH, ATX) during 
the Failed inhibition condition of the task. Talairach z-coordinates are indicated for slice distance (in 
mm) from the intercommissural line. The right side of the image corresponds to the right side of the 
brain. 
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Table 6.6. ANOVAs comparing controls and ADHD patients under each drug during failed motor response inhibition in the Stop task 












 Failed Stop – go trials  
C > ADHD Plac R inferior frontal gyrus/insula 
R+L thalamus/subthalamic nuclei/tail of caudate 
R middle temporal gyri 







36; 26; -13 
0; -19; -7 
47; -44; 3 
-36; -56; -3 
















ADHD Plac> C L occipital/parahippocampal gyri/cerebellum 18/19 -18; -63; -7 284 0.005 1.02 
C>MPH Nil      
ADHD MPH > C R + L posterior cingulate gyrus/precuneus 
L occipital gyrus 
31/7 
19/19/39 
0; -74; 23 







C > ADHD ATX L medial temporal gyrus 
R medial temporal gyrus 
21/22 
21/22 
-43; -59; -3 







ADHD ATX > C Nil      
Note: N voxels = number of voxels. L = left; R = right; the maps are thresholded to give less than 1 Type I error 3D cluster per map. Talairach 
coordinates, number of voxels and areas are included underneath the corres ponding clus ter.                                                                                                                        
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6.3.4. Significance of the “normalization” effects  
 We wanted to analyze the significance of the “normalization” effects observed 
in the between-groups fMRI analysis. Given that the data of the healthy control group 
was identical across the different case-control comparisons, non-parametric Friedman 
tests were conducted only within patients to identify whether there were significant 
differences in brain activation under each drug condition in each of those clusters 
where the case-control contrasts showed “normalization” effects.  
 For the successful inhibition contrast, there were significant differences 
between drug conditions in the right VLPFC (BOLD Placebo: -0.007; BOLD MPH: 
0.013; BOLD ATX: <0.001; ² (2, N=19) = 8.84, p<0.012), which, as shown by post-
hoc non-parametric Wilcoxon Tests, was due to significant enhanced activation when 
under MPH relative to placebo (p<0.04) and also to ATX (p<0.05). In the cluster of 
left VLPFC, there was a trend for activation differences between the three drug 
conditions (BOLD Placebo: -0.022; BOLD MPH: <0.001; BOLD ATX: -0.005; ² (2, 
N=19) = 5.16, p<0.076), due to the significant differences between Placebo and MPH 
(p<0.016), as well as between Placebo and ATX (p<0.030). In the occipito-cerebellar 
cluster, however, there were no significant differences between conditions (BOLD 
Placebo: <-0.001; BOLD MPH: 0.024; BOLD ATX: 0.017; ² (2, N=19) = 1.26, 
p<0.53), although post-hoc analyses showed significant differences between placebo 
and MPH drug conditions (p<0.04) and at a trend level, between placebo and ATX 
(p<0.1).  
 In the failed inhibition contrast, there was a trend for significant differences in 
brain activation between the three drug conditions in the right VLPFC (BOLD 
Placebo: -0.007; BOLD MPH: 0.011; BOLD ATX: 0.003; ² (2, N=19) = 5.47, 
p<0.06), which was due to the differences between placebo and MPH (p<0.022) and, 
at a trend level, with ATX (p<0.084), suggesting that only MPH had a significant 
“normalisation” effect on this region relative to placebo. Similarly, there was a trend 
for significant differences on brain activation in the thalamus (BOLD Placebo: -0.003; 
BOLD MPH: 0.007; BOLD ATX: 0.008; ² (2, N=19) = 5.03, p<0.08), due to almost 
significant differences between activation under placebo relative to MPH (p<0.077) 
and ATX (p<0.077), which did not differ between them. In the right temporal cortex, 
there were no significant differences between brain activation under the three drug 
conditions (BOLD Placebo: 0.013; BOLD MPH: 0.028; BOLD ATX: 0.037; ² (2, 
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N=19) = 1.37, p<0.50), however, there were significant differences in the right 
parietal region (BOLD Placebo: -0.001; BOLD MPH: 0.022; BOLD ATX: 0.015; ² 
(2, N=19) = 8.84, p<0.012), due to the differences between brain activation observed 
when patients were under Placebo relative to MPH (p<0.007) and ATX (p<0.022). 
Finally in the cluster of activation in the left temporal cortex, significant differences 
between the three drug conditions were observed (BOLD Placebo: -0.003; BOLD 
MPH: 0.018; BOLD ATX: 0.013; ² (2, N=19) = 11.47, p<0.003), due to the 
differences between the Placebo and MPH conditions (0<0.005) as well as between 
Placebo and ATX (p<0.004).  
 
 
6.3.5. ANOVA within-patients comparison between placebo, MPH and ATX 
conditions 
 Within–group effects of each drug condition were tested in the anatomically 
defined ROIs of frontal lobe, SMA/ACC, basal ganglia and thalamus in the two 
contrasts of successful and failed inhibition versus go trials. As described in the 
methods section, the selection of such ROIs was based on the results from a previous 
meta-analysis of 15 fMRI studies of motor response inhibition showing that ADHD 
children have consistent underativation in these regions relative to controls, i.e. in 
right VLPFC, SMA and ACC, left caudate and right thalamus (Hart, Radua, Nakao, et 
al., 2012).  
 
6.3.5.1. Successful inhibition – Go trials contrast  
 For the successful inhibition contrast, there was a main effect of drug 
condition within patients in a cluster in the SMA that reached ventrally into the ACC 
(103 voxels, peak Talairach coordinates (x;y;z):7; 11; 43; BA 6/32; p<0.001). This 
was due to the significantly enhanced activation during Go responses in patients under 
MPH compared to ATX (p<0.001) and placebo (p<0.001), the latter of which did not 
differ from each other (p<0.79) (Figure 6.6).  There were no other significant drug 
effects on any other ROI. 





6.3.5.2. Failed inhibition – Go trials contrast  
 In the failed inhibition contrast, there was a main effect of condition in 2 
clusters (Figure 6.7). One cluster comprised the left MFC, extending to SFC (51 
voxels, peak Talairach coordinates (x;y;z):-25;41;16; BA 9/10/46; p<0.008), due to 
enhanced activation during Go trials in patients under MPH relative to when under 
placebo (p<0.003) and ATX (p<0.033), with a trend for enhanced activation during 
Go trials when under ATX relative to placebo (p<0.09). A second cluster of activation 
differences was observed in the same SMA/ACC region that emerged during the 
successful inhibition contrast (80 voxels, peak Talairach coordinates (x;y;z):7; 11; 43; 
BA 6/32; p<0.001). Brain activation differences in this region were due to 
significantly enhanced activation during Go trials in patients when under MPH 
relative to ATX (p<0.001) and Placebo (p<0.001), which did not differ between them 
(p<0.3).  No other drug effects were observed in any of the ROIs. 
 








Figure 6.6. Results of the repeated measures ANOVA analysis on drug effect within 
ADHD boys during the Successful inhibition – Go trials contrast. Axial sections showing 
the repeated measures ANOVA results for the drug effect within ADHD patients (Placebo, 
MPH, ATX). Talairach z-coordinates are indicated for slice distance (in mm) from the 
intercommissural line. The right side of the image corresponds to the right side of the brain.  
 
 
Figure 6.7. Results of the repeated measures ANOVA analysis on drug effect within ADHD boys 
for the Failed inhibition-Go trials contrast. Axial sections showing the repeated measures ANOVA 
results for the drug effect within ADHD patients (Placebo, MPH, ATX). Talairach z-coordinates are 
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indicated for slice d istance (in mm) from the intercommissural line. The right side of the image 
corresponds to the right side of the brain.  
 
 
6.3.6. Inverse contrast of Go – Successful Stop trials and Go – Failed Stop Trials  
 No differences were observed between controls and patients under placebo or 
under ATX for the inverse contrast of Go-Successful Stop trials. However, patients 
under MPH showed enhanced activation in left insula/VLPFC and premotor cortex, 
reaching into caudate, putamen and globus pallidus (187 voxels, peak Talairach 
coordinates (x;y;z): -25; 19; 13; BA 45/6; p<0.006), and in ACC/SMA (162 voxels, 
peak Talairach coordinates (x;y;z;) 4; 11; 43; BA 6/24/32; p<0.003)(Figure 6.8).  The 
same regions were enhanced during observed in the inverse contrast of Go – Failed 
Stop trials, although in this case the cluster in the ACC/SMA reached also into the 
right striatum (262 voxels, peak Talairach coordinates (x;y;z): 4; 11; 43; BA 24/32/6; 
p<0.002) and the cluster in left basal ganglia and premotor regions showed a bigger 
cluster size (331 voxels, peak Talairach coordinates (x;y;z): -25;-4; 10; BA 45/4/6; 
p<0.001) (Figure 6.8). There were no significant correlations between brain activation 
and performance. In the Go - Successful Stop trials contrast, Friedman tests showed 
significant differences between brain activation within patients under each drug 
condition in the basal ganglia/ left premotor-VLPFC cluster (BOLD Placebo: -0.001; 
BOLD MPH: -0.031; BOLD ATX: 0.001; ² (2, N=19) = 6.42, p<0.04), due to the 
significantly enhanced activation during correct motor responses to go trials under 
MPH relative to that under placebo (p<0.002) and ATX (p<0.033). Similarly, 
Friedman tests showed significant differences SMA/ACC cluster (BOLD Placebo: 
0.035; BOLD MPH: -0.023; BOLD ATX: 0.024; ² (2, N=19) = 15.47, p<0.001), due 
to the significant differences between MPH and Placebo (p<0.001) and between MPH 
and ATX (0.004).   
 Similarly, in the contrast of Go - Failed Stop, Friedman tests showed 
significant differences between the three drug conditions in the cluster of basal 
ganglia/premotor activation (BOLD Placebo: <-0.001; BOLD MPH: -0.025; BOLD 
ATX: -0.005; ² (2, N=19) = 9.79, p<0.007), due to significantly enhanced activation 
during motor responses under MPH relative to placebo (p<0.004) and, at a trend level, 
to ATX (p<0.059). Significant differences were also observed between activation 
under the three drug conditions in the SMA/ACC cluster (BOLD Placebo: 0.014; 
 191 
BOLD MPH: -0.026; BOLD ATX: 0.009; ² (2, N=19) = 14.00, p<0.001), due to the 
enhanced activation during go responses under MPH relative to Placebo (p<0.001) 




Figure 6.8. Between-group ANOVA comparison between healthy control boys and boys with 
ADHD under Methylphenidate for the contrasts of a) Go – Successful inhibition trials and b) 
Go – Failed inhibition trials. Axial sections showing the ANOVA between-group difference 
effects in brain activation between healthy control boys and boys with ADHD under MPH. 
Talairach z-coordinates are indicated for slice distance (in mm) from the intercommissural line. 




 The study shows both shared and drug-specific normalisation and upregulation 
effects on inhibitory brain regions in ADHD patients. ADHD relative to control boys 
showed no performance deficits but significantly improved in their inhibitory capacity 
relative to controls under MPH. During the main contrast of successful inhibition, 
patients under placebo had reduced activation in left and right VLPFC, left MTG, and 
right cerebellum. Relative to controls, both drugs showed shared moderate 
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normalisation effects in left VLPFC activation, while only MPH showed drug-specific 
normalisation effects on the key inhibitory region of right VLPFC.  
 The underactivation in ADHD patients in key areas of motor response 
inhibition in right and left VLPFC as well as in parieto-temporal regions is in line 
with previous findings (Cubillo et al., 2012; Epstein et al., 2007; Rubia, 2011; Rubia, 
Cubillo, et al., 2010; Rubia et al., 2008; Rubia, Overmeyer, et al., 1999; Rubia et al., 
2005). While right VLPFC is a key area of inhibition (Chambers et al., 2009; Rubia, 
Smith, et al., 2003) left VLPFC forms also part of the inhibition network (Nee et al., 
2007; Swick et al., 2008), but has been suggested to mediate performance monitoring 
(Derrfuss et al., 2005; Stevens, Kiehl, Pearlson, & Calhoun, 2009). Although less 
commonly reported, the cerebellum is correlated with SSRT in the Stop task in 
healthy adolescents and adults (Rubia, Smith, Taylor, et al., 2007), which was also 
observed in this study. The finding replicates a previous finding of cerebellar 
underactivation during the Stop task in ADHD children (Rubia, Halari, Mohammad, 
et al., 2011). The enhanced activation in patients under placebo relative to controls in 
right STG-putamen and left cerebellum/occipital cortex was likely compensatory, as 
suggested by the negative association of STG-putamen activation with inhibitory 
capacity and with the (reduced) left VLPFC activation. This compensatory enhanced 
activation in STG, part of the inferior frontal-superior temporal junction that mediates 
inhibition (Chambers et al., 2009; Rubia, Smith, et al.; Rubia, Smith, Taylor, et al., 
2007) may have prevented patients from inhibitory impairment in the task.  
 Only MPH significantly normalised the right VLPFC underactivation 
suggesting a drug-specific effect on normalising the key inhibition area, the right 
VLPFC. Further normalisation effects were observed in the cerebellum, which, 
however, in exploratory post-hoc analyses showed to be significant for MPH only.   
The findings extend previous normalisation and upregulation findings with MPH in 
fronto-striato-cerebellar inhibitory network during inhibition tasks in children with 
ADHD (Epstein et al., 2007; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, 
Mohammad, et al., 2011; Vaidya et al., 1998). This is furthermore in line with a recent 
neuropsychological study, which showed that only acute dose challenge of MPH and 
not of ATX improved performance during the Stop task in healthy adults (Nandam et 
al., 2011). However, it is of note here that the normalisation effects of ATX on right 
VLPFC and cerebellar activation were not absent, but moderate. Considering that 
ATX typically takes longer to show significant behavioural effects than MPH 
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(Montoya et al., 2009), longer-term administration may have resulted in significant 
effect size differences relative to placebo for the below-threshold normalised right 
VLPFC and cerebellar underactivation. Future studies will have to compare long-term 
administration of both drugs to elucidate this question. In healthy adults, a 
comparatively lower dose of ATX has shown upregulation effects of ATX on right 
IFC activation (Chamberlain et al., 2009). Whether these effects would become 
significant at different doses of ATX or after repeated administration should be 
further studied. 
 The shared moderate normalisation findings of MPH and ATX in left VLPFC 
underactivation are interesting as these findings extend, for the first time, previous 
findings of upregulation of right (Chamberlain et al., 2009) and bilateral VLPFC 
(Graf et al., 2011) with ATX in healthy adults during motor inhibition tasks to 
medication-naïve children with ADHD. Although the left VLPFC is involved in 
motor inhibition processes (Nee et al., 2007; Swick et al., 2008), left lateralised 
effects may suggest stronger effects of ATX on performance monitoring (Derrfuss et 
al., 2005; Stevens et al., 2009) rather than inhibition per se.  Furthermore, the lack of 
association between inhibitory measures (SSRT) and activation in left VLPFC 
suggests the shared normalised effects of both drugs may be due to improved 
performance monitoring processes.  
 Patients under placebo showed enhanced activation compared to controls in 
two clusters, in the STG-putamen and a second one comprising the left 
occipital/posterior cerebellum. Their potentially compensatory role was furthermore 
supported by their association with inhibitory performance measures as also by the 
association between enhanced activation in STG-putamen and the reduced activation 
in left VLPFC. We observed shared and differential effects with regards to these two 
clusters of activation differences.  
 Both drugs showed shared normalization effects in the right STG-putamen 
cluster. The STG is anatomically connected to caudate and putamen (Yeterian & 
Pandya, 1998), and involved in selective visuo-spatial attention (Hopfinger, 
Buonocore, & Mangun, 2000) and spatial awareness (Karnath, Ferber, & 
Himmelbach, 2001). Enhanced activation in insula and putamen in medication-naïve 
children with ADHD, as well as its downregulation after stimulant administration has 
been previously reported during different cognitive tasks (Konrad et al., 2007; Rubia, 
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Halari, Christakou, et al., 2009), therefore this study shows that this finding is not 
task-specific and also extends to the non-stimulant ATX. 
 Differential effects were observed with regards to the second cluster of 
enhanced activation in patients under placebo relative to controls in left 
occipital/posterior cerebellum. Previous studies have shown enhanced activation in 
cerebellar and occipital regions in children (Rubia, Smith, et al., 2009) and adults with 
ADHD (Cubillo et al., 2012). Furthermore, MPH has shown to enhance/normalise 
activation in cerebellum and occipital regions in children with ADHD (Rubia, Halari, 
Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2009; Rubia, Halari, Mohammad, 
et al., 2011; Rubia, Halari, Christakou, et al., 2009). ATX completely normalised the 
enhanced activation in this cluster however, under MPH the enhanced activation in 
left occipital/cerebellar regions persisted, and reached dorsal regions of the PCC and 
to the left precuneus. The PCC and precuneus are typically involved in attention 
allocation to salient stimuli and performance monitoring processes (Cavanna & 
Trimble, 2006; Mesulam et al., 2001; Mohanty et al., 2008; Rubia, Smith, Taylor, et 
al., 2007; Sack, 2009). Furthermore, the association between the enhanced activation 
in left occipital/posterior cerebellum and inhibitory performance measures suggests its 
potential compensatory role.  
 Interestingly, MPH in addition, showed a drug-specific upregulation effect 
during the executive Go process of the task, both in the within-subjects and in the 
between-group comparisons, in key regions for response selection and motor 
execution in ACC/SMA, left premotor cortex and basal ganglia (Haber, 2003; 
Monchi, Petrides, Strafella, Worsley, & Doyon, 2006). Together, the findings thus 
suggest that MPH upregulates and normalises right- lateralised VLPFC-cerebellar 
motor inhibition networks as well as medial fronto-striatal circuits of motor response 
execution.  
 During failed inhibition, patients under placebo relative to controls showed 
underactivation in regions mostly overlapping those observed in the successful 
inhibition contrast, in line with the evidence that suggests that inhibition-related 
networks are active to a very similar degree during both conditions (Boehler, 
Appelbaum, Krebs, Hopf, & Woldorff, 2010). The only exception was the reduced 
activation in the thalamus, which may be associated to its relevance during error 
detection and feedback processing (Li, Yan, Chao, et al., 2008; Ullsperger & von 
Cramon, 2003). 
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 During failed inhibitory trials both drugs normalised right VLPFC, thalamic 
and temporo-parietal regions which were underactivated in patients under placebo 
compared with controls. However, as in the successful inhibition contrast, the 
normalising effects were only significant for MPH in the right VLPFC, while shared 
effects were observed for both drugs on temporo-parietal regions. These findings 
suggest significant normalisation effects of both drugs in temporo-parietal regions 
involved in the detection of salient events, i.e. failed inhibitory trials during the task 
(Kiehl, Laurens, Duty, Forster, & Liddle, 2001; Rubia, Hyde, et al., 2010; Stevens, 
Skudlarski, Gatenby, & Gore, 2000). On the other hand, only the effects of MPH were 
strong enough to “normalise” the right VLPFC underactivation in patients under 
placebo relative to controls, while the effects of ATX on this region are moderate.   
 While the inhibitory performance of the patients under MPH (as measured by 
the main inhibitory index of the task, the SSRT) was numerically better than when 
under Placebo or ATX, it did not reach significance. However, MPH significantly 
improved inhibitory performance in ADHD boys relative to that of the healthy control 
group, suggesting it had a positive impact on SSRT. The normalisation effects of 
MPH on key inhibitory activation areas right VLPFC and cerebellum after a single 
dose of Methylphenidate may have accounted for their relative improvement on 
inhibitory performance compared to healthy controls.  
 Nevertheless, it should be noted that the SSRT of the group of patients was not 
significantly different from that of controls during the placebo condition, which is not 
in line with the findings from previous neuropsychological studies, which, as 
reviewed in chapter 1, have shown longer SSRTs in ADHD patients relative to 
healthy controls  (Alderson et al., 2007; de Zeeuw et al., 2008; Epstein, Langberg, et 
al., 2011; Lee et al., 2008; Lijffijt et al., 2005; Lipszyc & Schachar, 2010; Martel et 
al., 2007; Nigg et al., 2005; Rommelse et al., 2008; Rubia, Smith, et al., 2007a; 
Willcutt et al., 2005). A number of factors may have contributed to the performance 
profile observed in this study. Case-control fMRI studies on cognitive functions that 
cannot be mastered well by patients are confounded by differences in performance, 
which makes necessary the use of easier task designs than those used in 
neuropsychological studies. Furthermore, there are the restrictions to the design of fast 
even-related fMRI tasks: target trials cannot be consecutive and need to be separated 
sufficiently from non-target trials (at least 3 trials) so as to allow for separability of 
the haemodynamic response. This resulted in Stop trials being less randomly 
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interspersed with Go trials than in typical neuropsychological designs of the task, 
making the Stop trials slightly more predictable (and consequently, easier) than in 
offline versions. A key factor may furthermore have been that the children with 
ADHD performed the task on three occasions, while the healthy control group only 
performed the task once. Although there were no significant effects of order of 
administration of the drugs within patients, the small numbers in each subgroup do 
not allow to totally exclude a potential effect of learning or the presence of potential 
sequence effects, and therefore need to be taken into account. However, although this 
may have contributed to the non-significant differences in SSRT, it seems unlikely to 
solely explain the significant difference between healthy controls and patients under 
MPH. While SSRTs were (non-significantly) longer in patients under placebo when 
this was administered during the first scanning session relative to the second or third 
sessions, this was not the case when patients were under MPH or ATX.  
 Some of the characteristics of the sample may have also led to a less impaired 
sample than those typically recruited during neuropsychological studies. Due to 
movement artefacts, fMRI studies of ADHD tend to recruit milder cases, which, 
together with the reduced number of subjects compared the larger sample sizes 
typically recruited in neuropsychological studies, may have reduced the power of the 
present study to reliably identify performance differences between the groups. 
Furthermore, the mean age of the subjects in neuropsychological studies is 8-10 years 
of age, while this study recruited an older sample (10 to 17 years of age). Given that 
in a significant proportion of cases inhibitory impairments tend to disappear with age, 
no longer presenting those in adulthood, it may be that the older age range with 
respect to that typical in neuropsychological studies may also have contributed to the 
performance observed in this study. In addition, some neuropsychological studies 
have reported no deficits in inhibitory function as measured by the SSRT in children 
with ADHD (i.e. Kuntsi et al., 2001; Manassis, Tannock, & Barbosa, 2000; Scheres et 
al., 2001), and recent studies have shown that only a proportion of children with 
ADHD show performance impairments during inhibitory measures (Nigg et al., 2005; 
Sonuga-Barke et al., 2010).  Most importantly, most fMRI studies in older ADHD 
adolescents have not shown any deficits in SSRT, likely for the above mentioned 
reasons (Rubia, Halari, Mohammad, et al., 2011; Rubia, Cubillo, et al., 2010; Rubia et 
al., 2008; Rubia, Overmeyer, et al., 1999; Rubia et al., 2005).   
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 In conclusion, the fMRI adaptation which makes the task easier than those 
versions used in neuropsychological studies, the older and potentially less severe 
ADHD group recruited relative to those patients typically recruited in 
neuropsychological studies and the repeated performance of the task by the group of 
children with ADHD relative to the single performance of controls may have 
contributed to the unusual performance profile observed in the present study of no 
SSRT deficits in ADHD patients under placebo.  
  A strength of this study is the double-blind, placebo-controlled crossover 
design in exclusively medication-naïve boys with combined type ADHD, thus testing 
a homogeneous sample and avoiding the potential confound of previous stimulant 
medication history, known to confound brain structure and function deficits (Frodl & 
Skokauskas, 2012; Konrad et al., 2007; Nakao et al., 2011). A limitation is that 
ADHD boys performed the task three times, while, for financial and ethical reasons, 
controls were scanned only once. Although we could not directly measure the practice 
effects in the between group analyses, given that there were no differences in the 
within group analysis, we assume that they were unlikely to have contributed to 
performance or brain activation differences between patients and controls. However, 
such assumption must be made with caution, as we could only test for potential order 
effects within subjects. Even then, this was conducted in a very small sample, and 
therefore the power to detect potential order effects is severely reduced. Furthermore, 
given the reduced number of participants on each condition, it was not possible to test 
for potential sequence effects derived from the randomisation order. That means that 
the administration of the drug conditions in a determined randomization order may 
have enhanced or reduced their effects. Further studies with sufficiently large samples 
should be conducted to rule out this possibility. In addition, the wider age range in the 
age of the healthy control group relative to the ADHD boys may have affected the 
results, potentially making more pronounced the between-groups differences in a 
disorder that has shown to be associated with neurodevelopmental delay (Rubia, 
2007; Shaw et al., 2007; Shaw et al., 2012). Therefore, future studies should ideally 
include more closely age-matched groups.   
  Another limitation is the single dose administration. While MPH has 
immediate effects on behaviour (Greenhill et al., 2001), ATX reaches its maximum 
behavioural efficacy at about 12 weeks (Montoya et al., 2009). Consequently, a single 
dose comparison may have favoured MPH. The investigation of acute mechanisms of 
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action, however, is a first step towards improving our understanding of drug-specific 
effects on brain activation and cognition, and has the advantage of avoiding potential 
confounds of long-term treatment such as symptomatic improvement, side effects or 
chronic effects on brain activation. However, the presence of significant effects for 
ATX on left VLPFC and of moderate effects on right VLPFC and cerebellar regions 
suggest it modulates activation on key inhibitory regions, which may be stronger at 
different doses or after prolonged administration. Therefore, future studies should 
compare different doses and long-term effects of both drugs on brain activation after 
reaching maximum clinical efficacy.  
 To summarise, the findings show shared effects of both drugs of normalising 
left VLPFC activation deficits in ADHD patients. MPH, however, had drug-specific 
normalisation effects in right VLPFC. In addition MPH not only upregulated fronto-
cerebellar areas of inhibitory control but also fronto-striatal regions mediating the 





CHAPTER 7: DRUG-SPECIFIC FRONTAL EFFECTS OF ATOMOXETINE 




 Attention Deficit Hyperactivity Disorder (ADHD) is characterised by age-
inappropriate symptoms of inattention, impulsivity and hyperactivity (American 
Psychiatric Association, 2000). One of the key neuropsychological deficits is WM 
(Martinussen et al., 2005), underpinned by fMRI evidence for reduced fronto-striatal 
and temporo-parietal activation (Kobel et al., 2009; Silk et al., 2005; Vance et al., 
2007). 
The stimulant MPH and the non-stimulant ATX are the most commonly 
prescribed pharmacological treatments for ADHD, showing comparable efficacy in 
65-70% of cases (Hazell et al., 2010). However, the drug-specific mechanisms of 
action on brain function in ADHD patients are unknown.  
MPH blocks DAT in the striatum (Volkow, Wang, Fowler, Gatley, et al., 
1998) and NET in NET-rich regions including prefrontal regions, where it enhances 
both catecholamines (Hannestad et al., 2010). ATX is a selective pre-synaptic NET 
blocker affecting NE and DA in prefrontal cortex (Bymaster et al., 2002) and NE in 
thalamus, locus coeruleus and cerebellum, with minimal striatal effects (Gallezot et 
al., 2011). 
A single dose of MPH in ADHD children has shown to upregulate and/or 
normalise fronto-striatal, temporo-parietal and cerebellar regions during cognitive  
control tasks (Epstein et al., 2007; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, 
Cubillo, et al., 2009; Rubia, Halari, Mohammad, et al., 2011; Rubia, Halari, 
Christakou, et al., 2009; Shafritz et al., 2004; Vaidya et al., 1998). 
Few fMRI studies, however, have tested for MPH effects on WM in ADHD 
children, with inconsistent results. Thus, MPH normalised IFC, MFC, and striatal 
underactivation in ADHD children off-MPH compared to controls (Prehn-Kristensen 
et al., 2011) and upregulated activation and functional integration in fronto-parietal 
WM networks (Wong & Stevens, 2012). However, a single dose of MPH 
downregulated MFC and parietal activation during WM in female ADHD (Sheridan et 
al., 2010) but with no effects in ADHD boys (Kobel et al., 2009). These studies, 
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however, did not include a placebo condition, had small sample sizes and recruited 
patients with a previous history of stimulant medication, shown to have effects on 
both brain activation and structure (Frodl & Skokauskas, 2012; Konrad et al., 2007; 
Nakao et al., 2011).  
No fMRI study has as yet investigated the effects of ATX on brain activation 
in ADHD patients during any cognitive function, or compared its effects to those of 
MPH. In healthy adults, acute ATX administration upregulates IFC and STG during 
inhibitory tasks (Chamberlain et al., 2009; Graf et al., 2011), and using multivariate 
pattern recognition analyses ATX had relatively stronger deactivat ion effects on the 
DMN while MPH has relatively stronger upregulating effects on WM networks 
(Marquand et al., 2011). 
We therefore conducted a randomised, double-blind, placebo-controlled, cross-
over pharmacological fMRI study to test for drug-specific effects of a single clinical 
dose of either MPH or ATX on brain activation of medication-naïve boys with ADHD 
during a verbal WM task. The focus on single rather than long-term drug effects on 
neurofunctional mechanisms avoids potential confounds including side effects, 
symptomatic improvement or chronic effects on brain activation. We furthermore 
compared brain activation during the WM task in patients under each drug co ndition 
with that of age-matched healthy controls to test for potential drug normalisation 
effects. Based on previous fMRI studies of WM in ADHD children (Prehn-Kristensen 
et al., 2011), we hypothesised that ADHD boys would show underactivation relative 
to controls in DLPFC and parietal regions. Furthermore, based on previous findings of 
upregulation of MPH on brain activation in ADHD (Prehn-Kristensen et al., 2011; 
Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Mohammad, et al., 2011; Rubia, 
Halari, Christakou, et al., 2009; Shafritz et al., 2004; Vaidya et al., 1998) and of ATX 
on brain activation in healthy adults (Chamberlain et al., 2009; Graf et al., 2011), we 
hypothesized that both drugs would upregulate and normalise the reduced activation 







7.2. Methods  
 
7.2.1. Subjects 
 Thirty medication-naive right-handed boys between 10-17 years with a clinical 
diagnosis of ADHD (DSM-IV-TR)(American Psychiatric Association, 2000) were 
recruited through clinics. Patients had clinical diagnosis of ADHD, 
inattentive/hyperactive-impulsive combined subtype, as assessed by an experienced 
child psychiatrist using the standardized Maudsley diagnostic interview that assesses 
ADHD according to DSM-IV-TR criteria (Goldberg & Murray, 2002). A 
multidisciplinary clinical team participated in the assessment, which typically 
included information from semi-structured clinical assessment interviews with 
parents/carers, questionnaires from parents and teachers, school reports, 
developmental history, cognitive assessments and behavioural observation of the 
child. The presence of learning disability was concluded from the information 
provided by parents and school during the clinical and cognitive assessments, or by 
the presence of significant discrepancies between verbal and performance IQ 
subscores, which is considered as an indicator of potential learning difficulties.  
ADHD boys scored above clinical threshold for hyperactive-
impulsive/inattentive symptoms on the SDQ (Goodman & Scott, 1999), the CPRS-R 
(Conners et al., 1998), and below clinical threshold on the SCQ (Rutter et al., 
2003)(Table 7.1). Patients were scanned in a double-blind, placebo-controlled, 
crossover design. On each scanning session, they received a single dose of either 
placebo (Vitamin C, 50mg), MPH (Equasym, 0.3mg/kg, range 5−20mg) or ATX 
(Strattera, 1mg/kg, range 16-66mg), in a pseudo-randomized order, and remained 
medication-free between scans. Dosages were determined following NICE guidelines 
of clinical efficacious dosages with minimal side effects at the time of the study 
(National Institute for Heath and Clinical Excellence, 2008). Based on 
pharmacokinetic evidence, both medications were administered 1.5 hours before the 
scan to allow for maximum absorption (Chan et al., 1983; Witcher et al., 2003). The 
same or similar dosages and time lapses between drug administration and scan have 
shown to be sufficient to observe changes in brain activation and performance in 
ADHD patients (MPH)(Lijffijt et al., 2006; Rubia, Halari, Cubillo, et al., 2011; Rubia, 
Halari, Mohammad, et al., 2011) and healthy controls (ATX)(Chamberlain et al., 
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2007; Chamberlain et al., 2009). All three medications were over-encapsulated using 
the same capsules by the pharmacist.  
 Twenty-one right-handed healthy boys (between 10-17 years) were recruited 
through advertisement in the same geographical South London area. They scored 
below clinical cut-offs for the SDQ, SCQ and CPRS-R (Table 7.1.). They were 
scanned once, unmedicated. 
 Exclusion criteria for all participants were IQ<70 on the Wechsler 
Abbreviated Scale of Intelligence (WASI)(Wechsler, 1999), history of substance 
abuse or neurological deficits, learning disability, reading, speech or language 
disorder, as well as the presence of psychiatric disorders (except for ADHD and 
conduct disorder (CD)/oppositional defiant disorder (ODD) in the ADHD group). 
When parental reports for potential participants were suggestive of the presence of 
such difficulties, questions addressing each of the criteria for CD/ODD were included 
in the semi-structured interviews. Thus, despite the fact that the mean score in the 
ADHD group for oppositional problems in the CPRS-R and behavioural difficulties in 
the SDQ scales were above clinical cut-offs (Table 7.1), only two cases received the 
formal diagnosis of ODD/CD. 
 Eleven participants (1 control, 10 ADHD boys) were excluded due to: above 
clinical threshold on the CPRS-R score in one control subject, IQ <70 (N=1), 
excessive motion parameters (>3mm)(N=1), neurological abnormalities detected at 
the scan (N=1), technical problems that led to loss of data (N=2), inability to tolerate 
the scanning situation (N=4) or braces (N=1). Thus, the final sample consisted of 20 











Table 7.1.  Sample characteristics for healthy control boys and patients with ADHD.  




Age (years, months) 13y, 8m (2y, 5m) 13y, 0m (1y, 7m) 
Age range (years, months)  10y,3m- 17y, 8m 10y, 1m-15y, 6m 
IQ 114 (11) 91 (11) 
SDQ Hyperactive-impulsive/ 
Inattentive Subscale 
2(2) 8 (2) 
SDQ  Total score 4 (4) 22 (7) 
SDQ Emotional difficulties subscale 1 (2) 4 (3) 
SDQ Behavioural difficulties subscale 0 (1) 6 (3) 
SDQ Getting along difficulties 
subscale 
1 (1) 3 (3) 
SDQ Kind and helpful behaviours  
subscale 
9 (2) 6 (2) 
SCQ Total 1 (1) 9 (5) 
CPRS-R Total T score 44 (5) 78 (11) 
CPRS-R oppositional T score  43 (4) 75 (12) 
CPRS-R Cognitive/ inattention 
problems T Score 
45 (4) 69 (9) 
CPRS-R hyperactivity T score 46 (4) 79 (14) 
CPRS-R anxious/shy T score 49 (9) 60 (16) 
CPRS-R Perfectionism T score 44 (4) 56 (16) 
CPRS-R social problems T score 47 (3) 59 (13) 
CPRS-R Psychosomatic T score 48 (7) 60 (15) 
CPRS-R Global Index: restless 
impulsive T score 
44 (3) 76 (12) 
CPRS-R Global Index: emotional 
liability T score 
44 (5) 72 (14) 
Note: SDQ=Strengths and Difficulties Questionnaire; CPRS -R: Conners’ Parent 
Rating Scale; SD= Standard Deviation 
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 One-way analyses of variance (ANOVAs) showed no between-group 
differences for age (F(1,38)=0.88; p<0.35) but for IQ (F(1,38)=41; p<0.001) (Table 
7.1.). Low IQ is associated with ADHD (Bridgett & Walker, 2006). WM tasks such as 
the N-Back task have shown to be closely associated with IQ measures, with 
additional indirect evidence suggesting they may share a common neurological base, 
with the DLPFC being a key region (Conway et al., 2003). WM is indeed one of the 
factors obtained in typical tests of general intelligence such as the Wechsler 
Intelligence Scale for Children (4th version) (WISC-IV) (Wechsler, 2004). Therefore, 
covarying for IQ during this task would indeed mean covarying for any differences in 
WM that may exist between the groups. Seven of the ADHD participants had been 
assessed using the WISC-IV. Therefore, all analyses were conducted without IQ as a 
covariate. However, in order to test for potential effects of outliers subjects with an IQ 
more than 2 SD above or below average, we repeated the analyses excluding these 
outliers (N=4 in each group).  
Participants were paid £50 for each scanning session. Parental/child informed 
consent/assent and approval from the local Ethical Committee were obtained.   
 
7.2.2. Paradigm: WM task (N-Back) 
Subjects practiced the task once before scanning. The 6-minute block design 
WM task consists of 4 conditions. During  “1-back”, “2-Back” and “3-Back” 
conditions, subjects are presented with series of letters (A-Z) and must respond with 
their right thumb using a button box whenever the letter presented is the same as one, 
two or three before it, respectively (e.g. 2-Back:B/J/A/J) (Figure 7.1.). In the baseline 
vigilance “0-Back” condition, subjects must respond to each X that appears on the 
screen. The task consists of 12 randomized blocks. At the beginning of each block, 
written instructions (e.g.“2-Back”, duration: 3 secs) are shown as to which condition 
is next (0-Back;1-Back;2-Back;3-Back). In each of the blocks (duration: 31 secs), 
only one condition is presented, and contains fifteen stimuli: three targets and twelve 





Figure 7.1. Schematic figure for the N-Back task. 
The 6 minutes working memory (WM) task consists of 4 
different conditions. In the control condition “It is X?” the 
subject is presented to series of letters, and the subject has to 
press for every X that appears on the screen. In the conditions 
“1-back”, “2-back” and “3-back”, the subject has to press the 
button whenever the letter presented is the same as one, two or 




7.2.3. fMRI acquisition and analyses 
 Gradient-echo echoplanar MR imaging (EPI) data were acquired on a GE 
Signa 3T Horizon HDx system (General Electric, Milwaukee, WI, USA) at the Centre 
for Neuroimaging Sciences, Institute of Psychiatry, King’s College London, UK. A 
semi-automated quality control procedure ensured consistent image quality (Simmons 
et al., 1999). A quadrature birdcage head coil was used for RF transmission and 
reception. In each of 39 non-contiguous planes parallel to the anterior-posterior 
commissure line, 186 T2*-weighted MR images depicting BOLD (Blood Oxygen 
Level Dependent) contrast covering the whole brain were acquired with TE=30ms, 
TR=2s, flip angle=75º, in-plane resolution=3mm, slice thickness=3.5mm, slice-
skip=0.5mm. This EPI dataset provided complete brain coverage.  
Blocked fMRI data were acquired in randomized block presentation, and 
analysed using the non-parametric XBAM software (Brain Image Analysis Unit, 
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2011; Brammer et al., 1997; Bullmore et al., 2001; Bullmore, Brammer, et al., 1999). 
XBAM uses median statistics to control for outlier effects and permutation rather than 
normal theory-based inference. Furthermore, the most common test statistic is 
computed by standardising for individual difference in residual noise before 
embarking on second level, multi-subject testing using robust permutation-based 
methods. This allows a mixed effects approach to analysis recommended for fMRI 
(Thirion et al., 2007).  
fMRI data were first processed to minimise motion related artifacts (Bullmore, 
Brammer, et al., 1999). A 3D volume consisting of the average intensity at each voxel 
over the whole experiment was calculated and used as a template. The 3D image 
volume at each time point was then realigned to this template by computing the 
combination of rotations (around the x y and z axes) and translations (in x y and z) 
that maximised the correlation between the image intensities of the volume in 
question and the template (rigid body registration). Following realignment, data were 
then smoothed using a Gaussian filter (FWHM, 7.2mm) to improve the signal to noise 
characteristics of the images.  
After preprocessing, time series analysis for each individual subject was based 
on a wavelet-based data resampling method for functional MRI data (Bullmore et al., 
2001; Bullmore, Brammer, et al., 1999). We first convolved each experimental 
condition (1-Back; 2-Back; 3-Back; contrasted with 0-Back) with two Poisson model 
functions (peaking at 4s and 8s) after motion correction, global detrending and spin-
excitation history correction. We then calculated the weighted sum of these two 
convolutions that gave the best fit (least-squares) to the time series at each voxel. A 
goodness-of- fit statistic (the SSQ-ratio) was then computed at each voxel consisting 
of the ratio of the sum of squares of deviations from the mean intensity value due to 
the model (fitted time series) divided by the sum of squares due to the residuals 
(original time series minus model time series). The appropriate null distribution for 
assessing significance of any given SSQ-ratio was established using a wavelet-based 
data re-sampling method (Bullmore et al., 2001) and applying the model- fitting 
process to the re-sampled data. This process was repeated 20 times at each voxel and 
the data combined over all voxels, resulting in 20 null parametric maps of SSQ-ratio 
for each subject, which were combined to give the overall null distribution of SSQ-
ratio. The same permutation strategy was applied at each voxel to preserve spatial 
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correlation structure in the data. After first-level analysis, the individual statistical 
maps were then normalised into Talairach standard space (Bullmore et al., 2001). 
A group activation map was then produced for each of the experimental 
conditions (1-Back; 2-Back; 3-Back) by calculating the median SSQ-ratio over all 
subjects at each voxel in standard space and testing them against the null distribution 
of median SSQ-ratios computed from the identically transformed wavelet re-sampled 
data (Brammer et al., 1997). The voxel- level threshold was first set to p <0.05 to give 
maximum sensitivity and to avoid type II errors. Next, a cluster- level threshold was 
computed for the resulting 3D voxel clusters such that the final expected number of 
type I error clusters was <1 per whole brain. Cluster mass rather than a cluster extent 
threshold was used, to minimise discrimination against possible small, strongly 
responding foci of activation (Bullmore, Suckling, et al., 1999). 
In both ANOVA designs, we used randomization-based tests for voxel or 
cluster-wise differences (Bullmore, Suckling, et al., 1999). Less than 1 false activated 
cluster was expected at a p-value of p<0.05 for voxel and p<0.01 for cluster 
comparisons. Thus, an expected cluster- level type I error rate of <1 per brain was 
achieved by first applying a voxel- level threshold of p<0.05 followed by thresholding 
the mass of the 3D clusters formed from the voxels that survived this initial step at a 
cluster-level threshold of p<0.01. The cluster level threshold of p<0.01, was therefore 
not applied to the whole brain (which would be lenient) but rather to the 
data previously thresholded at a voxel-wise level of p<0.05. The necessary 
combination of voxel and cluster level thresholds is not assumed from theory but 
rather determined by direct permutation for each data set. This combined voxel/cluster 
tests coupled with permutation testing allow for type I error control at the cluster level 
(Bullmore, Brammer, et al., 1999; Bullmore, Suckling, et al., 1999). For each 
analysis, <1 false positive 3D cluster per map were expected at a p-value of <0.05 at 
the voxel- level and <0.01 at the cluster-level. In large connected clusters, we 
identified local maxima that were farther apart than the upper bound of the likely 
Talairach mapping error (3 voxel radius:10 mm) (Thirion et al., 2007). Voxels were 
then assigned to the nearest local maximum with a statistic value that exceeded that of 
the voxels. 
 For between-group comparisons, a 2x3 split-plot design ANOVA (groups: 
controls, patients; WM-load: 1-Back, 2-Back, 3-Back, each separately contrasted with 
 208 
0-Back) was conducted. For within-group comparisons, a 3x3 factorial design 
repeated measures ANOVA (drug condition: placebo, MPH, ATX; WM-load: 1-Back, 
2-Back, 3-Back, separately contrasted with 0-Back) was conducted. Statistical 
measures of BOLD response were extracted for each participant in each of the clusters 
of activation differences for each of the three contrasts, and post-hoc analyses were 
conducted to clarify the direction of the differences. Within patients, repeated 
measures ANOVAs on the extracted BOLD response measures were conducted to test 
for potential order effects. 
 
7.2.4. Performance analysis 
For the main performance measures of errors and MRT in the case-control 
comparisons, three repeated measures ANOVAs (controls versus ADHD under 
placebo; controls versus ADHD under MPH and controls versus ADHD under ATX) 
were conducted with WM-load as the within-subjects factor and group as the 
between-subjects factor. Within patients, repeated measures ANOVAs were 
conducted with drug condition (Placebo, MPH, ATX) and WM-load (1-Back, 2-Back, 
3-Back) as within-subject factors. Repeated measures ANOVAs were conducted 




7.3.1. Performance data 
 Significant WM-load effects were observed for patients in errors (F(2,38)=34, 
p<0.001) and MRT (F(2,38)=18, p<0.001), and also in controls (Errors: F (2,38)=26, 
p<0.001; MRT:F(2,38)=13, p<0.001).  
In case-control comparisons, no group effects were found. However, there was 
a significant interaction between WM-load and group in the number of errors only 
when comparing controls with patients under placebo (F(2,76)=3; p<0.037), which 
was due to patients making less errors during 1-Back but more errors during 2- and 3-
Back than healthy controls (Table 7.2). There was also an interaction effect between 
WM-load and group in MRT when healthy controls were compared to patients under 
placebo (F(2,76)=6, p<0.005) or under ATX (F(2,76)=5, p<0.01), both due to patients 
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showing similar MRT to controls during 1-Back, but being slower than controls 
during 2-Back, and faster during 3-Back (Table 7.2).  
 Within patients, no drug condition, WM-load by drug condition interaction or 
order effects on performance variables were detected.  
 No other group, group by WM-load interaction or drug order effects were 
observed.  
 
Table 7.2. Performance data for 20 healthy control boys and 20 boys with ADHD under each 




















































Note: ATX = Atomoxetine; MPH = Methylphenidate  
 
 
7.3.2. Brain activation 
 
7.3.2.1. Motion 
 Multivariate ANOVA showed no significant group differences between 
controls and ADHD patients under each drug condition in the extent of mean rotation 
and translation movement parameters in the 3-dimensional Euclidean space 
(F(6,152)=1;p=0.43).  
 
7.3.2.2. Within-groups brain activation 
During the easier condition (1-Back), controls showed activation in right 
DLPFC, in left IFC extending to premotor areas, and in bilateral parietal regions. 
During 2-Back, activation was observed in the group of healthy controls in bilateral 
DLPFC, extending to inferior prefrontal cortex IFC, bilateral thalamus, STG, IPL, 
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precuneus and occipital regions. Additional activation was observed during the more 
difficult condition (3-Back) in the left caudate body extending to mid-cingulate gyrus, 
as well as in the dorsal ACC extending to the SMA (Table 7.3, Figure 7.2).  
Boys with ADHD under placebo showed activation during the easier 1-Back 
condition in bilateral medial frontal regions, in left IFC, striatum bilaterally, and in 
right IPL. During the 2-Back condition, children with ADHD showed activation in 
bilateral IFC, MFC and SFC, ACC, striatum, precuneus, IPL and SPL, as well as in 
the right lingual cortex. These regions were also activated during the more difficult 3-
Back condition of the task, with bigger cluster sizes especially in the striatum, and 
with additional activation in the cerebellar vermis, subthalamic nuclei and in left 
parahippocampal gyrus (Table 7.3, Figure 7.2). 
After acute MPH administration, boys with ADHD during the easier condition 
(1-Back) showed activation left IFC and MFC, in bilateral ITG and MTG, and in right 
parietal regions as well as in cerebellar vermis. During 2-Back, boys with ADHD after 
MPH showed activation in bilateral IFC, MFC, SFC brain regions, precentral cor tices, 
striatum, thalamus, insula, dorsal ACC, precuneus, IPL, subthalamic nuclei and the 
cerebellar vermis. During the more difficult condition (3-Back), activation was 
observed in the same brain regions, but extending further into the cerebellum and 
subthalamic nuclei, and with less activation in frontal and striatal regions (Table 7.3, 
Figure 7.2). 
Boys with ADHD under a single dose of ATX showed activation during 1-
Back in bilateral IFC, striatum, ACC, thalamus, MTG, as well as in right parietal 
regions and cerebellar vermis. During the 2-Back condition, children with ADHD 
under ATX showed activation in bilateral IFC, MFC and SFC, ACC and SMA, 
striatum, thalamus, insula, temporo-parietal regions, cuneus, precuneus and 
subthalamic nuclei. The same regions were activated during the difficult condition, 
but more extensively, with the exception of temporal regions that were no longer 







Figure 7.2. Within-group brain activation maps for the two task conditions. Axial sections 
showing within-group brain activation for the healthy comparison boys and boys with ADHD under 
each condition (placebo, MPH, ATX) for the contrasts a) 1-Back versus 0-Back, b) 2-Back versus 0-
back, c) 3-Back versus 0-Back. Talairach z-coord inates are indicated for slice distance (in mm) from 
the intercommissural line.  
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Table 7.3. Brain Activation within each group  







N of voxels P value 
a) 1-Back 
Healthy control boys 
R medial/superior frontal gyri 
L inferior/medial frontal/premotor gyri 
R postcentral/inferior parietal gyri 
L inferior/superior parietal gyri 
Boys with ADHD under PLACEBO 
R medial/superior frontal gyri 
L medial frontal gyrus 
L inferior frontal/caudate/putamen/pre/postcentral/insula/superior temporal/inferior parietal gyri  
R caudate/putamen/premotor/insula/anterior cingulate gyri 
R inferior parietal gyrus 
Boys with ADHD under MPH 
L inferior/medial frontal/premotor gyri/insula 
L inferior frontal gyrus 
L inferior parietal gyrus 
R inferior parietal gyrus/cunues/precuneus 



















40; 41; 26 
-43; 11; 37 
32; -44; 37 
-29; -48; 37 
 
36; 41; 20 
-25; 33; 20 
-43; 11; 4 
11; 22; 26 
43; -30; 37 
 
-40; 7; 20 
-58; -15; 4 
-40; -37; 26 
29; -41; 31 




































L medial/inferior temporal/medial occipital/fusiform gyri 
R + L vermis cerebellum/subthalamic nuclei 
Boys with ADHD under ATX 
R inferior/medial/superior frontal/premotor gyri 
L inferior frontal gyri/insula/lenticular nucleus/thalamus  
R anterior cingulate/medial frontal/premotor/caudate/putamen/thalamus/insula  
R putamen/thalamus/insulamedial/superior temporal gyri  
L medial temporal/fusiform gyri/caudate tail 
R inferior parietal/postcentral gyri 











-43; -67; -13 
4; -26; -13 
 
29; 33; 26 
-29; 30; -2 
18; 4; 4 
40; -33; 4 
-32; -37; -2 
32; -44; 31 






















Healthy control boys  
R medial/superior/inferior frontal gyri 
L medial/superior/inferior frontal gyri 
R anterior cingulate gyrus 
R & L thalamus  
L superior temporal/inferior parietal gyri 
R cuneus/precuneus/middle/superior occipital/inferior parietal gyri 
L precuneus/occipital/medial temporal/inferior parietal gyri 
Boys with ADHD under PLACEBO 
R inferior frontal gyrus/insula/caudate/putamen 
R superior/medial frontal gyri 
L inferior/middle/superior frontal/pre/postcentral gyri/caudate/putamen/thalamus  















36; 37; 26 
-36; 22; 31 
11; 18; 37 
-4; -18; 9 
-40; -48; 20 
29; -63; 42 
-32; -48; 37 
 
29; 26; -2 
36; 30; 26 
-25; 26; 4 




























R subthalamic nuclei/thalamus  
R lingual/middle temporal gyri 
R precuneus/inferior/superior parietal gyri 
L superior occipital gyrus/cuneus 
Boys with ADHD under MPH 
R + L inferior frontal/middle/precentral gyri/insula/caudate/putamen/thalamus  
R middle/superior frontal gyri 
R + L anterior cingulate gyrus 
R + L inferior parietal gyrus/precuneus /superior temporal gyri  
L inferior/medial temporal/medial occipital/fuisform gyri 
R superior temporal/ inferior parietal gyri 
R fusifurm gyrus 
Boys with ADHD under ATX 
R inferior/middle/superior frontal/precentral gyri/insula/caudate/putamen/globus 
pallidus/thalamus, R + L subthalamic nuclei/L globus pallidus  
R + L mesial frontal/anterior cingulate/supplementary motor area 
L medial temporal gyri 
R inferior parietal/medial temporal/precuneus  




















7; -11; -13 
29; -55; 4 
11; -59; 37 
-18; -59; 26 
 
-29; 26;-2 
40; 41; 26 
11; 30; 9 
32; -41; 31 
-36; -52; -13 
51; -37; 9 
40; -41; -18 
 
29; 48; 9 
 
-4; 18; 37 
-32; -41; -7 
32; -48; 31 








































Healthy control boys 
L inferior frontal gyrus/putamen 
R superior/middle/inferior frontal gyri 






-25; 26; -7 
32; 30; 31 










R + L dorsal anterior cingulate/supplementary motor area 
L thalamus/caudate body/mid-cingulate gyrus 
L thalamus/subthalamic nuclei 
R cuneus/precuneus/superior occipital/inferior/superior parietal gyri  
L precuneus/superior occipital/inferior/superior parietal gyri  
Boys with ADHD under PLACEBO 
R + L inferior/middle/superior frontal/precentral gyri/caudate/putamen/thalamus/nucleus 
accumbens/subthalamic nuclei /hippocampus/parahippocampal/lingual gyri 
L inferior frontal gyrus 
R + L anterior cingulate gyrus 
R + L anterior cingulate gyrus 
R + L inferior/superior parietal/superior occipital/precuneus  
L, cerebellar vermis 
Boys with ADHD under MPH 
R middle/superior frontal gyri 
L inferior frontal gyrus 
L inferior/middle/superior frontal/precentral/insula/R + L caudate/putamen/globus 
pallidus/thalamus/subthalamic nuclei/L superior temporal/fusiform gyri 
R + L inferior parietal/precuneus/R postcentral gyri 
Boys with ADHD under ATX 
L middle frontal gyrus 
R inferior parietal gyrus/precuneus 
L inferior /middle frontal/precentral gyri 
R + L inferior frontal/anterior cingulate/supplementary motor/R middle/superior frontal/R + L 


























11; 26; 26 
-7; -7; 9 
4; -18; -7 
29; -63; 26 
-22; -63; 42 
 
-22; 59; 9 
 
-36; 4; 26 
-4; 26; 31 
7; 26; 20 
29; -44; 31 
25; -33; -29 
 
26; 55; 4 
-54; 37; -13 
-40; 26; 26 
 
32; -41; 31 
 
-36; 48; 4 
36; -48; 31 
-36; 22; 26 





















































R + L precuneus 









Note: N voxels = number of voxels. L = left; R = right; the maps are thresholded to give less than 1 Type I error 3D cluster per map. Talairach 
coordinates, number of voxels and areas are included underneath the corres ponding cluster.                                                                                                                        
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7.3.2.3. ANOVA between-group comparisons between healthy controls and 
ADHD boys under placebo, MPH or ATX 
 
Controls compared to patients under placebo 
 Group effects showed that controls compared to patients under placebo 
showed enhanced activation in bilateral DLPFC (Table 7.4, Figure 7.3). No areas 
were enhanced in patients compared to healthy controls. There were no significant 
WM-load by group interaction effects.  
Given that patients had larger error rates than controls in the 2- and 3-Back 
conditions, we hypothesised that the error rates would be negatively correlated with 
the DLPFC activation in these conditions. Hence, one-tailed Pearson correlations 
were conducted in both groups separately between statistical measures of the BOLD 
response in left and right DLPFC and errors. As expected, activation in right DLPFC 
was negatively associated with errors within controls during 3-Back (r=-0.39, p<0.04) 
and within patients at a trend- level during 2-Back (r=-0.29, p<0.1). No correlations 
were observed for left DLPFC activation.  
 Post-hoc Pearson correlations were conducted within each group separately to 
examine the linear relationship between IQ scores and BOLD signal response on the 
clusters of between-group brain activation differences. There were no significant 
correlations within patients or controls.  
 
Controls compared to patients under MPH 
 After the single dose of MPH, patients compared to controls showed 
underactivation in the same left and right DLPFC clusters as under placebo. However, 
ADHD patients relative to controls showed additional, enhanced activation in a 
cluster comprising right STG, premotor cortex, striatum, thalamus, insula and 
reaching into the cerebellar vermis (Table 7.4, Figure 7.3). To test whether the 
increased right medial fronto-STG-striatal activation in patients under MPH was  
compensatory for the reduced bilateral DLPFC activation, statistical measures of 
BOLD response were extracted for each patient in these 3 clusters and correlated with 
the DLPFC activation clusters as well as with errors. Pearson correlations showed that 
the medial fronto-STG-striatal activation was negatively correlated with the left 
DLPFC activation (r= -0.5, p<0.012) and with errors during the 2-Back condition (r= -
0.52, p<0.01).  
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 A significant interaction of group by WM-load was observed in the left IFC 
reaching into DLPFC, putamen and anterior insula, due to enhanced activation in 
patients under MPH relative to controls during 2-Back (p<0.01) (Table 7.4, Figure 
7.4). Additional interaction effects were observed in bilateral occipital regions 
extending to cuneus, due to the enhanced deactivation of this cluster in patients under 
MPH compared to controls during 2-Back (p<0.001). Within patients, the enhanced 
deactivation in occipital regions was correlated with reduced errors during 2-Back 
(r=-0.47, p<0.019), and with the abnormally enhanced activation relative to controls 
in left IFC/DLPFC during 2-Back (r=-0.5, p<0.012) and 3-Back (r=-0.49, p<0.014).  
 To test whether the cluster of activation differences in occipital regions and 
cuneus was due to excessive movement in the ADHD group, Pearson correlations 
were conducted within patients between movement parameters (mean rotation and 
translation values) and the SSQs in occipital regions and cuneus under each WM load 
condition. There were no significant correlations.   
 
Controls compared to patients under ATX 
 Under the single dose of ATX, patients compared to controls still showed 
reduced activation in the left DLPFC. However, they no longer showed 
underactivation of right DLPFC. In addition, abnormally enhanced activation was 
observed in ADHD relative to controls in a right- lateralised cluster of IFC and STG, 
reaching deep into insula, thalamus and striatum (Table 7.4, Figure 7.3), which within 
patients was negatively associated with errors during 2-Back (r= -0.52, p<0.009) and 
at a trend level during 3-Back (r= -0.35, p<0.066). 
 Significant interaction effects of group by WM-load were observed in the 
ACC and PCC extending to precuneus (Table 7.4, Fig 7.4), due to significantly 
enhanced activation within patients relative to controls during 1-Back (p<0.004) and 
enhanced deactivation during 3-Back (p<0.005).  
When those subjects whose IQ scores were more than 2 SD above or below 
average were excluded, findings from all the case-control contrasts remained 
significant, although at a more lenient p value (p<0.03) (See Appendix Figure A2). 
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Figure 7.3. Between-group ANOVA comparisons between healthy boys and boys with ADHD 
under either Placebo, Methylphenidate or Atomoxetine. Axial sections showing the ANOVA 
between-group difference effects in brain activation between healthy control boys and boys with 
ADHD under each condition (placebo, MPH, ATX). Clusters in orange denote areas where control 
boys showed enhanced activation compared to ADHD boys, clusters in blue denote areas where ADHD 
boys showed enhanced activation compared to control boys. Talairach z-coordinates are indicated for 
slice distance (in mm) from the intercommissural line. The right side of the image corresponds to the 
right side of the brain. The maps are thresholded to give less than 1 Type I error 3D cluster per map 
(p<0.01). The graphs show the BOLD response in each area for each group and WM condition. The x-
axis of the graphs corresponds to the statistical measure of the BOLD response in this region. 1B= one -
Back, 2B = two-back, 3B = three-back. R = Right, L = Left, DLPFC = dorsolateral prefrontal cortex, 
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IFC= in ferior frontal cortex, PCC= posterior cingulate cortex, BOLD= Blood Oxygen -Level 
Dependent, Plac= p lacebo, MPH= Methylphenidate, ATX=Atomoxetine.  
Figure 7.4. Between-group ANOVA interaction effect (Group x WM-load) for the comparison 
between healthy boys and boys with ADHD under Methylphenidate. Axial sections showing the 
ANOVA between-group difference effects in brain activation between healthy control boys and boys 
with ADHD under MPH depending on WM load. Clusters in orange denote areas where control boys 
showed enhanced activation compared to ADHD boys, clusters in blue denote areas where ADHD boys 
showed enhanced activation compared to control boys. Talairach z-coordinates are indicated for slice 
distance (in mm) from the intercommissural line. The right side of the image corresponds to the right 
side of the brain. The graphs show the BOLD response in each area for each group and WM condition . 
The maps are thresholded to give less than 1 Type I error 3D cluster per map (p<0.01). 1B= one-Back , 
2B = two-back, 3B = three-back. R = Right, L = Left, IFC= in ferior frontal cortex, ACC/PCC/Precu= 
anterior cingulate cortex/posterior cingulate cortex/precuneus. BOLD= Blood Oxygen -Level 
Dependent, MPH= Methylphenidate. 
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a) Group Effect 
C > ADHD Plac 
 
R medial/superior frontal  
L medial/superior/inferior frontal  
9/8 
9/8 
25; 37; 31 







C > ADHD MPH  
 
R medial/superior frontal 
L medial/superior frontal  
9/8 
9/8 
25; 44; 31 







ADHD MPH > C R superior temporal/parahippocampal gyri/premotor cortex/basal 
ganglia/thalamus/ /insula/ amygdala/vermis cerebellum      





C> ADHD ATX L medial/superior frontal 9/8 -25; 41; 37 169 0.004 1.65 
ADHD ATX >C R inferior frontal/insula/ medial/superior temporal/insula/amygdala/basal 
ganglia/thalamus  
44/45/21/22 29; -15; -7 395 0.003 1.82 
b) Group by WM load Interaction Effect 
C vs ADHD MPH L inferior/middle/superior frontal/putamen 











C vs ADHD ATX R anterior/posterior cingulate gyri/precuneus  24/32/23/31/7 11;15;26 167 0.004 0.98 
Note: N voxels = number of voxels. L = left; R = right; the maps are thresholded to give less than 1 Type I error 3D cluster per map. 
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7.3.2.4. Significance of the “normalization” effects 
 We wanted to analyze the significance of the “normalization” effects observed 
in the between-groups fMRI analysis. Given that the data of the healthy control group 
was identical across the different case-control comparisons, non-parametric Friedman 
tests were conducted only within patients to identify whether there were significant 
differences in brain activation under each drug condition in each of those clusters 
where the case-control contrasts showed “normalization” effects.  
There were significant differences between drug conditions in the right 
DLPFC (BOLD Placebo: <-0.001; BOLD MPH: -0.007; BOLD ATX: 0.004; ² (2, 
N=60) = 10.43, p<0.005), which, as shown by post-hoc non-parametric Wilcoxon 
Tests, were due to significant differences between brain activation in patients under 
MPH relative to that observed when they were under ATX (p<0.003) and under 
placebo (p<0.018). 
 For the cluster of enhanced right fronto-STG-striatum activation under MPH 
relative to controls, the differences in brain activation within patients under the three 
drug conditions only reached a trend level (BOLD Placebo: -0.002; BOLD MPH: 
0.006; BOLD ATX:0.0005; ² (2, N=60) = 5.63, p<0.060). However, further 
exploratory post-hoc Wilcoxon tests showed there were significant differences 
between brain activation when under MPH relative to when under placebo (p<0.001) 
and, at a trend level, also when under MPH relative to ATX (p<0.095).  
Finally, for the cluster of enhanced right IFC-STG-striato-thalamic activation 
under ATX relative to controls, there were significant differences between the 
activation within ADHD boys under the three conditions (median BOLD Placebo: 
0.005; BOLD MPH: 0.006; BOLD ATX: 0.013; ² (2, N=60) = 9.03, p<0.011). These 
were due to the differences on brain activation in this clusters when they were under 
ATX relative to placebo (p<0.001) and MPH (p<0.022).   
 
7.3.2.5. Significance of the “laterality” effects 
 In order to test for the significance of the laterality effects on the BOLD signal 
changes observed in the right DLPFC under MPH and ATX, we conducted a repeated 
measures analysis within patients with laterality (2 levels: right DLPFC, left DLPFC) 
and drug condition (3 levels: placebo, MPH and ATX) as within-subjects factors. The 
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results show a trend for a significant laterality x drug interaction effect 
(F(2,118)=2.58, p<0.08), due to the significant differences between ATX and MPH 
(p<0.039), with ATX showing the strongest laterality effects and MPH having no 
differential laterality effects (Fig 7.5).  
 
 
Fig. 7.5. BOLD signal in right and left DLPFC within patients under each drug condition. While 
MPH had similar effects on BOLD signal in the right and left DLPFC, ATX showed enhanced 
activation in right DLPFC.  
 
Furthermore, to test whether the interaction group x WM load effects observed 
when patients were under MPH on the left IFC/DLPFC during the 2-Back condition 
were specifically left-lateralised, we re-run the between-group comparison analysis at 
a higher p-value. Only at a p=0.09, a small and more dorsally located cluster emerged, 
in the right medial frontal cortex (27 voxels, peak Talairach coordinates (x;y;z):29; 
26; 26; BA 9/46) (Figure 7.6). As can be seen in the figure 7.6, the differences 
observed in this cluster were due to the progressive increase of activation in this area 
in healthy controls but not in patients. Therefore, the positive effects of MPH were 
only observed on left hemispheric prefrontal regions.   
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Fig. 7.6. Additional cluster of activation differences in right medial prefrontal cortex observed in 
the group (healthy controls, boys with ADHD under MPH) x WM load comparison (1 -Back, 2-
Back, 3-Back) (p<0.09). The graph shows the progressive increase of activation with increasing WM 
load in the group of healthy control boys, while such increase is not observed in ADHD boys under 




7.3.2.6. ANOVA within-patient comparison between placebo, MPH and ATX 
 Given the reduced activation in left and right DLPFC, we tested for significant 
upregulation effects of both drugs in frontal cortex. The Talairach Client (Lancaster et 
al., 1997; Lancaster et al., 2000) was used to define an anatomical mask of the frontal 
lobe, restricting the analysis to those voxels present in the mask. A significant effect 
of drug condition was observed in a cluster in the right DLPFC (13 voxels, peak 
Talairach coordinates (x;y;z):25; 44; 26; BA 10/9 p<0.044), which was due to 
significantly  enhanced activation when under ATX relative to MPH (p<0.002), as 
well as when under placebo relative to MPH (p<0.01)(F igure 7.7a). Activation in this 
cluster was negatively correlated with errors during 2-Back under ATX (r= -0.53, 
p<0.008), during 3-Back under placebo (r= -0.40, p<0.04) and during 1-Back under 
MPH (r= -0.48, p<0.015).  
The same analysis was conducted at a higher p-value, in order to investigate 
whether the effects of ATX were bilateral or exclusively right- lateralised. At p<0.07, 
a small cluster of activation difference was observed in the left premotor cortex (4 
  226 
voxels, peak Talairach coordinates (x;y;z): -51;-11;26; BA6).  However, as can be 
seen in Fig 7.8a, in this case was due to the effects of MPH relative to Placebo 
(p<0.001) and MPH relative to ATX (P<0.001).  
 Significant interaction effects of drug condition by WM-load were observed in 
one cluster comprising left IFC (14 voxels, peak Talairach coordinates (x;y;z):-36; 22; 
9; BA 44/45; p<0.019) (Figure 7.7b), due to significantly enhanced activation in this 
cluster during 2-Back when under MPH compared to placebo (p<0.001) and ATX 
(p<0.015). There were no significant correlations between activation in this cluster 
and performance. The same interaction analysis was conducted at a higher p-value, in 
order to investigate whether the effects of MPH were bilateral or exclusively left-
lateralised. At p<0.05, a small cluster of brain activation difference was observed in 
the more ventral location of right OFC extending to putamen (7 voxels, peak 
Talairach coordinates (x;y;z):22; 11; -18; BA 47). However, and as can be seen in Fig 
7.8b, in this case it was due to the significant differences between the effects of 
placebo and ATX during 2-back (p<0.03). 
Repeated measures ANOVAs showed no practice effects on the extracted 
BOLD response measures. 
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Figure 7.7. Results of the repeated measures ANOVA analyses within ADHD boys, showing the 
effects for a) drug condition and b) interaction drug condition by WM-load interaction effects 
within ADHD boys. Axial sections showing the repeated measures ANOVA results for a) drug 
condition and b) drug condition by WM-load interaction effects within ADHD patients (placebo, MPH, 
ATX). Talairach z-coordinates are indicated for slice distance (in mm) from the intercommissural line. 
The right side of the image corresponds to the right side of the brain. The maps are thresholded to give 
less than 1 Type I error 3D cluster per map (p<0.01). The graphs show the BOLD response in each area 
for each medication and WM condition. 1B= one-back, 2B = two-back, 3B = three-back, R = Right, L= 
left, DLPFC= dorsolateral p refrontal cortex, IFC= inferior frontal cortex, BOLD= Blood Oxygen-Level 
Dependent, MPH= Methylphenidate, ATX=Atomoxetine.  
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Figure 7.8. Additional cluster of activation di fferences when repeated measures ANOVA analyses 
within ADHD boys were conducted at higher p values, showing the effects for a) drug condition 
and b) interaction drug condition by WM-load interaction effects within ADHD boys. Axial 
sections showing the repeated measures ANOVA results for a) drug condition (p<0.07) and b) drug 
condition by WM-load interaction effects within ADHD patients (placebo, MPH, ATX) (p<0.05). The 
graph shows the BOLD response in this cluster for each medication and WM condition. 1B= one -back, 
2B = two-back, 3B = three-back, R = Right, L= left, OFC= orbitofrontal cortex, Plac=Placebo, MPH= 
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Methylphenidate, ATX=Atomoxet ine. Talairach z-coordinates are indicated for slice d istance (in mm) 
from the intercommissural line. The right side of the image corresponds to the right side of the brain.  
 
7.4. Discussion 
To our knowledge, this is the first fMRI comparison between single dose 
challenges of MPH and ATX on brain activation in medication-naïve children with 
ADHD. We show both shared and drug-specific effects of both drugs on neural 
correlates of WM. Medication-naïve ADHD boys under placebo relative to controls 
showed impaired performance under high but not low WM-load and underactivated 
left and right DLPFC, which was normalised by both drugs. ATX had drug-specific 
effects on right DLPFC: within patients, ATX significantly upregulated right DLPFC 
activation relative to MPH. Furthermore, relative to MPH, ATX had a drug-specific 
significant normalisation effects on this region, which was underactivated relative to 
controls under placebo and MPH. By contrast, MPH showed a drug-specific WM 
load-dependent effect on left-lateralised IFC, which was upregulated during 2-Back 
both relative to controls as well as relative to ATX and placebo in the within-subject 
contrast. Both drugs shared WM load-dependent deactivation effects on midline 
ACC-PCC areas for ATX, and in bilateral occipital regions for MPH, which were 
negatively associated with improved performance, potentially due to the deactivation 
of regions of the DMN. Both drugs, in addition, elicited abnormally enhanced 
activation in patients relative to controls in different fronto-STG-striatal networks, 
which were associated with improved performance, suggesting a compensatory effect.   
Thus, the findings show both shared effects as well as drug-specific laterality 
effects in prefrontal WM regions. ATX had a drug-specific normalisation and 
upregulation effect on right-hemispheric DLPFC relative to MPH across all WM load 
conditions. MPH, by contrast, upregulated and enhanced left IFC, but only during the 
2-Back condition, relative to ATX and placebo within patients and relative to controls 
in the case-control comparison. Both drugs had shared effects of increasing fronto-
STG-striatal activation relative to controls, while also eliciting DMN deactivation 
during higher WM load conditions, both of which improved WM performance in 
patients. 
ADHD patients under placebo showed no deficits during the relatively easy 
WM task condition, but made significantly more errors than controls during the 2-
Back and 3-Back conditions. The findings show WM load-dependent impaired 
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performance relative to controls and are in line with previous evidence for deficits on 
complex executive function paradigms in ADHD patients but not in simpler cognitive 
tasks (Willcutt et al., 2005), in line with previous evidence for WM deficits 
(Martinussen et al., 2005). Both drugs showed a beneficial effect on these 
performance deficits, since they were normalised under both drug conditions.  
Compared to controls, patients showed underactivation in bilateral DLPFC, a 
key region for WM, involved in the storage and coding of the temporal sequence of 
stimuli (Owen et al., 2005). The findings extend previous findings of 
underfunctioning of DLPFC in adult ADHD during WM (Valera et al., 2010) and in 
ADHD children during other cognitive control tasks (Christakou et al., 2012; Cubillo 
et al., 2012; Rubia, 2011). 
The most interesting findings are those of drug-specific lateralisation effects 
on frontal activations during task performance. ATX relative to MPH showed a drug-
specific right-hemispheric frontal upregulation and normalisation effect in right 
DLPFC. MPH showed a drug-specific left-lateralised WM-load dependent effect on 
left IFC/DLPFC activation during the 2-Back condition, which was upregulated 
within patients relative to ATX and placebo and abnormally enhanced in patients 
relative to controls. WM is mediated in the DLPFC by noradrenergic α2 receptors that 
increase neural “signal” (increased firing to relevant stimuli) and by dopaminergic D1 
receptors that decrease “noise” (suppressing firing to irrelevant stimuli) (Gamo et al., 
2010). Although ATX affects both DA and NE in the PFC (Bymaster et al., 2002), in 
non-human primates it increases “signal” more frequently than it decreased “noise” 
(Gamo et al., 2010), suggesting relatively stronger effects on NE-mediated WM 
networks. Furthermore, the shared enhanced, presumably compensatory activation in 
fronto-STG-striatal regions reached the right IFC only when patients were under 
ATX. The right IFC in particular has been associated with WM load processing (Baier 
et al., 2010). These right- lateralised drug-specific upregulation and normalisation 
effects of ATX on right-hemispheric frontal regions potentially suggest a stronger 
noradrenergic implication in mediating right frontal ac tivation during WM (Gamo et 
al., 2010), in line with the notion of a stronger right-hemispheric lateralisation of 
noradrenergically modulated networks (Tucker & Williamson, 1984). This study 
shows for the first time that upregulation of right frontolateral activation is not only 
observed with a single dose of ATX in healthy adults (Chamberlain et al., 2009; Graf 
et al., 2011), but also in children with ADHD, implying similar mechanisms of action 
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in both healthy subjects and ADHD patients. Furthermore, and most importantly, we 
show that, during WM, the right frontal normalisation and upregulation effects with 
ATX were drug-specific relative to MPH.  
The results are suggestive of potentially stronger right-hemispheric frontal 
upregulation and normalisation effects of ATX relative to MPH during WM, and of 
drug-specific left- lateralised WM load-dependent effects of MPH relative to ATX and 
placebo.  The findings would be in line with previous evidence for increased levels of 
DA within left- lateralised sub-cortical structures (Flor-Henry, 1986) and more 
strongly left- lateralised DA system (Glick, Ross, & Hough, 1982). The left IFC is 
important for subvocal rehearsal processes during WM (Owen et al., 2005; Smith, 
Jonides, Marshuetz, & Koeppe, 1998), is also an important area for cognitive control 
(Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Mohammad, et al., 2011) and 
mediates selective attention and performance monitoring (Derrfuss et al., 2005; 
Stevens et al., 2009), necessary to correctly perform the task. Furthermore, during 
WM maintenance, enhanced dopaminergic function in the caudate has been associated 
with increased left IFC activation (Landau, Lal, O'Neil, Baker, & Jagust, 2009), and 
therefore the findings may possibly reflect that association between dopaminergic 
function in the striatum and left IFC activation during WM. However, future studies 
should further examine the drug-specific laterality of these effects. These results 
extend previous findings of fronto-striatal upregulation and/or normalisation in 
ADHD children with a single dose of MPH during WM (Prehn-Kristensen et al., 
2011), performance monitoring (Rubia, Halari, Mohammad, et al., 2011), TD (Rubia, 
Halari, Christakou, et al., 2009), and inhibition (Epstein et al., 2007; Vaidya et al., 
1998), some of which were also, like here, predominantly left-hemispheric (Epstein et 
al., 2007; Rubia, Halari, Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 
2009).  
Both MPH and ATX elicited enhanced deactivation in regions of the DMN in 
ADHD relative to controls during the high WM load conditions, suggesting that 
catecholamine agonists work not only by increasing task-positive but also by 
switching off task-negative DMN activation. ATX showed progressively stronger 
deactivation in ACC-PCC with increasing WM load. MPH, on the other hand, showed 
enhanced deactivation in bilateral occipital regions during 2-Back, associated with 
improved performance. The DMN is associated with stimulus- independent thought 
and self-referential mental activity and is typically anti-correlated with networks 
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engaged by effortful cognitive tasks (Broyd et al., 2009). Problems with deactivation 
of the DMN have been linked to attention lapses in ADHD (Broyd et al., 2009; 
Fassbender et al., 2009; Sonuga-Barke & Castellanos, 2007). In children with ADHD, 
a single dose of MPH has previously been shown to enhance DMN deactivation 
during a GNG task (Liddle et al., 2010). We thus extend these findings to another task 
and show for the first time that not only MPH but also ATX enhances task-related 
DMN deactivation in ADHD children. The findings also extend previous findings of 
enhanced DMN deactivation after single doses of MPH and ATX in healthy adults 
during WM (Marquand et al., 2011) to a patient group with ADHD. The negative 
correlation within patients between the more deactivated bilateral occipital regions 
under MPH and the abnormally enhanced task-positive left IFC/DLPFC activation 
relative to controls, as well as the correlation with less errors, may reflect a 
strengthening of attention networks, which are typically enhanced with reduced DMN 
activity (Fox et al., 2005).  
An alternative explanation for the reduced activation in occipital regions when 
patients were under MPH is also possible. Occipital cortex, cuneus, precuneus and 
posterior cingulate cortex have consistently been involved in visuo-spatial attention 
processes (Ardekani et al., 2002; Kiehl et al., 2001; Madden, Whiting, Provenzale, & 
Huettel, 2004; Mesulam et al., 2001; Small et al., 2003).  Cholinergic systems have 
been shown to affect not only sensory processing but also WM processes, increasing 
the efficiency of visual processing regions and reducing the necessary executive 
prefrontal processing typically involved in WM (Bentley, Driver, & Dolan, 2011; 
Furey, Pietrini, & Haxby, 2000). MPH may therefore have affected positively the 
imbalance between dopaminergic and anticholinergic systems, necessary for adequate 
cognitive function (Levin, McGurk, Rose, & Butcher, 1990). The increased function 
in DA-regulated WM networks involving the IFC/DLPFC may have downregulated 
cholinergic function in occipital regions, hence the reduced activation in these areas. 
It may be thus hypothesized that MPH may have reduced the activation observed in 
occipital areas during 2-Back as a consequence of the reduced need for bottom-up 
visuo-spatial processing, given the increased involvement of the top-down left 
IFC/DLPFC activation, which would be further supported by the negative correlation 
between the activation in these two clusters. However,  reduction with MPH on 
occipital areas of visuo-spatial attention is not in line with evidence for reduced 
activation in such regions in children with ADHD (Booth et al., 2005; Hart, Radua, 
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Nakao, et al., 2012; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, Mohammad, et 
al., 2011; Vance et al., 2007) and evidence that MPH has been shown to increase and 
even normalise reduced occipital activation within children with ADHD relative to 
healthy control boys during motor response inhibition (Rubia, Halari, Mohammad, et 
al., 2011).  
Another alternative hypothesis could be that activation differences in occipital 
cortex may suggest potential movement issues. However, there was no significant 
association between movement parameters and brain activation within patients. Thus, 
it is unlikely that occipital differences on brain activation were due to movement 
artefacts. Therefore, further studies are needed to identify the potential mechanisms 
by which MPH administration reduces activation in occipital, cuneus and PCC 
regions.  
Both drugs showed abnormally enhanced fronto-STG-striatal activation in 
ADHD boys relative to controls, although in somewhat different locations, affecting 
premotor cortex with MPH and right IFC with ATX. The findings echo previous 
findings of fronto-striatal upregulation/normalisation in ADHD children with MPH 
during WM (Prehn-Kristensen et al., 2011) and other cognitive control tasks (Epstein 
et al., 2007; Rubia, Halari, Mohammad, et al., 2011; Vaidya et al., 1998). The 
findings also extend for the first time previous evidence of enhanced IFC/STG 
activation after a single dose ATX challenge in healthy adults (Chamberlain et al., 
2009) to a pediatric ADHD sample. Furthermore, the upregulation effect of MPH of 
STG parallels previous findings of STG upregulation/normalisation effects in 
medication-naïve children with ADHD during other executive function tasks (Rubia, 
Halari, Cubillo, et al., 2011; Rubia, Halari, Cubillo, et al., 2009). We hypothesise that 
the upregulation effects of ATX on right fronto-STG-striatal networks known to 
mediate WM (Owen et al., 2005; Wang, 2001) may have been due to direct effects on 
frontal and thalamic activation, which may indirectly have enhanced striatal activation 
(Easton, Marshall, Fone, & Marsden, 2007; Niijima et al., 2010).  
The strength of the study is the double-blind, placebo-controlled design and 
the recruitment of medication-naïve children with ADHD, thus avoiding the potential 
confound of a previous history of stimulant medication (Frodl & Skokauskas, 2012; 
Konrad et al., 2007; Nakao et al., 2011). A limitation of the study is that due to 
ethical, feasibility and financial reasons, healthy controls performed the task only 
once, unmedicated. However, the counterbalanced randomized design for the ADHD 
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group adequately controlled for practice effects in patients. Furthermore, we found no 
order effects on performance or brain activation within patients. Therefore, although 
we could not directly measure the practice effects in the between group analyses, we 
assume that they were unlikely to have contributed to performance or brain activation 
differences between patients and controls. However, it needs to be highlighted that 
such assumption must be made with caution. We could only test for the presence of 
potential order effects within subjects, conducted in a very small sample. Therefore, 
the power to detect potential order effects is severely reduced. Furthermore, given the 
reduced number of participants on each condition, it was not possible to test for 
potential sequence effects derived from the randomisation order. Thus, the 
administration of the drug conditions in a determined randomization order may have 
enhanced or reduced their effects. Further studies with sufficiently large samples 
should be conducted to rule out this possibility. In addition, the wider age range in the 
age of the healthy control group relative to the ADHD boys may have affected the 
results by widening the between-groups differences in a disorder that has shown to be 
associated with neurodevelopmental delay (Rubia, 2007; Shaw et al., 2007; Shaw et 
al., 2012). Therefore, future studies should ideally compare more closely age-matched 
groups.   
 An important caveat is that while MPH has an immediate effect on ADHD 
symptoms (Greenhill et al., 2001), ATX reaches its maximum clinical efficacy after 
12 weeks of treatment (Montoya et al., 2009). This investigation of acute mechanisms 
of action is a first step towards improving our understanding of drug-specific effects 
on brain activation and cognition, avoiding potential confounds of long-term 
treatment such as symptomatic improvement, side effects or chronic effects on brain 
activation. Given the differences of the two drugs in temporal courses to clinical 
efficacy, however, future studies should also compare their long-term effects on brain 
activation when they have reached maximum clinical efficacy.   
 In conclusion, the findings show both drug-specific as well as shared effects 
on task-positive and task-negative WM networks. ATX appears to be more potent 
than MPH in upregulating and normalising WM-related right DLPFC dysfunction in 
ADHD, while MPH appears to upregulate compensatory activation of left IFC 
activation, but only during the 2-Back condition. 
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CHAPTER 8: DIFFERENTIAL NEUROFUNCTIONAL EFFECTS OF 
METHYLPHENIDATE AND ATOMOXETINE IN BOYS WITH ATTENTION 
DEFICIT HYPERACTIVITY DISORDER DURING TIME PERCEPTION 1 
 
8.1. Introduction 
 Attention Deficit Hyperactivity Disorder (ADHD) is defined by problems with 
inattention, impulsivity and hyperactivity (DSM-IV-TR)(American Psychiatric 
Association, 2000). Children with ADHD are impaired in EF (Willcutt et al., 2005) 
but also in temporal processes (Rubia, Halari, Christakou, et al., 2009), particularly 
TD (Rubia, Smith, et al., 2007a; Smith et al., 2002) which has been shown to be one 
of the best discriminatory measures for ADHD among a large battery of tasks (Rubia, 
Smith, et al., 2007a). Using fMRI, TD deficits have been shown to be underpinned by 
neurofunctional deficits in fronto-striatal regions, including right IFC and DLPFC, 
SMA, ACC, the basal ganglia and cerebellum (Rubia, Halari, Christakou, et al., 2009; 
Smith et al., 2008).  
 One of the most frequently prescribed medications for ADHD is the stimulant 
MPH, which blocks DAT in the striatum (Volkow, Wang, Fowler, Gatley, et al., 
1998) and NET in NET-rich cortical regions, including PFC, where it increases 
concentrations of both DA and NE (Hannestad et al., 2010). There is a strong 
association between DA, the striatum and fine temporal processes (Takahashi, 2007) 
and accordingly, the striatal DA agonist MPH has been shown to improve motor 
timing deficits in children with ADHD in the millisecond ( Ben-Pazi et al., 2006; 
Rubia et al, 2003) and second range (Baldwin et al, 2004; Ben-Pazi et al., 2006). 
FMRI studies have shown that MPH consistently upregulates and normalises fronto-
striatal activation during EF (Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, 
Cubillo, et al., 2009; Shafritz et al., 2004). The only fMRI study investigating the 
influence of MPH on brain function in patients with ADHD during TD showed that 
MPH significantly enhanced left inferior and right DLPFC, ACC and cerebellum and 
completely normalised these fronto-striato-cerebellar differences between controls 
and patients on placebo (Rubia, Halari, Christakou, et al., 2009). 
 Another frequently prescribed medication for patients with ADHD is the non-
stimulant ATX. Two meta-analyses have shown that ATX demonstrates comparable 
                                                 
1
 This chapter has been submitted as a paper to Biological Psychiatry, where is under re-revision 
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efficacy rates with MPH in reducing ADHD symptoms (Hanwella et al., 2011; Hazell 
et al., 2010) and, as a non-stimulant, has less potential for abuse but takes longer to 
have a clinical effect on behaviour (Hazell et al., 2010). ATX is a selective 
presynaptic blocker of NETs (Bymaster et al., 2002), leading to enhanced NE and DA 
in PFC but also significant effects in other regions including ACC, thalamus, locus 
coeruleus and cerebellum (Takano et al., 2009).  Importantly, compared with MPH, 
ATX has no direct effect on the basal ganglia (Takano et al., 2009). 
 In healthy adults, a single dose of ATX increased right IFC and STG 
activation during cognitive control (Chamberlain et al., 2009; Graf et al., 2011). 
Multivariate pattern recognition analyses comparing single doses of MPH and ATX 
during WM in healthy adults showed a stronger effect of MPH on upregulating task 
relevant networks, but a relatively stronger effect of ATX on the suppression of the 
DMN (Marquand et al., 2011). Nevertheless, no study has carried out a single dose 
challenge, investigating the immediate effects of ATX on brain function in ADHD or 
compared its effects on brain activation in ADHD to those of MPH. We focused on 
TD since it is a disorder-sensitive function (Rubia, Smith, et al., 2007a; Smith et al., 
2008; Smith et al., 2002) shown to be mediated by fronto-striatal networks (Rubia, 
2006) (Wiener et al., 2010) and modified by dopamine agonists (Baldwin et al., 2004; 
Rubia, Noorloos, et al., 2003). 
 Given the strong association between DA and fronto-striatal networks in TD 
(Rubia, 2006) and the evidence for positive effects of MPH on time estimation 
(Baldwin et al., 2004; Rubia, Noorloos, et al., 2003) and its underlying fronto-striatal 
networks in ADHD (Rubia, Halari, Christakou, et al., 2009) we hypothesised that 
MPH would enhance TD performance and its associated fronto-striatal correlates. 
However, we proposed that ATX would also increase right fronto-cortical activation, 
as observed in healthy adults during tasks of cognitive control (Chamberlain et al., 
2009; Graf et al., 2011). 
 
8.2. Methods and Materials 
 
8.2.1. Participants  
 Twenty nine medication-naive right-handed adolescent boys between 10-17 
years with a clinical diagnosis of inattentive/ hyperactive- impulsive combined ADHD 
as assessed by an experienced child psychiatrist using the standardized Maudsley 
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diagnostic interview (Goldberg & Murray, 2002) which assesses ADHD according to 
DSM-IV-TR criteria (American Psychiatric Association, 2000) were recruited from 
clinics. A multidisciplinary clinical team participated in the assessment, which 
included information from semi-structured clinical assessment interviews with 
parents/carers, questionnaires from parents and teachers, school reports, 
developmental history, cognitive assessments and behavioural observation of the 
child. The presence of learning disability was concluded from the information 
provided by parents and school during the clinical and cognitive assessments, or by 
the presence of significant discrepancies between verbal and performance IQ 
subscores, which is considered as an indicator of potential learning difficulties.  
 Nine patients were excluded due to: neurological abnormalities detected 
during the scan (N=1), technical difficulties that led to loss of data (N=2), braces 
(N=1), IQ<70 (N=1) or intolerance to the scanning situation (N=4). In line with their 
diagnoses, all patients scored above clinical cut-off for hyperactive/ inattentive 
symptoms on the parental SDQ (Goodman, Ford, Simmons, Gatward, & Meltzer, 
2000), and the CPRS-R (Conners et al., 1998), and below clinical cut-off on the SCQ 
(Rutter et al., 2003). They were scanned over three consecutive weeks using a double-
blind, pseudo-randomised, cross−over drug design, receiving a single dose of either 
placebo (Vitamin C, 50mg), MPH (Equasym 0.3mg/kg: range 5−20mg) or ATX 
(Strattera 1mg/kg: range 16-66 mg), all identical in appearance. Dosages were 
determined following NICE guidelines at the time of the study for typical clinical 
efficacious dosages with minimal side effects (National Institute for Heath and 
Clinical Excellence, 2008). As suggested by evidence from pharmacokinetics studies, 
both medications were administered 1.5 hours before the scan to allow for maximum 
absorption (Chan et al., 1983; Swanson & Volkow, 2002; Witcher et al., 2003).   
 Twenty-one male right-handed healthy boys between 10-17 years old were 
recruited through advertisements. They scored below clinical cut-off for the SDQ, 
SCQ, and CPRS. One healthy boy was excluded due to CPRS-R and SDQ scores 
above clinical threshold. Controls were scanned once, unmedicated, for feasibility and 
ethical reasons. The final subject numbers were therefore 20 ADHD and 20 controls 
(Table 8.1). 
 Participants were excluded if they had learning disability, reading, speech or 
language disorder, neurological abnormalities, epilepsy, drugs or substance abuse or 
any comorbid psychiatric disorders (except for conduct disorder and oppositional 
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defiant disorder in the ADHD group: N=2). When parental reports for potential 
participants were suggestive of the presence of such difficulties, questions addressing 
each of the criteria for ODD/CD were included in the semi-structured interviews. 
Thus, despite the fact that the mean score in the ADHD group for oppositional 
problems in the CPRS-R and behavioural difficulties in the SDQ scales were above 
clinical cut-offs (Table 8.1), only two cases received the formal diagnosis of 
ODD/CD. 
One-way ANOVA showed no group differences for age (F(1,38)=2, p<0.15). 
All participants had an IQ>70 on the Wechsler Abbreviated Scale of Intelligence 
(WASI) (Wechsler, 1999) but significant group differences were observed (mean 
controls: 113 (10) mean ADHD: 91 (11): F (1,38)=41, p<0.0001).  
 IQ scores have consistently been shown to be lower in patients with ADHD 
than in age-matched healthy controls (Bridgett & Walker, 2006; Kuntsi et al., 2004). 
It has furthermore been shown that measures of perceptual timing vary with IQ scores 
(Paule et al., 1999; Wearden et al., 1997), suggesting that abnormal timing functions 
in ADHD might be associated with low IQ. Indeed, such a link has been demonstrated 
in children with ADHD during time perception and temporal foresight tasks, 
including duration reproduction (Smith et al., 2002; Toplak et al., 2003), estimation 
(Barkley et al., 2001), and temporal discounting tasks (Bitsakou et al., 2009; Kuntsi et 
al., 2001; Marco et al., 2009). Overall, IQ seems to mediate specific abnormalities of 
timing functions, in particular reproduction of temporal intervals, but this is not 
consistently observed.  
 We conducted an exploratory analysis comparing brain activation between 
healthy controls and children with ADHD under placebo with and without using IQ as 
a covariate. When using IQ as a covariate, the resulting clusters of activation 
differences between groups included only those that have been closely related with 
time perception.  These included the IFC/DLPFC and the SMA/ACC, both of which 
which have been associated with the estimation and d iscrimination of stimulus 
durations in the seconds and milliseconds’ range (Coull & Nobre, 2008; Lewis & 
Miall, 2006b; Rubia, 2006; Rubia & Smith, 2004; Shih et al., 2009; Smith et al., 2003; 
Wiener et al., 2010). On the other hand, when IQ scores were not used as a covariate, 
the areas included the above mentioned plus two additional clusters of activat ion 
differences in bilateral parietal regions. These are not areas typically involved in time 
perception processes per se, but rather their role is more indirectly associated to time 
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processes by facilitating sustained attention to time (Rubia, 2006). Thus, as the results 
were restricted to areas directly associated to time perception processes when IQ was 
used as a covariate, this option was selected for the case-control fMRI and 
performance analyses.  
 Participants were paid £50 for each visit. Written informed consent and assent 
were obtained and the study was approved by the local ethics committee.  
 
Table 8.1. Sample characteristics for healthy control boys and patients with ADHD.  




Age (years, months) 13y, 11m (2y, 4m) 12y, 11m (1y, 8m) 
Age range (years, months) 10y, 8m - 17y,6m 10y, 1m – 15y, 6m 
IQ 113 (10) 91 (11) 
SDQ Hyperactive-impulsive/ 
Inattentive Subscale 
2 (2) 8 (2) 
SDQ – Total score  4 (4) 22 (7) 
SDQ Emotional difficulties subscale 1 (2) 4 (3) 
SDQ Behavioural difficulties 
subscale 
0 (1) 6 (3) 
SDQ Getting along difficulties 
subscale 
1 (1) 3 (3) 
SDQ Kind and helpful behaviours  
subscale 
9 (2) 5 (2) 
SCQ Total 1 (1) 9 (5) 
CPRS-R Total T score 44 (5) 78 (11) 
CPRS-R oppositional T score  43 (4) 76 (13) 
CPRS-R Cognitive/ inattention 
problems T Score 
45 (4) 69 (9) 
CPRS-R hyperactivity T score 47 (4) 79 (14) 
CPRS-R anxious/shy T score 49 (10) 60 (16) 
CPRS-R Perfectionism T score 44 (4) 59 (16) 
CPRS-R social problems T score 47 (3) 61 (15) 
CPRS-R Psychosomatic T score 49 (7) 63 (16) 
CPRS-R Global Index: restless 
impulsive T score 
44 (3) 76 (12) 
CPRS-R Global Index: emotional 
liability T score 
45 (5) 72 (15) 
CPRS-R ADHD T score 44 (4) 75 (8) 
Note: SDQ=Strengths and Difficul ties Questionnaire; CPRS-R: Conners’ Parent Rating 
Scale; SD= Standard Deviation 
  240 
8.2.2. Time Discrimination Task 
  After one practice session outside the scanner, the task was visually presented 
in the MRI scanner via a prism from a liquid crystal diode projector. The 5 min block-
design task consisted of 5 x 30-second alternated blocks for two conditions: TD 
(active condition) and temporal order judgement (TOJ) (control condition), which was 
always presented first. The TD condition began with the appearance of a centrally 
located grey circle (5 cm in diameter) with the letter “L” for 3 seconds. This was 
followed by two equally sized red (left side of screen) and green circles (right side of 
screen), appearing consecutively with no intermittent pause and in random order. One 
circle was randomly presented for 1s, and the comparison circle for either 1.3s, 1.4s or 
1.5s, with two trials for each comparison and with 2.1s response time for each trial. 
The subjects were told that in this experimental condition indicated by the letter “L” 
they had to decide which circle stayed on the screen for the longest time by 
responding with a left-sided button if the red circle, (displayed left), lasted longest, or 
a right-sided button if the green circle, (displayed right), lasted longest (Figure 8.1).  
 The TOJ (control) condition was presented identically. The only difference 
was that these blocks began with the presentation of the number ”2” and required 
subjects to indicate which circle came second using the same response buttons as 
described above.  
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Figure 8.1. Temporal Order Judgement and Time Discrimination conditions. Time discrimination 
blocks: after the appearance of a cue letter ‘L’ fo r 3s, subjects are presented with 6 pairs of red and 
green coloured circles, which appear consecutively left and right from each other. One of them is 
randomly presented for a standard duration of 1s, and the comparison circle for either 1,3s, 1,4 or 1,5s. 
Subjects have to decide which of the two circles had the longer duration, by pressing the left/right 
button. Temporal order judgement blocks: after the appearance of the cue number ‘2’ fo r 3s, subjects 
are presented with the same stimuli, but they have now to indicate which circle came second.  
 
8.2.3. Task performance analysis 
 Accuracy of TD and TOJ defined by number of errors was analysed by three 
one-way ANOVA comparing healthy controls and patients under each medication, 
separately. Within-patients, repeated measures ANOVAs were conducted to compare 
the effects of medication as well as for the presence of potential practice effects.  
 
8.2.4. MRI Acquisition 
 Gradient echo echoplanar MR imaging (EPI) data were acquired on a GD 
Signa 3T Horizon DHx system (General Electric, Milwaukee, WI, USA) at the Centre 
for Neuroimaging Sciences, Institute of psychiatry, King’s College London, UK. A 
semi-automated quality control procedure ensured consistent image quality (Simmons 
et al., 1999). A quadrature bircage head coil was used for RF transmission and 
reception. In each of 48 non-continguous planes parallel to the anterior-posterior 
commissure line 100 T2*-weighted MR images depicting BOLD (Blood Oxygen 
Level Dependent) contrast covering the whole brain were acquired with TE=30ms, 
TR =3s; flip angle =90º, in plane resolution=3.1mm, slice thickness=3.0mm, slice 
skip = 0.3mm. This EPI dataset provided complete coverage.  
 We used the non-parametric XBAM software (Brain Image Analysis Unit, 
2011) developed at the Institute of Psychiatry, Kings College, London (Brammer et 
al., 1997; Bullmore et al., 2001; Bullmore, Brammer, et al., 1999) which uses median 
statistics to control outlier effects and permutation rather than normal theory based 
inference, recommended for fMRI. Furthermore, the most common test statistic is 
computed by standardising for individual difference in residual noise before 
embarking on second level, multi-subject testing using robust permutation-based 
methods. This allows a mixed effects approach to analysis recommended for fMRI 
(Thirion et al., 2007)  
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 FMRI data were first processed to minimise motion related artifacts 
(Bullmore, Brammer, et al., 1999). A 3D volume consisting of the average intensity at 
each voxel over the whole experiment was calculated and used as a template. The 3D 
image volume at each time point was then realigned to this template by computing the 
combination of rotations (around the x y and z axes) and translations (in x y and z) 
that maximised the correlation between the image intensities of the volume in 
question and the template (rigid body registration). Following realignment, data were 
then smoothed using a Gaussian filter (FWHM, 7.2mm) to improve the signal to noise 
characteristics of the images.  
 After preprocessing, time series analysis for each individual subject was based 
on a previously published wavelet-based data resampling method for functional MRI 
data (Bullmore et al., 2001; Bullmore, Suckling, et al., 1999). Briefly, we first 
convolved the experimental condition with two Poisson model functions (peaking at 
4s and 8s) after motion correction, and performed global detrending and spin-
excitation history correction. We then calculated the weighted sum of these two 
convolutions that gave the best fit (least-squares) to the time series at each voxel. A 
goodness-of- fit statistic (the SSQ-ratio) was then computed at each voxel consisting 
of the ratio of the sum of squares of deviations from the mean intensity value due to 
the model (fitted time series) divided by the sum of squares due to the residuals 
(original time series minus model time series). The appropriate null distribution for 
assessing significance of any given SSQ-ratio was established using a wavelet-based 
data re-sampling method (Bullmore et al., 2001) and applying the model- fitting 
process to the re-sampled data. This process was repeated 20 times at each voxel and 
the data combined over all voxels, resulting in 20 null parametric maps of SSQ-ratio 
for each subject, which were combined to give the overall null distribution of SSQ-
ratio. The same permutation strategy was applied at each voxel to preserve spatial 
correlation structure in the data.  
 After first-level analysis, the individual statistical maps were then normalised 
into Talairach standard space (Bullmore et al., 2001). A group activation map was 
then produced for the experimental condition (TD–TOJ) by calculating the median 
SSQ-ratio over all subjects at each voxel in standard space and testing them against 
the null distribution of median SSQ-ratios computed from the identically transformed 
wavelet re-sampled data (Brammer et al., 1997). The analysis was then extended from 
the voxel to the 3D cluster level. An initial voxel- level statistical threshold was first 
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set to p <0.05 to give maximum sensitivity and to avoid type II errors. 3D clusters 
were then built from these significant voxels by linking together adjacent voxels into 
3D structures. The same process was performed both in the real and in the randomised 
data. The statistic used for the rest of the process is the cluster mass, which is the sum 
of the individual voxel statistics over the whole cluster. Cluster mass rather than a 
cluster extent was used, to minimise discrimination against possible small, strongly 
responding foci of activation (Bullmore, Suckling, et al., 1999). The statistical masses 
from all the 3D clusters were then pooled together to build a null distribution of 
cluster masses. The cluster mass of any cluster could then be tested against this null 
distribution. Using this distribution, we set the cluster-level statistical threshold in 
such a way that the final expected number of type I error 3D clusters was <1 per 
whole brain.  
 The necessary combination of voxel and cluster level thresholds is not 
assumed from theory but rather determined by direct permutation for each data set. In 
large connected clusters, we identified local maxima that were farther apart than the 
upper bound of the likely Talairach mapping error (3 voxel radius:10 mm) (Thirion et 
al., 2007). Voxels were then assigned to the nearest local maximum with a statistic 
value that exceeded that of the voxels. 3D clusters were constructed from these 
significant voxels and the mass of the clusters was then tested for significance in such 
a way as to obtain less than 1 false positive cluster over the whole brain. This 
combined voxel/cluster tests coupled with permutation testing allow for excellent type 
I error control at the cluster level (Bullmore, Brammer, et al., 1999; Bullmore, 
Suckling, et al., 1999). For each analysis, <1 false positive 3D cluster per map was 
expected at a p-value of <0.05 at the voxel- level and <0.01 at the cluster- level.  
 For between-group comparisons, a series of three ANOVAs were carried out 
comparing controls with a) patients on placebo; b) patients on MPH; and c) patients 
on ATX.  For within-group comparisons, a one-way ANOVA was carried out for 
medication condition: (placebo, MPH, ATX). Statistical measures of BOLD response 
were then extracted for each participant in each of the clusters of between- and 
within-group differences and post-hoc analyses were conducted to clarify the 
direction of the differences. Within patients, repeated measures ANOVAs on the 
extracted BOLD response measures were conducted to test for potential order effects.  
 In order to test whether the between-and within-group differences in brain 
activation were related to performance in all subjects, statistical measures of BOLD 
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response (SSQ-ratios) were extracted for each participant in each of the clusters of 




8.3.1. Task Performance  
 Time discrimination 
 One-way ANOVAs showed that healthy controls had significantly lower error 
rates than boys with ADHD when these were under placebo (F(1,38)=5, p<0.026) and 
ATX (F(1,38)=7, p<0.014), but did not differ from those of ADHD boys when they 
were under MPH (F(1,38)=2, p<0.16) (Table 6.2). However, when IQ was used as a 
covariate, group differences disappeared.  
 A repeated measures ANOVA comparing errors within children with ADHD 
under each medication condition was significant (F(2,38)= 4.8; p = 0.022), which was 
due to fewer errors in ADHD patients during the MPH condition relative to placebo  
(trend level, p<0.06) and ATX (p<0.03) (Table 8.2).  
   
Temporal Order Judgement 
 One-way ANOVAs showed no differences between healthy controls and 
ADHD boys under placebo (F(1,38)=0, p<0.89), MPH (F(1,38)=0, p<0.87) and ATX 
(F(1,38)=0, p<0.55) (Table 6.2).  Differences remained not significant when IQ was 
used as a covariate.  
 A repeated measures ANOVA comparing errors within children with ADHD 
under each medication condition showed no significant drug effect on this condition 
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Table 8.2. Performance of healthy controls and children with ADHD under 
placebo, MPH and ATX during Time Discrimination 






Healthy control boys 22 (22) 6 (14) 
Boys with ADHD under 
placebo 
40 (29) 6 (9) 
Boys with ADHD under MPH 32 (26) 5 (11) 
Boys with ADHD under ATX 40 (24) 8 (8) 
Note: MPH= Methylphenidate; ATX= Atomoxetine  
 
8.3.2. Brain Activation 
 
8.3.2.1. Motion 
 Multivariate ANOVA showed no significant group differences between 
controls and ADHD patients under each drug condition in the extent of mean rotation 
and translation movement parameters in the 3-dimensional Euclidean space 
(F(6,152)=1.5; p=0.18). 
 
8.3.2.2. Within-group activation  
 During the contrast of TD versus TOJ, healthy control boys showed activation 
in bilateral IFC, right DLPFC, SMA/ACC, bilateral pre- and post-central gyri and 
right IPL (Figure 8.2, Table 8.3).  
 Patients under placebo during TD showed activation in right VMPFC and 
bilateral IFC, SMA/ACC, striatum and brain stem, right MTG and STG, right IPL and 
bilateral cerebellum (Figure 8.2, Table 8.3).  
 When under a single dose of MPH, patients showed activation during the 
contrast of TD versus TOJ in bilateral IFC and DLPFC, caudate, SMA/ACC and 
cerebellum, as well as in right lateralised regions including the right MTG and IPL 
and right cuneus (Figure 8.2, Table 8.3).  
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 After a single dose of ATX, children with ADHD showed activation during 
the contrast of TD versus temporal order judgement in bilateral IFC and DLPFC, 
ACC extending to SMA, right IPL and in bilateral lingual gyrus reaching into 




Figure 8.2. Within group activation maps for the Time Discrimination Task. Axial sections 
showing within-group brain activation for the healthy comparison boys and boys with ADHD under 
each condition (placebo, MPH, ATX) for the contrast TD-TOJ. Talairach z-coordinates are indicated 
for slice distance (in mm) from the intercommissural line. The right side of the image corresponds to 
the right side of the brain.  
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 Table 8.3. Brain Activation within each group 









Time discrimination – Temporal Order Judgement Contrast 
Healthy control boys 
R inferior/medial frontal/pre/postcentral gyri/insula 
L inferior frontal/precentral gyri/insula 
R + L anterior cingulate gyrus/ supplementary motor area 
R inferior parietal gyrus 
Boys with ADHD under PLACEBO 
R inferior frontal/precentral gyri/insula/putamen, caudate, thalamus 
R +L anterior cigulate/medial frontal/supplementary motor area 
L pre/postcentral gyri 
R inferior/medial/superior frontal/premotor gyri 
L putamen/caudate/insula 
R medial/superior temporal gyri/thalamus  
R inferior parietal gyrus 
R+L brain stem/cerebellar vermis  
R+L brain stem/subthalamic nuclei 
L cerebellum 



















47; 11; 20 
-29;22;10 
7; 11; 40 
51; -37; 33 
 
40; 18; -4 
43; 7; 33 
-54; -4; 16 
4; 4; 53 
-18; 11; 7 
47; -33; -3 
40; -48; 36 
4; -26; -16 
4; -15; -10 
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L medial frontal gyrus 
L inferior frontoal/precentral gyri/insula/lenticular nucleus 
R inferior/medial/superior frontal/precentral/anterior cingulate gyri/supplementary motor 
area/lenticulate nucleus/caudate/thalamus  
L caudate 
R medial temporal gyrus 
R inferior parietal gyrus 
R + L cuneus 
L lateral cerebellum/vermis  
R+ L lingual gyrus/cuneus/cerebellum 
Boys with ADHD under ATX 
R inferior/medial/superior frontal/insula/precentral/lenticular nucleus/caudate/nucleus accumbens  
L medial frontal gyri 
L inferior frontal/precentral gyri/insula/lenticular nucleus 
L inferior frontal/precentral/postcentral gyri 
R + L anterior cingulate gyrus/supplementary motor area 
R thalamus 
R inferior parietal gyrus 
R parahippocampal gyrus 





















-47; 41; 10 
-36; 15; 7 
4; 30; 33 
 
-11; -4; 16 
54; -26; -3 
47; -44; 40 
7; -81; 30 
0; -52; -20 
4; -67; -4 
 
32; -33; 43 
-32; 37; 20 
-29; 15; 7 
-54; 0; 20 
4; 18; 40 
7; -18; 0 
47; -33; 43 
18; -44; -3 









































Note: N voxels = number of voxels. L = left; R = right. The maps are thresholded to give less than 1 Type I 3D error cluster per map.  
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8.3.2.3. ANOVA between-group comparisons of healthy controls and children 
with ADHD under placebo, MPH or ATX 
  
Controls compared to patients under placebo  
 Compared to controls, boys with ADHD showed reduced activation under 
placebo in SMA/ACC, in bilateral IFC, reaching into insula and putamen in the le ft 
hemisphere, and right DLPFC. A small cluster in left MFC was enhanced in children 
with ADHD compared with controls (Figure 8.3, Table 8.4). A negative correlation 
approaching significance was observed between the number of errors and brain 
activation within SMA/ACC for all subjects for the comparison between controls and 
children with ADHD under placebo (r=-0.28; p<0.07). 
  
Controls compared to patients under MPH 
 Under MPH, compared to controls, patients with ADHD only showed reduced 
activation in the cluster in the ACC but this was reduced in size and no longer 
included the SMA (Figure 8.3, Table 8.4). No areas of enhanced activation for the 
ADHD group compared with controls were observed. A significant negative 
correlation was observed between number of errors and brain activation within SMA 
for all subjects for the comparison between controls and ADHD patients under MPH 
(r=-0.38, p<0.01). 
  
Controls compared to patients under ATX 
 Under ATX, compared to controls, ADHD boys showed reduced activation in 
the same regions of left IFC, reaching into insula and SMA/ACC that were reduced 
under placebo, although both clusters were reduced in size (Figure 8.3, Table 8.4). No 
areas of enhanced activation for the ADHD group compared to healthy subjects were 
observed. 
  
  250 
 
Figure 8.3. Trans versal images of the between-group ANOVA comparison between healthy 
control boys and boys with ADHD on a) placebo b) MPH c) ATX during time discrimination.   
Statistical threshold selected at p<0.05 for voxel and p<0.01 for cluster levels. Slices are marked with 
the z-coordinate as distance in millimetres from the anterior–posterior commissure.  The right side of 
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Table 8.4. Between-group ANOVA results showing differences between controls and boys with ADHD under either placebo, MPH, or ATX for the contrast of T D 
versus order judgement.  
 
Note: N voxels = number of voxels. L = left; R = right. The maps are thresholded to give less than 1 Type I 3D error cluster per map. 











C > ADHD Plac R + L supplementary motor area/anterior cingulate cortex 
R dorsolateral prefrontal cortex 
L inferior frontal gyrus, insula, putamen 
R inferior frontal gyrus 






7; 11; 40 
36; 37; 33 
-29; 22; 10 
47; 11; 20 
















ADHD Plac> C L superior frontal gyrus 24 -25; 11; 52 24 0.009 1.13 
C > ADHD MPH  R + L anterior cingulate cortex 32 7; 11; 40 31 <0.001 1.32 
C> ADHD ATX  R + L  supplementary motor area /anterior cingulate gyrus 
L Inferior frontal gyrus, insula 
32/6 
45 
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8.3.2.4. Significance of the “normalization” and “laterality” effects 
 We wanted to analyze the significance of the “normalization” effects observed 
in the between-groups fMRI analysis. Given that the data of the healthy control group 
were identical across the different case-control comparisons, non-parametric 
Friedman tests were conducted only within patients to identify whether there were 
significant differences in brain activation under each drug condition in each of those  
clusters where the case-control contrasts showed “normalization” effects.   
None of the clusters of activation showed significant differences between 
brain activation under each drug condition (Right IFC/insula: BOLD Placebo: 0.029; 
BOLD MPH: 0.076; BOLD ATX: 0.047; ² (2, N=20)=1.20, p<0.55; right IFC: 
BOLD Placebo: 0.039; BOLD MPH: 0.046; BOLD ATX: 0.044; ² (2, N=20)=0.90, 
p<0.64; right DLPFC: BOLD Placebo: 0.036; BOLD MPH: 0.061; BOLD ATX: 
0.062; ² (2, N=20)=2.70, p<0.26; SMA/ACC: BOLD Placebo: 0.038; BOLD MPH: 
0.061; BOLD ATX: 0.060; ² (2, N=20)=0.10; p<0.95) although they were all in the 
right direction, suggestive of only “relative” or “moderate” normalisation effects. 
However, in the cluster comprising the left IFC/putamen, there was a trend for 
significant differences in activation (BOLD placebo: 0.042; BOLD MPH: 0.091; 
BOLD ATX: 0.072; ² (2, N=20)=4.30, p<0.11), which, as shown by the post-hoc 
Wilcoxon test, was due to the differences between brain activation under placebo 
relative to MPH (p<0.009) and at a trend level between placebo and ATX (p<0.057).  
 
 In order to test for the significance of the laterality effects on the BOLD signal 
changes observed in the right IFC/insula and left IFC under MPH and ATX, we 
conducted a repeated measures analysis within patients with laterality (2 levels: right 
IFC, left IFC) and drug condition (3 levels: placebo, MPH and ATX) as within-
subjects factors. There were no significant laterality x drug interaction effects 
(F(2,38)=0.11, p<0.90). 
 
8.3.2.5. Within-patients comparison between placebo, MPH and ATX 
 Given the reduced activation in prefrontal regions and SMA/ACC, we tested 
for significant upregulation effects of both drugs in prefrontal regions and SMA/ACC. 
For this purpose, the Talairach Client (Lancaster et al., 1997; Lancaster et al., 2000) 
was used to define a mask of the frontal lobe, which also included the ACC/SMA, 
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restricting the analysis to those voxels present in the mask. Repeated measures 
ANOVA showed a significant effect of drug condition in one cluster of activation 
comprising the SMA/ACC (105 voxels, peak Talairach coordinates (x;y;z):0;15;46; 
BA 6/32; p<0.01) due to enhanced activation in this cluster when ADHD boys were 
under MPH relative to ATX (p<0.05, one-tailed) and at a trend level, also relative to 
placebo (p<0.07, one-tailed) (Figure 8.4). No significant correlations were observed 
between TD errors and activation differences between any drug conditions.  
 
Figure 8.4. Trans versal images of the within-group ANOVA analysis for the TD-TOJ contrast. 
The figure shows the areas of increased brain activation in  boys with ADHD with an acute dose of 
MPH compared with placebo and ATX during time discrimination contrasted with order judgement.  
Statistical threshold set at p<0.05 for voxel- and p<0.01 for cluster-wise analysis. Slices are marked  
with the z coordinate as distance in millimetres from the anterior–posterior commissure.  Mean 
statistical BOLD response is shown for each drug condition within SMA/ACC (Supplementary Motor 
Area/Anterior Cingulate). The bar chart shows the SSQs for all the groups (healthy controls, ADHD 
boys under placebo, ADHD boys under Methylphenidate and ADHD boys under Atomoxetine).  
  
 Despite the randomised controlled design, to exclude the possibility that order 
effects may have accounted for some of the differences in performance or brain 
activation within patients or between cases and controls, a repeated measures 
ANOVA within patients analysis was conducted. There were no significant practice 
effects on performance or BOLD response in the clusters of activation differences in 
the within group analyses. 
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8.4. Discussion  
 This study demonstrates a significant drug-specific effect of MPH relative to 
placebo and ATX on performance and underlying networks of TD in children with 
ADHD. Relative to controls, boys with ADHD had reduced activation in typical areas 
of time perception of SMA/ACC, bilateral IFC, left insula and putamen, and right 
DLPFC. Within patients, MPH relative to ATX and placebo significantly decreased 
TD errors and upregulated SMA/ACC. Case-control comparisons showed that MPH 
had drug-specific moderate normalisation effects of the reduced activation when 
under placebo in SMA as well as in left IFC and insula. Shared effects were also 
observed, however, with both drugs reducing the right frontal underactivation.  
 ADHD patients had reduced activation under p lacebo relative to controls in 
key regions associated with temporal perception, particularly the SMA reaching into 
ACC, as well as bilateral IFC, insula and reaching into left putamen, which are typical 
areas of time perception in adults (Rubia & Smith, 2004; Smith et al., 2003; Wiener et 
al., 2010; Wittmann & van Wassenhove, 2009) and adolescents (Smith et al., 2011). 
The SMA is a key area for TD, frequently co-activated with ACC, insula and left IFC, 
although right IFC is more commonly thought to mediate attention to time (Rubia, 
2006; Wiener et al., 2010). The association between SMA and TD errors in ADHD 
patients is supported in this study by the correlation between SMA/ACC and 
percentage of TD errors across all subjects, which replicates earlier correlation 
findings between underactivation in this region and inaccuracy in ADHD (Smith et 
al., 2008). Left and right IFC and DLPFC deficits during the same task have also 
previously been observed in this patient group (Rubia, Halari, Christakou, et al., 2009; 
Smith et al., 2008)  
 The finding of a significant upregulation effect of MPH on SMA/ACC and the 
moderate normalisation effect on SMA, bilateral inferior and dorso-lateral prefronto-
striatal underactivation in ADHD boys during placebo extends previous findings of 
neural upregulation and normalisation with MPH of these key regional 
underactivations during the same TD task (Rubia, Halari, Christakou, et al., 2009). 
The same brain areas were also found to be normalized with a single dose of MPH 
during other tasks of cognitive control (Rubia, Halari, Mohammad, et al., 2011). 
 The novelty of these findings is that we show for the first time that only MPH 
upregulated and moderately normalised SMA activation, while it also completely 
normalized left IFC/putamen activation relative to ATX, while the moderate drug 
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normalisation effects on right fronto- insular underactivation are shared. The drug-
specific normalisation effects of MPH on left putamen are in line with its key role 
during fine temporal discrimination processes (Rubia, 2006; Wiener et al., 2010) and 
with the modulatory effects shown by a single dose of MPH in basal ganglia in 
medication-naïve children with ADHD (Rubia, Halari, Christakou, et al., 2009). The 
moderate normalisation of right IFC activation during ATX extends previous 
evidence for upregulation of this region in healthy adults (Chamberlain et al., 2009), 
showing for the first time that ATX also upregulates right lateral frontal areas in 
children with ADHD, suggesting the same mechanism of action in healthy subjects as 
well as ADHD patients. 
 The moderate normalisation effects of ATX on right but not left-sided 
IFC/insula in children with ADHD suggest that ATX has stronger effects on right 
hemispheric, noradrenergically modulated regions than left-hemispheric frontal 
regions (Chamberlain et al., 2009; Lawrence et al., 2003; Malone, Kershner, & 
Swanson, 1994). However, ATX showed some effects on the left IFC activation, with 
reduced size of the activation cluster and trend- level normalization effects. The 
bilateral frontal upregulation effects under MPH may reflect stronger left-hemispheric 
upregulation effects of MPH rather than ATX (Epstein et al., 2007; Rubia, Halari, 
Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 2009). Previous evidence 
shows increased levels of DA within subcortical structures in the left hemisphere 
(Flor-Henry, 1986) underpinning the proposal that this side of the brain may be 
associated with dopaminergic fronto-striatal pathways of arousal (Malone et al., 
1994). Consequently, stimulants such as MPH may have a stronger effect than ATX 
on left hemispheric mesolimbic dopaminergic pathways between the basal ganglia 
and left frontal regions and SMA.  
 The drug-specific improvement of performance deficits in ADHD by MPH, 
but not ATX, could potentially be explained by the fact that MPH had a more global 
effect on the different components of TD neural networks. Thus, MPH showed 
upregulation and moderate normalisation effects on SMA activation, and moderate 
normalisation effects in left IFC/insula and putamen activation, considered as a key 
region of time estimation, together with the SMA (Rubia, 2006; Rubia & Smith, 2004; 
Wiener et al.). The moderate normalisation effects on right frontal activation with 
both drugs may also reflect an enhancement of more generic catecholamine-mediated 
attention functions that are co-measured in timing functions (Berridge et al., 2006; 
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Rubia, 2006; Wiener et al., 2010). In frontal regions, MPH upregulates not only DA 
but also NE (Balcioglu et al., 2009; Berridge et al., 2006; Hannestad et al., 2010), via 
reuptake inhibition of NETs which clear up both DA and NE (Moron et al., 2002; 
Yamamoto & Novotney, 1998) and effects may therefore have been similar with both 
drugs, mediated by enhanced catecholamine neurotransmission.  
 The moderate normalisation of the underlying networks of left insula, IFC, 
putamen and the SMA with MPH are in line with behavioural evidence which shows  
consistently positive effects of dopamine-agonists on TD in humans (Rubia, 2006), 
while there is only scarce evidence for the relationship between NE agonists and TD 
functions in healthy adults (Rammsayer, Hennig, Haag, & Lange, 2001).  The 
findings also suggest that DA may play a more crucial role in SMA within the context 
of TD, and are consistent with the presence of DAT (Ciliax et al., 1999) relative to the 
scarce NET presence (Smith, Beveridge, & Porrino, 2006) in the SMA. The 
upregulating effects on the SMA/ACC may hence have been mediated by meso-
limbic dopaminergic pathways between the striatum and the SMA (Akkal, Dum, & 
Strick, 2007), operating within a wider hypothesized timekeeping circuit (Stevens, 
Kiehl, Pearlson, & Calhoun, 2007) involving bilateral IFC, insula and the SMA. 
Parkinsonism patients with striatal dopamine deficiencies consistently show TD 
deficits (Artieda, Pastor, Lacruz, & Obeso, 1992) and underactivation in the SMA 
which receives dopaminergic projections from the striatum (Akkal et al., 2007; 
Galvan & Wichmann, 2008). While poor function is consistently normalized with L-
DOPA (Rascol et al., 1994) and other DA agonists (Le & Jankovic, 2001), there are 
less consistent findings with NE agonists (Jenner, Sheehy, & Marsden, 1983), further 
supporting a predominant role of DA in SMA function. Therefore, MPH seems to 
have stronger effects on time discrimination networks, with more pronounced 
normalisation effects than those of ATX, which are likely to be mediated by 
dopaminergic effects.  
 This study is strengthened by the recruitment of medication-naïve children 
with ADHD thus controlling for the confounding effects of long-term stimulant 
medication on brain activation. A limitation is that for ethical reasons, controls were 
only tested once, while patients were tested three times. However, for the within 
subjects analysis, potential practice effects were controlled for by the counterbalanced 
design and furthermore, no practice effects were observed. This suggests that is 
unlikely that practice effects have contributed to performance or brain activation 
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differences between patients and controls. However, such assumption must be made 
with caution, as we could only test for potential order effects within subjects. Even 
then, this was conducted was a very small sample, and therefore the power to detect 
potential order effects is severely reduced. Furthermore, given the reduced number of 
participants on each condition, it was not possible to test for potential sequence effects 
derived from the randomisation order. This means that the administration of the drug 
conditions in a determined randomization order may have enhanced or reduced their 
effects. Further studies with sufficiently large samples should be conducted to rule out 
this possibility. In addition, the wider age range of the healthy control group relative 
to the ADHD boys may have affected the results by widening the between-groups 
differences in a disorder that has shown to be associated with neurodevelopmental 
delay (Rubia, 2007; Shaw et al., 2007; Shaw et al., 2012). Therefore, future studies 
should ideally include more closely age-matched groups.   
 An important limitation is the investigation of acute rather than chronic doses 
of each drug. As a single dose challenge, this design reduces  long-term confounds 
such as symptomatic improvement, side effects or chronic effects on brain activation. 
However, it may be biased towards MPH effects, given that they are clinically 
relatively immediate, while ATX is slower to act, with maximum clinical efficacy 
after 4-6 weeks of chronic administration (Montoya et al., 2009). Future studies 
should compare the long-term effects of both drugs on brain function to accommodate 
differences in time to maximum efficacy.  
 To conclude, to our knowledge this is the first study to directly compare 
neurofunctional effects of ATX and MPH in children with ADHD. We observed both 
drug-specific and shared effects of single doses of ATX and MPH on abnormal time 
estimation networks in ADHD. While MPH had a drug-specific upregulation and 
moderate normalising effect on SMA underactivation, both drugs showed moderate 
normalisation effects of lateral frontal underactivations, albeit these were stronger for 
MPH. The drug-specific upregulation findings of MPH on performance and error-
correlated SMA activation strengthen the association between abnormalities in 
dopaminergic neurotransmission, ADHD and temporal processing (Rubia, Halari, 
Christakou, et al., 2009).  
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CHAPTER 9. GENERAL DISCUSSION 
 
9.1. Summary of the results  
 MPH and ATX are currently the two most commonly prescribed drugs for the 
treatment of ADHD symptoms. However, their mechanisms of action have remained 
poorly understood and their compared effects on brain activation in ADHD patients 
are as yet unexplored. This thesis has compared, for the first time, the effects of single 
dose challenges of MPH and ATX on brain activation in ADHD. To do so, 
medication-naïve ADHD boys were recruited from clinics and scanned after a single 
dose of each drug. They performed cognitive tasks in which, relative to healthy boys, 
they typically present with performance deficits and abnormal brain act ivation. The 
results show that single doses of either MPH or ATX had both drug-specific and 
shared effects on their performance and brain activation which were, however, highly 
task-dependent.   
 During WM, children with ADHD under placebo showed impaired 
performance, with better performance than controls in the most simple 1-Back 
condition, but increased errors in the more difficult 2-Back and 3-Back conditions. 
ADHD boys under placebo showed reduced activation relative to healthy controls in 
bilateral DLPFC. Activation in the right DLPFC was negatively associated with errors 
both in healthy controls and at a trend level also in patients under placebo, supporting 
the key role of this region in WM processes. ATX showed drug-specific effects in the 
right DLPFC, which was upregulated in activation by ATX relative to MPH, within 
patients. Furthermore, relative to MPH, only ATX significantly normalised the 
underactivation observed in the same region when patients were under placebo 
relative to healthy control boys. On the other hand, MPH showed WM load-dependent 
drug-specific effects during the WM task. Only MPH upregulated left IFC activation, 
both within subjects as well as relative to healthy control boys, but only during the 2-
Back condition. Thus, the differential drug-specific normalisation and upregulation 
effects in right DLPFC underactivation in patients after ATX administration relative 
to controls and the upregulated activation in left IFC in patients after MPH are in 
contrast with the initial hypothesis of the study. We hypothesised that both drugs 
would modulate brain activation in PFC and that MPH would additionally do so in 
basal ganglia activation. WM is known to be mediated by DA and NE in PFC (Gamo 
et al., 2010). Both MPH and ATX enhance NE and DA in PFC (Berridge et al., 2006; 
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Bymaster et al., 2002; Swanson et al., 2006). MPH has shown to upregulate PFC and 
striatum activation in children with ADHD during WM (Prehn-Kristensen et al., 
2011; Sheridan et al., 2010). Dopamine has been shown to play a key role in WM 
processes (Chudasama & Robbins, 2004; Cools & D'Esposito, 2011; Landau et al., 
2009). However, WM has also been shown to be sensitive to noradrenergic 
manipulations (Chamberlain, Muller, Blackwell, Robbins, et al., 2006). The findings 
suggest that ATX had more prominently right-hemispheric upregulation and 
normalisation effects in the key WM area of DLPFC, while MPH showed left-
hemispheric drug-specific effects in IFC. Both MPH and ATX may have had similar 
effects on DA and NE networks, given that both drugs enhance DA and NE in PFC 
(Berridge et al., 2006; Bymaster et al., 2002; Swanson et al., 2006). Alternatively, the 
results suggest that the drug-specific effects during the WM task were differentially 
lateralised in prefrontal regions, consistent with evidence for a hemispheric bias of 
dopaminergic and noradrenergic systems (Flor-Henry, 1986; Glick et al., 1982; 
Tucker & Williamson, 1984), which should however be further investigated in future 
studies.  
 Shared effects during WM included the normalisation of the impaired 
performance of children with ADHD under placebo relative to controls. At the brain 
activation level, both drugs abnormally enhanced activation in fronto-STG-striatal 
regions relative to controls. Furthermore, both drugs enhanced WM load-dependent 
deactivation of the DMN relative to healthy controls. The presumably compensatory 
role of the enhanced fronto-STG-striatal activation was supported by its association 
with performance and, in the case of MPH, by its negative association with the 
reduced activation in DLPFC. However, even when these effects were shared they 
presented with some differences. The enhanced activation in boys with ADHD 
relative to controls in fronto-STG-striatal regions reached the right IFC only when 
subjects were under a single dose of ATX but not when they were under MPH. 
Similarly, although both drugs shared enhanced deactivation effects in the DMN, the 
location and temporal pattern of these effects differed depending on the drug. When 
under MPH, these effects were observed only during the 2-Back condition, were 
located in bilateral occipital regions reaching into precuneus, and were negatively 
associated with the drug-specific enhanced activation in left IFC during the same 2-
Back condition as well as with improved performance. On the other hand, the 
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deactivation effect of ATX was progressively stronger with increased WM-load and 
localised in midline ACC-PCC regions.  
 During the motor response inhibition task, medication-naïve children with 
ADHD relative to controls showed reduced activation in bilateral VLPFC, in right 
cerebellum reaching into occipital regions, as well as in left temporo-parietal cortices. 
During the SST, only MPH showed drug-specific effects. Behaviourally, only MPH 
sped up inhibitory processes in ADHD boys, which exceeded that of healthy control 
boys. At the brain activation level, only MPH showed significant drug-specific effects 
on right VLPFC-cerebellar inhibitory networks. Thus, only MPH significantly 
normalised the reduced activation when under placebo relative to healthy boys in right 
VLPFC, as well as in right anterior cerebellum extending to occipital areas. As during 
WM, only MPH showed some drug-specific effects during this task, which were more 
prominently left- lateralised. Thus, during the motor execution component of the SST, 
only MPH upregulated brain activation relative to healthy boys in left basal ganglia 
reaching into left IFC, in left premotor regions an in SMA/ACC.  
 Although ATX showed normalisation effects in right VLPFC and cerebellar 
regions during the SST, these effects were moderate and not statistically significant. 
Whether these would be stronger under prolonged administration of ATX or different 
dosages of the drug needs to be further studied. ATX only showed significant effects 
that were shared with those of MPH. Thus, both drugs normalised the underactivation 
observed under placebo relative to healthy boys in left VLPFC. Although this region 
has shown to be highly relevant for motor response inhibition processes (Nee et al., 
2007; Swick et al., 2008), it has also shown to be involved in performance monitoring 
processes (Derrfuss et al., 2005). Furthermore, previous evidence in medication-naïve 
ADHD boys during the same SST task used here showed upregulation and 
normalisation of left IFC activation after a single dose of MPH in children with 
ADHD (Rubia, Halari, Mohammad, et al., 2011). Hence, although the effects on left 
VLPFC activation may be due to upregulation of motor inhibition neural networks by 
both drugs, we hypothesised that these effects were due to improved performance 
monitoring processes.  
 Thus, the results from the SST are partially in line with the initial hypotheses 
of the study. In healthy adults, a single dose of ATX has shown upregulation effects 
in the key inhibitory area of right IFC during a Stop task (Chamberlain et al., 2009). 
MPH has also been shown to have upregulation effects on prefrontal and striatal brain 
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activation within children with ADHD during motor inhibition tasks (Epstein et al., 
2007; Rubia, Halari, Mohammad, et al., 2011; Vaidya et al., 1998). The left IFC has 
also shown its crucial role during motor inhibition (Nee et al., 2007; Swick et al., 
2008). Based on this evidence, we expected that a single dose of ATX and MPH 
would show comparable effects in inhibitory regions including the right but also the 
left IFC, with perhaps slightly stronger effects for ATX given the evidence supporting 
the relevance of NE during motor inhibition processes as measured by the SST (Bari 
et al., 2009; Eagle et al., 2008). We also hypothesised that only MPH would show 
upregulation and normalisation on brain activation in the basal ganglia, given that 
only MPH and not ATX have been shown to have dopaminergic effects in the 
striatum (Bymaster et al., 2002; Swanson et al., 2006; Volkow, Wang, Fowler, Gatley, 
et al., 1998). Although we find shared normalisation effects in left VLPFC by both 
drugs, only MPH showed significant normalisation and upregulation effects in right 
VLPFC and cerebellar regions.  
 Finally, during TD, medication-naïve boys with ADHD under placebo showed 
reduced activation relative to healthy boys in key TD regions including bilateral 
VLPFC and ACC/SMA. As in the SST, only MPH showed drug-specific effects. 
Behaviourally, only MPH relative to ATX and placebo improved performance in the 
task. At the brain activation level, only MPH showed upregulation effects in SMA 
and ACC, with additional drug-specific moderate normalisation effects in SMA. The 
shared effects during this task were located in the VLPFC : on the right VLPFC, both 
drugs showed moderate normalisation of the underactivation of this area under 
placebo relative to controls, whereas on the left VLPFC both drugs showed 
normalisation effects, although only when patients were under MPH the 
underactivation observed when patients were under placebo relative to controls was 
completely normalised. Our findings were therefore partially consistent with the 
initial hypothesis of the study. Previous evidence has shown that a single dose of 
MPH had normalisation and upregulation effects on key regions for TD, including 
lateral prefrontal regions, basal ganglia, ACC and cerebellum (Rubia, Halari, 
Christakou, et al., 2009). Furthermore, TD is known to be most prominently 
dopaminergically innervated and has been shown to be sensitive to dopaminergic 
manipulations (Baldwin et al., 2004; Ben-Pazi et al., 2006; Rammsayer, 1999; Rubia, 
2006; Rubia, Halari, Christakou, et al., 2009; Rubia, Noorloos, et al., 2003; Smith et 
al., 2003). Thus, we hypothesised that a single dose of MPH would have drug-specific 
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effects on in bilateral prefrontal and striatal regions, ACC and cerebellum. The results 
are therefore mostly in line with the initial hypotheses of drug-specific normalisation 
and upregulation effects of MPH on brain activation in bilateral IFC, striatal and 
SMA/ACC regions. However, we did not expect the shared moderate normalisation 
effects of ATX in VLPFC, which may have been due to its effects on both DA and 
NE on prefrontal regions (Bymaster et al., 2002).  
 Although these results have been discussed separately in Chapters 6-8, they 
will be more globally discussed here to arrive to general conclusions on the compared 
effects of both drugs.  
 
9.2. Task-specific effects 
 The findings of task-specific drug effects are the most relevant of this study, 
given their potential implication in the future development of individually tailored 
treatments for ADHD. A potential explanation for these task-dependent effects may 
be the inverted-U mode of functioning observed for both noradrenergic and 
dopaminergic systems. Too low or too high levels of DA or NE have been shown to 
impair cognitive function (Arnsten, 2009; Berridge et al., 2011; Robbins, 2010), and 
different levels of DA and NE are required by different cognitive functions (Cools & 
D'Esposito, 2011; Robbins, 2010).  
 Hence, the administration of MPH during tasks that have a strong 
dopaminergic innervation, such as the TD task or the motor execution component of 
the SST, may have allowed for the neural systems to achieve more adequate 
dopaminergic levels, needed to perform those tasks. On the other hand, the 
dopaminergic increase after a single dose of MPH during the WM task may have 
exceeded the necessary dopaminergic tone in fronto-striatal regions to be able to 
perform during the most difficult condition of the task, due to its impact on the 
flexibility-stability trade-off in fronto-striatal networks. The upregulation of the 
dopaminergic system would have stimulated prefrontal D1 receptors in excess, 
suppressing firing to relevant and irrelevant stimuli, while it would have engaged D2 
striatal receptors thus facilitating the rapid updating of information (Cools & 
D'Esposito, 2011). Thus, the enhanced dopaminergic tone in the striatum may have 
facilitated this rapid updating and improved performance during the 2-Back condition, 
but not during 3-Back condition, whose higher WM load requires longer stability of 
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the representations in WM and which may require only moderate dopaminergic levels 
of DA in prefrontal regions.  
 As described in the previous section, we expected comparable effects for ATX 
and MPH during the SST. Both drugs showed normalisation effects of the 
underactivation in ADHD boys under placebo, relative to controls, in the left VLPFC. 
Activation in this region may be associated to improved inhibitory function, given the 
evidence for its role during motor response inhibition processes (Nee et al., 2007; 
Swick et al., 2008). However, activation in this region was not associated with SSRT 
in patients under either drug condition or in healthy boys. On the other hand, there is 
evidence for a) the involvement of this region on performance monitoring processes 
(Derrfuss et al., 2005); b) its stronger upregulation/normalisation as part of 
performance monitoring networks after a single dose of MPH in children with ADHD 
(Rubia, Halari, Mohammad, et al., 2011) and c) its upregulation in healthy adults after 
a single dose of ATX during error monitoring processes (Graf et al., 2011). Thus, we 
hypothesised that these effects were due to improved performance monitoring 
processes.  
 However, while ATX showed only moderate normalisation effects in right 
VLPFC and cerebellar/occipital regions, MPH showed drug-specific normalisation 
and upregulation effects on right VLPFC and cerebellar regions, which furthermore 
were associated with improved SSRT performance and hence directly involved in 
motor inhibition speed.  
 The difference between the present findings of no direct upregulation and only 
a moderate normalisation effect on right VLPFC and those from Chamberlain et al 
(Chamberlain et al., 2009), where a single dose of ATX showed a direct upregulation 
effect on this region, may be due to differences in ATX dosages, sample 
characteristics (healthy adults versus children with ADHD) or a combination of both 
factors. While in the present study the dose of ATX was weight-adjusted (1mg/kg), 
Chamberlain et al (Chamberlain et al., 2009) administered a fixed 40 mg dose, which 
for an adult may have resulted in lower doses than the ones we administered. If we 
consider an average male adult may weight approximately 70kg, a 40mg dose would 
be equivalent to a weight-adjusted dose of 0.57 mg/kg. Furthermore, children with 
ADHD may show reduced function of the NE system, which may have not been 
adequately modulated during motor response inhibition by a single dose of ATX, 
perhaps due to different doses or repeated administration being required. On the other 
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hand a single (and comparatively lower) dose of ATX, as the dose administered by 
Chamberlain et al, may have been enough to upregulate activation in the key motor 
inhibition region of right IFC in healthy adults with adequately functioning NE 
systems. Also using a single dose of MPH, studies in healthy adults have shown 
different effects than those in children with ADHD. Thus, fMRI studies have shown 
that while MPH typically enhances activation in prefrontal and striatal regions during 
motor inhibition in ADHD patients (Epstein et al., 2007; Rubia, Halari, Mohammad, 
et al., 2011; Vaidya et al., 1998), it has been shown to reduce activation in right IFC 
during successful inhibition in healthy adults (Pauls et al., 2012). Hence, the effects of 
single doses of MPH and ATX may differ in paediatric patients and healthy adults, 
potentially due to the presence or absence of dysfunctional catecholaminergic 
systems.  
 Another potential explanation is that at higher doses, ATX may act on 
performance monitoring networks and not on motor inhibition networks. Thus, the 
dose of ATX administered in the present study may have been too high to adequately 
modulate brain activation in regions involved in motor inhibition processes. This 
would be in line with a recent study in healthy adults where a single dose of 80 mg of 
ATX showed upregulation effects during a combined GNG/Flanker task on 
performance monitoring networks including bilateral IFC, while impairing inhibition 
performance during incongruent (but not during congruent) NoGo trials (Graf et al., 
2011).  
 Thus, the dose of ATX administered in the present study may have been too 
high to adequately modulate key motor inhibition regions, but may have shown the 
effects of ATX on performance monitoring networks. The non-significant 
normalisation effects of a single dose of ATX on right VLPFC and 
cerebellar/occipital activation would support this. On the other hand, the dose of MPH 
may have been more adequate to show its beneficial effects on brain activation during 
motor inhibition, which may have been partially due to its effects on noradrenergic 
receptors (Berridge & Devilbiss, 2011).  
 Furthermore, it is possible that prolonged administration of ATX may have 
also resulted in significant results, given that ATX takes at least 4 weeks to 
significantly improve symptoms and 12 weeks to reach maximal clinical efficacy 
(Montoya et al., 2009). ATX showed moderate normalisation effects on right VLPFC 
activation, which were not statistically significant. Whether this moderate effect may 
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become stronger after prolonged administration or at different doses merits further 
investigation. Hence, studies on the compared effects of different doses and prolonged 
administration of both drugs would extend these findings. 
 However, it is important to note that an alternative explanation is that the 
effects of both drugs are due to their action on both DA and NE systems, given that 
both MPH and ATX enhance DA and NE in prefrontal regions (Berridge et al., 2006; 
Bymaster et al., 2002; Swanson et al., 2006) and that MPH has been shown to block 
both DAT and NET (Hannestad et al., 2010; Volkow, Wang, Fowler, Gatley, et al., 
1998). It may therefore be that the moderate effects shown by a single dose of ATX 
on right VLPFC and cerebellar activation may be due to its effects on both DA and 
NE, and that these moderate effects of ATX would have been significant at different 
doses or prolonged administration.  
  We expected MPH to show drug-specific effects on the basal ganglia across 
tasks, given its effects on striatal DA where it significantly blocks the DAT (Bymaster 
et al., 2002; Volkow, Wang, Fowler, Gatley, et al., 1998). This effect has not been 
reported for ATX (Bymaster et al., 2002; Swanson et al., 2006).  
 In line with this hypothesis, we observed moderate normalisation effects of 
MPH on left putamen activation during the TD task. These effects are in line with the 
key role of the basal ganglia during fine temporal discrimination processes (Rubia, 
2006; Rubia & Smith, 2004; Wiener et al., 2010) and with the modulatory effects 
shown by a single dose of MPH in basal ganglia in medication-naïve children with 
ADHD during the same task (Rubia, Halari, Christakou, et al., 2009).  However, we 
did not observe the expected effects of MPH in basal ganglia during the SST, which 
contrasts with previous evidence of modulatory effects of MPH on brain activation in 
basal ganglia not only during motor response inhibition (Epstein et al., 2007; Rubia, 
Halari, Mohammad, et al., 2011; Vaidya et al., 1998), TD (Rubia, Halari, Christakou, 
et al., 2009) or WM (Prehn-Kristensen et al., 2011; Sheridan et al., 2010), but also 
during other tasks of cognitive control (Rubia, Halari, Cubillo, et al., 2011; Rubia, 
Halari, Cubillo, et al., 2009; Shafritz et al., 2004).  
 However, we observed drug-specific effects of MPH on basal ganglia during 
the motor execution component of the SST. Although not hypothesised, these effects 
are not surprising, given the key role of the basal ganglia within neural motor circuits 
(Alexander, DeLong, & Strick, 1986).  
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 Unexpectedly, we observed shared enhancing effects for both drugs during 
WM in fronto-STG-striatal regions, including the thalamus. While the upregulation 
effects of MPH may be due to its direct dopaminergic effect in the basal ganglia, the 
unexpected striatal effects of ATX may be due to direct noradrenergic effects on 
frontal and thalamic activation, which may have indirectly enhanced striatal act ivation 
(Easton et al., 2007; Niijima et al., 2010). 
 A potential explanation for the lack of expected effects of MPH on basal 
ganglia during the SST task is that children with ADHD did not show reduced 
activation in basal ganglia during the SST, and therefore the effects of MPH may have 
not been observed because the basal ganglia activation was already optimal and 
normal. This would be in line with the evidence that we observed some striatal 
normalisation effects in TD, where in fact the basal ganglia were decreased in 
activation under placebo. Also, we did find upregulation effects on basal ganglia 
during motor execution and WM processes. Thus, MPH may have also had an 
upregulation effect on fronto-striatal motor response inhibition neural networks, but 
only on those regions where patients showed underactivation relative to controls when 
under placebo. 
 Thus, the results highlight the need for studies focused on several aspects. On 
the one hand, studies are needed to identify the effects of different doses of MPH and 
ATX on different cognitive functions and the underlying brain activation. 
Furthermore, the results of the present study are suggestive of the potential benefits of 
one of the drugs over the other depending on the cognitive function. Thus, while MPH 
would be better for those patients presenting with TD, motor inhibition or motor 
execution deficits, ATX would be better suited for those cases presenting with WM 
problems. However, because these drugs are administered not on a single dose basis 
but over prolonged periods of time, these results can only be taken as a first 
suggestion on the differential positive effects of both compounds on cognitive 
functions and brain activation and need to be confirmed with long-term studies. 
Additionally, studies on the compared effects of different doses of ATX and MPH 
would help to determine whether the moderate and non-significant effects of ATX in 
right VLPFC and cerebellar regions during the SST and in right IFC during the TD 
become significant at different doses or with longer-term administration given the 
different time course of the drugs to reach clinical efficacy (Greenhill et al., 2001; 
Montoya et al., 2009).  Furthermore, studies focused on the compared effects of both 
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drugs on a wider range of executive and non-executive tasks, and over a longer time 
period, would help to determine whether these task-specific effects can be observed in 
other cognitive tasks and in the underlying neural networks, or whether these 
modulatory effects persist over time. Finally, given the evidence for a dissociation of 
the cognitive and behavioural effects of MPH (Sprague & Sleator, 1977; Tannock, 
Schachar, et al., 1995), only longitudinal studies will be able to shed some light on the 
potential association between different dosages, the long-term task-specific effects of 
the drugs on cognition and brain activation, and their potential association with 
symptomatic and behavioural improvement.  
 
9.3. Drug-specific effects  
 As mentioned above, both MPH and ATX showed drug-specific task-
dependent effects.  
 Only MPH sped up inhibitory processes, which exceeded that of healthy 
controls, during the SST. Although both MPH and ATX normalised the reduced 
activation in right VLPFC, cerebellum and occipital regions during motor response 
inhibition processes, these effects were only significant for MPH. This is in line with 
previous studies where single doses of MPH in children with ADHD normalised and 
upregulated activation in frontal and cerebellar regions underlying inhibitory 
processes (Epstein et al., 2007; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, 
Mohammad, et al., 2011; Vaidya et al., 1998). The findings are also in line with a 
recent neuropsychological study, which showed that only a single dose challenge of 
MPH, and not of ATX, improved performance during the Stop task in healthy adults 
(Nandam et al., 2011). Thus, taken together, and as discussed in Chapter 6, the 
findings are suggestive of a stronger effect of MPH relative to ATX in typical motor 
response inhibition networks.  
 However, and as mentioned in the previous section, the moderate effects of 
ATX in right VLPFC and cerebellar regions during motor inhibition may have been 
influenced by the single dose administration, and may require prolonged 
administration to become significant given that it reaches maximal clinical efficacy 
after 12 weeks of treatment (Montoya et al., 2009). Alternatively, these moderate 
effects may have become significant after a different dose of ATX. Therefore, to 
clarify these aspects, studies on the compared effects of both drugs after prolonged 
administration and at different dosages are needed.  
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 During the TD task, only MPH reduced the number of errors within subjects 
relative to placebo and ATX. In the ACC/SMA, MPH showed upregulation effects 
within subjects and normalised the underactivation observed in SMA when patients 
were under placebo relative to controls. It is interesting that only MPH showed drug-
specific effects on brain activation in these regions across tasks, as only MPH 
enhanced activation in SMA/ACC both within patients and in patients relative to 
healthy control boys during motor execution. Thus, these findings are in line with 1) 
the hypothesised drug-specific enhancing effects of MPH on SMA/ACC during TD; 
2) with previous studies showing upregulation and normalisation effects of a single 
dose of MPH in children with ADHD in SMA/ACC during both TD (Rubia, Halari, 
Christakou, et al., 2009) and other cognitive control tasks (Rubia, Halari, Mohammad, 
et al., 2011); 3) with the known DAT distribution in sensorimotor regions (Ciliax et 
al., 1999) and 4) the dopaminergic innervation of both motor execution (Haber, 2003; 
Monchi et al., 2006) and TD processes (Rammsayer, 1999; Rubia, 2006; Wiener et 
al., 2010).  
 The compared apparent lateralisation of the drug-specific effects shown by the 
two compounds is highly interesting. During WM, while MPH showed drug-specific 
left lateralised effects, the drug-specific effects of ATX were right lateralised. 
  Only MPH showed WM load-dependent effects in the left IFC. Left IFC is 
involved in subvocal rehearsal processes during WM tasks (Owen et al., 2005; Smith 
et al., 1998). Thus, the left IFC was upregulated within patients and enhanced in 
patients relative to controls only by MPH.  
 In addition, during the TD and the SST tasks, MPH showed also some left-
lateralised effects that were stronger than those of ATX. However, it is important to 
note that in these tasks the effects of MPH were not restricted to the left hemisphere. 
Thus, during TD, only MPH completely normalised the underactivation observed in 
children with ADHD under placebo compared to healthy control boys in left IFC and 
putamen.  
 Finally, activation in the left basal ganglia and premotor cortex (reaching into 
left IFC) was enhanced in ADHD boys relative to healthy controls during motor 
execution processes only after a single dose of MPH. These left lateralised findings 
are in line with previous studies where the effect of MPH administration in children 
with ADHD was most prominently left- lateralised (Epstein et al., 2007; Rubia, Halari, 
Mohammad, et al., 2011; Rubia, Halari, Christakou, et al., 2009), as well as with 
  269 
some evidence for a left- lateralised bias in the dopaminergic system (Flor-Henry, 
1986; Glick et al., 1982). Therefore, the findings are suggestive of a potentially 
stronger effect of MPH on most prominently left- lateralised networks including the 
basal ganglia, left IFC and premotor regions and ACC/SMA. However, it cannot be 
overlooked that the effects of MPH were not exclusively left lateralised, and therefore 
further studies are needed in order to clarify the potential laterality effects of MPH. 
Alternatively, these results may have been due to the combined effect o f MPH on 
both DA and NE.  
 This is particularly interesting in contrast with the drug-specific effects of 
ATX, which were more predominantly (although not exclusively) right lateralised. 
During the WM task, and compared to MPH, ATX showed drug-specific right-
lateralised upregulation effects within patients in the right DLPFC, a key region for 
the manipulation and storage of information during WM processes (Owen et al., 
2005). The reduced activation in this region shown by ADHD boys under placebo 
relative to controls was also normalised under ATX. In addition, both compounds 
enhanced activation in children with ADHD relative to controls in fronto-STG-striatal 
regions during WM. However, only when ADHD boys were under ATX did it reach 
the right IFC, which has been shown to be involved in WM load processing (Baier et 
al., 2010). Therefore, these findings suggest that the effects of ATX may be stronger 
on right lateralised prefrontal regions, in line with the evidence for more strongly 
right- lateralised fronto-parietal noradrenergic networks, which underlie arousal, 
phasic alertness and attention processes (Tucker & Williamson, 1984). Furthermore, 
as described in Chapter 3, phasic responses of the noradrenergic system have been 
shown to act as an attention filter that selectively modulates the responsiveness of 
task-related cortical circuits (Aston-Jones & Cohen, 2005; Berridge & Waterhouse, 
2003). This would be in line with previous evidence from non-human primates, where 
ATX showed potentially stronger effects on noradrenergic than on dopaminergic 
systems during WM (Gamo et al., 2010). 
 Thus, while ATX showed drug-specific effects that were right- lateralised, 
potentially reflecting its effects on right- lateralised noradrenergic networks involving 
prefrontal regions (Tucker & Williamson, 1984), MPH showed some left- lateralised 
effects, which may reflect the left- lateralised bias of the dopaminergic system (Flor-
Henry, 1986; Glick et al., 1982). It is important to highlight at this point that in 
prefrontal regions, DA is reuptaken by the NET given the reduced presence of DAT 
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in these regions (Moron et al., 2002; Yamamoto & Novotney, 1998). Therefore, as 
ATX is a selective presynaptic NET blocker (Bymaster et al., 2002) and MPH has 
been shown to block both DAT and NET (Hannestad et al., 2010; Volkow, Wang, 
Fowler, Gatley, et al., 1998), both drugs enhance DA and NE in prefrontal regions 
(Berridge et al., 2006; Bymaster et al., 2002; Swanson et al., 2006). Consequently, 
both drugs may have acted on both DA and NE systems, although the results are 
suggestive of slightly differential stronger effects of the two drugs on one 
neurotransmitter system over the other, given the stronger left lateralisation of the 
dopaminergic system (Flor-Henry, 1986; Glick et al., 1982) and the stronger right 
lateralisation of noradrenergic systems (Tucker & Williamson, 1984).   
 
9.4. Shared effects 
 The results show a significant degree of overlap of the effects of MPH and 
ATX on performance and brain activation during the different paradigms.  
 During the WM task, both drugs showed shared effects on performance and 
brain activation. Both MPH and ATX normalised the increased number of errors 
made by patients under placebo relative to controls in the more difficult conditions of 
the task. Furthermore, both drugs showed enhanced fronto-STG-striatal activation. 
There is evidence for the involvement of cortico-striato-thalamic-cortical neural 
networks in the maintenance of information in WM (Frank, Loughry, & O’Reilly, 
2001; Jonides et al., 1997; Wang, 2001). Thus, both drugs may have upregulated this 
network and improved WM function, which is supported by the association between 
the enhanced activation in this network and performance under both drugs. It would 
be interesting to study the effects of more selective compounds that affect only one of 
these two neurotransmitters, as that would allow to elucidate the relative role of the 
different neurotransmitters in the enhanced activation observed in this network. The 
effects of MPH on striatal activation are not surprising, as these were hypothesised 
based on previous evidence of basal ganglia blockade of DAT effects of MPH 
(Bymaster et al., 2002; Volkow, Wang, Fowler, Gatley, et al., 1998), as well as on 
normalisation effects of MPH during WM tasks in this region (Prehn-Kristensen et al., 
2011). However, the enhanced striatal activation when patients were under ATX was 
unexpected. At present, and as mentioned in the previous section, we hypothesise that 
these striatal effects may be due to direct noradrenergic effects of ATX on frontal and 
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thalamic activation, which may indirectly have enhanced striatal activation within 
fronto-striato-thalamic networks (Easton et al., 2007; Niijima et al., 2010).  
 In addition, during the WM task there were shared WM load-dependent 
enhanced deactivation effects, which we hypothesise were due to enhanced 
deactivation of  the DMN. However, these differed in their location and timing: when 
under MPH, these effects were observed only during the 2-Back condition and were 
located in bilateral occipital regions and precuneus, whereas the deactivation effects 
of ATX were stronger with increased WM-load and localised in midline ACC-PCC 
regions.  Although only MPH has been previously shown to enhance the deactivation 
in the DMN during different cognitive tasks in children with ADHD (Liddle et al., 
2010; Peterson et al., 2009), both drugs significantly deactivated the DMN in healthy 
adults during WM (Marquand et al., 2011). However, Marquand et al (Marquand et 
al., 2011) also showed that compared to each other, MPH had greater enhancing 
effects on WM networks, while ATX had stronger deactivation effects on the DMN. 
Although the DMN has more frequently been associated with dopaminergic 
regulation (Delaveau et al., 2010; Tomasi et al., 2009), it has also shown to be 
sensitive to noradrenergic manipulations (Minzenberg, Yoon, & Carter, 2011). The 
reduced presence of DAT in occipital cortices (Ciliax et al., 1999) and the presence of 
NET in cingulate regions (Smith, Beveridge, et al., 2006) suggest that the 
involvement of NE in the regulation of the DMN may be highly relevant. However, 
and as mentioned in previous sections of this chapter, it is possible that both drugs had 
an effect on both neurotransmitters systems not only in PFC (Berridge et al., 2006; 
Bymaster et al., 2002; Swanson et al., 2006) but also in other cortical brain regions, 
which could also explain some of the observed shared effects in fronto-temporo-
striatal regions.  
 Therefore, the results highlight the need for studies on the compared effects of 
both drugs in ADHD patients on the DMN across different cognitive tasks to further 
confirm or refute this finding. As suggested above, the use of compounds with more 
selective effects on these two neurotransmitters would help to elucidate the relative 
role of each neurotransmitter on the DMN in ADHD patients.   
 However, alternative explanations for the deactivation observed in the 
occipital regions and precuneus when patients were under MPH relative to healthy 
controls are also plausible. The lack of association between movement parameters and 
brain activation within patients suggests that the clusters of activation differences 
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between groups are unlikely to be due to movement artefacts in the patient group. 
However, this should be further tested with larger sample sizes to be totally excluded.  
Alternatively, MPH may have affected the dopamine/acetylcholine imbalance, 
necessary for adequate cognitive functioning (Levin et al., 1990), by increasing DA-
regulated IFC activation during the 2-back condition,  and by downregulating 
cholinergic function in occipital regions, which would suggest reduced bottom-up 
visual-spatial processing. However, given the association between the reduced brain 
activation in these areas and improved performance in the task, the previous evidence 
of reduced  activation in such regions in children with ADHD (Booth et al., 2005; 
Hart, Radua, Nakao, et al., 2012; Rubia, Halari, Cubillo, et al., 2011; Rubia, Halari, 
Mohammad, et al., 2011; Vance et al., 2007) and its normalisation after MPH 
administration (Rubia, Halari, Mohammad, et al., 2011), it seems unlikely that this 
may be the case, although future studies should further investigate more closely the 
effects of MPH on occipital, cuneus and PCC regions.  
 During the SST, both drugs showed shared normalisation effects in left 
VLPFC, which was underactivated in patients under placebo relative to controls. 
Activation in this region may be associated with improved inhibitory function, given 
the evidence for its role during motor response inhibition processes (Nee et al., 2007; 
Swick et al., 2008). However, given previous evidence of the involvement of this 
region on performance monitoring processes (Derrfuss et al., 2005) and its 
upregulation/normalisation after a single dose of MPH in children with ADHD 
(Rubia, Halari, Mohammad, et al., 2011), we hypothesised that these effects would be 
due to improved performance monitoring processes. The shared effects of both drugs 
may be due to the upregulation of the dopaminergic and/or noradrenergic systems, as 
both drugs enhance extracellular levels of DA and NE in prefrontal regions (Berridge 
et al., 2006; Bymaster et al., 2002; Swanson et al., 2006).  
 However, our findings suggest that, at a dose of 1mg/kg, ATX may have 
stronger effects on performance monitoring rather than on motor response inhibition 
neural networks. This would be in line with the hypothesised role of the noradrenergic 
system as an attention filter that upregulates higher task-related cognitive processes 
necessary for the detection of the relevant/salient stimuli (Aston-Jones & Cohen, 
2005; Berridge & Waterhouse, 2003). However, as described in the previous section, 
the potential effects of the dose of ATX administered needs to be taken into account. 
  273 
Hence, studies on the effects of different doses of ATX and MPH are needed to 
confirm this aspect.  
 During TD, both drugs showed shared moderate normalisation effects in right 
IFC, which was underactive under placebo relative to controls. Time perception 
processes have been shown to be sensitive to dopaminergic manipulations, in line 
with the suggestion of its dopaminergic innervation (Baldwin et al., 2004; Ben-Pazi et 
al., 2006; Rammsayer, 1999; Rubia, 2006; Rubia, Halari, Christakou, et al., 2009; 
Rubia, Noorloos, et al., 2003; Smith et al., 2003). Thus, the shared but only moderate 
normalisation effects of both drugs are likely to be associated with the potential 
upregulation of the dopaminergic system in prefrontal regions.  
 Alternatively, ATX may have enhanced a right- lateralised noradrenergic 
attention network, which may have modulated the responsiveness of task-related TD 
dopaminergic frontal cortical circuits (Berridge & Waterhouse, 2003; Aston-Jones & 
Cohen, 2005).  
 On the other hand, MPH showed shared effects on right IFC, drug-specific 
performance improvement within patients, stronger effects on left IFC and drug-
specific effects on SMA/ACC activation, which are key regions for TD processes 
(Koch et al., 2009; Rubia, 2006; Rubia & Smith, 2004; Shih et al., 2009; Wiener et 
al., 2010). Taken together, the results suggest that MPH modulated activation on all 
the different components of the TD neural network, which may have thus improved 
performance during the task.  
 These findings highlight several aspects that merit further investigation. One 
open question is whether moderate effects on different key regions for the cognitive 
function studied would be enough to improve such function. The evidence from the 
present study suggests this may be the case; however, studies on the compared effects 
of different doses of MPH and ATX may help clarify this point. This finding 
highlights the need for further additional research on the compared neurofunctional 
effects of both drugs during TD processes, whether these effects are dose-dependent 
and how they are compared over time after prolonged administration.  
 
9.5. Conclusions 
 In conclusion, single dose challenges of MPH and ATX in medication-naïve 
children with ADHD showed shared and drug-specific effects, which were highly 
task-dependent, and are suggestive of potential differences in the benefic ial effects of 
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the drugs. There was a significant degree of overlap between the effects of both drugs, 
with shared effects observed across tasks in cortical networks including bilateral IFC, 
fronto-temporo-striatal regions and DMN. Nevertheless, while MPH significantly 
improved performance and brain activation during TD, motor execution and motor 
inhibition processes, ATX differentially enhanced brain activation in key regions for 
WM processes. These task-dependent and drug-specific effects suggest potential 
differential effects of the two drugs on different cognitive processes. These effects can 
be confirmed after long-term drug administration, which could potentially lead to 
individually tailored treatments based on which areas are most impaired in each 
patient.  
 The most relevant findings, which are task-dependent effects of the drugs, can 
furthermore be interpreted in light of previous theoretical approaches of ADHD. As 
reviewed in Chapter 1, ADHD has been described as a disorder whose symptoms may 
arise from deficits in behavioural inhibition processes due to dysfunctional fronto-
striatal regions (Barkley, 1997); deficits in WM resulting from a dysfunctional 
dorsolateral prefrontal cortex (DLPFC) (Castellanos & Tannock, 2002), or deficits in 
reinforcement processes as a result of underfunctioning nigrostriatal dopaminergic 
systems (Sagvolden et al., 2005).  
However, the results from the present study would potentially be better related 
to other approaches.  Thus, ADHD has been described as a disorder affecting multiple 
neural systems, with structural and functional abnormalities in functional networks 
underlying the cognitive deficits observed (Hart, Radua, Mataix-Cols, et al., 2012; 
Hart, Radua, Nakao, et al., 2012; Makris et al., 2009; Nigg & Casey, 2005). Thus, the 
results of the present study suggest that despite a significant overlap on the effects of 
both MPH and ATX on brain activation, they also have task-specific effects on the 
functional networks underlying the cognitive functions studied. Should single dose 
and long-term studies in larger samples confirm this aspect, this would help to the 
design of better treatment plans, individually tailored, given the evidence that shows 
how different subtypes of children with ADHD may have deficits in one cognitive 
domain and not others, i.e. they may present with deficits in temporal processing but 
not inhibitory functions (Nigg et al., 2005; Sonuga-Barke et al., 2010), and the fact 
that depending on the functional abnormalities underlying the cognitive deficits the 
patient presents with, one of the medications may be better suited for the treatment of 
a particular subject.  
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Alternatively, Sergeant (Sergeant, 2000) proposed that ADHD symptoms 
would arise from an arousal/activation dysregulation, in which arousal deficits would 
be due to a hypofunctioning right lateralized noradrenergic neural system, and 
activation deficits would arise from a hypofunctional dopaminergic network. Both 
MPH and ATX are effective medications for the treatment of ADHD, with 
neurofunctional effects in the neural systems hypothesised by Sergeant as core to the 
disorder. Indeed, as it has been shown, ATX showed effects that were stronger (but 
not limited to) right- lateralised prefrontal regions, potentially due to its stronger 
(although not exclusive) effects on noradrenergic systems, whereas MPH showed 
stronger effects on (albeit not limited to) dopaminergic fronto-striatal networks. 
Hence, the present study suggest that although both drugs affect DA and NE in 
prefrontal regions, the two compounds may be differentially suited to treat the deficits 
shown by children with ADHD, with ATX being better suited to improve arousal 
deficits and MPH better suited for activation dysregulation. More studies would be 
needed to further clarify this aspect. 
 
9.6. Strengths and limitations of the study  
 The main strength of this study is the double blind, randomised, placebo-
controlled, cross-over design, together with the recruitment of a sample of boys with 
ADHD who had never been on stimulant medication before. As discussed in the 
introductory chapters of this thesis, this avoids the most important confound of a 
pharmacological study in ADHD, which is the previous history of stimulant 
medication, shown to have long-term effects on brain structure and function (Frodl & 
Skokauskas, 2012; Konrad et al., 2007; Nakao et al., 2011). Furthermore, this study 
recruited a relatively large sample for an fMRI study, whose homogeneity was 
ensured by the recruitment of only boys, with the combined subtype of the disorder, 
and with only 2 of the participants with a confirmed diagnoses of CD/ODD.  
 The present study furthermore provides evidence of the usefulness of a 
relatively unusual approach. Pharmacological studies can be typically classified in 
two types. The present study would be placed in between the two types, filling the 
existing gap between them. This has its strengths and limitations.  
 Both animal and human PET studies on the mechanisms of action of the drugs 
allow for the identification of the specific neurotransmitter or transporter location 
where in the brain the drugs are acting, either after a single dose or how the long-term 
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administration of such drug may modify the expression of determined 
neurotransporter or its function. However, it needs to be considered that these studies 
typically focus on single neurotransmitter systems, making it therefore difficult to 
extrapolate the results from such studies from neurochemical effects to behaviour, as 
the different neurotransmitter systems do not act in isolation but intensely interact 
between them.  
Clinical pharmacological fMRI studies allow on the other hand for the 
identification of the neurofunctional effects of the drugs and their association with the 
behavioural changes observed (e,g, symptoms and/or cognitive functions). 
Pharmacological fMRI studies can focus on the effects of a single dose of a drug, or 
on the long-term effects of the administration of the drug. Most often, single doses 
studies are conducted in healthy subjects, whereas on clinical populations typically 
the main interest is on the effect of long-term administration of such drug. However, it 
is important to note that the effects of single doses of the drugs must also be studied in 
clinical populations, as their effects may differ between clinical and healthy 
populations.  
Furthermore, there are a number of factors to consider when interpreting the 
results of the long-term effects of a given medication on brain activation and 
cognitive function. First of all, the potential symptomatic improvement experienced 
by patients after long-term medication administration may have an impact on brain 
function and cognition. It is therefore difficult to disentangle which of the observed 
effects are due to the drug administration and which are due to the symptomatic 
improvement. The presence of potential side effects such as dizziness, nausea or 
sleepiness may also affect brain function and cognition and therefore constitute 
potential additional confounding factors. Furthermore, and most importantly, long-
term administration of a drug may lead to changes in brain structure and function, 
such as those described for MPH (Frodl & Skokauskas, 2012; Konrad et al., 2007; 
Nakao et al., 2011; Shaw, Sharp, et al., 2009). Therefore, such studies cannot 
unequivocally conclude on the potential effects of these drugs on the cognitive 
functions studied and the underlying brain activation, as those confounding factors are 
inherent to the long-term administration of the drug.  
Therefore, studies on the effects of the administration of single doses of a drug 
allow for the identification of the effects of a drug avoiding such confounding factors. 
Such studies also allow to refine the design of studies of long-term effects, based on 
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the data of the effects of single doses of the drug. Since these studies do not suffer 
from the potential effects of symptomatic improvement, their results can be more 
directly associated with the drug administration, and allow for better hypotheses on 
the potential long-term effects of the drug on brain function and cognition. Thus, 
studies like the present one constitute the intermediate step necessary to achieve a 
comprehensive understanding of the effects of drug administration on brain 
activation, cognitive functions and the way they modify symptoms and behaviours.  
 The use of a single dose of MPH and ATX was chosen to avoid those potential 
confounds associated with long-term administration. Thus, the study allows for the 
identification of the compared effects of both drugs on brain activation during 
cognitive functions typically impaired in patients with ADHD and which are potential 
target of the treatment. This study thus helps to identify the effects of each drug on 
brain activation and cognition before any clinical effects are manifested, and therefore 
it is less likely to be confounded by symptomatic improvement. Based on this, the 
potential differential effects the drugs will have on brain function during different 
cognitive processes can be more precisely hypothesised, thus guiding the design of 
studies on the compared effects of long-term administration. As an example, it could 
be hypothesised that ATX will have stronger or at least faster effects on working 
memory function, as it showed more pronounced effects than MPH after a single 
dose. Furthermore, and given the preliminary knowledge from animal, single cell and 
human PET studies, these studies also enable us to hypothesise on the potential 
neurotransmitters involved in the different cognitive functions, which may potentially 
underlie the symptomatic presentation of the disorder.   
 Therefore, this study makes a relevant contribution towards a preliminary 
understanding of drug-specific effects on brain activation and cognition.  
 However, the results from the present study have to be interpreted in light of 
its limitations. These have already been mentioned in Chapters 6-8, during the 
individual discussions of each of the chapters, but will be discussed more in depth 
here.  
 This study recruited right-handed ADHD boys with the comorbid subtype of 
the disorder, which limits the generalizability of the findings.  
 Healthy control boys were scanned only once and unmedicated, while children 
with ADHD were scanned on three occasions, which may have led to the presence of 
potential practise effects. The results suggest there were no such practise effects 
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within patients. However, this does not control for the differential practise effects 
when comparing their performance and brain activation in children with ADHD to 
that of healthy control boys. Furthermore, the assumption of the lack of practise 
effects within patients needs to be considered with caution, as the sample size is too 
small to adequately test this. The reduced number of subjects on each condition of the 
randomisation order does not allow to test for potential sequence effects, which 
should be tested in further studies with larger sample sizes.  
 The difference in IQ between groups is an additional limitation. It has 
consistently been reported that ADHD patients show lower IQ compared to healthy 
control subjects (Bridgett & Walker, 2006; Dennis et al., 2009). Low IQ is part of the 
disorder, and therefore it is not possible to control for IQ differences between groups 
without removing part of the variance associated to ADHD (Evans & Anastasio, 
1968; Miller & Chapman, 2001).  
 This is particularly problematic in the case of WM. WM has been shown to be 
closely associated with IQ, with additional indirect evidence suggesting that IQ and 
WM may share a common neurofunctional base, with the DLPFC being a key region 
for both functions (Conway et al., 2003). WM is indeed one of the measures obtained 
in widely used tests of general intelligence such as the Wechsler Intelligence Scale for 
Children (4th version) (WISC-IV) (Wechsler, 2004). Therefore, in the WM task, we 
did not covary for IQ but repeated the analyses after excluding outliers, and the 
findings remained although at a slightly more lenient p-value. Another possibility 
commonly used is to covariate for IQ differences between groups (ANCOVA 
analysis). IQ has been shown to be a moderator of the differences between ADHD 
patients and healthy subjects during motor inhibition (Lipszyc & Schachar, 2010; 
Willcutt et al., 2005) and TD tasks (Paule et al., 1999; Wearden et al., 1997). In these 
tasks, we conducted preliminary case-control WB analyses with and without using IQ 
as a covariate, in order to help to determine the impact of IQ on the differences in 
brain activation between healthy controls and children with ADHD under placebo. 
During TD, covarying for IQ restricted the areas of between group differences in 
brain activation to those typically described as most closely associated with TD 
networks, including the IFC and SMA/ACC (see Chapter 8). On the other hand, 
during the SST, the areas of brain activation differences between groups were the 
same as when IQ was not used as a covariate, but at a higher p value (see Chapter 6). 
Hence, we conducted the rest of the analyses in the TD using IQ as a covariate, and 
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without IQ as a covariate in the case of the SST. Thus, the results suggest that the 
presence of IQ differences between the groups moderated but did not explain the 
differences on brain activation between groups or the effects of both compounds on 
brain activation.  
The healthy control group showed a wider age range relative to the ADHD 
boys, despite no differences in mean age. Taking into account that patients with 
ADHD show a neurodevelopmental delay (Rubia, 2007; Shaw et al., 2007; Shaw et 
al., 2012), future studies should ideally more closely match the age ranges of both 
groups.  
Another potential limitation is the presence of drop-outs in the sample. We 
recruited 30 patients with ADHD. Of these, 4 (13%) (2 participants under placebo, 2 
under ATX) terminated their participation in the study prematurely, due to their 
inability to tolerate the scanning situation, which is commonly reported in fMRI 
studies of children. One subject (3%) was excluded due to his low IQ, another one 
due to the presence of neurological abnormalities and a third one due to braces. Data 
from another 2 subjects (7%) were not usable or lost due to technical problems. 
During the Stop task, one additional subject had to be excluded due to technical 
problems during the task (incorrect positioning inside the scan, too tilted) and another 
one due to incorrect performance of the task (with >60% omission errors). During the 
WM task, one subject had to be excluded due to excessive movement inside the scan 
(>3mm). The need to recruit subjects who show minimal motion parameters while 
inside the scan needs to be considered: it may be that only those subjects with less 
pronounced hyperactivity symptoms have been recruited. However, the differences in 
SDQ and Conners’ scores (where the specific DSM-IV hyperactivity subscale showed 
vales of T>80 in the ADHD group) suggest that the group of children with ADHD 
showed severe hyperactivity symptoms.   
 The study was designed to compare effects of single doses of MPH and ATX 
administration on brain activation and performance in medication-naïve children with 
ADHD, and constitutes the first step towards an understanding of their differential 
mechanisms of action. However, it needs to be taken into consideration that MPH and 
ATX have very different time courses to reach their maximum clinical efficacy. 
While behavioural effects are typically reported after a single dose of MPH (Greenhill 
et al., 2001), ATX requires 10-12 weeks to reach maximal efficacy for symptomatic 
improvement (Hazell et al., 2010; Montoya et al., 2009). Thus, the design of this 
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study may initially seem unfavourable for ATX, as less pronounced effects would be 
expected. However, when children with ADHD were under ATX, drug-specific 
upregulation effects within patients and normalisation effects relative to MPH were 
observed in the key WM region of right DLPFC. Furthermore, ATX showed 
significant effects in left VLPFC activation during the SST, and moderate effects on 
activation in right VLPFC and cerebellar regions during the SST, and in right IFC 
during the TD task. This is highly relevant, as it suggests that ATX may show 
beneficial effects on cognition and brain activation before behavioural effects are 
evident. Different dosages and/or prolonged treatment may have resulted in stronger 
effects. Thus, whether these effects are dose-dependent and how stable they are in 
time can only be studied in follow-up longitudinal studies.   
 The main goal of the present study was the investigation of the compared 
effects of both drugs on brain activation. Despite the presence of drug-effects on 
performance measures, this study may have been underpowered to identify 
neuropsychological performance differences in the different cognitive tasks used.  
 Because of the design of the study, focused on the compared effects of a single 
dose challenge of MPH and ATX, the results cannot be extrapolated to clinical 
settings at present. However, this leads to the next question, open for future studies: 
what are the compared effects of MPH and ATX on cognition and brain function in 
ADHD after their prolonged administration?  
 
9.7. Future directions  
 MPH and ATX are routinely prescribed to treat ADHD. However, their 
mechanisms of action on brain function in ADHD are relatively unknown. Studies on 
MPH have shown it has upregulation and normalisation effects in children with 
ADHD in prefrontal and striatal brain activation during motor inhibition tasks 
(Epstein et al., 2007; Rubia, Halari, Mohammad, et al., 2011; Vaidya et al., 1998), in 
bilateral prefrontal regions, ACC and cerebellum activation during TD (Rubia, Halari, 
Christakou, et al., 2009) and in prefrontal and striatal activation during WM (Prehn-
Kristensen et al., 2011; Sheridan et al., 2010). However, nothing was known on the 
drug-specific brain function effects of MPH relative to ATX and nothing was known 
on effects of ATX in ADHD brain function. Therefore, the present study constitutes a 
pioneering step towards a first understanding of their compared effects on brain 
function in ADHD.   
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 The focus of the study on a single dose challenge of MPH and ATX precludes 
the findings from being extrapolated to clinical settings at present. Future studies 
should ideally include a battery of tasks comprising both executive and non-executive 
functions so as to identify whether the effects of the drugs are task-specific, limited to 
executive functions or also affect other non-executive cognitive functions. 
Furthermore, this would shed some light on which aspects of cognition respond better 
to which medication, and how this is associated with changes in brain activation. As 
mentioned in the previous section, this study can be considered as the first step to 
understand the neurofunctional effects of both medications on brain activation of 
children with ADHD, and their potential selective benefits. Following the results of 
the present study, studies on longer-term effects of both drugs or longitudinal follow-
up tests with different timepoints would help to identify the different time courses of 
the effects of both drugs across different cognitive domains. Furthermore, such 
studies would also clarify whether the time courses of the drugs on cognition and 
brain activation parallel those described for symptomatic improvement.  
 Clinicians commonly report the need for a progressive increase in the doses of 
stimulants used in order to maintain the beneficial effects of the drugs on symptoms 
of ADHD. It has also been reported that the superior beneficial effects of medication 
therapy compared to other therapies fade after 3 years of treatment (Jensen et al., 
2007). Longitudinal studies on the effects of MPH and ATX would allow one to 
identify the stability of those drug-related cognitive and brain activation changes over 
time. To achieve this, several key time points would need to be identified: 1) 
measures at baseline, 2) measures at the time when both drugs have reached their 
maximum clinical efficacy, and 3) measures after long-term treatment, as this has 
shown to have effects on the dopaminergic system (Fusar-Poli et al., 2012), brain 
structure (Frodl & Skokauskas, 2012; Nakao et al., 2011) and brain function  (Konrad 
et al., 2007). 
 Another aspect that merits further investigation is the effect of different doses 
on cognitive function and brain activation. Some neuropsychological studies on the 
effects of MPH have addressed this issue (Bedard et al., 2002; Bedard & Tannock, 
2008; Coghill et al., 2007; Gunther et al., 2010; Konrad et al., 2004; Lijffijt et al., 
2006; McInnes et al., 2007; Scheres et al., 2003; Shiels et al., 2009; Spencer et al., 
2009; Tannock et al., 1989; Tannock, Schachar, et al., 1995), with results suggesting 
that dose-effects may be task-dependent. Thus, linear effects with more pronounced 
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improvements at higher doses have been reported during change-RT (Tannock, 
Schachar, et al., 1995) and attention tasks (Gunther et al., 2010; Konrad et al., 2004). 
Meanwhile, an inverted-U relationship between dose and performance has been 
reported during focused attention or sustained attention tasks (Gunther et al., 2010). 
However, results are more controversial with regards to motor inhibition tasks 
(Coghill et al., 2007; Konrad et al., 2004; Lijffijt et al., 2006), and during auditory-
verbal WM tasks (Bedard & Tannock, 2008; McInnes et al., 2007; Tannock, 
Ickowicz, et al., 1995), where the linearity of the behavioural effects has not been 
clearly established. Furthermore, no study has focused on dose-dependent effects of 
ATX on cognition, and there are no fMRI studies on the compared effects of different 
doses of MPH and ATX on brain activation in ADHD patients. Given the inverted-U 
mode of function of both dopaminergic and noradrenergic systems, which 
furthermore varies depending on the different cognitive functions, it seems necessary 
to assess the effects of different doses of both compounds on a battery of cognitive 
tasks in ADHD patients.  
 Finally, another area where more research is needed is on the presence of 
abnormalities in the noradrenergic system of patients with ADHD. PET studies in 
adults with ADHD (as PET cannot be used in children), would help to identify the 
presence of abnormalities in the NE system in ADHD. However, advances in this area 
depend greatly on the development of adequate radioligands for the NET and NE 
receptors. Nevertheless, once these radioligands are available, PET studies should 
help to clarify not only those abnormalities but also the compared effects of both 
drugs on the noradrenergic system, both after single doses and after prolonged 
administration. Furthermore, such studies may help to elucidate whether the clinical 
response to ATX and/or MPH may be associated with the presence of abnormalities 
in NE systems, which is unexplored thus far. The evidence from this field, together 
with that from fMRI studies in ADHD patients on the compared effec ts of both drugs 
on brain activation and performance during cognitive tasks, would significantly 
increase our understanding of the compared mechanisms of action of both drugs in 
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9.8. Final remarks and conclusions 
  This PhD has provided the first evidence of the compared effects of single 
doses of MPH and ATX on brain activation during task-relevant cognitive tasks in 
ADHD patients.  
 The main conclusions of the study can be summarised as follows:   
 a) The effects of both drugs on performance and brain activation are highly 
task-dependent. Drug-specific effects were observed for MPH during TD and motor 
execution processes, whereas the drug-specific effects of ATX on brain activation 
were restricted to WM. Furthermore, both drugs showed normalisation effects during 
the motor response inhibition task, although these were only moderate for ATX but 
significantly stronger for MPH on right VLPFC-cerebellar regions. These results 
could have implications for treatment indications. However, these drugs are not 
administered on a single dose basis but over prolonged periods of time. Therefore, 
these results can be considered as the first step to the understanding of the drug-
specific and shared effects of both drugs on brain function in ADHD patients and 
should be considered in the design of studies on the compared effect of prolonged 
administration of both drugs on cognitive function and brain activation, which would 
be the following step to further achieve a better understanding of the mechanisms of 
action of both drugs.   
 b) The drug-specific effects of MPH and ATX showed a differential pattern of 
lateralisation in prefrontal regions, which were more prominently left- lateralised for 
MPH and right-lateralised for ATX, in line with evidence for a hemispheric bias in 
dopaminergic and noradrenergic systems (Flor-Henry, 1986; Glick et al., 1982; 
Tucker & Williamson, 1984). These results suggest that despite the shared effects on 
DA and NE on prefrontal regions (Berridge et al., 2006; Bymaster et al., 2002; 
Swanson et al., 2006), MPH may have a more prominent effect on left- lateralised 
dopaminergic networks, while ATX may have a more prominent effect on right-
lateralised noradrenergic networks.  However, whether this lateralisation effect is 
task-dependent, or really present needs to be further studied.  
 c) There is a significant overlap between the effects of both compounds on 
brain activation, which goes beyond the expected overlap in PFC, such as shared 
normalised in left VLPFC activation during motor inhibition, in right VLPFC during 
TD, shared enhanced fronto-temporo-striatal activation reaching into the thalamus and 
shared deactivation of the DMN. A significant proportion of children with ADHD 
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have been shown to respond positively to both medications (Sangal et al., 2006). 
Therefore, future longitudinal studies focused on the compared effects of both drugs 
on cognition, brain activation and symptoms should investigate whether these shared 
effects on brain function underlie the positive effects of both medications on clinical 
symptoms in that subgroup of children with ADHD that respond positively to both 
medications.    
 d) The effects of ATX on cognition and brain activation were observed after a 
single dose. This is highly interesting, as it suggests that these effects may be 
observed before the behavioural effects, which typically take a minimum of 4-6 
weeks of persistent treatment (Montoya et al., 2009). However, whether the effects of 
ATX are observable on cognition and brain activation before significant symptomatic 
improvement is observed, and how stable these effects are in time can only be studied 
using longitudinal studies. Future longitudinal studies should further investigate 
whether these effects become stronger at different doses or with prolonged 
administration. 
 This investigation on the effects of MPH and ATX in medication-naive 
patients is a first step towards improving our understanding of their drug-specific 
effects on brain activation and cognition, avoiding potential confounds of long-term 
treatment such as symptomatic improvement, side effects or chronic effects on brain 
activation.  
 The study makes a novel contribution to the field, as it compares for the first 
time the effects of both drugs on brain function in ADHD, and shows that both MPH 
and ATX have shared and task-specific effects on brain activation even after a single 
dose. Relative to ATX, MPH showed stronger effects on brain areas that are crucial 
for TD, motor execution and motor response inhibition processes, while ATX showed 
stronger effects than MPH on brain regions that mediate working memory. Given the 
differences of the two drugs in their temporal courses to clinical efficacy, however, 
further studies on the compared effects of prolonged administration of both drugs on 
cognitive deficits and the activation of the underlying neural networks seem necessary 
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APPENDICES 
 
- Appendix Figure A1: Results of the between-group ANCOVA comparisons 
between healthy control boys and ADHD under either Placebo, Methylphenidate 




- Appendix Figure A2. REsulst of the between-group ANCOVA comparisons 
between healthy boys and boys with ADHD under either Placebo, 
Methylphenidate or Atomoxetine after exclusion of outliers subjects with regards 
to IQ. 
 
- Appendix Figure A3: Results of the between-group ANOVA comparisons 
between healthy control boys and ADHD under either Placebo, Methylphenidate 
or Atomoxetine for the Time Discrimination- Temporal Order Judgement 
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 Appendix Figure A1. Between-group ANCOVA comparisons between healthy control boys and 
boys with ADHD under either Placebo, Methylphenidate or Atomoxetine for the successful 
inhibition-Go trials contrast with IQ as a covariate. Axial sections showing the ANCOVA between-
group differences in brain activation between healthy control boys and boys with ADHD under each 
drug condition (Placebo, MPH, ATX) during successful inhibition in the Stop task. Talairach z-
coordinates are indicated fo r slice distance (in mm) from the intercommissural line. The right side of 
the image corresponds to the right side of the brain.  
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Appendix Figure A2. Between-group ANCOVA comparisons between healthy boys and boys 
with ADHD under either Placebo, Methylphenidate or Atomoxetine after exclusion of outliers 
subjects with regards to IQ. Axial sections showing the ANCOVA between-group difference effects 
in brain activation between healthy control boys and boys with ADHD under each condition (placebo, 
MPH, ATX). Clusters in orange denote areas where control boys showed enh anced activation 
compared to ADHD boys, clusters in blue denote areas where ADHD boys showed enhanced activation 
compared to control boys. Talairach z-coordinates are indicated for slice distance (in mm) from the 
intercommissural line. The right side of the image corresponds to the right side of the brain
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Appendix Figure A3. Trans versal images of the between-group ANOVA comparison between 
healthy control boys and boys with ADHD on a) placebo b) MPH c) ATX during time 
discrimination without IQ as a covariate.  Slices are marked with the z-coordinate as distance in 
millimetres from the anterior–posterior commissure.  The right side of the image corresponds to the 
right side of the brain. 
 In order to explore whether group differences in brain activation could be 
explained by significant group differences in IQ, we performed correlations between 
IQ scores and the SSQs of children with ADHD extracted from clusters of activation 
which differed between children with ADHD on placebo and controls.  None of these 
were significant. 
 
 
